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Abstract
Previous studies have revealed that embryonic stem (ES) cells are capable of 
differentiating spontaneously towards pancreatic P cells. The use of growth factors 
and specific agents, such as nicotinamide, can further enhance this effect in a process 
known as directed differentiation. In vivo monitoring of pancreatic development 
indicates that the pancreas is derived from an endodermal lineage. This thesis 
investigated the differentiation of an embryonic carcinoma cell line, F9, which is 
characterised as having minimal spontaneous differentiation, towards endoderm and 
from there, on to pancreatic lineages.
Treatment of monolayer F9 cells with 10'7 M retinoic acid (RA) or a combination of 
retinoic acid and 10'3M dibutyryl cyclic adenosine monophosphate (db cAMP) for 72 
hours generates both primitive and parietal endodermal types. Culture of F9 cells in 
suspension leads to the formation of embryoid bodies (EBs). Treatment of these 
aggregates with RA generates visceral endoderm on the outer surface of the EB. 
These endodermal subtypes were found to express the full catalogue of cytokeratins 
(CKs) associated with the pancreatic islets i.e. CKs 8, 18, 7 & 19.
The F9-derived endoderm was then treated with agents that have been shown to 
promote endocrine differentiation from progenitor cells i.e. activin A, betacellulin 
hepatocyte growth factor (HGF), nicotinamide and sodium butyrate. Certain 
treatments were found to increase the levels of important pancreatic mRNAs i.e. a 
combination of HGF and activin A increased pancreatic and duodenal homeobox gene 
1 (PDX1) and preproinsulin (PPI) expression in RA-treated F9 monolayers. Sodium 
butyrate was shown to have positive effects on the expression of somatostatin and 
pancreatic polypeptide (PP) mRNAs. Other p cell genes detected in differentiating F9 
cells include Pax6 and indian hedgehog (Ihh).
To further study the role of the transcription factor PDX1 in pancreatic development, 
cell trapping was employed. In this system, a specialised construct was designed with 
the zeocin resistance gene (Sh ble) under the control of the PDX1 promoter region. 
This construct was shown to be capable of selectively maintaining the viability of F9 
cells with the capability to drive the PDX1 promoter, in the presence of zeocin. The 
cells purified using this technique were found to exhibit increased levels of PDX1 
mRNA and in certain cases PPI also, even though PDX1 protein was not detected.
Further evidence for the presence of functional PDX1 in cell trapped lines was 
provided by the observation that these cell lines co-expressed somatostatin, which is 
known to be transactivated by PDX1.
Upon culturing p cells for prolonged periods in vitro it has been noticed that these 
cells lose the ability to secrete insulin in response to environmental glucose signals 
(glucose stimulated insulin secretion, GSIS), in a process sometimes referred to as de- 
differentiation. Upon culturing the murine P cell line, Min6, for 40 passages similar 
effects were noticed. Analysis of the gene expression profiles in continuously cultured 
Min6 cells via DNA array led to the discovery that a number of genes associated with 
rapidly proliferating primitive type cells were upregulated in the high passage Min6 
cells (e.g. the polycomb group gene EED & p55CDC). This analysis also revealed 
that a number of genes critical for the regulated secretion of insulin were 
downregulated, including; nucleobindin, secretogranin II, secretogranin V, 
chromogranin B and prohormone convertase 2 (PC2). These observations and the 
associated reduction/loss of terminal differentiation markers such as PDX1, glucagon 
and somatostatin were all consistent with de-differentiation or with overgrowth of the 
culture by a more poorly differentiated subpopulation.
The human insulin gene has been successfully expressed in a number of cell lines as a 
possible method for ‘artificial p cell delivery’. BHK-21 cells are characterised as a 
safe cell line to implant into humans in a suitably encapsulated format. Expression of 
the human PPI gene in BHK-21 cells resulted in large amounts of proinsulin 
production. There was no evidence of proinsulin processing to mature insulin and this 
was associated with an inability to store the protein properly. This also resulted in the 
continuous secretion of proinsulin at a steady rate of 0.12 pmol proinsulin/hr/105 cells. 
These cells were found to be unable to regulate proinsulin secretion in response to 
glucose. Overexpression of glucokinase resulted in a moderate GSIS but 
overexpression of GLUT2 and glucokinase resulted in the total loss of insulin 
secretion. This may be due to a deleterious increase in the metabolic burden in the 
cells. Proinsulin secreting BHK-PPI-C16 cells were also capable of increasing 
proinsulin secretion upon treatment with cAMP and it is proposed that this increase in 
secretion is due to a general increase in intracellular proinsulin i.e. the rate of 
secretion was determined by the availability of the protein.
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1.0 INTRODUCTION.
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1.0 General Introduction
The pancreatic islets of Langerhans secrete glucoregulatory hormones in response to 
metabolic fuels. In the case of glucose, its transport into the pancreatic (3 cells and its 
subsequent metabolism lead to the controlled release of the polypeptide hormone 
insulin. Following the discovery of insulin, and advances in the study of metabolism, 
it was discovered that higher mammals could avoid continuous food consumption due 
to the presence of a regulated system of energy storage. The main regulator in this 
system is insulin, levels of which rise post-prandially and fall again during fasting. 
Insulin is absolutely required to maintain normoglycemic conditions in the blood, this 
and its unique role as an anabolic peptide hormone means it is regulated in a 
controlled fashion to allow it to respond to blood glucose levels rapidly. When this 
system is impaired i.e. through autoimmune destruction of P cells as in the case of 
insulin dependent diabetes mellitus, (Type I Diabetes), serious complications and 
illness may result.
Polyuric states (passing large amounts of urine), resembling diabetes mellitus, have 
been observed since before 1000 BC. Diabetes was discovered to be a disease of the 
pancreas in the 19th century (discovered when a pancreatectomy induced diabetes in 
dogs (Mering & Minkowski, 1890)). Early therapeutic strategies were based on 
pancreatic replacement and some of these trials caused a reduction in the 
hyperglycemic state. Others began searching for the pancreatic extracts that were 
responsible for the control of glycemia in the blood. In 1922 a collaborative effort 
between F. Banting, C. Best, J. Collip, and J.J.R. Me Leod resulted in the discovery of 
a pancreatic extract, that saved the life of a 14-year old boy dying of diabetes. This 
was the proposed ‘insulin’ (it was named prior to discovery, and refers to the Latin 
root for the islet cells in the pancreas) (Banting & Best, 1922).
Insulin dependent diabetes mellitus (IDDM), is generally synonymous with type I 
diabetes and is a result of massive autoimmune destruction of P-cells. In the initial 
stages of IDDM, patients usually experience severe thirst and polyuria. Extreme 
tiredness, weight loss and muscle cramps are also symptoms of IDDM. Following 
diagnosis, patients are prescribed insulin. A remission period of up to two years may 
then occur, this is due to improved P-cell function as a result of lowered blood
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glucose. This allows for very low insulin requirements. This respite is temporary 
however and eventually a stage is reached when the quantity of P-cells available 
becomes so low that regular insulin injections are required to survive.
While insulin is a life saving drug, there are problems associated with injecting 
insulin. These supplements do not mimic the way the normal P-cells constantly 
regulate circulating glucose levels in the body. Complications that can occur include, 
kidney failure, blindness, atherosclerosis in large vessels and nerve damage leading to 
pain or numbness in the extremities (peripheral neuropathy). All of these are basically 
due to the presence of too much glucose in the blood (hyperglycemia), however 
increased insulin doses can lead to confusion, shakes and blackouts, due to blood 
glucose being lowered too far (hypoglycemia). As well as the obvious adverse effects 
on the quality of life for the diabetic, these complications are very expensive for 
health services/patients to maintain i.e., EDDM has a prevalence of about 0.4% 
therefore ~1 million Americans have the disorder (Mitanchez et al., 1997).
Alternative therapies are currently under investigation. The transplantation of 
pancreatic material including P-cells (as whole pancreata or isolated islets) is 
expensive and limited due to the scarcity of donated material. The most promising 
methods for the future may employ gene technology and undifferentiated stem cells to 
produce artificial p-cells, which on implantation would, in theory, regulate blood 
glucose constantly. Before these therapies are possible however, it is necessary to 
have a full understanding of the in vivo processes such as the development of fetal 
pancreata, specification of islet cell types and regulation of insulin synthesis and 
secretion in response to metabolic signals.
The purpose of this study is to investigate the possibility of generating endocrine 
tissue from undifferentiated embryonic carcinoma (EC) cells (F9), and to monitor the 
events dictating cell fate determination. Also the generation of human insulin 
secreting cell lines from BHK21 cells through direct genetic manipulation is 
examined. It is hoped that the results outlined here will add to the understanding of 
the issues surrounding the generation of artificial p cells and thus may lead to the 
development of cells that could maintain normoglycemia following transplantation 
into a diabetic host.
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1.1 Development of Fetal Pancreata
The pancreas is a pinkish tan organ and is divided in to four regions: the head, neck, 
body and tail (Bockman, 1993). Study of the development of the pancreas is of 
interest due to its unusual property of being both an exocrine and endocrine gland, and 
also, to understand the events surrounding its organogenesis. This knowledge will be 
necessary to generate fully functional replacement tissue for diabetes treatment in the 
future. To achieve this, a full understanding of the extrinsic and intrinsic factors 
employed in p cell specification is required, and also the identification of a catalogue 
of markers to correctly distinguish p cell-producing stem cells.
1.1.1 The Origins of the Fetal Pancreas
Embryonic cells arrange themselves in to three ‘layers’ known as the primary germ 
layers, the ectoderm, the mesoderm and the endoderm. The digestive tract of the 
embryo originates from the endodermal germ layer (Edlund, 2001; Kim & Melton, 
1998; Madsen et al., 1996). Within the developing embryo the dorsal mesenchyme 
condenses and evagination of the foregut occurs on about day 11 of gestation (20-22 
somites) (Githens, 1993; Kim et al., 1997). This region of the embryonic gut is 
composed of two ‘buds’ known as the dorsal and ventral buds. These buds grow, 
branch and later fuse to form the vertebrate pancreas (Edlund, 2002). The vertebrate 
pancreas consists of exocrine acinar cells that synthesise digestive enzymes, and the 
branched ductal epithelium which secretes the enzymes in to the intestine. The 
endocrine portion of the pancreas is much smaller (Bishop & Polak, 1991; Madsen et 
al., 1996), and consists mainly of four types of hormone secreting cells (a, P, 8 and 
PP cells) in clusters called islets (the Islets of Langerhans) (Bishop & Polak, 1991).
1.1.2 Initiation of Pancreatic Organogenesis
The early commitment of the region of the embryonic gut to initiate dorsal and ventral 
budding is not well understood, i.e. how a single layer of epithelial cells in the foregut 
is instructed to commence organogenesis. It is known that the region of the gut that 
subsequently becomes the pancreas expresses the transcription factor PDX1
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(discussed separately in Section 1.1.3.5.1), and that m ice and humans lacking this 
gene do not form a pancreas (Jonsson et al., 1994; Stoffers et al., 1997). However this 
factor must act downstream o f  the initial commitment signal as apancreatic m ice 
(P D X l7") still form the pancreatic buds and the appearance o f  early pancreatic 
markers is unaffected (Kim et al., 1997; Edlund, 1999). The observation that in vitro 
culture o f  embryonic endodermal tissue with exogenous mesenchymal tissue can lead 
to the formation o f  dorsal buds (Ahlgren et al., 1997), infers that there are intrinsic 
determinants within this region o f  the gut for its eventual fate.
1.1.2.1 Hedgehog Signalling and Initiation of Pancreatic Organogenesis
Sonic H edgehog (Shh) and Indian H edgehog (Ihh) are expressed in regions o f  the gut 
endoderm except where the dorsal and ventral buds form and can almost describe a 
molecular boundary between pancreas and stomach/duodenal analgen. Repression o f  
Shh expression, using the steroid alkaloid teratogen cyclopam ine, can lead to ectopic 
pancreatic development in the stomach and intestine (Kim & M elton, 1998). The 
repression o f  hedgehog gene expression can also be used to explain why only a 
restricted region o f  P D X l expressing foregut actually goes on to form the dorsal and 
ventral buds.
1.1.2.2 Implications for Notochord Repression in Pancreatic Development
The region o f  the foregut destined to becom e the dorsal pancreatic bud is in direct 
contact with the notochord (the notochord is a flexible structural organ that runs the 
length o f  the body. This is the organ from which vertebrae evolve), at the period when  
pancreatic commitment occurs (Kim  et al., 1997). Rem oval o f  the notochord from  
embryonic m ice just prior to the time when pancreatic fate is specified prevents 
expression o f  P D X l and Is ll (crucial for dorsal m esenchym e formation, (Ahlgren et 
al., 1997); Section 1.1.3.5.4), and the dorsal bud does not form. The ventral bud is 
unaffected by this change (Kim et al., 1997). The notochord appears to function 
through the release o f  notochord factors such as activin PB and FGF2. These factors 
were found to repress Shh expression thus allow ing normal morphogenesis (Section
1.1.2.1). Rem oval o f  the notochord allow ed Shh expression and prevented induction
5
o f  the genes required for pancreatic differentiation. Similarly, culture o f  midline 
endoderm from the pre-pancreatic region o f  the gut with isolated notochord resulted 
in the generation o f  cells expressing PDX1 and insulin (Hebrok et al., 1998). These 
experiments were carried out in chick endoderm; however, in similar experiments 
using murine tissue, recombination o f  dorsal endoderm with exogenous notochord 
generated PDX1 expressing cells only (i.e. insulin expression was not present) 
(Edlund, 2002). This may reflect either differing mechanism s between chick and 
m ouse differentiation or contamination o f  the chick cultures with endothelial cells 
which would have supported the differentiation o f  insulin expressing cells (Lammert 
et al., 2001). W hile the notochord related effects on dorsal bud formation are clear, it 
is not known how  Shh is repressed in the pre-ventral bud region. In fact FGF2 had a 
negative effect on endocrine development in the ventral bud (Deutsch et al., 2001). 
Therefore, ventral bud differentiation and dorsal bud differentiation appear to involve 
different initiation signals.
1.1.2.3 Mesenchymal Effects on Pancreatic Organogenesis in the Developing 
Embryo
M esenchym al tissue surrounding the dorsal pancreatic bud expresses Is ll (a LIM  
hom eodomain protein (Section 1.1.3.5.4)). I s l- l7' null mutants fail to form dorsal 
m esenchym e and thus do not form the dorsal pancreatic bud. The expression o f  
P D X land  Beta2 in I s l l7" m ice (Ahlgren et al., 1997), however, indicates that Isll 
expression and thus m esenchym al factors are not the initiator signals for embryonic 
foregut commitment and should be considered as permissive factors required to 
facilitate proper development.
M esenchym al effects on pancreatic dorsal bud formation are effected through the 
release o f  soluble factors. This was demonstrated by the observation that mesenchyme 
could induce differentiation across a millipore filter (G olosow  & Grobstein, 1962). 
These m esenchymal secretions appear to be involved in regulating the relative 
proportions o f  endocrine versus exocrine tissue in the developing pancreas by 
repressing endocrine development. Follistatin could duplicate these effects and has 
been shown to be present in embryonic pancreatic m esenchym e (Miralles et al.,
1998),
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HGF secretion has also been implicated in the m esenchymal effects on developing 
islets and the HGF receptor (the c-met protooncogene) is expressed in both 
developing and mature P cells. HGF has been shown to have m itogenic action on 
developing p cells. However, this was accompanied by a decrease in insulin content 
(Otonkoski etal, 1996).
1.1.2.4 Homeobox Hlxb9 and Pancreatic Development
Although the effects o f  Shh expression and signalling through the notochord and 
mesenchymal layer are understood, the early events in the morphogenesis o f  the 
pancreatic buds are still unclear. Hlxb9 (encodes Hb9 protein), is a hom eobox gene 
that is transiently expressed in the regions o f  the gut that commit to pancreatic 
morphogenesis and is later restricted to the P cells (Li el al., 1999). These 
investigators noted that m ice lacking this gene did not form a dorsal pancreas and 
although the ventral pancreas was present, its organisation was disrupted. Phenotypic 
comparisons o f  Hlxb9 and PDX1 deficient m ice do indicate that the role o f  Hb9 is 
upstream from PDX1. W hile the actual role o f  Hb9 is unknown there are three 
possible explanations as to its function and distribution in the developing pancreas:
(I) Expression o f  Hlxb9 confers a com petence to that region o f  the foregut to 
respond to subsequent signals to initiate pancreatic morphogenesis.
(II) The ventral function o f  Hb9 is compensated by a gene product with similar 
activity.
(III) Expression o f  Hlxb9 in the gut epithelium is not as important as its reported 
expression in the notochord at an early stage, thus it is possible that the actions 
o f  Hb9 may be to regulate notochord secretions involved in 
activating/repressing pancreatic determinants. H owever, this is unclear 
follow ing observations that Hlxb9 mutants exhibit normal Ihh/Shh restrictions; 
thus, Hb9 does not appear to affect this aspect o f  developmental control (Li el 
a l,  1999)).
(Edlund, 1999).
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1.1.2.5 HNF 3p/Foxa2 Expression and the Developing Pancreas
HNF-3p or Foxa2, a member o f  the forkhead/winged fam ily o f  transcription factors, 
is expressed in the notochord and gut o f  m ouse embryos and knockout animals die in 
utero due to the lack o f  a notochord which leads to defects in the patterning o f  the 
neural tube (Monaghan et al, 1993; A ng & Rossant, 1994; W einstein et al, 1994). 
Foxa2 is expressed throughout the fetal gut (including the region that evaginates into 
the pancreatic buds) and is w idely expressed in islet and acinar cells (Monaghan et al, 
1993; Cockell et al, 1995; Wu et a l, 1997). The importance o f  Foxa2 is that it is 
involved in the regulation o f  pancreatic genes such as a  amylase (Cockell et al., 1995) 
and, more significantly, PDX1 where it also contributes to tissue specific expression 
(Sharma et al, 1997; W u et al, 1997). D ue to the lethality o f  Foxa2v' mutants, when  
the cre-lox system was em ployed to disrupt its expression in pancreatic p cells the 
animals had significantly reduced PDX1 levels (Lee et al, 2002). This places Foxa2 
upstream o f  PDX1 in pancreas developm ent which infers that this is the key regulator 
o f  pre-pancreatic gut development.
1.1.2.6 Pancreatic Stem Cells?
The adult pancreas does have limited regenerative ability follow ing partial 
pancreatectomy or injury (Lehv & Fitzgerald, 1968; Pearson et al., 1977; Bouwens, 
1998b). The regeneration appears to stem from activation o f  cells within the ductular 
region o f  the pancreas (W ang et a l, 1995; Bonner-Weir et a l, 2000). This suggests 
that cells exist w ithin the pancreas that can be called upon to differentiate when 
needed, these cells would have to be able to propagate in vivo in the undifferentiated 
state until required. Such proliferating cell lines have been generated from duct 
epithelial cells (Tsao & Duguid, 1987). However there is also the possibility that the 
regenerated tissue is as a result o f  transdifferentiation o f  fully differentiated cells 
within the pancreatic ducts (Bouw ens, 1998b; Rosenberg, 1995). Differentiation o f  
the embryonic pancreas has m any similarities to neuronal differentiation (Edlund,
1998) and critical transcription factors involved in endocrine differentiation are also 
required for neuronal differentiation e.g. I s ll, N euroD l, N kx2.2 and Pax6 (Edlund,
1999). This seem s to imply a com m on origin for pancreatic and neuronal tissue. This
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theory is som ewhat validated follow ing a study whereby the SV40 T antigen under 
the insulin gene regulatory control was found to be transiently expressed in the neural 
tube and crest o f  embryonic transgenic m ice (Alpert et al., 1988). Insulin II mRNA  
transcripts have also been identified in the developing rat CNS (Devaskar et al.,
1993). Thus it was unsurprising to discover the presence o f  nestin (an intermediate 
filament protein expressed in undifferentiated neuronal progenitor cells during the 
developm ent o f  the CNS) in a subset o f  hormone negative cells o f  the pancreas 
(Zulewski et al., 2001). These nestin positive cells were found to be capable o f  
differentiating towards endocrine, exocrine and hepatic phenotypes. In a similar study 
by Lum elsky et al., (2001) a protocol to promote and purify nestin expressing cells 
from undifferentiated stem cells was used and these cells could be differentiated in to 
insulin expressing cells. It is unlikely however, that these ES derived cells are truly 
representative o f  pancreatic stem cells due to their lack o f  PDX1 expression. Ramiya 
et al., (2000) identified duct epithelial cells (in m ice) as pancreatic stem cells and 
generated islet-like structures follow ing long term cultures o f  these cells. However, 
these ‘adult stem ce lls’ are not necessarily the same cells as those initial epithelial 
cells that derived all the pancreatic cell types and probably represent a population o f  
pre-committed cells.
Thus the identity or even existence o f  pancreatic stem cells in the developing gut 
epithelium  remains unclear.
1.1.3 Development of the Pancreatic Endocrine Cell Types
The pancreas contains exocrine, endocrine and ductal cells which are all originally 
derived from the same region o f  gut epithelium in the developing embryo. The 
developm ent o f  the individual cell types and the order o f  their appearance is o f  major 
importance for the understanding o f  developmental b iology and also for 
implementation o f  this information for the generation o f  replacement tissue for 
diabetes treatment. This study is m ostly concerned with the development o f  the 
endocrine pancreas thus the developm ent o f  the four main cell types o f  endocrine 
islets are more closely examined.
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1.1.3.1 The Cell Types Within the Islet
The endocrine islets comprise only 1-3% o f  the whole pancreatic mass (Bishop & 
Polak, 1991; M adsen et ah, 1996). There are four main endocrine cell types within the 
pancreatic islet i.e. the a  cells, which secrete glucagon and comprise 15-20% o f  the 
cells in the islet; insulin secreting |3 cells (P cells also secrete small amounts o f  IAPP) 
account for 60-80 % o f  the islet cell mass; the 8 cells (5-10%  o f  the islet) synthesise 
somatostatin (and som e IAPP); and the pancreatic polypeptide producing PP cells  
make up <  2% o f  the total cell m ass (Edlund, 2002). Insulin is released following  
feeding and subsequent increases in blood sugar, the insulin released causes the 
uptake o f  blood sugar by the tissues o f  the body e.g. muscles. Insulin also inhibits 
glucose production in the liver (Hardie & Cohen, 1991). Glucagon is released in 
conditions o f  low  glucose and promotes gluconeogenesis. Somatostatin and pancreatic 
polypeptide are inhibitors o f  endocrine and exocrine secretion (Kreymann & Bloom , 
1991).
1.1.3.2 Chronological Appearance of the Islet Cell Types
Numerous studies have been carried out on the development o f  islet cell types with an 
aim to discovering the progenitor cells that give rise to mature endocrine cells, 
especially P cells. The data obtained suggests that p cell turnover (especially  
fo llow ing injury) is facilitated by the differentiation o f  a precursor cell-type, due to 
the very low  rate o f  proliferation o f  P cells (Bouwens et al., 1997; Polak et al., 2000).
RT-PCR analysis o f  m icrodissected m ouse embryos indicates that the induction o f  the 
hormone gene expression occurs even before evagination o f  the foregut to form the 
dorsal and ventral buds. In this study, Gittes & Rutter (1992), discovered that 
somatostatin RNA was initially detectable, follow ed by glucagon and insulin. PP 
transcripts were not detected until the dorsal and ventral buds were undergoing fusion 
to form the pancreas.
Immunohistochemical studies have revealed that during islet development the 
pancreas evolves from a position o f  hormone-negativity to the eventual secretion o f
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the four endocrine hormones. The order o f  appearance o f  immunoreactive hormone 
protein is different however from the appearance o f  their m RNA transcripts. Using  
immunohistochemistry, insulin and glucagon expressing cells are the initial endocrine 
cells detected and, while exclusive glucagon expressing cells are present at this stage 
(embryonic day 9.5; E9.5), all o f  the initial insulin expressing cells co-express 
glucagon (Teitelm an et al, 1993). Somatostatin is not detected until much later and 
PP is only imm unohistochem ically detectable after birth (possibly due to the fact that 
there are fewer cells o f  this type in the developing pancreas, therefore the making the 
protein more difficult to detect). Earlier reports o f  PP expression prior to the other 
islet hormones (Herrera et al., 1991) is likely to be as a result o f  cross reaction o f  the 
PP antibody with PYY (Upchurch et al., 1994) which is expressed early in the 
developing islet (Section 1.1.3.3).
1.1.3.3 Co-expression of Endocrine Hormones During Islet Cell Development
Peptide Y Y  (PYY ) is a pancreatic and intestinal hormone that can be found in 
glucagon expressing cells in pancreatic islets. Studies using the SV40 large T antigen 
under the regulatory control o f  the PY Y  gene revealed that this peptide is co­
expressed in all four lineages o f  the developing m ouse pancreas. In fact it was 
hypothesised that the earliest endocrine cell in the pancreas is a 
PY Y +/Insulin+/Glucagon+ expressing cell (Upchurch et al., 1994). In mature 
pancreata, PYY is only found in a subset o f  a  cells, 8 cells and PP cells. Similar data 
was presented for m ice by Teitelman et al. (1993); however this study suggested that 
neuropeptide Y  (NPY ) was co-expressed in the early endocrine progenitors. It is 
likely that the N P Y  antibody cross reacted with the closely related PY Y  peptide. As 
already indicated, the earliest insulin expressing cells co-express glucagon, studies 
using human fetal islets demonstrated that these cells also co-express somatostatin 
(measured at 8 weeks o f  development). W ithin one w eek however, the co-expression  
o f  hormones was much reduced and cells expressing only insulin could be detected 
(Polak et al., 2000).
Mature islet cells do not tend to co-express any o f  the other four main islet hormones. 
This co-expression at the early stages o f  developm ent is likely to be a result o f  the
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initial activation o f  key regulatory factors resulting in non-specific hormone 
expression. As the pancreas differentiates, selective activation/inactivation o f  
regulatory m olecules leads to mature endocrine cells expressing a single hormone 
(M adsen et al., 1996). It has been suggested that cells co-expressing multiple 
hormones represent progenitor cells that can segregate into the individual endocrine 
cell types (Alpert et al., 1988, Teitelman et al., 1993). This hypothesis is disputed by a 
number o f  observations including the fact that the insulin/glucagon/PYY co­
expressing cells were found to have a high level o f  D N A  synthesis w hile newly  
derived insulin cells do not (Jackerott et al., 1996). The multihormonal cells were also 
found largely negative for the hom obox proteins PDX1 and N k x6 .1 which are crucial 
for p cell development (Larsson, 1998).
1.1.3.4 The Origins of P Cells in the Developing Pancreas
Over time, typical islets develop to a mature state consisting o f  a rim o f  glucagon 
expressing cells surrounding the insulin positive cells. The co-expressing  
glucagon/insulin cells are typically found to be more associated with the glucagon  
expressing cells and becom e far fewer in number as the islet develops. (It is possible 
that these cells are progenitors o f  a  cells rather than p cells (Larsson, 1998). However 
Herrera (2002) presented data whereby it appeared that glucagon expressing a  cells in 
the developing m ouse arose from PDX1 expressing, hormone-negative cells. This 
disputes other observations whereby disruption o f  PDX1 expression in cultured rat 
islet cells led to increased numbers o f  a  cells (Wang et al., 2001)). The appearance o f  
the insulin-only expressing cells occurs during a phase known as the secondary 
transition o f  pancreatic development. These insulin+/+ cells initially appear in the 
parenchyma in the vicinity the glucagon and glucagon/insulin expressing cells. It is 
postulated that the insulin-only cells are as a result o f  differentiation o f  the hormone 
negative parenchymal cells (which do however express critical P cell transcription 
factors e.g. PDX1 and N k x6 .1). Potential signalling m olecules to induce this transition 
include the TGFp superfamily ligand activin, which together with m itogens such as 
betacellulin or HGF (Larsson, 1998), has been shown to be capable o f  inducing p cell 
neogenesis in vitro from hormone negative AR42J cells (Mashima et al., 1996a,b).
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GLUT2 is a critical component in the glucose sensing apparatus o f  p cells and 
although it has widespread expression in fetal and adult tissues, it is restricted to [3 
cells in the pancreas. Immunohistochemical monitoring o f  GLUT2 expression in the 
developing pancreas indicates that exclusive insulin expression occurs initially within 
GLUT2 expressing cells in the ductal network. These GLUT2/Insulin cells were 
found to aggregate in to the (3 cell m asses o f  the islets o f  Langerhans (Pang et al.,
1994).
1.1.3.5 Endocrine Cell Determination Through the Expression of Transcription 
Factors
P cell neogenesis is a com plex process and direct monitoring o f  immunoreactive 
hormones has often led to confusion and contradictory data. A s already indicated in 
Section 1.1.2, transcription factors such as PDX1 play an important role in the 
determination and maturation o f  the islet cells o f  the pancreas. A  selection o f  the most 
significant (usually determined by the effects in knockout m ice) are discussed below. 
The cascades and interrelationships o f  the transcription factors are summarised at the 
end in Figure 1.1.1
1.1.3.5.1 PDX1 Expression in the Developing Pancreas
PDX1 was initially identified as a p cell transcription factor in studies with m ouse p 
and a  cell tumours, when it was shown to be present only in the p cells (Ohlsson et 
al., 1991). PDX1 was first cloned by Ohlsson et al., (1993), (who called it IPF1, 
Insulin Promoter Factor 1). The rat version was cloned soon after by two groups and 
called somatostatin transactivating factor (STF1) (Leonard et al., 1993) or islet 
duodenal hom eodomain protein (ID X1) (M iller et al., 1994). PDX1 (pancreatic 
duodenal hom eodom ain protein) has been proposed as the official term for this gene 
in m ice by the International Committee on Standardisation o f  Genetic Nomenclature 
for M ice and is used throughout this thesis.
A s indicated earlier (Section 1.1.2.2), FGF2 and activin PB are secreted from the 
notochord in contact with the region o f  the gut epithelium destined to evaginate in to
13
the dorsal pancreas (Hebrok et al., 1998; Kim & M elton, 1998). This facilitates PDX1 
expression through the concomitant repression o f  Shh expression. In early 
development, PDX1 is expressed in the ductular regions o f  the pancreas, the exocrine 
cells and in the endocrine cells. As the pancreas develops however its expression 
becom es more restricted to (3 cells and to a portion o f  5 cells (10-20% ) (Ohlsson et al, 
1993; M adsen et al., 1996; Carty et al., 1997; Serup et al., 1995; 0ster  el al., 1998).
The critical importance o f  PDX1 to pancreatic development is clear from clinical and 
knockout studies. Pancreatic agenesis (lack o f  a pancreas) in a patient hom ozygous for 
a point mutation in the PDX1 coding region was attributed to the lack o f  expression o f  
functional PDX1 (Stoffers et al., 1997). Transgenic m ice hom ozygous for a targeted 
mutation o f  the PDX1 gene lack a pancreas; although the mutation is not lethal in- 
utero, the pups died soon after birth (Jonsson et al., 1994). Using the CRE-Lox 
system, Ahlgren and collegues (1998) specifically disrupted PDX1 in the (3 cells. 
These pups were normal at birth and remained so for 3-5 months. At this point all 
animals were overtly diabetic. Analysis revealed that 17% o f  the insulin positive cells  
still co-expressed PD X1, however the total number o f  insulin positive cells was 60% 
lower than in normal animals (Ahlgren el al., 1998). Further analysis revealed that the 
number o f  a  cells was increased and that there were insulin/glucagon co-expressing 
cells in the mutant pups. U sing clonal populations o f  the rat INS-1 cell line it was 
shown that to promote a  cell differentiation in the transitory Insla(3 population, 
PDX1 expression had to be eliminated. Overexpression o f  the a  cell differentiation 
marker Brain4 did not have the same effect (W ang et al., 2001). Thus PDX1 appears 
to be a fate determinant between a  and p cells in the pancreas. Expression o f  P cell 
specific genes is also dependent on PDX1 levels, e.g. pancreatic GLUT2 expression  
was non-existent when PDX1 was specifically knocked out o f  p cells. The role o f  
PDX1 in GLUT2 transcription is dose-dependent as shown by GLUT2 levels in 
heterozygous (PD X 1+/ ) animals and thus may be also implicated in the poor glucose  
sensing associated with Type II diabetes (Ahlgren et al., 1998; Ramirez & Raskin,
1991).
In summary there appears to be two related but separate functions o f  PDX1 in the 
developing pancreas, i.e. (I) to aid in determination o f  which region o f  the gut
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epithelium will evolve in to a pancreas (global activity) and (II) as a P cell 
determinant through positively regulating p cell genes such as insulin and GLUT2. 
The specific p cell role o f  PDX1 in determining p cell fate follow s preliminary cell 
fate determination which is controlled by the N otch signalling pathway (reviewed  
separately Section 1.1.3.5.2). It is interesting to note that while monitoring PDX1 
expression, another p cell transcription factor was identified that had very similar 
expression patterns i.e. N k x 6 .1. PDX1 was seen to activate N k x6 .1 (0ster  et al., 1998; 
Ahlgren et al., 1998) and it is suggested that N k x6 .1 may mediate some o f  the effects 
o f  PDX1. Transfection experiments have shown that although PDX1 expression can 
stimulate insulin gene expression (and thus direct a cell towards a p cell type), it is not 
always the case and depends on the co-expression o f  Beta2 to exert its effects (Serup 
et al., 1996; M adsen et al., 1996; M adsen et al., 1997). Based on this it is likely that 
the effects o f  PDX1 are mediated through, or at least require, the co-operation o f  other 
gene products such as Beta2, Nkx6.1and Pax6 (M adsen et al., 1997).
1.1.3.5.2 Ngn3 Expression and Notch Signalling in Specifying Pancreatic Cell 
Fate
The development o f  individual cell types from a relatively hom ogenous initial cell 
population can be executed through a process known as ‘lateral specification’ 
(Edlund, 1999), which is controlled by the N otch signalling pathway. The appearance 
o f  scattered differentiated endocrine cells within a field o f  progenitor cells is 
indicative o f  lateral specification (Apelqvist et al., 1999), thus the Notch signalling  
pathway appears to dictate cell fate follow ing initial pancreatic determination. Notch  
is a transmembrane receptor and Delta is its transmembrane ligand. Ngn3 is a bHLH  
protein that stimulates expression o f  D elta and pushes cells towards an endocrine fate 
through its effects on p cell differentiation factors such as Beta2 (Huang et al., 2000). 
Stimulation o f  Notch by a Delta-expressing neighbouring cell causes the expression o f  
H esl (another bHLH protein), which inhibits Ngn3 (Lee et al., 2001). Thus a cell that 
is undergoing endocrine fate specification through Ngn3 actively inhibits its 
neighbours from taking the same fate (Edlund, 1999; M e Kinnon & Docherty, 2001). 
A s differentiated endocrine cells form they are seen to migrate into the adjacent 
mesenchyme. This removal o f  differentiated (Delta expressing) cells thus allows
15
further differentiation o f  endocrine cells through a decrease in Notch signalling and 
facilitates the formation o f  islet structures (Edlund, 2001).
N otch signalling in endocrine differentiation can be studied through the disruption o f  
the signalling by creating transgenic m ice deficient in Delta-like gene 1 (Delta) or 
similarly through overexpressing Ngn3 (by placing it under the control o f  the PDX1 
promoter). These transgenic m ice were found to have poorly developed pancreatic 
buds primarily consisting o f  differentiated endocrine cells. The islet cells produced 
were predominantly a  cells, which may indicate that this is the default pathway in 
endocrine differentiation (Schwitzgebel et al, 2000; Ritz-Laser et al, 2002). The poor 
developm ent and small size o f  the dorsal and ventral buds was as a result o f  premature 
differentiation o f  the progenitor cell population to the slower proliferating endocrine 
cells. Exocrine differentiation was totally disrupted in these animals (Apelqvist et al,
1999).
These observations regarding Ngn3 led to interest in Ngn3'/_ knockout mutants, which  
died from diabetes due to the total lack o f  endocrine cells in the pancreas. Ngn3 is 
present transiently in hormone negative cells just prior to the appearance o f  endocrine 
cells, and it is proposed that Ngn3 is a likely candidate for a marker o f  the endocrine 
progenitor cell (Gradwohl et al., 2000; Schwitzgebel et al., 2000). These Ngn3+ cells 
also co-express the proliferation marker Ki-67 which is in keeping with their proposed 
role as self-replicating progenitor cells (Jensen et al., 2000).
1.1.3.5.3 Beta2 Expression in Developing Islet Cells
Insulin enhancer factor 1 (IEF1) (Section 1.2.1.2) was discovered due to its 
enhancement o f  insulin gene transcription in rats (Walker et al., 1990). IEF1 was 
found to be a heterodimer o f  Beta2 (also known as N euroD l, and is a novel bHLH  
protein (Naya et al., 1995)) and the E2A gene product, the ubiquitous bHLH proteins 
E12/E47. This com plex is important for insulin gene transcription (Dum onteil et al., 
1998; Glick et al., 2000). Beta2 expression is detected early in the developing  
pancreas and is one o f  the first genes induced by Ngn3 follow ing notch based entry to 
endocrine differentiation (Huang et al., 2000; Jensen et al., 2000; Gradwohl et al.,
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2000; Apelqvist et al, 1999). Transgenic m ice w ith disrupted Beta2 genes died 
perinatally from severe diabetes due to a significant reduction in (3 cell numbers and 
improperly formed islets. These results indicate that Beta2 plays a role in islet 
morphogenesis (Naya el a l, 1997). Islet morphogenesis has been found to be 
dependent on the presence o f  neural cell adhesion m olecule (N-CAM ), as m ice  
deficient in this m olecule have disrupted islets (Esni el a l, 1999). However, N aya and 
collègues report that N -CA M  expression is not affected in Beta2-disrupted mutants. 
Thus there may be novel CAM s that are affected by the loss o f  Beta2 or possibly  
other known CAM s, it is known for instance that Ep-CAM  expression is also 
implicated in islet organisation in the developing pancreas (Cirulli et al, 1998).
Thus Beta2 expression facilitates correct spatial organisation o f  the developing islet. It 
is also important in specifying p cell-type determination, i.e. PDX1 mediated 
induction o f  insulin gene expression, and subsequent transcription o f  the insulin gene, 
is impaired without the presence o f  Beta2 (Serup el a l,  1995; Serup et al., 1996; 
M adsen et al., 1996; Ohneda et al., 2000).
1.1.3.5.4 Isll Expression in Developing Islet Cells
The insulin gene transcription factor/endocrine determinant Is ll (Islet 1), is a LIM  
homoedomain protein and is involved in lineage determination o f  pancreatic 
endocrine cells (Karlsson et al., 1990). Isll is expressed in the mesenchymal cells that 
surround the dorsal bud o f  the embryonic gut. M ice engineered with a disrupted Isll 
gene were found to lack dorsal mesenchymal cells and therefore did not form a dorsal 
pancreas. The ventral exocrine cells were found to be present, however there was a 
com plete lack o f  differentiated endocrine tissue. Exocrine differentiation in the dorsal 
bud was recoverable by exposing the dorsal évagination to w ild type m esenchymal 
cells  (Ahlgren et al., 1997). The importance o f  m esenchymal secretions in the 
developing pancreas has already been discussed in Section 1.1.2.3, and it is 
noteworthy that fetal m esenchym e can cause islet neogenesis when co-cultured with 
pancreatic ductal epithelium or when they are co-transplanted into nude m ice (Dudek 
& Lawerence, 1988; Dudek et al., 1991).
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Is ll has been shown to act downstream o f  Beta2 in the transcription factor cascade 
towards endocrine cells (Ahlgren et al, 1997; Jensen et al, 2000).
1.1.3.5.5 Pax6 Expression in Developing Islet Cells
Pax genes are members o f  the paired-box fam ily o f  genes which encode nuclear 
transcription factors. Pax genes are involved in the development o f  a number o f  
organs in the body including the eyes, brain, kidney, immune system and the pancreas 
and a number o f  genetic disorders are as a result o f  Pax gene mutations (Dohrmann et 
al, 2000). During m ouse embryogenesis, Pax6 is w idely expressed in developing 
embryos including the eyes, nose, CNS and pancreas.
Pax6 expression can be initially detected in a subset o f  cells throughout the 
development o f  the dorsal and ventral buds. Pax6 is restricted to the islets in newborn 
animals where it is expressed in the four main pancreatic cell types. Knockout animals 
(Pax6'A) were found to have a similar phenotype to the naturally occurring small eye 
mutant animals, SeyNcu (these animals lack eyes due to point mutations in the Pax6 
gene). A ll islet hormones were expressed with the exception o f  glucagon and the 
hormone producing cells were disorganised (St-Onge et al., 1997). Thus Pax6 is 
critical in a  cell differentiation and has a role in the organisation o f  the islets. A  study 
o f  hom ozygous mutants found that all Sey^011 animals had decreased numbers o f  all 
four hormone producing cell types, however a  cells were the most seriously affected  
(Sander et al., 1997). Again there were structural abnormalities in the organisation o f  
the islet; how ever the mechanism for this disruption was unclear. The N-CAM  
promoter is a known target o f  Pax6. N-CA M  levels, however, were unaffected in 
Sey1^ 11 animals (Sander et al., 1997). This is similar to results obtained from Beta2 
disrupted animals (Section 1.1.3.5.3) and again raises the possibility o f  a novel 
cadherin/CAM involved in structural organisation o f  the islet e.g. E-cadherin (E- 
CAD) has been shown to be important in spatial organisation o f  M in6 generated 
pseudoislets (Hauge-Evans et al, 1999). The reduction in hormone levels in SeyNeu 
animals may be due in part to transcriptional effects. Pax6 binding sites are present on 
the promoter sequences o f  insulin, glucagon and somatostatin (Sander et al., 1997).
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1.1.3.5.6 Pax4 Expression in Developing Islet Cells
Pax 4 is also a member o f  the paired box family o f  transcription factors. The 
expression o f  Pax4 is far more restricted than that o f  Pax6 in the embryo (i.e. Pax4 
has been detected in a few  cells in the ventral spinal cord and in the developing  
pancreas) (Dohrmann et ah, 2000). M ice with disrupted Pax4 genes were found to 
lack insulin- and somatostatin-expressing cells and the animals died within a few  
days. The knockout m ice had an abundance o f  a  cells, however (Sosa Pineda et ah,
1997). This suggests that Pax4 may be important for pushing cells towards p and 8 
lineages and away from what may be possibly the ‘default’ a  cell differentiation 
pathway (Schwitzgebel et ah, 2000; Ritz-Laser et ah, 2002). W hen ectopically  
expressed in a  cells, the m ode o f  action o f  Pax4 in diverting the default a  cell 
differentiation may be related to its inhibition o f  glucagon gene expression through 
com petitively binding Pax6 sites within the promoter region (Ritz-Laser et ah, 2002). 
This action restricts glucagon expression to a  cells in the pancreas.
Interestingly a double knockout o f  Pax4 and Pax6 resulted in the complete lack o f  
endocrine hormone production (St-Onge et ah, 1997).
1.1.3.5.7 Nkx6.1 Expression and Islet cell Determination
Nkx6.1 is a hom eodomain transcription factor (a member o f  the NK2 hom eobox  
transcription factor fam ily) that is specifically expressed in p cells in the endocrine 
pancreas (Jensen et ah, 1996). Nkx6.1 is initially detected with PDX1 in parenchymal 
cells during early developm ent (however this only represents a subset o f  PD X 1+ 
cells), and as the pancreas develops both factors becom e progressively more islet/p  
cell specific. In fact the PD X1/Nkx6.1 co-expressing parenchymal cells have been  
identified as possible P cell precursors within the developing pancreas (0ster et ah, 
1998; Larsson, 1998).
Preliminary data indicates that Nkx6.1 knockout m ice lack any insulin expressing 
cells (Edlund, 1998).
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1.1.3.5.8 Nkx2.2 Expression and Islet cell Determination
N kx2.2 is also a member o f  the NK 2 fam ily o f  transcription factors present in the 
developing pancreas (and in the developing CNS). N kx2.2 expression can be found in 
the developing dorsal pancreatic bud and it is widespread in the early stages o f  the 
pancreas. A s the pancreas specialises and develops distinct endocrine cells and 
exocrine cells, Nkx2.2 expression can be found associated with m ost endocrine cells. 
In fact N kx2.2 is present in all insulin producing cells, 80 % o f  a  cells and most PP 
cells. But it is com pletely absent from 8 cells. Knockout studies (Nkx2.2 '') resulted 
in m ice that developed severe diabetes within a few  days o f  birth due to the total lack 
o f  (3 cells, a  cell numbers were also reduced as were PP cells, 8 cells were unaffected 
by the absence o f  Nkx2.2. There were large numbers o f  hormone negative cells  
expressing (3 cell markers (IAPP and PD X 1) in the N kx2.2 knockout m ice (Sussel et 
al., 1998). From this it appears that N kx2.2 is not directly involved in the early stages 
o f  J3 cell development (due to the expression o f  other (3 cell markers e.g. N kx6.1), but 
that its absence prevents insulin expression possibly due to a role in final maturation 
o f  the P cell. PDX1 expression w as present in reduced amounts in the knockout m ice  
(Sussel et al., 1998) and this may account for the lack o f  final maturation o f  the P 
cells.
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Figure 1.1.1 Summary o f the transcription factor involvement in islet cell specification and the order in 
which they appear. (+) indicates that a factor is ‘on’ and (-) indicated it is ‘o ff .
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1.1.4 Monitoring Pancreatic Differentiation Through Cytokeratin Expression
Cytokeratins are classed among the intermediate-sized filaments o f  the eukaryotic 
cytoskeleton and show cell-type specific expression. There are more than 20 types o f  
cytokeratins and they are classed as type I (9-20) and type II (1-8). As the expression  
o f  pairs o f  type I and type II cytokeratins is relatively tissue specific, this makes them  
a useful tool in the study o f  differentiating systems. Cytokeratins (CKs) are 
imm unocytochem ical markers o f  epithelial cells (Bouwens, 1998a).
The pancreas is com posed o f  sim ple epithelial cells that generally show two 
combinations o f  CK expression. The exocrine ducts usually contain CK’s 7 and 19 
(Bouwens et a l,  1994), while CK’s 8 and 18 are present in the exocrine acinar cells, 
duct cells and in the endocrine islets o f  Langerhans (Bowens, 1998a). Rat pancreata 
also contain CK20 as a potent marker for precursor cells but CK20 is absent in mature 
endocrine cells (Bow ens et al, 1994; B ow ens & D e Blay, 1996).
Specific imm unohistochem ical CK markers for duct, endocrine and mesenchymal 
cells have been employed in studies to fo llow  islet morphogenesis in developing  
pancreata. In the human fetus all epithelial cells initially express CK19 and CK7 
(Bouwens et a l, 1997; Kasper et a l,  1991). The loss o f  expression o f  these CKs is 
progressive with increasing differentiation, leading to a stage where the islets do not 
express these markers and the ducts stain positively for them. The expression o f  these 
markers is paralleled by proliferation marker expression (e.g. K i-67) demonstrating 
that while the ducts retain their ability to proliferate and grow, the islets have limited 
proliferative ability (Bouw ens et a l,  1997).
Cytokeratin-based identification o f  tissues must be considered as preliminary and 
requires additional knowledge o f  other markers for positive identification, e.g., in rats 
the liver has a similar cytokeratin profile to the pancreas i.e., the bile ducts are 
positive for CKs 7, 19 & 20 w hile the hepatocytes express CKs 8 & 18 (Bouwens, 
1998a). (This observation is the basis for the proposal o f  a com m on progenitor cell- 
type for the liver and the pancreas. It has also been observed that pancreatic 
progenitor epithelial cells can differentiate in to hepatocytes upon transplantation in to 
the liver (Dabeva et al., 1997) or after treatment o f  regenerating pancreatic cells with
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N-nitrosobis(2-oxopropyl)am ine (Scarpelli & Rao, 1981)). H owever despite these 
limitations, cytokeratin profiling can reveal on-going activities within the pancreas 
when combined with other markers e.g., in duct ligated rat pancreata and low  dose 
streptozotocin treated rats (both stimulate (3 cell neogenesis) one can observe the 
appearance o f  individual P cells and small aggregates o f  P cells. Transient co­
expression o f  CK20 within these cells indicates that the new  P cells are o f  ductal 
origin. R eg expression was also present in these cells (Reg expression can be seen in 
regenerating islets in de-pancreatized rats, and is linked to D N A  synthesis in the 
regenerating cells) (W ang et al. 1995; Anastasi et al., 1999; Rosenberg, 1995). This is 
in agreement with findings that during rat pancreatic m orphogenesis, aggregates o f  
CK20-expressing duct cells form, and over tim e the cells at the center o f  these 
aggregates were found to be insulin+/CK20'. Thus these aggregates were termed ‘islet 
forming units’ (Bouwens & D e Blay, 1996). Similar p-cell units were observed in 
donated pancreata o f  humans (Bouw ens & Pipeleers, 1998).
Thus the use o f  double immunofluorescence/immunohistochemistry for pancreatic 
hormones and cytokeratins is a useful m ethod o f  ‘tracking’ differentiating cells and 
can reveal the location and identity o f  the progenitor populations when used in 
combination with carefully chosen differentiation markers.
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1.2 The |3 Cell
As discussed in Section 1.1 the origins of the P cell are complex and highly regulated. 
Furthermore the p cell itself is complex and extensive research o f this cell and its 
specialised functions have been reported.
1.2.1 The Insulin Gene
P cells are the only cells in the body that actively express the insulin gene for the 
purposes o f glucose homeostasis; many reviewers regard P cells as the only cells in 
the body that express this gene however there is evidence of insulin expression in the 
CNS (Alpert et al., 1988; Devaskar et a l, 1993) and retinas (Budd el al., 1993). The 
human insulin gene is located on the short arm of chromosome 11 and contains three 
exons and two introns. In rats and mice there are two insulin genes, and although the 
mRNAs of these genes are quite similar, they are differentially regulated e.g. there is a 
preferential expression o f rat Insulin I under stimulatory conditions (Kakita et al., 
1982; Wentworth et al., 1986). The duplicate genes are non-allelic and in the case of 
mouse are on two different chromosomes (6 & 7). The ancestral gene is Insulin II and 
Insulin I arose due to a retro-transposition which resulted in a 6 bp deletion from the 
mouse insulin I gene (Wentworth et al., 1986). Transcription o f the insulin gene 
yields a 600 nucleotide mRNA and this is translated in to an 11.5 kDa polypeptide. 
Tissue specific regulation and the regulation of transcription rates are controlled by 
the 5’ region o f the gene.
1.2.1.1 Tissue Specific Regulation of the Insulin Gene
As already mentioned (Section 1.2.1) expression of the insulin gene is under the 
control o f a tissue specific promoter. The extreme importance o f the insulin gene to 
human wellbeing and health prompted many studies to elucidate the factors that 
restrict the expression o f this gene. Most studies on the insulin promoter have been 
carried out on the rat insulin I promoter region. Targeted deletions identified a cell- 
specific enhancer in the region -103 to -333 relative to the transcriptional start site 
(Walker et al., 1983; Edlund et al., 1985). Mutational analysis o f this region identified
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critical regions for insulin gene transcription which, when combined together restrict 
insulin gene transcription. Other negative response elements also serve to restrict 
insulin gene expression in non-islet cell types (Nir et al, 1986; Boam et al, 1990; 
Clarke et a l, 1995).
1.2.1.2 E Boxes Within the Insulin Gene Enhancer
Synthetic oligonucleotides spanning the 5’ region of the gene led to the discovery of 
two major regulatory sequences in the 5’ region o f the promoter between -104 to -  
112 and -233 to -241 (Karlsson et al, 1987). These are illustrated in Figure 1.2.1. 
Individual disruption o f these sequences led to a reduction in insulin gene 
transcription and disruption o f both led to abolishment o f transcriptional activity. 
These regions have been termed IEB1 and IEB2 boxes; FAR and NIR boxes; and E4 
and E5 boxes; respectively, but are more conveniently termed the El and E2 boxes 
(Philippe, 1991; Me Kinnon & Docherty, 2001). These regions were found to contain 
an 8 bp homologous sequence GCCATCTG which was found to interact with the 
same protein i.e. IEF1. As already discussed (Section 1.1.3.5.3) IEF1 was discovered 
to be a heterodimer o f the ubiquitous E2A gene product(s) E12/E47 and the novel 
bHLH protein Beta2 (Naya et al, 1995).
1.2.1.3 A Boxes Within the Insulin Gene Enhancer
The A boxes (or CT boxes as they were originally known) are present at positions -77  
to -84, -210 to -217 and -313 to -320 relative to the transcriptional start site (Figure
1.2.1). These A boxes can bind several homeodomain transcription factors such as 
Isll, HNF1 and Lm xl.l and contain the sequence TAAT (Mitanchez et al., 1997; 
Karlsson et al., 1990; Emens et al., 1992; Ohneda et al., 2000). Electro shift mobility 
assays (EMSAs) identified another factor, IUF1, that strongly bound to A boxes 
(Boam & Docherty, 1989). One of these sites i.e. the CT2 site, resembled a site in the 
rat insulin I promoter that although void of activity, potentiated the activity o f the E2 
box close by (known as the E2A3/4 minienhancer (Ohneda et al., 2000)). IUF1 is now 
better known as the PDX1 transcription/differentiation factor (Section 1.1.3.5.1 & 
Section 1.2.1,3.1).
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E2 (-233 to -241) E l (-104 to -112)
Minienhancer
Figure 1.2.1 Summary o f the layout o f the 5’ region o f the insulin gene and the 
control elements within it. A boxes are in blue while E boxes are in orange. All 
positions referenced as the nucleotide position upstream from the transcriptional start 
site (0).
1.2.1.3.1 PDX1 and Insulin Gene Transcription
PDX1 (Section 1.1.3.5.1) is a homobox transcription factor protein with a predicted 
molecular weight o f 31kDa. PDX1 is present in almost all (-91%) o f p cells and a 
subpopulation o f 8 cells. In the presence o f glucose, PDX1 is activated through 
phosphorylation and translocates to the nucleus o f the P cell where it exerts its effects 
on the transcription o f insulin, glucokinase, GLUT2 and 1APP (Mac Farlane et al., 
1999; McKinnon & Docherty, 2001; Serup et al., 1996). The loss o f insulin gene 
transcription in continuously cultured HIT-T15 cells (hamster p cell line) is at least 
partially due to the loss o f PDX1 expression (Olson et al, 1995; Moran et al, 1997). 
Transfection o f PDX1 cDNA in to high passage HIT-T15 cells however, can lead to 
partial restoration o f insulin promoter activity (Harmon et al, 1998). The ability of 
PDX1 to activate transcription, is dependent on the co-operation of other transcription 
factors especially the EEF1 or Beta2-E12/E47 heterodimer combination (Serup et al, 
1996; Madsen et al., 1996; Harmon et a l, 1998). In fact, the design o f the promoter 
region and the close association o f the E and A boxes within the E2A3/A4 
minienhancer (Figure 1.2.1) indicate that the co-activation properties o f PDX1 and 
Beta2/E47 are due to co-operative DNA binding (Ohneda et al, 2000). The
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requirement for the presence o f Beta2 expression was clearly seen in the activation of 
endogenous insulin expression in the glucagonoma cell line MSL-G-AN following 
overexpression o f PDX1 (Serup et al., 1996). Three subdomains exist within the N 
terminal region of PDX1 that are conserved between PDX1 and the related Xenopus 
homoeprotein, XIHbox8. These subdomains are required for the synergistic 
transactivation o f the insulin gene (Peshavaria et al., 1997; Peshavaria et al., 2000). A 
recent study has in fact demonstrated that the homoedomain of PDX1 acts as to 
facilitate protein-protein interaction and recruitment to form an activation complex 
(Ohneda et al., 2000). The recruitment o f other p cell specific proteins and 
arrangement of the insulin gene enhancer contribute to the tissue specific expression 
o f this gene (Peshavaria et al., 2000).
PDX1 appears to be present in large excess in P cells as an 86% reduction in PDX1 
levels (achieved through antisense technology) did not result in a significant reduction 
in insulin gene transcription (Kajimoto et al., 1997). Overexpression of PDX1 in 
insulin expressing RIN1046-38 cells and HIT-T15 cells increased insulin promoter 
activity in a dose-dependent manner until a point was reached where the 
overexpression began to repress insulin transcription, again in a dose dependent 
manner (Seijffers et al., 1999). PDX1 expression is not entirely necessary for basal 
insulin gene transcription however, as shown by the presence o f insulin expression in 
PDX1-negative cells in the developing pancreas (0ster et al., 1998); the presence of 
insulin positive cells in mutant mice with disrupted PDX1 expression in their p cells 
(Ahlgren et al., 1998); and the low level insulin gene transcription noted in pTC3 
cells with mutant (non-functional) PDX1 (Peshavara et al., 1997).
1.2.1.4 Hedgehog Signalling and Insulin Gene Transcription
In Section 1.1.2.1 the role of hedgehog signalling in pancreas development was 
discussed, however it appears as i f  hedgehog signalling may also be implicated in 
insulin gene transcription. Indian hedgehog (Ihh) and Desert hedgehog (Dhh) were 
both shown to positively regulate insulin gene transcription in cultured INS1 and 
Min6 cell lines, and administration o f the hedgehog inhibitor, cyclopamine, caused a 
decrease in insulin promoter activity (Thomas et al., 2000).
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1.2.1.5 Glucose Regulation of the Insulin Gene
Short term exposure of insulin secreting cells to stimulatory levels o f glucose leads to 
significant increases in insulin gene transcription in HIT-T15 (3 cells and in isolated 
islets within 60-90 minutes (Leibiger et a l, 1998a). Prior to this report it was believed 
that the short term effects o f glucose were predominantly at the post-transcriptional 
level such as stabilisation o f insulin mRNA (Welsh et al, 1985; Skelly et al, 1996; 
Docherty et al, 1996). Glucose was observed to be capable o f direct interaction with 
the insulin gene enhancer through the ‘Z element’ located -292 to -243 in 5’ region of 
the human insulin gene. This was shown to function through the binding o f the Zal 
complex (identified in the nuclear extracts o f fetal and adult islets), the binding of 
which was increased significantly upon exposure o f the islets to glucose (Sander et 
al., 1998).
Glucose also affects insulin gene transcription rates through the action of 
intermediates such as cAMP. cAMP levels increase upon glucose metabolism in |3 
cells (Charles et al., 1975; Nielsen et al, 1985; Hammonds et al, 1987; Inagaki et al.,
1992). There are four cAMP responsive elements between the 5’ enhancer region of 
the insulin gene and within the gene itself, which additively contribute to cAMP 
induction o f insulin transcription (Inagaki et al, 1992). The interaction o f cAMP with 
these elements is mediated by a cAMP responsive element binding protein (CREB) 
(Philippe & Missotten, 1990). Thus cAMP could almost be described as a form of 
second messenger for glucose activation of the insulin gene. These effects o f cAMP 
were negatively regulated by the protooncogene c-jun which, is increased in 
conditions o f low glucose. The direct effects o f cAMP may be demonstrated through 
the exposure o f cells to membrane permeable cAMP (dibutyryl cAMP) or through the 
use of activators o f the adenylate cyclase cascade such as cholera toxin or forskolin 
(Nielsen et al, 1985; Hammonds et al., 1987).
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1.2.1.5.1 Glucose Regulation of Insulin Gene Expression via Modulation of PDX1 
Binding
The metabolism of glucose causes the phosphorylation of PDX1 through a cascade of 
factors including phosphatidylinositol 3-kinase (PI 3-kinase) and a stress activated 
kinase p38/SAPK2. This causes the activation o f PDX1 and its molecular weight is 
seen to increase (from 31 to 46 kDa). This is followed by translocation o f PDX1 to the 
nucleus (Macfarlane et al, 1997; Macfarlane et al, 1999). The activation o f PDX1 
was mediated through phosphorylation but it is unknown if  the phosphorylation alone 
is responsible for the increase in molecular weight (Macfarlane et al, 1999). As well 
as mediating its transport in to the nucleus, glucose increases the DNA binding ability 
o f PDX1 thus facilitating its role as a transactivator o f the insulin gene (Petersen et 
al, 1998; Wu et al, 1999). PDX1 has also been shown to be involved in the glucose 
responsiveness of another p cell gene i.e. the GAD(67) isoform of the P cell 
autoantigen glutamic acid decarboxylase (Pedersen et al, 2002).
1.2.1.6 Regulation of the Insulin Gene by Hormones
Regulation o f the insulin gene is complex and occurs at a number o f levels within the 
cell, including hormonal regulation. Decoding of the glucagon gene revealed two 
other peptides encoded in the proglucagon molecule (precursor to glucagon) called 
glucagon like peptide I and II (GLP I & GLP II). The shorter o f these, GLP-1 can 
stimulate cAMP levels within the P cell causing an increase in insulin gene 
transcription (Drucker et a l,  1987). Epinephrine and somatostatin both suppress 
insulin gene transcription (Redmon et a l, 1994), while insulin may positively affect 
its own transcription through an autocrine action which may involve the activation of 
PDX1 (Leibiger et a l, 1998b; Wu et al, 1999; McKinnon & Docherty, 2001).
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1.2.2 Insulin Biosynthesis and Processing
Glucose stimulates initiation of insulin translation and causes increased transfer of 
initiated ribosome bound RNA from the cytoplasam to the rough endoplasmic 
reticulum (Welsh et al., 1987).
Insulin is synthesised as the precursor protein preproinsulin (PPI). This 11.5 kDa 
polypeptide is rapidly discharged into the rough endoplasmic reticulum where it is 
converted into proinsulin via the action of proteolytic enzymes. Proinsulin is a 9 kDa 
polypeptide containing the A and B chains o f insulin and the C-peptide (connecting 
peptide) fragment. Within the Golgi apparatus disulphide bond formation occurs. 
Proinsulin is then passed through the Golgi cistemae to the trans-Golgi network 
(TGN). Here the proinsulin is packaged into immature secretory granules. Proinsulin 
is very similar to insulin in structure. The C-peptide aligns the proinsulin molecule for 
correct cleavage to mature insulin (Hoiwell, 1991; Docherty, 1997).
At this point the immature secretory granules can either form part o f the constitutive 
pathway or the regulated pathway o f protein secretion (regulated and constitutive 
methods of secretion are discussed in Section 1.2.4.1). During constitutive secretion, 
the immature granules are transported immediately to the P cell membrane and a 
mixture o f proinsulin and insulin is released. On the regulated pathway, the proinsulin 
is stored in secretory granules where it is converted to mature insulin via the action of 
two endoproteases and carboxypeptidase. The two endoproteases PC2 and PCI (also 
called PC3; PC = prohormone convertase) are members o f a subtilisin-like family of 
calcium-dependent enzymes that are restricted to neuroendocrine cells (Smeekens et 
al., 1991; Bennet et al., 1992; Docherty, 1997). PC3 cleaves the Arg31-Arg32 sequence 
at the B-chain C-peptide junction and PC2 cleaves at Lys64-Arg65 at the A-chain C- 
peptide junction. These two intermediate molecules are converted to mature insulin 
and C-peptide via the action of carboxypeptidases (Figures 1.2.2 & 1.2.3).
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Insulin B Chain C-Peptide Insulin A Chain
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Figure 1.2.2 Cleavage Points for PC2 and PC3
Cut and trim at Lys^ -Arg65
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Figure 1.2.3 Processing of Proinsulin to insulin. Following initial cleavage by either 
PC2 or PC3, trimming o f the residual C-terminal residues is carried out by the action 
of ubiquitously expressed carboxypeptidases.
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Insulin has a lower solubility than C-peptide and thus co-operates with zinc ions to 
form microcrystals within the secretory granule. The precipitation is facilitated by the 
low pH within the granule which is due to the excision and loss o f basic amino acids 
during proteolytic conversion (Howell, 1991). From this it is apparent that insulin and 
C-peptide will be released from the P cell in eqimolar amounts by exocytosis upon 
stimulation by glucose. The advantage of storing proteins in storage granules is that 
having such a large concentration of the hormone/protein in the granules facilitates 
the release o f large amounts upon stimulation by a secretagogue (Halban & Irmanger,
1994).
A Chain
B Chain
Figure 1.2.4 The Primary Structure o f Human Insulin. The primary structure refers to 
the amino acid sequence o f the peptide.
1.2.3 Glucose Sensing Within the P Cell
To correctly control blood glucose levels, the P cell needs to accurately determine 
how much glucose is present in the blood stream. Understanding of glucose sensing is 
important for both non-insulin dependent diabetes mellitus (NIDDM), where the
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glucose stimulated insulin secretion (GSIS) may be impaired (Ramirez & Raskin, 
1991), and for the generation o f ‘artificial p cells’. The level of glucose is determined 
from the metabolism of the blood glucose and the subsequent changes in glucose 
metabolites (Ashcroft, 1980; German, 1993). Thus the most important components o f 
the ‘glucose sensor’ are (I) the transport mechanism allowing glucose in to the cell i.e. 
GLUT2 and (II) the initial rate limiting step in the metabolism of glucose i.e. 
glucokinase (Hexokinase family member IV) (Figure 1.2.5). GSIS requires that the 
metabolism of glucose can be increased within the P cell over the entire physiological 
range. This is facilitated by the fact that both GLUT2 and glucokinase have kms above 
the physiological range of glucose (Marshall et al., 1993; Ishihara et al., 1994). The 
relative importance o f the two components o f the glucose sensor were compared by 
the overexpession of their low km counterparts i.e. GLUT1 and hexokinase I in the 
Min6 cell line. The presence o f GLUT1 did not affect the GSIS ability o f the cells; 
however, the expression o f hexokinase I did increase glucose utilisation and release at 
concentrations below 10 mM (Ishihara et al., 1994). In similar experiments with rat 
islets, the expression o f hexokinase I abolished GSIS over the entire physiological 
range (German, 1993). Patients with maturity onset diabetes o f the young (MODY) 
have impaired GSIS and this is due to heterozygous point mutations in the 
glucokinase gene. Similarly, disruption of the glucokinase gene in transgenic mice 
leads to the same phenotypic effects (Bali et al., 1995). While this data indicates that 
the critical portion of the glucose sensor is glucokinase, GLUT2 is still relevant. 
Mutations in the GLUT2 gene totally abolished glucose transport and thus the ability 
to ‘sense’ glucose over the physiological range in a patient with NIDDM, while the 
expression o f GLUT2 antisense led to diabetes in transgenic mice (Mueckler et al., 
1994; Valera et al., 1994). RINm5F insulinoma cells (Section 1.5.1.1) were 
insensitive to external glucose levels until GLUT2 was transfected in to this cell line. 
Following this transfection, insulin content and glucose uptake were improved and the 
RINm5F-GLUT2 cells were found to have functional GSIS (Tiedge et al., 1993). 
Similarly in glucokinase expressing cell lines (AtT20 & HEP G2) transfected with the 
PPI cDNA, these cells were not capable o f responding to the external glucose levels 
unless GLUT2 was transfected also. (Hughes et al., 1992; Simpson et al, 1997). 
Thus, while the presence o f glucokinase is the main rate limiting glucose sensor, the 
combination o f GLUT2 and glucokinase is required for effective glucose sensing.
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This was again seen in the case o f the Min7 insulinoma cells that were isolated at the 
same time as Min6 cells. Min7 cells were found to be glucose insensitive due to a 
combination o f high levels o f hexokinase I and GLUT1 (Miyazaki et al., 1990; 
Ishihara et ah, 1993).
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Figure 1.2.5 Glucose stimulated secretion from P cells depends on the presence of 
correct glucose sensing, insulin storage and regulated secretion pathways.
1.2.4 Stimulated Insulin Secretion from p Cells
The main difference between the maintenance o f glucose homeostasis through the 
action o f  fully functional P cells and insulin injections is the fact that insulin 
injections do not provide the minute to minute control o f  blood glucose levels in the 
same way as P cells. This temporal control is facilitated by proportional release o f  
stored insulin depending on the blood glucose level. Thus insulin secretion pathways 
are highly regulated.
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1.2.4.1 Regulated Pathways of Protein Secretion
Most of the secretory proteins from eukaryotic cells share a common origin in the 
rough endoplasmic reticulum (RER) from where they are transferred to the Golgi 
apparatus. It is here that the protein either enters a regulated pathway of secretion or 
the more common constitutive pathway of secretion. The sorting of constitutive 
proteins from regulated proteins occurs in the trans-Golgi network (TGN) (Kelly, 
1985).
Secretion via the regulated pathway allows the release of the protein to be controlled 
via secretagogues. The action of the secretagogue occurs at the level of exocytosis and 
allows the discharge of protein from mature secretory granules at an appropriate 
moment. The constitutive pathway results in continuous exocytosis meaning that 
protein availability is the main modulator of this pathway and thus is only regulated at 
the level of biosynthesis (Halban & Irminger, 1994). This pathway of secretion is 
typically used to transfer membrane proteins, viral glycoproteins and other rapidly 
secreted proteins to the cell surface (Docherty, 1997).
The regulated pathway of secretion requires secretory granules. The earliest form of 
the granule is clatherin coated although the reason for this is unknown. It is in this 
clatherin-coated granule that the bulk of prohormone conversion occurs as the granule 
matures. The maturation of the granule continues with the eventual loss of the 
clatherin coat. While it has been well established that the sorting of the regulatory and 
constitutive proteins occurs in the TGN it is unknown how the processing of 
constitutive from regulated proteins is carried out (Halban & Irminger, 1994).
When cDNA encoding proinsulin was transfected into a mouse cell line secreting 
ACTH via the regulated pathway, storage, processing and secretion of the proinsulin 
on stimulation occurred (Moore et ah, 1983; Motoyoshi et al, 1998). Thus it seems 
that regulated proteins have structural determinants, which cause them to be sorted in 
to the regulated pathway. In a series of experiments, it was demonstrated that 
constitutive proteins w ill be secreted via the constitutive pathway even in cells 
containing a regulated pathway of protein secretion, but regulated proteins from one 
cell w ill be regulated again in the new cell type. Interestingly it was observed that
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when a constitutive viral protein was fused to the C-terminal domain of a regulated 
protein, that the new hybrid protein was released in a regulated manner, (Halban & 
Irminger, 1994).
1.2.4.2 Glucose Stimulated Insulin Secretion (GSIS) from (3 Cells
Insulin secretagogues can be divided in to two groups i.e. initiators and potentiators 
(Howell, 1991). Initiators are capable of stimulating secretion on their own and 
include glucose, and the sulphonurea drugs while potentiators such as L-Arganine can 
increase insulin secretion when present with an initiator. Glucose is the most 
important initiator of insulin secretion, p cells are sensitive to changes in glucose 
from around 5-8 mM to 20 mM (Knaack et a l,  1994; Poitout et a l, 1996; Best,
2000) i.e., there is no stimulation of secretion below 5 mM glucose and the maximum 
glucose stimulated insulin secretion (GSIS) occurs at approximately 20 mM.
Studies have shown that stimulation by glucose triggers characteristic electrical 
responses at the (3 cell membrane (Ullrich et a l ,  1996). These changes in membrane 
potential are due to the knock-on effects resulting from the metabolism of glucose, p 
cells can monitor increases in blood glucose via the ‘glucose sensing system’ (Section
1.2.3). Increased blood glucose leads to increased glucose metabolism, which 
determines the extent of the insulin response. The simplest model of GSIS is that the 
direct result of increased glucose metabolism is an increase in the ATP/ADP ratio 
within the p cell. This causes the closure of ATP sensitive potassium channels on the 
P cell membrane. In resting p cells these channels are open and allow a steady flow of 
K+ ions outward, this holds the membrane potential of the cell at a negative level o f-  
70 mV to -80 mV (Ashcroft and Gribble, 1999; Best, 2000; Ullrich et al., 1996). 
There are also voltage gated ( L-type) calcium channels in the P cell membrane. At 
the resting potential -  70 mV they are closed, however once the ATP sensitive K+ 
channels are closed membrane depolarisation occurs i.e. the cell becomes less 
negative as a result of the build up of K+ ions. Membrane depolarisation results in the 
opening of the voltage gated Ca2+ channels, thus allowing Ca2+ ions to flow in to the P 
cell. The increase in intracellular calcium results in the translocation of the insulin
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storage granules to the P cell membrane and facilitates release of the stored insulin 
(Ashcroft & Gribble, 1999; Howell, 1991). This is outlined in Figure 1.2.5.
Evidence for an alternative Ca2+ independent mode of secretion has been presented 
also. Evidence for this was provided by the observation that the adenylate cyclase 
activator forskolin (increases intracellular cAMP) did not cause an increase in 
intracellular calcium ([Ca2+]i) but did result in increased secretion in Min6 cells. This 
and other observations involving glucose, leucine and arganine in Ca2+-free systems 
indicated that there is another mechanism of secretion that involved cAMP and 
cellular alkalinization (Sakuma et al., 1995). This was also shown by the use of 
analogues of forskolin that did not activate the adenylate cyclase pathway (and 
therefore did not increase cAMP) and thus did not stimulate insulin secretion (Ullrich 
et a l, 1996). It has also been observed that although tolbutamide causes significant
9 +  « •membrane depolarisation (and therefore Ca influx) it does not increase insulin 
secretion in INS1 cells (Ullrich et a l, 1996). The relative contribution of the Ca2+ 
independent pathway was not found to be of major significance to the physiological 
regulation in mouse islets however (Sato el al., 1998).
The response of P cells to glucose is heterogeneous in nature both at the level of 
insulin biosynthesis and secretion (Moitoso de Vargas et a l, 1997; Giordano et al, 
1993). It was discovered that the GSIS response from P cells is heterogeneous due to 
differing p cell size, and not as a result of individual cell metabolism of glucose. The 
release of insulin in response to glucose is also dependent on cell to cell contacts 
within the intact islets (Section 1.2.4.2.2).
1.2.4.2.1 Implications for the Cell-Matrix Interactions in GSIS
Islets cultured in vitro show altered functions compared to their in vivo counterparts, 
which is partly due to altered cell-cell interactions and altered cell matrix interactions. 
Culture of primary rat p cells on 804G matrix (produced by rat carcinoma cell line) 
was found to increase cell spreading, the percentage of insulin secreting cells and the 
amount of insulin secreted. This effect was mediated at least in part, through a6pi 
integrin (Bosco et a l,  2000). Integrins are involved in the attachment of cells to
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various matrices including fibronectin and laminin. They are dimers of an a  and a (3 
subunit, subgroups of integrin families share their p subunit and the a subunit seems 
to confer the ligand specificity (Burdsal et a l,  1994). Integrin subunits a3, a5, and 
aV are also important in maintaining P cell function in culture (Wang & Rosenberg,
1999).
1.2.4.2.2 Implications for Connexin Expression and Gap Junctions in GSIS
Gap junctions are cell to cell channels which allow direct transfer of ions and 
metabolites e.g. cAMP, IP3 and calcium between cells. Channels are formed by the 
interaction of hemichannels on one cell with the open channel of another. These 
hemichannels consist of 6 protein subunits, the connexins which are coded for by a 
multigene family (Willecke, et a l ,  1991). Over 15 different types of connexins are 
known for mammals and they are characterised by molecular weight.
When the insulin levels, secretion rates and GSIS capabilities of intact islets, 
dispersed islet cells and re-aggregated islet cells were compared, it was found that the 
single cells and the aggregates had a reduced response to glucose signals in perfusion 
assays. This was considered to be, at least partly, due to disruption of cell-to-cell 
signalling due to loss of gap junctions (Linzel et a l, 1988). In fact it has been shown 
that homologous contact between p cells rather than with other islet cell types is 
critical to effective GSIS (Bosco et a l, 1989). Connexin 43 (Cx43) was identified as 
a critical component in stimulation of insulin secretion in gibenclamide treated rats 
(Meda et a l,  1991). Expression of Cx43 in INS1, to levels comparable with those in 
native islets, led to increased insulin content and preserved GSIS. Overexpression of 
Cx43 in INS1 resulted in diminished insulin content and GSIS (Vozzi et a l, 1995). 
Cx36 has also been implicated in insulin secretion from P cells (Calabrese et a l,
2001).
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1.2.4.3 cAMP Mediated Insulin Secretion from ß Cells
— 9-4- •As discussed previoulsy cAMP levels are implicated in Ca independent secretion 
from p cells (Section 1.2.4.2). Compounds that increase cAMP through activation of 
adenyl cyclase (cholera toxin) or through inhibition of cAMP phosphodiesterase 
(theophylline and 3-isobutyl-methylxanthine (IBMX)) have been shown to increase 
secretion from insulin secreting cells (Nielsen et al., 1985; Ullrich et al., 1996; 
Hammonds et al., 1987; Simpson et al., 1997; Lu et a l, 1998). Overexpression of 
cAMP degrading phosphodiesterase (converts cAMP to cGMP) led to significant 
decreases in insulin secretion and GSIS was reduced by 40-50 %. The incretin effect 
of GLP1 on insulin secretion (mediated through cAMP (Drucker et al., 1987)), was 
also affected (Hamdahl et al., 2002).
1.2.4.4 Insulin Secretion Through the Action of the Sulphonurea Drugs
The main factor in common between initiators of insulin secretion is the closure of the 
ATP dependent potassium channels. While the metabolism of glucose can cause this 
by increasing the ATP/ADP ratio, other drugs can have the same effect by direct 
interaction with the channel. The most common drug type employed to close 
potassium channels are the sulphonurea drugs. These drugs are used by patients with 
Type II diabetes to enhance insulin secretion (Ashcroft & Gribble, 1999).
The ATP dependent potassium channel ( K a t p )  found in p  cells is composed of two 
different types of subunits i.e. the pore forming unit (Kir6.2) and the regulatory 
subunit (SUR1). These subunits assemble with a 4:4 stoichiometry. K ir 6.2 is a 
member i f  the inwardly rectifying K + channel family and is the subunit that ATP 
interacts with to close the channel. K ir 6.2 is unlike other members of this family in 
that it is unable to form functional channels in the absence of the sulphonurea receptor 
(SUR), due to the role of SUR as a chaperone protein allowing the surface expression 
of Kir 6.2. The sulphonurea receptors are members of the ABC-transporter 
superfamily, which also includes the cystic fibrosis transmembrane receptor (CFTR) 
and p-glycoprotein (a membrane pump implicated in multidrug resistance in cancer). 
(See review by Ashcroft & Gribble (1999)).
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The sulphonurea drugs interact with the p  cell K Atp  channel via a low affinity site on 
the Kir 6.2 unit and a high affinity site on SUR1 (Gros et a l, 1999). Glibenclamide is 
the most potent sulphonurea drug employed to stimulate insulin secretion and is active 
within a narrow operating range 50 -  200 nM, which corresponds to a very low oral 
dose (Luzi & Pozza, 1997).
1.2.4.5 Insulin Secretion Mediated by Amino Acids and Vitamins
The amino acids L-Arganine and L-Leucine have been found to be potentiators of 
GSIS. L-Arganine is a cationic amino acid and induces secretion via membrane 
depolarization of p cells allowing for the opening of the voltage gated Ca2+ channels. 
This facilitates Ca2+mediated secretion as outlined above (Section 1.2.4.2). L-leucine, 
on the other hand, causes cellular alkalinization (Sakuma et a l, 1995). L-leucine is 
also a metabolizable P cell substrate, which generates high-energy compounds such as 
ATP (Welsh et al, 1987). An increase in ATP levels within cells as a result of leucine 
metabolism may result in closure, or partial closure, of the K a t p  channels allowing for 
a potentiating effect in the presence of glucose.
The regulation of insulin secretion by Vitamin A has also been observed. Vitamin A 
deficient perfused islets had impaired insulin secretion. Furthermore vitamin A 
deficient rats had an impaired acute insulin response to glucose stimulation, (Chertow 
etal., 1987).
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1.3 Differentiation of Cells Towards a (3 Cell Lineage for Diabetes Treatment
Replacement of correctly functioning (3 cells is the ultimate goal for treatment of 
IDDM. However, due to shortages of donor tissue this cannot be carried out unless a 
pool of self-replicating tissue could be isolated, from which p-like cells could be 
generated for transplant. Such sources of replicating cells include embryonic stem 
(ES) cells, and pancreatic precursor cells.
1.3.1 Stem Cells
Tissues that become differentiated to carry out certain roles in the body are subject to 
turnover, however the differentiation of these cells is often accompanied with a loss of 
proliferative ability. Thus to match replacement with loss, progenitor cells must 
differentiate to fill the void. These proliferating progenitor cells are a type of stem cell 
(Bach et a l, 2000). Embryonic stem (ES) cells are pluripotent cells isolated from the 
inner cell mass of pre-implantation embryos and theoretically represent totally 
undifferentiated cells with unlimited differentiation potential. A sub class of the ES 
cells are embryonic carcinoma (EC) cells, which are generally derived from testicular 
or ovarian tumors and exhibit similar properties to ES cells (Dinsmore et a l,  1998). 
The isolation and culture of the first human stem cell line H9 (Thompson et a l, 1998) 
was a breakthrough that has heralded a new branch of diabetes research aimed at the 
identification of the factors and signals required to generate insulin producing (3 cells 
(or even better, replicating p cell precursors) for diabetes treatment.
1.3.1.1 Determination of Stem Cell Fate
To culture a cell to a desired type the conditions that precede this event in vivo should 
be known. This is more straightforward for simple organisms such as Drosophila it is 
quite difficult for larger animals and humans. Stem cell fate determination follows 
relatively standard rules however.
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1.3.1.1.1 Internal Factors Involved in Determining Stem Cell Fate
Internal factors control division and gene expression in developing stem cells. The 
asymmetric pathway of stem cell division involves the generation of a stem cell and a 
differentiated progeny from a mother cell therefore the stem cell population can 
maintain itself. This has been shown in Drosophila (Morrison et al., 1997; Jan & Jan,
1998). In higher mammals, symmetric division takes place i.e. either the stem cell 
divides to give two stem cells or differentiation signals (combination of internal and 
external), result in the generation of two differentiated progeny. Sometimes a 
combination of asymmetric and symmetric cell division occurs (Morrison et a l, 1997; 
Wagers et al., 2002). Transcription factors also control stem cell fate, e.g., SCL/Tal-1 
which is essential for the formation of blood cell lineages in the mouse (Watt & 
Hogan, 2000) and, as already discussed, the expression of Ngn3 can lead to cell fate 
determination in developing (3 cells (Section 1.1.3.5.2).
1.3.1.1.2 External Factors Influencing Stem Cell Fate
Secreted factors e.g., growth factors (GFs) are classical determinants of cell fate. 
These have however, both instructive and selective/enabling mechanisms of action. 
The instructive mode involves a specific GF instructing a cell to take a specified 
lineage (Shah et al., 1996), whereas the selective mechanism involves the promotion 
of survival of pre-committed cells from a population, and driving them into their more 
differentiated compartments (Faribaim et al., 1993; Gandarillas & Watt, 1997). 
Instructive and selective-like differentiation has been observed in the developing 
pancreas where mesenchymal secretions actively select for exocrine cell survival and 
differentiation while instructively repressing endocrine cell differentiation (Section
1.1.2.3).
Cell-cell contact is an external stimulus that can influence differentiation. Notch and 
its ligand, Delta, are involved in Drosophila for sensory organ fate determination 
(Artavanis-Tsakonas, 1999) and in developing endocrine cells from proliferating 
precursors (Section 1.1.3.5.2).
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The interaction of cells with their extracellular matrix via surface proteins can 
influence stem cell lineage determination e.g. the matrix can render the cells 
competent to respond to other signals by allowing them to assume a particular spatial 
organisation. The extracellular matrix can also potentially sequester and modulate the 
local concentrations of secreted differentiation agents available within the stem cell 
niche (Watt & Hogan, 2000). Integrins have a critical role in this level of stem cell 
determination, pi integrin is required at high levels to maintain epidermal cells in the 
stem cell compartment. Expression of a dominant negative p i integrin subunit 
(CD8pi) in proliferating keratinocytes led to an exit from the stem cell compartment 
(Zhu et al., 1999). Selective differentiation of epidermal stem cells through 
overexpression of c-myc was accompanied with a reduction in p i integrin also 
(Gandarillas & Watt, 1997).
1.3.2 Differentiation of Stem Cells to an Endocrine Lineage
For clarity the generation of P cell-like cells through differentiation of ES cells and 
adult ‘stem’ cells/progenitors w ill be discussed separately, as the cells involved are 
quite different, i.e. the ES cells are pluripotent while the adult stem cells/progenitor 
cells are likely to be more committed. It is still relevant to refer to both cell types as 
stem cells as the definition of a stem cell is a cell that has the ability for long-term 
proliferation with the capacity to produce at least one type of highly differentiated 
descendent (Watt & Hogan, 2000).
1.3.2.1 Differentiation of ES cells in to P Cells
The H9 ES cell line (Thomson et al., 1998) can be grown in an undifferentiated state 
through careful culture, however spontaneous differentiation is easy to induce by 
simply allowing the cells to form aggregates called embryoid bodies (EBs) in 
suspension culture. Previous studies had demonstrated that following EB formation, 
pluripotent stem cells were found to differentiate and express markers associated with 
neural, vascular, hematopoietic, and endodermal lineages (Vogel, 1999). Schuldiner et 
al. (2000) investigated the effects of different differentiation agents on the EBs but 
surprisingly it was found that formation of EBs alone led to the expression of insulin
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and PDX1. Similar reports regarding the differentiation of EBs are present in the 
literature (Gerrish et al., 2000; Shiroi et al., 2002). Endodermal markers such as 
alfafeto protein (AFP) and HNF3P were also discovered in spontaneous EBs 
(Shamblott et a l,  2001). As pancreatic origins are known to be endodermal (Section
1.1.1), spontaneous EBs from human ES cells were probed for immunoreactive 
insulin, and a number of cells were found to express the protein. These cells were also 
able to secrete immunoreactive insulin in to the medium in a differentiation related 
manner, and the increased secretion was correlated with expression of p cell markers 
(Assady et al., 2001). This was an important study of functionality as the constitutive 
expression of random differentiated cell markers in stem cells is not unknown 
(Wagers et al., 2002).
A purified population of insulin secreting cells has already been generated from 
mouse stem cells. These cells were differentiated as EBs in the presence of low 
glucose and nicotinamide (Section 1.3.4.4) and the insulin expressing cells were 
purified from the population as a whole using the ‘cell trapping’ method of Klug et al. 
(1996). In this system the undifferentiated cells were transfected with a construct 
whereby the transfected cells could be selected through acquired resistance to a 
constitutively expressed antibiotic resistance gene. The gene encoding another 
resistance gene (neomycin) was also present under the regulatory information of the 
insulin gene. Thus, following differentiation, the cells resistant to neomycin were 
selected, resulting in a purified population of insulin secreting cells i.e. these cells 
contained the cellular machinery to drive the insulin promoter (Soria et al., 2000a). 
These cells were capable of GSIS and normalised the blood glucose of streptozotocin 
induced diabetic mice. These implanted cells did not become tumorigenic and 
maintained normoglycemia for at least 12 weeks.
As discussed already the differentiation of pancreatic islets and that of neurons have a 
number of features in common (Section 1.1.2.6). Neuron turnover in the adult is 
facilitated by multipotential cells e.g. subventricular zone astrocytes (Doetsch et al.,
1999). The intermediate filament protein nestin has been identified as a neural stem 
cell (NSC) marker (Lendahl et al., 1990; McKay 1997; Bjomson et al., 1999; Momma 
et al., 2000). Culture of ES cells in bFGF and serum free conditions results in a
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population of proliferating nestin rich cells that can be further differentiated in to 
neuronal cells by mitogen withdrawal (Okabe et a l,  1996). Multipotential nestin- 
positive cells have been isolated from the ducts of rat pancreata that could 
differentiate towards endocrine, exocrine and hepatic lineages when cultured in vitro  
(Zulewski et al., 2001). Nestin positive cells were purified from partially purified ES 
cells using supplemented serum free medium (Okabe et a l, 1996; Lee et a l, 2000) 
and expanded in the presence of bFGF. Removal of the bFGF mitogen and addition of 
nicotinamide resulted in clusters of cells of which, approximately 30 % were insulin 
positive (Lumelsky el a l, 2001). These cells were found to have an intact GSIS 
response, and they had a very low proliferation index.
1.3.2.2 Differentiation of Precursor Tissue to Functional (3 Cells
1.3.2.2.1 Differentiation of Ductular Tissue
There is convincing evidence for the existence of a self-renewing population of cells 
within the adult pancreas that are capable of differentiating/transdifferentiating into P 
cells upon injury or other such stimulus (Tsao & Duguid, 1987; Wang et a l, 1995; 
Rosenberg, 1995; Bouwens & DeBlay, 1996; Bouwens & Pipeleers, 1998; Anastasi et 
a l,  1999).
When isolates from the pancreatic ducts were digested and cultured as a monolayer of 
epithelial-type cells, islet cell masses budded from these monolayers. These 
proliferating islet cell masses (islet progenitor cells, IPCs) were found to contain low 
levels of insulin at their core and were also positive for glucagon and somatostatin. 
Following exposure to nicotinamide, the IPCs were found to secrete large amounts of 
insulin and to have a functional GSIS. Implantation of the immature IPCs into 
diabetic mice led to differentiation of the IPCs and to reversal of diabetes (Cornelius 
et a l, 1997; Ramiya et a l,  2000). The advantage of this system over some of the ES 
cell to p cell systems in Section 1.3.2.1 is that there is a possibility for constant self- 
renewal of progenitor material. Also the presence of a, p and 5 cells in an islet-like 
arrangement may offer a co-ordinated insulin response like that obtained in normal 
pancreata (Soria, et al., 2000b). The human pancreatic duct cell line Capan-1 was
45
differentiated in to insulin producing cells via treatment w ith Exendin-4 (an agonist o f 
the incretin hormone GLP-1). This differentiation was facilitated by the expression o f 
important transcription factors such as PDX1 and HNF3p/Foxa2 (Section 1.1.2.5). In 
this system similar effects were noted by overexpression o f PDX1 in the Capan-1 cell 
line (Zhou, et al, 2002).
1.3.2.2.2 Nestin Expresing Progenitors
As already discussed (Section 1.3.1.2.1) nestin expressing cells have been located 
w ithin the ducts o f adult pancreas which differentiated upon reaching confluency in 
culture and were found to express and secrete insulin (Zulewski et al., 2001). These 
do not appear to be ductal cells, however, as they lack CK19 expression which is a 
ductal cell marker in the pancreas (Bouwens et al., 1994). Treatment o f these cells 
with GLP-1 leads to differentiation to insulin secreting cells through the activation o f 
PDX1. In fact the differentiation o f cultured nestin positive cells to insulin secreting 
cells may be due to GLP-1 expression in those cultures, therefore resulting in 
autocrine-controlled differentiation (Abraham et al., 2002).
1.3.2.2.3 Epithelial Precursors
As already outlined in Section 1.1.1 the pancreas generates from epithelial cells o f the 
endoderm in the developing embryo. The mesenchyme is very important in dictating 
the extent o f endocrine/exocrine differentiation from these epithelial cells and does so 
by the release o f soluble secreted factors such as follistatin (Miralles et al., 1998). 
Removal o f pancreatic epithelial tissue from rats and culturing in the absence o f 
mesenchyme led to the development o f insulin secreting cells expressing P cell 
terminal differentiation factors e.g., Nkx6.1 (Miralles et al., 1999). The intestinal 
epitheloid cell line IEC-6 could also be induced to adopt a p cell-like fate. These cells 
were found to express a number o f p cell markers following transfection o f PDX1, 
and follow up betacellulin treatment or upon transplantation under the renal cap o f a 
rat, these cells synthesised and secreted insulin in a non-regulated fashion (Yoshida et 
al, 2002).
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1.3.2.2.4 Acinar Cells (AR42J)
The pancreatic acinar cell line AR42J possesses both exocrine and neuroendocrine 
properties in that they secrete amylase and y-aminobutyric acid, while expressing such 
markers as neurofilament (Christophe, 1994). Upon treatment with dexamethasone 
they resemble acinar cells (Logsdon et al., 1985; Guthrie et al., 1991). Treatment o f 
AR42J cells w ith the TGF(3 fam ily member activin A  resulted in neuronal-like 
differentiation (Ohnishi et al., 1995). This alone was not significant as neuronal 
differentiation appears to be a ‘default’ mechanism o f differentiation (Vogel, 1999). 
However, these cells also displayed what appeared to be both the sulphonurea 
receptors and calcium channels associated w ith p cells. Closer examination o f activin 
A  treated AR42J cells revealed that pancreatic polypeptide expression and GLUT2 
were also expressed. Thus, in a wider study a range o f growth factors and 
differentiation agents were applied to these cells and it was found that betacellulin 
could induce 4% o f the cells to express insulin. A  combination o f activin A  and 
betacellulin resulted in 10% o f the treated cells expressing insulin (Mashima et al., 
1996a). These insulin secreting cells did not have a functional GSIS but did respond 
to tolbutamide, indicating the presence o f the functional potassium and calcium 
channels (Ohnishi et al., 1995). Combining activin A  w ith HGF produced similar 
results (Mashima et al., 1996b). This is in keeping w ith the theory that these 
compounds are involved in P cell specification in the developing pancreas (Larsson,
1998). As with the ductal cells and nestin expressing precursor cells (Zhou, et al., 
2002; Abraham et al., 2002), extendin-4 and GLP-1 also caused differentiation o f 
AR42J cells to insulin secreting cells.
The differentiation o f AR42J cells was mediated by the mitogen activated protein 
kinase pathway (MAPK) through which the expression o f a number o f other genes is 
controlled (Mashima et al., 1999). Besides the genes affected directly by the MAPK 
pathway, some more characteristic determinants o f P cells were affected in 
differentiating AR42J cells, including Ngn3 and Pax4. Overexpression o f Ngn3 had 
similar effects to activin A  treatment (Zhang et al., 2001). It has also been reported 
that Nkx2.2 expression can induce PP expression while the expression o f other
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transcription factors PDX1, Nkx6.1, or Is ll had no effect (alone or in combination) 
(Palgi et al., 2000).
1.3.3 Transdiferentiation of Hepatocytes to P Cels
Transdifferentiation o f one cell type to another is not uncommon, in fact upon 
changing environment cells may respond to different environmental factors and take 
up new lineages. Neuronal cells can differentiate to form smooth muscle (Shah et al.,
1996), and haematopoietic cells can differentiate in to neuronal (Eglitis &  Mezey,
1997) and muscle cells (Ferrari et al., 1998). Pancreatic epithelial cells are also 
capable o f differentiating into hepatocytes following transplantation in to the liver 
(Dabeva et al., 1997). Adult rat hepatic ‘oval’ cells (hepatic oval cells may be hepatic 
stem cells (Petersen et al., 1999)), have been found to be capable o f differentiating in 
to glucose-sensitive insulin secreting cells which express a number o f p cell markers 
upon culture in a high glucose environment (Yang et al., 2002). a cell tumor derived 
cells can also be differentiated in to insulin expressing cells through the over­
expression o f PDX1 and the treatment o f the transfected cells with betacellulin 
(Watada et al., 1996). This is not as significant as the transdifferentiation o f hepatic 
cells to P cells as a and P cells are developmentally related and the expression o f 
PDX1 alone stimulates IAPP expression in transformed a cells (Serup et al., 1996; 
Watada et al., 1996)
1.3.4 Comon Agents Employed in the Diferentiation of Cels Towards and 
Endocrine Lineage
While ES cells can be seen to spontaneously differentiate in to insulin secreting cells, 
it can be seen that the addition o f nicotinamide promoted a larger proportion o f the 
cells to adopt a P cell fate. This is one o f a few common agents employed in the 
directed differentiation towards P cells which are discussed individually below.
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1.3.4.1 Activin A
Activin A  is a member o f the transforming growth factor beta (TGFP) family o f 
secreted proteins. It was successful in experiments with AR42J cells where it initiated 
endocrine differentiation (Section 1.3.2.2.4). ES cell derived EBs were found to 
express the activin A  receptor (Activin R II B) and generated mesodermal cells upon 
treatment with activin A (Schuldiner et al, 2000). Activin A  has been implicated in 
the differentiation o f endocrine precursor cells in the developing pancreas (Larsson, 
1998; Demeterco et al., 2000) where it has shown to be expressed (Furukawa et al.,
1995). Activin A was shown to inhibit DNA synthesis in cultured 1NS1 cells while at 
the same time increasing insulin content by almost three-fold (Huotari et al., 1998).
1.3.4.2 Betacelulin
Betacellulin is the most recently identified member o f the epidermal growth factor 
(EGF) fam ily o f growth factors, and it was in itia lly discovered in the conditioned 
medium o f P tumors (Shing et al., 1993). It has mitogenic activity on Balb/c 3T3 
fibroblasts (Watanabe et al, 1994) and on fetal pancreatic tissue in culture 
(Demeterco et al, 2000). It was shown to have potent effects on the proliferation o f 
cultured P cells (INS1), w ith no effect on insulin levels (Huotari et al, 1998). 
Betacellulin is capable o f differentiating small percentages (< 5%) o f AR42J cells into 
insulin secreting cells (Mashima et al, 1996a). PDX1-transfected epithelial cells and 
a cell derived lines only expressed insulin following betacellulin treatment (Watada et 
al, 1996; Yoshida et al., 2002). Injections o f recombinant betacellulin have led to the 
generation o f islet-like cell clusters in the ducts o f glucose intolerant mice after 8 
weeks. These clusters were found to be predominantly composed o f P cells 
(Yamamoto et al, 2000). Betacellulin is reported to interact with the EGF receptor 
(EGFR/c-erb B l)  and c-erb B4 (Watanabe et al, 1994; Riese et al, 1996). Another 
190 Kd receptor has been isolated that seems to interact specifically with betacellulin 
in AR42J cells (Ishiyama et al, 1998), however its identity is unknown.
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1.3.4.3 HGF
Hepatocyte growth factor (HGF), also known as the scatter factor (SF), was identified 
as a mitogen for hepatocytes in a screen to identify factors involved in liver 
regeneration. HGF exerts its mitogenic effects through its receptor c-met 
(Michalopouls &  DeFrances, 1997). The c-met receptor is present in the fetal 
pancreas, it is preferentially expressed in developing p cells, and it is restricted to the 
P cells o f adults. This distribution reflects the importance o f mesenchymal derived 
HGF to the growth o f pancreatic p cells (Otonkoski et al, 1996). The formation o f 
islet-like cell clusters (ICCs) from human fetal tissue was increased 2-3 fold in the 
presence o f HGF w ith an associated insulinotropic activity (Otonkoski et al, 1994). 
The increase in p cell mass w ithin fetal pancreatic epithelial tissue was accompanied 
however, with an associated reduction o f insulin content (Otonkoski et al, 1996). 
HGF was found to have no effect on the proliferation o f cultured IN SI cells (Huotari 
et al, 1998) and this may reflect its role in differentiation o f more undifferentiated 
tissue. The action o f HGF on AR42J cells was very similar to betacellulin (Mashima 
et al, 1996b).
1.3.4.4 Nicotinamide
Nicotinamide is a metabolite o f the vitamin niacin. Nicotinamide was shown to be a 
potent inducer o f P cell regeneration following partial pancreatectomy in rats, this 
appears to be due to its role in inhibiting poly(ADP-ribose) synthetase (Yonemura et 
al, 1984). Experimental states o f diabetes can be instigated by administration o f 
streptozotocin to cause breaks in the DNA strands o f p cells which induces 
poly(ADP-ribose) synthetase, this results in reduced NAD, thus causing inhibition o f 
P cell functions (Yamamoto &  Okamoto, 1980). ICCs isolated from the pancreata o f 
fetal pigs are o f lim ited use as they secrete low amounts o f insulin, however upon 
culture in nicotinamide containing medium these clusters synthesised and secreted 
more insulin (Sjoholm et al, 1994; Otonkoski et al, 1999). The increase in P cell 
number and insulin content could be correlated with increased polyamine levels (i.e., 
spermidine, putrescine and spermine) and the effects o f nicotinamide were blocked by 
inhibitors o f polyamine synthesis (Sjoholm et al, 1994). This is consistent w ith the
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observations regarding the requirement o f polyamines for p cell function (Sjoholm et 
al, 1990; Welsh &  Sjoholm, 1988).
Nicotinamide has been found to have a potent insulinotropic effect on fetal pancreatic 
tissue (resulting in p cell outgrowths) (Otonkoski el al, 1993), and on cultured p cells 
(Ohgawara et al, 1995; Huotari et al, 1998). Direct administration o f nicotinamide 
following partial pancreatectomy in to the OLTEF (Otsuka Long-Evans Tokushima 
fatty strain o f rat) rat model (impaired ability to regenerate P cells) resulted in 
significant increases in P cell mass and ameliorated hyperglycemia (Shima et al,
1998).
1.3.4.5 Sodium Butyrate
Sodium butyrate is a short chain aliphatic acid that occurs naturally in the colon 
through fermentation o f dietary fiber (Otonkoski et al, 1999). Sodium butyrate was 
identified as a differentiation agent for insulinoma cell lines in a study relating 
cessation o f proliferation with differentiation (Philippe et al., 1987). It was found that 
sodium butyrate increased the levels o f insulin and glucagon in cultured RIN cell lines 
through the recruitment o f hormone negative cell lines to differentiate (Powers et al,
1988). Combinations o f sodium butyrate and nicotinamide resulted in significant 
increases in the insulin content o f INS 1 cells and in porcine fetal ICCs (Huotari et al., 
1998; Otonkoski et al., 1999), but this effect was associated w ith increased apoptotic 
cell death (Otonkoski et al., 1999). Sodium butyrate is a member o f a class o f 
compounds known as histone deacetylase (HDAC) inhibitors, this inhibition leads to 
increased histone acetylation. Highly transcribed genes are associated with highly 
acetylated core histones (Marks el al., 2000; Wade et al., 1997). This possibly infers 
the mechanism by which sodium butyrate operates.
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1.4 F9 Cell Biology
Human ES cell lines have only been available for the last two to three years thus most 
o f the research to date has been carried out using mouse ES and EC cell lines. EC 
(Embryonic Carcinoma) cells are derived from testicular or ovarian tumors and 
exhibit similar properties to those o f ES cells (Lethonen et al., 1989). They make an 
excellent model for study due to their ease o f culture and the large cell numbers that 
can be generated, however their applications in therapy may be lim ited due to their 
tumor forming abilities (Dinsmore et al, 1998).
The F9 line was isolated from the OTT6050 teratocarcinoma in 1973 (Bernstein et al., 
1973) and are characterised by their lack o f spontaneous differentiation and thus are 
referred to as being nullipotent (Martin &  Evans, 1975; Alonso et al., 1991). F9 cells 
have a short doubling time (8 hours) during the exponential phase o f growth due to a 
very short G1 phase. Differentiation o f the cells leads to lengthening o f the G1 phase 
and a reduction in  the proliferative ability o f the cells (Linder et al, 1981). It is 
speculated that the short G1 phase o f F9 cells prevents the expression o f the genes 
required for differentiation (Lethonen el al., 1989). This would be consistent with 
observations that inhibitors o f DNA synthesis can induce differentiation o f F9 cells 
(Nishimune etal., 1983; Griep &  De Luca, 1986a).
1.4.1 Diferentiation of F9 cels
1.4.1.1 Spontaneous Diferentiation
Although characterised as being nullipotent, F9 cells have been observed to show 
some low level differentiation in normal culture over time, e.g. low levels o f Ihh 
expression (mRNA and protein) has been detected in untreated F9 cells after 8 days 
culture (Becker et al, 1997). Spontaneous differentiation has also been discovered in 
low-density cultures o f F9 cells i.e., F9 cells plated at a density o f 12 cells/cm2 gave 
rise to neuroblast cells as determined by a silver staining method specific for colonies 
differentiating neuroblasts (Zakany et al, 1984). Mummery et al. (1990) identified 
low level spontaneous differentiation in F9 cultures due to the presence o f transcripts
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for the cytokeratin Endo A (Cytokeratin A  now known as Cytokeratin 8 (M oll et al, 
1982)) and tissue plasminogen activator (tPA).
1.4.1.2 Diferentiation Through the Action of Diferentiation Agents
F9 differentiation studies have generally employed retinoic acid or a combination o f 
retinoic acid and di butyryl cyclic AMP and are described below. Other data 
concerning differentiation agents with roles in |3 cell differentiation are discussed also. 
There do not appear to be any references to any previous F9 studies involving 
betacellulin, HGF or nicotinamide.
1.4.1.2.1 RA and db cAMP
Treatment o f the F9 cells with Retinoic acid (RA) alone or w ith dibutyryl cAMP (db 
cAMP) leads to the differentiation o f F9 cells and is associated with a number o f 
changes in differentiation markers. The action o f RA on genes is most likely mediated 
by the RA receptors (RARs) and retinoid X  receptors (RXR) that are present on the 
nuclei o f most cells. Cytoplasmic proteins such as cellular retinoic acid binding 
protein I or II (CRABP I or II) mediate the binding o f RA to the receptors (Means et 
al., 2000). This leads to the activation o f the receptors to RA responsive elements in 
the promoter regions o f certain genes e.g. laminin (Vasios et al., 1991; Manglesdorf et 
al, 1991).
Upon differentiation with RA or RA/db cAMP, F9 cells are characterised as having 
increased synthesis o f tissue-type plasminogen activator, laminin, collagen type IV, 
cytokeratins (Alonso, 1991; Lehtonen et al., 1989; Mummery et al., 1990; Clairmont 
et al., 1996). Alkaline phosphatase activity is reduced and there is a disappearance o f 
the stage-specific embryonic antigen (Moore et al, 1986). A ll o f these are indicators 
o f parietal endoderm (Alonso et al, 1991). Differentiated F9 cells adopt a number o f 
morphologies dependent on the mode and duration o f the differentiation. Treatment o f 
the cells with RA alone commits the cells to irreversible differentiation after only 8 
hours and brings the cells to a prim itive cell type which is then capable to adopting
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either parietal (PE) or visceral (VE) endoderm (Hogan et al, 1981; Lethonen et 
al, 1989).
1.4.1.2.2 Sodium Butyrate
Sodium Butyrate is a HDAC inhibitor (Section 1.3.4.5) and was found to inhibit RA 
mediated differentiation o f F9 cells i f  added w ithin the initial critical 8 hour period o f 
RA-induced differentiation (most changes in  gene expression occur during this period 
see Section 1.4.1.4) (Levine et al., 1984). Sodium butyrate treated F9 cells 
demonstrate morphological changes as well as changes in protein and gene 
expression, including increased expression o f metallothionen genes, tissue and 
urokinase type plasminogen activator and endo A (Andrews & Adamson, 1987; 
Kosaka et al, 1991; Takeda et al., 1992; Miyashita et al, 1994). Differentiation using 
sodium butyrate was found to inhibit F9 proliferation (Takana et al., 1999). Sodium 
butyrate induced differentiation was largely found to be reversible upon removal from 
the culture medium (Kosaka et al., 1991; Shimada et al., 2001). The effect o f sodium 
butyrate on endo A expression was as a result o f changes in the chromatin structure 
(Miyashita et al, 1994), which suggests its mechanism o f action in differentiation.
1.4.1.2.3 Activin A
F9 cells were found to express Activin pB, levels o f which dropped dramatically upon 
differentiation towards endoderm. This was seen to be consistent with the proposed 
role o f activin in mesoderm formation (Albano et al, 1993). F9 cells were found to 
express 3500-20,000 activin receptors per cell, including activin receptor II B. This 
gene was found to be transcriptionally induced following RA treatment (Kondo et al, 
1989; Wan et al, 1995).
1.4.1.2.4 DMA and BRDU
Differentiation o f F9 cells has been carried out via N’-N’-dimethylacetamide (DMA) 
and 5-bromodeoxyuridine, (Moore et al, 1986). The observations made during this 
differentiation indicate a similar differentiation pathway for RA and BrdU, however
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the differentiated phenotype as a result o f DMA treatment appeared to be unique 
suggesting a novel pathway. Also like the action o f RA and dbcAMP it was found that 
the action o f BrdU and DMA seemed irreversible.
1.4.1.3 Formation of F9 Embryoid Bodies in vitro
When EC cells are cultured in vitro in the absence o f feeder layers/support matrix 
(e.g., gelatin) they m ultiply rapidly for several days and form tight rounded aggregates 
which can be maintained indefinitely. I f  the EC cell line is pluripotent then the outer 
layers o f the aggregates (Embryoid Bodies) w ill differentiate to endodermal-type cells 
without the aid o f differentiation agents. It was also found that nullipotent EC lines 
also formed embryoid bodies, however these exhibit a smooth outer surface o f 
undifferentiated cells (Martin &  Evans, 1975). Subsequent findings demonstrated that 
nullipotent cell lines such as F9 cells could form differentiated embryoid bodies in the 
presence o f RA, with the outer layers being composed o f predominantly alpha- 
fetoprotein expressing visceral endoderm (Hogan et al, 1981; Burdsal et al, 1995; 
M ik i el al, 1999). Embryoid bodies are interesting because they resemble a 5-6 day- 
old embryo. Plating o f embryoid bodies to certain types o f substratum (e.g. gelatin) 
leads to the outgrowth o f the differentiated outer layer. The endodermal cells migrate 
outwards from the bodies forming a ‘halo’ which can give rise to such cells as 
fibroblasts, cartilage, adipose tissue, beating heart muscle and neural tissue (Martin & 
Evans, 1975). It has been discovered that the maturation o f the visceral endoderm 
outer layer in RA primed embryoid bodies o f F9 cells is dependent on the size o f the 
embryoid body. Embryoid bodies w ith diameters o f about 180 fj.m or larger resulted in 
expression o f AFP (M iki, 1999).
1.4.1.4 Diferentiation and Gene Expresion
Differentiation is mediated by the alteration o f gene expression, however it is 
d ifficu lt to determine the genes that are the effectors o f differentiation rather than 
genes that are expressed differently as a result o f differentiation. RNA polymerase I 
based transcription was found to be reduced upon parietal differentiation o f F9 cells 
(Alzuherri &  White, 1999). The first 8 hours o f RA treatment are considered to be the
55
commitment stage o f differentiation in F9 cells (Levine et al., 1984; Alonso et al, 
1991), thus this is the crucial period in which to monitor the in itia l changes in gene 
expression. A  recent study identified 109 differentially expressed genes following 
only 6h differentiation (Harris &  Childs, 2002).
The level o f c-myc oncogene expression in F9 cells is seen to decrease sharply after 
RA treatment, i.e. expression is at 50% o f normal w ithin 3 hours o f exposure and 
decreased by 90% within 12 hours (Greip and DeLuca, 1986). This study also 
demonstrated that other oncogenes were differentially expressed in RA treated F9 
cells, e.g., c-erbB mRNA increased 4 fold between 6 and 9 hours following RA 
treatment (this had been noticed previously by Adamson &  Rees, 1981). The 
regulation o f the c-myc expression following differentiation was linked to methylation 
o f sites w ithin the c-myc gene (Griep &  DeLuca, 1986b). Expression o f the c-myc 
antisense sequence in F9 cells resulted in differentiation similar to that o f mediated by 
RA, sim ilarly overexpression o f c-myc resulted in F9s resistant to differentiation by 
RA (Griep &  Westphal, 1988). Other authors have been unable to reproduce these 
results so they remain controversial (Nishikura el al, 1990).
A similar experiment was reported whereby RA-like differentiation was duplicated 
via the transfer o f the c-fos proto-oncogene into F9 cells (M uller &  Wagner, 1984). 
These results concur with the study where antisense to c-fos was transfected into F9 
cells leading to inhibition o f endodermal differentiation, (Edwards et al, 1988).
Table 1.4.1 outlines a number o f genes that have been altered in F9 differentiation 
experiments.
1.4.1.4.1 Hedgehog gene expresion in Diferentiating F9 Cels
It has been shown that Ihh is upregulated dramatically in the differentiation o f F9 cells 
from EC to an endodermal (visceral or parietal) fate (Becker et al, 1997; Grabel et 
al., 1998). Its role is active and not just structural as determined by transfection o f the 
fu ll length cDNA for Ihh (under an inducible promoter) resulting in morphological 
and other changes indicative o f endodermal differentiation including the expression o f 
alpha fetoprotein and tissue type plasminogen activator (tPA) (Becker, et al, 1997).
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1.4.1.4.2 Negative Regulation of Viral Promoters
While discussing gene expression in F9 systems it should be pointed out that 
undifferentiated F9 cells appear to possess a negatively acting factor(s) which 
prevents/reduces the transcription o f viral promoters. This effect is more pronounced 
in retroviral promoters. This block is absent in differentiated F9 cultures (Kelly and 
Condamine, 1982). Studies have demonstrated that heterologous genes can be driven 
at high efficiency by the GRP78 promoter in undifferentiated F9 cells (K im  el ah, 
1990), possibly providing an alternative to constitutive viral promoters for F9 studies. 
Nowling et al. (2002) have recently presented protocols on highly efficient 
transfection o f F9 cells via liposome mediated gene transfer.
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Genes with altered expression levels in differentiated F9 cells
Gene F9 (Untreated) Diferentiated F9 Cels
Alkaline Phosphatase + -
Apolioprotein E + -/++'
Bmp2# + ++
Bmp4# ++ +
CRABP1*** ++ -/+
Cytokeratins 8 and 18 - +
EGF Receptors + ++
Enactin - +
Era-1 - +
Fetomodulin - +
c-fos - ++
G LU T3**** ++ +/-
Indian Hedgehog** - ++
Laminin + ++
c-myc + +/-
Retinol Binding Protein - +
Sparc - +
TGFß2 - +
Transferrin Receptors + +
Type IV  Collagen - +
Table 1.4.1 A selection o f genes with altered expression levels as a result o f 
differentiation o f F9 EC cells. (*= varying levels). Table adapted from Alonso et al. 
(1991) and references therein.
(**Becker et al., 1997)
(***Means et al., 2000)
(****Faria et al., 1998)
(#Grabel, et al., 1998)
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1.4.2 Monitoring F9 Differentiation
1.4.2.1 Monitoring of F9 Diferentiation by Intermediate Filament Expresion
Intermediate filament expression patterns are classic markers for the differentiation- 
state of cells. Undifferentiated EC lines express only vimentin (Paulin et a l ,  1982). 
Overexpression o f vimentin in F9 cells leads to aberrant vimentin structures and the 
collapse of K8/K18 filaments in the differentiated phenotype (Andreoli & Trevor,
1995). The differentiation of F9 cells to PE via RA and RA/db cAMP, respectively, 
results in the cells expressing large amounts o f cytokeratin filaments (8 & 18) and a 
reduction in vimentin expression (Kurki et al., 1989; Paulin et al., 1982; Ramaekers et 
al., 1984). Using a monoclonal antibody against keratin 18 it was shown that this was 
induced in at least 50% o f F9 cells differentiated with RA and cAMP (Ramaekers et 
al, 1984).
1.4.2.2 Integrin expresion in Diferentiating F9 Cels
p i integrin expression has been found to be extremely important to F9 differentiation. 
When the p i integrin genes were disrupted (F9 cells maintain three copies o f the 
gene, so triple knockout lines (TKO) had to be generated), the parental cells showed a 
disrupted morphology and demonstrated poor adhesion to typical p i integrin 
substrates such as laminin or fibronectin. More interesting however was the 
observation that the triple knockout (TKO) cell lines did not differentiate normally 
when exposed to RA and/or db cAMP. The morphology o f RA treated cells was 
altered. However it was also discovered that the TKO cells, while not appearing to be 
properly differentiated, did express the correct tissue specific markers one would 
expect from the above treatments (Stephens et al, 1993). Following RA induced 
differentiation o f F9 cells there is a switch in the expression levels o f different 
integrin subunits, namely there is a reduction in a5 p iand  a massive increase in the 
a 3 p i  subunit (Burdsal, et al, 1994). The p i integrin subunit was also shown to be up- 
regulated in a study o f RA mediated differentiation o f F9 cells (Ross et al., 1994).
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1.4.2.3 Gap Junctions and Connexin Expression in Differentiating F9 Cells
F9 EC cells express connexins 26, 32 and 37 while the differentiated primitive and 
parietal endoderm cells express connexins 26,32, 37 and 43. Connexin43 is the most 
abundant and thus more relevant in F9 communication (van der Heyden et al, 2000). 
External agents that alter the differentiation-state o f the cell regulate cell-to-cell 
communication, i.e. tumor promoting factors tend to down regulate communication 
with differentiating agents tending to promote it (Clairmont et al, 1996). This group 
discovered that RA (10~7 M) can increase cell-cell communication due to increases in 
connexin43 (Cx43) mRNA and protein. The change in Cx43 appears to be incidental 
to the differentiation of F9 cells i.e. it does not have an active role in the process.
1.4.3 Pluripotency of F9 Cels
As discussed, the F9 cell line shows some low-level spontaneous differentiation and is 
typically induced to differentiate with agents such as RA. The cell types generated by 
this treatment have been limited thus F9 cells were considered unsuitable for the study 
o f overall development. However in a study where the action o f RA was retarded by 
conditioned medium from STO fibroblasts or by using 10~8 M RA rather than 10'7 M, 
it was found, that low density cultures of F9 cells expressed the differentiation 
markers o f a number o f cell types, such as parietal and visceral endoderm, adipocytes, 
neurons, fibroblasts and trophoblasts (Koopman & Cotton, 1987). F9 cells were also 
found to be capable o f expressing neuronal markers following RA/db cAMP 
treatment, and if  nerve growth factor was also applied the adrenergic neuronal marker 
tyrosine hydroxylase was expressed (Liesi et al., 1983). Zakany et al. (1984) 
identified neuronal markers in spontaneously differentiated F9 cells generated from 
single cells, merocyanine-540 incorporation also indicated the presence of electrically 
excitable membranes. Certain neuronal markers were found to be constitutively 
present within undifferentiated F9 cultures and a subclone o f F9, D9L2, was shown to 
be capable o f extending neurites and expressing several neuronal antigens under 
conditions o f serum depravation (Murtomaki et a l, 1999).
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1.5 Engineering ß Cells for Replacement Therapy in IDDM
(3 cells have been used in the treatment o f diabetes in the form of pancreas or islet 
transplants (this procedure is typically carried out with or after a kidney transplant). 
Although this therapy has shown some success, there is a problem with the 
availability of donor tissue, thus the regulated expression of the human insulin gene 
has been examined in non-p cell lines. These cell lines would represent a continuous 
source o f replacement material. Somatic cell therapy has been proposed as another 
option i.e. whereby cells would be isolated from a patient, transfected with the human 
insulin gene, purified characterised and replaced in to the body (Bailey et al, 1999). 
This would overcome immunological considerations as the cells would not be 
considered as foreign. Finally insulinoma cell lines have been generated through 
transformation of p cells, these cells already have the correct machinery for proinsulin 
biosynthesis and processing and can be expanded to large numbers in culture.
1.5.1 Insulinoma Cel Lines as a Treatment for IDDM
Cell lines derived from insulinoma tumors have been generated and are of interest due 
to the fact that these cells have the cellular machinery required for GSIS, however 
thus far these cell lines have mostly been derived from rodents.
1.5.1.1 RIN 1046-38 (RIN-38)
The rat derived RIN cell line was one of the first isolated from radiation induced rat 
tumors (Gazdar et al., 1980). These cells were found to show a 5-9 fold increase in 
secretion upon glucose stimulation sub-physiological levels. As the passage number 
increased the cells were seen to show decreased cellular insulin and they lost GSIS 
capability (Clark et al., 1990). RIN-38 cells transfected with the human insulin gene, 
glucokinase and GLUT2 and the human insulin gene with glucokinase alone, 
demonstrated increased cellular insulin and a higher fold response that in the parental 
population. These RIN-derived cells had a maximal glucose stimulation at 25 jj.M 
glucose due to the expression o f low km hexokinases (Hohmeier et al., 1997) thus
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limiting thier usefulness for therapy unless those enzymes were knocked out by 
molecular means.
1.5.1.2 P-Tumor-Cel (PTC) Cel Lines
pTC cell lines are derived from transgenic mice expressing the SV40-T-antigen 
oncogene under the control o f the insulin promoter. This results in expression of the 
T-antigen (Tag) in p cells and immortalization o f the cell line (Soria et ah, 2000b). 
Although the cells exhibit GSIS, the phenotype is unstable and can be lost through 
serial passaging. When single cell clones were isolated from the BTC6 cell line 
however, two of the resultant cell lines were found to maintain GSIS for over a year in 
culture. This was due to the fact that these clones contained high 
glucokinase/hexokinase ratios and no GLUT1 expression (only GLUT2) (Knaack et 
ah, 1994).
1.5.1.3 INS-1
INS-1 cells were derived from an x-ray-induced insulinoma. The continued growth of 
these cells was found to be dependent on the presence o f 2-mercaptoethanol. INS-1 
cells secrete insulin in response to glucose signals and were shown to demonstrate 
approximately 2.2-fold stimulation of insulin secretion upon glucose stimulation 
(Asfari et al., 1992). Other researchers have noted 4 -13 fold increases in insulin 
secretion from INS1 upon stimulation with glucose (Hohmeier el al., 2000). The cells 
proliferate extremely slowly (doubling time ~ lOOh) and have maintained stable 
glucose responsiveness for 2 years (80 passages) (Asfari et al., 1992). This cell line is 
an ideal model for the study o f P cells due to its differentiated nature.
1.5.1.4 Min6
Min6 cells were isolated from insulinomas from SV40 T antigen expressing mice and 
were shown to exhibit an increase in insulin secretion o f almost 10-fold upon 
stimulation with 25 mM glucose (Miyazaki et al., 1990). However literature data 
varies from 2-fold to 10-fold increase in secretion between 3 and 25 mM glucose
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(Kayo et al., 1996; Ishihara et a l, 1993, Zhao & Rutter, 1998). The reported stability 
o f Min6 in culture also varies. Min6 cells are described as being fully GSIS capable at 
passage 3CM0 (Miyazaki et al., 1990; Ishihara et al., 1995), however Kayo et al. 
(1996) identified a mere 1.2 fold increase in secretion at passage 35 (from 5 mM to 25 
mM glucose). Loss o f GSIS in Min6 cells was accompanied with a decrease in the 
proinsulin processing enzymes PCI (PC3) and PC2 with a concomitant increase in 
furin that, was linked to Min6 cells adopting a de-differentiated state with increasing 
passage number (Kayo et al., 1996). Min6 cells are also known to express glucagon, 
somatostatin and IAPP (Ohgawara et al., 1995; Kanatsuka et al., 1992). Culture of 
Min6 in an agarose-PVMA-collagen matrix led to the formation o f islet like cell 
clusters (ICCs). In the presence o f nicotinamide the ICCs maintained GSIS and were 
in a better state o f preservation than ICCs cultured without nicotinamide. These ICCs 
were implanted into chemically induced diabetic mice (in a diffusion chamber) and 
maintained normoglycemia for up to 12 weeks (Ohgawra et al., 1995). Min6 cells 
inoculated subcutaneously into the backs of an obese-diabetic-model mouse 
(C57BL/KsJ-db/db) formed a vascularised tumor and effected a return to 
normoglycemia for 100 days, although the obesity was unchanged (Inada et a l,
1996). Min6 cells cultured on gelatin coated flasks can form 3-D structures with good 
cell- cell contacts, Formation of these ‘pseudoislets’ relied upon the expression of the 
Ca2+ dependent adhesion molecule E-cadherin (E-CAD). Pseudoislets generated from 
non-responsive Min6 cells (passage 43-53) were seen to have restored glucose and 
secretagogue stimulated insulin secretion (Hauge-Evans et al., 1999). Thus the Min6 
ICCs or pseudoislets would be ideal for IDDM therapy if  they were engineered to 
express the human insulin gene, and if  the endogenous insulin genes could be 
disrupted as these may illicit an immunological response in a human.
1.5.2 Enginering of non-P Cel Lines to Synthesise and Secrete Human Insulin
Most o f the work regarding replacement therapies for IDDM has centred on the 
engineering of non-(3 cell lines to secrete insulin. The advantage of non-P cells is that 
these cells do not express the antigenic determinants that are targeted in the 
autoimmune destruction of p cells in IDDM. Ideally the cells should have some of the 
features o f P cell lines which would allow them to regulate the synthesis and secretion
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o f insulin (Mitanchez et al, 1997). No such complete cell line exists so existing cell 
lines have been modified via gene transfer to resemble functional P cell lines. The 
main cell types investigated are discussed below.
1.5.2.1 Neuroendocrine Cels as Artificial p Cels
A variety o f neuroendocrine cell lines contain secretory granules to allow for storage 
and regulated secretion o f peptide hormones e.g., the adrenocorticotropic hormone 
(ATCH) secreting cell-type AtT20 from the anterior pituitary (Newguard, et a l,
1997). These cells have other features which make them suitable for the regulated 
expression and secretion o f insulin such as the expression o f the PCI (PC3) and PC2 
prohormone convertases (Smeekens et a l, 1991; Bennet et a l, 1992) and the high km 
glucose phosphorylating enzyme glucokinase, even though this was not accompanied 
by GLUT2 expression (Hughes et a l, 1991). Proinsulin synthesis, processing and 
secretion upon stimulation following transfection into AtT20 cells was reported by 
Moore et a l  (1983). The insulin-expressing AtT20ins cells were found to be glucose 
responsive between 0 and 2.5 mM glucose i.e. below the physiological range of 
glucose but demonstrated large secretagogue stimulated secretion using agents known 
to increase intracellular cAMP, such as db cAMP and 8-bromo-cAMP (Moore et a l, 
1983; Hughes el a l, 1991). Transfection o f AtT20ins cells with GLUT2 resulted in a 
large increase in the insulin content o f AtT20ms cells and to a more significant GSIS, 
however this was maximal at 10 ,uM glucose which is far below the point at which p 
cells respond to glucose (4-5 mM). It was discovered that although the AtT20ins cells 
expressed glucokinase, the predominant glucose-phosphorylating enzyme in the cell 
was its low km counterpart hexokinase I (Hughes et al., 1992). Previous studies have 
shown that overexpression of hexokinase I can abolish GSIS in p cells (German,
1993). Similar results were obtained in another study whereby GLUT2 and insulin 
were co-transfected in to AtT20 cells. These researchers noted maximal GSIS at 
around 50 jjM, also the hexokinase I inhibitor 2 deoxy-glucose caused an increase of 
insulin secretion at all glucose concentrations up to 10 mM glucose. Thus it was 
theorised that the glucokinase:hexokinase I ratio was too low to achieve proper GSIS 
in AtT20 cells (Davies et a l, 1998). This was confirmed by the overexpression of 
glucokinase, GLUT2 and insulin in AtT20 cells which resulted in GSIS over the
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whole physiological range. These cells also demonstrated glucose potentiation upon 
stimulation o f the cells with agents that cause closure o f the potassium channels e.g., 
glibenclamide (Motoyoshi et al., 1998).
Although this cell line appears to have addressed all the requirements for an artificial 
(3 cell line, the inherent secretion of ACTH is undesirable. ACTH secretion leads to 
adrenal glucocorticoid secretion which can cause insulin resistance (Stewart et a l,
1994). Following implantation if insulin secreting AtT20inS cells to streptozotocin 
diabetic mice, overgrowth o f the cells led to tumor-like growths with a periphery of 
healthy cells surrounding a necrotic core (Stewart et al 1994., Davies et al., 1998). 
This highlights the requirement for physical containment to prevent implant- 
overgrowth which would also provide a barrier to prevent immunological rejection.
1.5.2.2 Hepatocytes as Artificial p Cels
Hepatocytes are possibly the only other cell type to have the same glucose sensing 
system as p cells i.e. GLUT2 and glucokinase (Mitanchez et al., 1997). Initial 
experiments with rat hepatoma cells (FAO cells) demonstrated that proinsulin 
processing was present in these cells (albeit inefficient) despite the fact that these cells 
secreted the transfected protein constitutively (Vollenweider et al., 1992). The human 
hepatoma cell line HEP G2 was also shown to be capable o f processing transfected 
insulin and the mature form of the peptide was preferentially stored while there was 
constitutive release o f the unprocessed proinsulin. These cells were observed to 
exhibit secretagogue stimulated insulin secretion (SSIS) following stimulation with 
agents leading to increased intracellular cAMP such as 8-bromo-cAMP or 
theophylline. Mature-processed insulin was predominantly secreted as a result o f SSIS 
and these cells were not capable of GSIS (Simpson et a l, 1995). Cultured HEP G2 
cells do not express the high capacity glucose transporter GLUT2 (Permutt et a l,
1989) and are therefore missing a critical component o f the glucose sensing system. 
Overexpression of GLUT2 in the insulin secreting HEP G2 cell line (HEP G2ins) 
resulted in GSIS capability over the entire physiological range, although initial 
minimal stimulation occurred at ~ 2 mM glucose which is lower than that the minimal 
stimulation level in P cells (4-5 mM) (Simpson et a l, 1997).
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Efficient processing of insulin in rat hepatoma cells (FTO-2B) was achieved by 
genetically engineering the PC1/PC2 cleavage sites so that they were susceptible to 
cleavage by the ubiquitous endoprotease furin as described by Groskerutz et a l, 
(1994) (Figure 1.5.1). Expression of the mutant proinsulin resulted in 90% conversion 
o f proinsulin to mature insulin (Gros et a l, 1997).
The liver has also been considered a viable target for direct gene therapy for diabetes. 
Studies have already been carried out on transgenic mice expressing wild type and 
furin cleavable proinsulin in their livers and also on mice infected with adenoviral 
vectors carrying these forms o f insulin (Mitanchez et a l, 1998; Auricchio et al,
2002).
B Peptide C Peptide A Peptide Wild type proinsulin
cleavable by PCI &
A  À
PC2
KTRR J.QKR 
Site directed mutagenesis
B Peptide C Peptide A Peptide
Mutant proinsulin 
cleavable by furin
A  A
RTKR RQKR
Figure 1.5.1 Site directed mutagenesis o f wild type proinsulin to render it susceptible 
to cleavage by the ubiquitous endoprotease furin.
1.5.2.3 Enginering Fibroblasts as Artificial f3 Cels
Fibroblasts would not be considered as the ideal choice for an artificial (3 cell due to 
the fact that they only posses constitutive protein secretion pathways and do not have 
the capacity to store and process proteins (Kelly, 1985). However, fibroblasts would 
be considered an excellent option for ex-vivo somatic cell therapy. This would involve 
the removal o f a convenient cell type (without causing trauma to the patient), 
transfection o f the insulin gene (and any extra genes to aid processing, etc.), selection
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and characterisation o f  transfected cells, cell stock generation and re-implantation o f  
the patients own cells (thus avoiding im m unological rejection) (Bailey et a l ,  1999). 
Temporary reversal o f  diabetes in m ice has already been demonstrated by 
transplanting primary human fibroblasts expressing furin cleavable proinsulin (Falqui 
e t a l ,  1999).
Initial work with m ouse Ltk' fibroblasts led to the generation o f  insulin secreting cells 
Ltk+Ins cells which were characterised as secreting proinsulin constitutively. 
Implantation o f  these cells into diabetic m ice led to norm oglycemia after two weeks 
(proinsulin is 8-20% as effective as insulin (Taniguchi e t a l ,  1997; Selden et a l ,  
1987; Falqui et a l ,  1999)), however these animals eventually died due to implant 
overgrowth and the resulting hypoglycem ia (Selden et a l , 1987). This also occurred 
in a study by Kawakami et a l  (1992). This group also designed a system  whereby the 
transplanted cells could be specifically rem oved by the co-transfection o f  an antigenic 
determinant that could be specifically targeted by a m onoclonal antibody. Regulated 
secretion o f  proinsulin from fibroblasts was achieved through an inducible promoter 
system  (which regulates the secretion at the level o f  protein availability) (Kawakami 
e t a l ,  1992). Encapsulation o f  Ltk+Ins cells in 5% agarose prevented overgrowth o f  
the proinsulin secreting fibroblasts w hile allow ing proinsulin secretion unimpeded. 
These encapsulated cells were capable o f  growing for up to 80 days in culture and 2 x 
107 encapsulated cells maintained norm oglycem ia in m ice for up to 30-50 days 
(Taniguchi e t a l ,  1997). The constitutive release o f  endogenous insulin is reported to 
significantly aid in control o f  IDDM  in patients and may prevent som e diabetes- 
associated complications (Falqui e t a l ,  1999). In an attempt to confer GSIS to 
fibroblast cells, Vero cells were co-transfected with furin cleavable proinsulin, 
GLUT2 and glucokinase. Although the cells did manage to process 62 % o f  the 
proinsulin formed to mature insulin, the cells were not rendered glucose sensitive by 
the presence o f  GLUT2 and glucokinase (the GLUT2 expression was predominantly 
nuclear, which may have affected glucose sensing) (O ’Driscoll e t a l ,  2 0 0 2 ).
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1.5.3 BHK-21 Cells as Artificial (3 Cells
BHK-21 cells have not as yet been transfected with the human insulin gene and were 
considered a suitable cell line for research due to the fact that the cells have already 
been used in a cell-therapy based clinical trial for amyotropic lateral sclerosis (ALS) 
(Aebischer e t a l ,  1996). BHK cells were engineered to constitutively secrete human 
ciliary neurotrophic factor (hCNTF). The cells were encapsulated and implanted in a 
tethered device intrathecally, which allow ed for retrieval o f  the implanted cells. Thus 
these cells have already been considered safe for human therapy. A lso BHK cells can 
grow in serum free m edia (Merten e t a l ,  1999), which is advantageous for a 
therapeutic cell line.
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1.6 Aims of this Thesis
Previous work by other researchers has focused on the generation o f  (3-like cell lines 
from ES cells, but there are difficulties with maintaining these cell lines in culture in 
an undifferentiated state and they require expensive medium supplements and/or 
feeder cell layers. EC lines e.g. F9 cells, have not been reported in any such studies as 
o f  yet. F9 cells exhibit low  spontaneous differentiation as long as the cells are 
maintained in the active growing phase (Nishim une e t ah, 1983; Griep & D e Luca, 
1986a) and are easy to culture and maintain. Although F9 cells were characterised as 
differentiating towards a number o f  cell types, the methods used were essentially 
random (Section 1.4.3). Thus it was undertaken to design a ‘directed differentiation’ 
protocol to push F9 cells towards an endocrine lineage using the follow ing steps:
1. Generation o f  partially differentiated parietal (PE) and visceral (VE) from 
F9 cells.
2. Treatment o f  these resultant cell types with endocrine differentiation 
agents and monitoring crucial endocrine differentiation markers via RT- 
PCR and im m unological techniques (where applicable).
3. To purify PDX1 expressing sub-populations from F9/ differentiated F9 
cells using cell trapping (Klug e t ah, 1996; Soria et al., 2000a; Section
1.3.2.1) and to characterise the resultant cells.
4. To investigate the effects o f  overexpression o f  genes believed to be 
relevant to pancreatic development in partially differentiated F9 cells.
The stability o f  cultured insulinom a cell lines with regard to the maintenance o f  GSIS 
is an important issue i f  such cells are to be used for therapeutic applications. M in6  
cells had been characterised as almost adopting a de-differentiated phenotype with 
increased passage number (Kayo e t al., 1996).
Thus this system afforded a useful m odel system  in which to investigate the changes 
occurring in the de-differentiating (3 cells. This was considered to be important as it 
may identify important markers/junction points which could aid in directed 
differentiation o f  F9 cells towards (3 cells. It also allow ed the opportunity to
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investigate why the cells were loosing their specialised function during their time in  
culture.
This study was addressed using D N A  microarrays and RT-PCR to identify the 
differences between the GSIS-capable and G SIS-deficient M in6 s.
Finally, much research has been carried out on the generation o f  artificial p cells 
through the direct genetic m odification o f  non-p cell lines. A s BHK-21 cells had 
already been em ployed in an approved human clinical trial (Aebischer e t ah, 1996), it 
was proposed that these cells m ay be a suitable target for such modification, In 
carrying out this work it w as hoped to obtain a suitable therapeutic cell line but also to 
examine the factors involved in  regulated protein expression and secretion.
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2.0 MATERIALS AND METHODS.
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2.1 Cell Culture Methods
2.1.1 Water
Ultrapure water was used in the preparation o f  all m edia and solutions. Initially the 
water was pre-treated which involved activated carbon, pre-filtration and anti-scaling. 
This water was then purified by a reverse osm osis system  (M illipore M illi-RO 10 
Plus, Elgastat UHP) to a standard o f  12 -1 8  M Q /cm  resistance.
2.1.2 Treatment of Glasware
A ll solutions for use in cell culture and maintenance were prepared and stored in 
sterile glass bottles. Bottles (and lids) and all other glassware used for any cell-related 
work were prepared as follows: - all glassware and lids were soaked in a 2 % (v/v) 
solution o f  RBS-25 (AG B Scientific) for at least 1-hour. This is a deproteinising 
agent, which rem oves proteineous material from the bottles. Glassware was scrubbed 
and rinsed several times in tap water, the bottles were then washed by machine using 
Neodisher detergent, an organic, phosphate-based acid detergent. The bottles were 
then rinsed tw ice with distilled water, once with ultrapure water and sterilised by 
autoclaving.
2.1.3 Sterilisation
Water, glassware and all thermostable solutions were sterilised by autoclaving at 
121°C for 20 minutes (min) under pressure o f  lbar. Thermolabile solutions were 
filtered through a 0.22 jim sterile filter (Millipore, m illex-gv, SLG V -025BS). Low  
protein-binding filters were used for all protein-containing solutions.
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2.1.4 Media Preparation
M edium was routinely prepared and sterility checked b y  Mr. Joe Carey (technician) as 
in SOP NCTCC 003-02. The basal media used during routine cell culture were 
prepared according to the formulations shown in Table 2.1.1. lOx m edia were added 
to sterile ultrapure water, buffered with HEPES and NaH C 0 3  and adjusted to a pH o f  
7.45 - 7.55 using sterile 1.5M NaOH and 1.5M HC1. The m edia were then filtered 
through sterile 0.22jim  bell filters (Gelman, 121-58) and stored in 500m l sterile 
bottles at 4°C. Sterility checks were carried out on each 500m l bottle o f  medium as 
described in Section 2.2.8.
The basal media were stored at 4°C up to their expiry dates as specified on each 
individual lOx medium container. Working stocks o f  culture media was prepared as 
100ml aliquots, supplemented with L-glutamine (Gibco, 25030-024) and fetal ca lf  
serum as required. This was stored for up to 2 w eeks at 4°C, after which time, fresh 
culture medium was prepared.
DMEM
(Gibco, 12501- 
029)
Hams F12
(Gibco, 21700- 
109)
MEM
(Gibco, 21430- 
0 2 0 )
10X Medium 500m l Powder 500m l
Ultrapure H20 4300m l 4700m l 4300m l
1M HEPES*
S ig m a , H -9136
1 0 0 ml 1 0 0 ml 1 0 0 ml
7.5% NaHC03 
B D H , 30151
45m l 45m l 45m l
* HEPES =N -(2-H ydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
Table 2.1.1 Preparation o f  basal media
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F9 EC cell lines were cultured in DMEM supplemented with 10% FCS (Sigma, 
F7524, lot N o.-010K 3361). and 4 inM L-Glutamine. M in6  cells were routinely grown 
in DMEM supplemented with 20% FCS (heat inactivated for 35 minutes at 56 °C). 
For DLKP, ATCC medium (H am ’s F12/ DMEM (1:1)) was supplemented with 5% 
FCS and 2mM L-glutamine (Gibco, 25030-024). BHK-21 cells and clones were 
cultured in MEM supplemented with 5% FCS, 2mM L-glutamine, IX NEAA (Gibco, 
11140-035) and IX  sodium pyruvate (Gibco, 11360-039).
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2.2 Methods Used in Maintaining Ceil Lines
2.2.1 Safety Precautions
A ll cell culture work was carried out in a class II dow n-flow  re-circulating laminar 
flow  cabinet (Nuaire B iological Cabinet) and any work, which involved toxic 
compounds, was carried out in a cytoguard (Gelman). Strict aseptic techniques were 
adhered to at all times. The laminar flow  cabinet was swabbed with 70% industrial 
methylated spirits (IMS) before and after use, as were all item s used in the cabinet. 
Each cell line was assigned specific m edia and waste bottles and only one cell line 
was used at a time in the cabinet, which, was allowed to clear for 15min between 
different cell lines. The cabinet itse lf was cleaned each w eek with industrial 
detergents (Virkon, Antec. International; TEGO, TH.Goldschmidt Ltd.), as were the 
incubators.
The cell lines used during the course o f  this study, their sources and their basal media 
requirements are listed in Table 2.2.1.
2.2.2 Culture of Adherent Cel Lines
The cell lines employed during the course o f  this research are listed in Table 2.2.1, these
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cells were generally maintained in non-vented 25 cm (Costar, 3050) and 75 cm flasks 
(Costar, 3075) or vented 25 cm 2 (Costar, 3056), 75 cm 2 (Costar 3376) and 175 cm 2 
flasks (Nunclon, 178883). F9 cells were maintained on a layer o f  0.1 % gelatin (Sigma 
G1890). Coating o f  flasks was carried out by adding enough gelatin to cover the tissue 
culture surface o f  the flask, these were then placed at 4 °C for at least 2 hours (usually 
overnight). The flasks were then rinsed X3 in sterile UHP. These coated flasks were 
stored at room temperature until required.
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Cel Line Source of Cel Line Medium Cel Type co2
Requirement
F9 ATCC (CRL-1720) DMEM Undifferentiated Murine EC 
Line
5% C 02
Min6 Dr. Per Bendix Jeppesen DMEM Murine ß Cell Line 5% C 02
BHK-21 NCTCC MEM Hamster Fibroblast Cell Line 5% C 02
DLKP NCTCC ATCC
Medium
Poorly Differentiated Human 
Squamous Carcinoma
No C 02 
Requirement
Table 2.2.1 Cell lines used in this thesis including sources, growth conditions and type. 
2.2.3 Subculture of Adherent Cel Lines
During routine sub-culturing or harvesting o f  adherent lines, cells were removed from 
their flasks by enzymatic detachment. The follow ing protocol outlines the methods 
used in subculturing F9, BH K  and DLKP cell lines.
Waste medium was removed from the flasks and rinsed with a pre-warmed (37°C) 
trypsin/EDTA (TV) solution (0.25%  trypsin (Gibco, 25090-028), 0.01% EDTA  
(Sigma, E5134) solution in PBS (Oxoid, BR14a)). The purpose o f  this was to 
eliminate any naturally occurring trypsin inhibitor, which w ould be present in residual 
serum. Fresh TV was then placed on the cells (lm l/25cm 2 flask or 2m l/75cm 2 flask) 
and the flasks were incubated at 37°C until the cells were seen to have detached (5 
min). The trypsin was deactivated by addition o f  an equal volum e o f  growth medium  
(i.e. containing serum). The entire solution was transferred to a 30m l sterile universal 
tube (Greiner, 201151) and centrifuged at 1,000 rpm for 5 m in (F9 cells were 
centrifuged at 125 x g for 10 minutes). The resulting cell pellet w as re-suspended in 
pre-warmed (37°C) fresh growth medium, counted (Section 2 .2.5) and used to re-seed  
a flask at the required cell density or to set up an assay.
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2.2.3.1 Subculture of Min6 Cell Lines
M in6  flasks were emptied o f  conditioned medium and rinsed in pre-warmed IX  
Ca2+/M g2+- free PBS (Gibco 14200-067). Trypsin/EDTA was then added (1 m l/ 25 
cm 2 flask and 2 m l/ 75 cm 2 flask) and incubated at 37°C for 2 minutes exactly. The 
flask was tapped sharply to dislodge the cells and then 5 ml o f  culture medium was 
added to inhibit the trypsin. The cell suspension was aspirated gently and with care to 
avoid separating the cells in to a single cell suspension. Follow ing this the cells were 
centrifuged at 900 rpm for 5 minutes. The resulting pellet was re-suspended in pre­
warmed culture medium, counted (Section 2.2.5) and re-seeded to flasks or assay 
plates. M in6  cells were never re-seeded back in to the same flask.
2.2.4 Subculture of Suspension Embryoid Bodies
Culture o f  F9 cells at a cell density o f  1 x  105 cells/ml in mini bacteriological-grade petri 
dishes (Greiner, 627102), resulted in the formation o f  aggregates called embryoid bodies 
(EBs). These cells grew in suspension and thus did not require enzymatic detachment. 
Subculture was effected by gentle removal o f  the cells to a universal using a Pasteur 
pipette (Copan, 200CS01). The EBs were separated from the medium using gentle 
centrifugation at 100 x  g for 10 minutes. Following centrifugation the universals were 
treated gently as the pellet was quite loose and the waste medium removed carefully 
using a Pasteur pipette. The pellet was gently re-suspended in pre-warmed medium and 
the EBs were transferred to new petri dishes.
2.2.5 Cel Counting
Cell counting and viability determinations were carried out using a tryphan-blue 
(Gibco, 15250-012) dye exclusion technique.
An aliquot o f  tryphan-blue was added to a sample from a single cell suspension in a 
ratio o f  1:5. After 3 m in incubation at room temperature, a sample o f  this mixture was 
applied to the chamber o f  a haemocytometer over which a glass coverslip had been  
placed. Cells in the 16 squares o f  the four outer com er grids o f  the chamber were
counted m icroscopically. A n average per comer grid was calculated with the dilution
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factor being taken into account and final cell numbers were m ultiplied by 1 0 4 to 
determine the number o f  cells per m l (volum e occupied by sample in chamber is 
0 . 1 cm x 0 . 1 cm x 0 .0 1 cm i.e. 0 .0 0 0 1 cm 3 therefore cell number x 1 0 4 is equivalent to 
cells per m l). Non-viable cells were those, which stained blue w hile viable cells 
excluded the tryphan-blue dye and remained unstained.
2.2.6 Cel Frezing
To allow long term storage o f  cell stocks, cells were frozen and cryo-preserved in 
liquid nitrogen at temperatures below  -180°C . Once frozen properly, such stocks 
should last indefinitely.
BHK-21 and DLKP were frozen using the standard freezing m ethod as follows. Cells 
to be frozen were harvested in the log phase o f  growth (i.e. actively growing and 
approximately 60-70%  confluent) and counted as described in Sections 2.2.5. 
Pelleted cells were re-suspended in serum and an equal volum e o f  a DM SO/serum  
(1:9, v/v) freezing solution. The freezing solution was slow ly  added (drop-wise) to the 
cell suspension (as DM SO  is toxic to cells). A  final concentration o f  at least 5x106 
cells/m l was generated. The suspension was then aliquoted into cryovials (Greiner, 
122 278) which were then quickly placed in the vapour phase o f  liquid nitrogen 
containers (approximately -80°C). After 2.5 to 3.5 hours, the cryovials were lowered 
down into the liquid nitrogen where they were stored until required.
2.2.6.1 Frezing F9 EC Cels
F9 Cells were trypsinised as outlined previously (Section 2.2.3), w hile the cells were
being trypsinised, freezing m edium  (a filter sterilised mixture o f  DMSO/culture
medium (1:19 v/v)), was pre-chilled on ice as were labelled cryovials. Upon isolation
o f  the cell pellet, the cells were re-suspended in the freezing medium to give
approximately 1-5 x 106 cells/m l and aliquoted in to the pre-chilled cryovials. These
cryovials were placed in the centre o f  an enzym e box (Boehringer M annheim), (i.e.
with Styrofoam surrounding the cryovial on all sides) and placed at -  80°C. This
method o f  freezing ensures an approximate cooling rate o f  l°C /m in. The cells could
be stored like this for long periods but to spread out the cell stocks, som e vials were
stored in liquid nitrogen (after at least 12 hours at -80°C ).
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2.2.6.2 Freezing of Minó Cells
Prior to trypsinisation o f  M in6  cells, a freezing medium containing DM SO  and FCS 
was prepared (1:4) and filter sterilised. The freezing medium was then placed on ice 
until ready. The cryovials were also placed on ice at this point. M in6  cells were 
trypsinised as outlined previously (Section 2.2.3.1). The pellet was re-suspended in 
culture medium to give a cell density o f  5 x  106 — 1 x 107 cells/m l. To this suspension, 
an equal volum e o f  freezing medium was added, dropwise, with stirring on ice. This 
suspension was aliquoted to cryovials (also on ice). The cryovials were cooled on ice 
for 10 minutes, and then transferred to a -20°C  freezer in a Boehringer Mannheim  
enzym e box for 1 hour. Follow ing this, the cells were placed at -80°C  for at least 12 
hours. The cells could be stored at this temperature for long periods, reserve stocks 
were placed in liquid nitrogen containers however.
2.2.7 Cel Thawing
For thawing M in6 , BHK-21 cells and DLKP, very similar thawing protocols were 
employed. Immediately prior to the removal o f  a cryovial from the liquid nitrogen 
stores for thawing, a sterile universal tube containing 5 m l growth medium was 
prepared. This allowed for the rapid transfer and dilution o f  thawed cells to reduce 
their exposure time to the DM SO  freezing solution (it is toxic at room temperature). 
The cryovial was partially thawed and its contents were transferred to the universal. 
The suspension was centrifuged at 1,000 rpm for 5 m in (900 rpm for M in6 ), the 
DM SO-containing supernatant was removed and the pellet was then re-suspended in 
fresh growth medium. Viability counts were carried out (Section 2.2.5) to determine 
the efficacy o f  the freezing/ thawing procedures. A  sample was also taken for sterility 
analysis (Section 2.2.8). Thawed cells were placed into tissue culture flasks with the
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appropriate volum e o f  medium (10m l/25cm  flask and 15m l/75cm  flask) and allowed  
to attach overnight. M in6  medium was pre-warmed and conditioned in a vented flask 
in the presence o f  5% CO2 for at least 30 minutes prior to thawing. 24 hours after 
thawing, the cells were re-fed with fresh medium to remove any residual traces o f  
DM SO.
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2.2.1.\  Thawing F9 EC Cells
Prior to thawing F9 cells, 14 m l o f  culture m edium  was placed in a gelatin coated 25 
cm 2 flask (vented) and conditioned for temperature and pH in a CO2  incubator for at 
least 30 minutes. The frozen F9 cryovial was then thawed and the contents were 
transferred directly in to the medium. A  sample was taken for cell counting, viability 
(Section 2.2.5) and for sterility checks (Section 2.2.8). This medium was changed 12- 
24 hours later.
2.2.8 Sterility Checks
Sterility checks were routinely carried out on all media, supplements and trypsin used 
for cell culture. Samples o f  basal m edia were inoculated into Columbia (Oxoid, 
CM 331) blood agar plates, Sabauraud (Oxoid, CM 217) dextrose and Thioglycollate 
(Oxoid, CM 173) broth’s which should between them detect m ost contaminants 
including bacteria, fungus and yeast. Growth m edia (i.e. supplemented with serum 
and L-glutamine) were sterility checked at least 3 days prior to use by  incubating 
samples at 37°C. These were subsequently examined for turbidity and other 
indications o f  contamination. Freshly thawed cells were also subjected to sterility 
checks.
2.2.9 Mycoplasma Analysis
M ycoplasm a  examinations were carried out routinely (at least every 3 months) on all 
cell lines used in this study. These analyses were performed by Dr. Mary Heenan, 
Ms. Bojana Cumpf, and Mr. M ichael Henry.
2.2.9.1 Indirect Staining Procedure
In this procedure, M ycoplasm a -negative NRK cells (a normal rat kidney fibroblast
line) were used as indicator cells i.e. these cells were incubated with supernatant from
test cell lines and then examined for M ycoplasm a  contamination. N R K  cells were
used for this procedure because cell integrity is w ell maintained during fixation. A
fluorescent H oechst stain was utilised which binds specifically to D N A  and so will
stain the nucleus o f  the cell in addition to any M ycoplasm a  D N A  present. A
80
M ycoplasm a  infection would thus be seen as small fluorescent bodies in the 
cytoplasm o f  the NRK  cells and sometim es outside the cells.
NRK  cells were seeded onto sterile coverslips in sterile Petri dishes (Greiner, 633 
185) at a cell density o f  2 x l0 3 cells per m l and were allow ed to attach overnight at 
37°C in a 5% CO2 , humidified incubator. 1 ml o f  cell-free (cleared b y  centrifugation 
at 1,000 rpm for 5 min) supernatant from each test cell line was then inoculated onto a 
NRK petri dish and incubated as before until the cells reached 20 - 50% confluency  
(4-5 days). After this time, the waste medium was removed from the petri dishes, the 
coverslips (Chance Propper, 22 x 22 mm) were washed tw ice with sterile PBS, once 
with a cold PBS/C am oys (50/50) solution and fixed with 2m l o f  Cam oys solution 
(acetic acid:m ethanol-l:3) for 10 min. The fixative was then rem oved and after air 
drying, the coverslips were washed tw ice in deionised water and stained with 2 ml o f  
Hoechst 33258 stain (BDH ) (50ng/m l) for 10 min.
From this point on, work proceeded in the dark to limit quenching o f  the fluorescent 
stain.
The coverslips were rinsed three times in PBS. They were then mounted in 50% (v/v) 
glycerol in 0.05M  citric acid and 0.1M  disodium phosphate and examined using a 
fluorescence m icroscope with a U V  filter.
2.2.9.2 Direct Staining
The direct stain for M ycoplasm a  involved a culture method where test samples were 
inoculated onto an enriched M ycoplasm a  culture broth (Oxoid, CM 403) - 
supplemented with 20% serum, 10% yeast extract (Oxoid L21, 15% w /v) & 10% 
stock solution (12 .5g D -glucose, 2 .5g L-arganine & 250 m is sterile-filtered UHP). 
This medium was designed to optim ise the growth o f  any contaminants and was 
incubated at 37°C for 48 hours. Samples o f  this broth were then streaked onto plates
o f  M ycoplasm a  agar base (Oxoid, CM 401) which had also been supplemented as
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above and the plates were incubated for 3 weeks at 37°C in a CO2 environment. The 
plates were view ed m icroscopically at least every 7 days and the appearance o f  small, 
“fried egg” -shaped colonies would be indicative o f  a m ycoplasm a infection.
2.3 Specific Cel Culture Techniques Employed in this Thesis
2.3.1 Diferentiation Studies
Differentiation Studies were carried out using the differentiation agents listed in Table 
2.3.1.
Diferentiation Agent Suplier Stock
Concentration
Working
Concentration
A ll trans Retinoic A cid (RA) Sigma (R2625) 1 0 '3 M 1 0 '7 M
D i Butyryl cAM P (db cAM P) Sigma (D 0260) 1 0 0  m g/ml 1 0 'JM
Activin A Sigma (A 4941) 2 0  |J.g/ml 2 n M
Betacellulin (BTC) Sigma (B 3670) 2  (.ig/ml 1 nM
Hepatocyte Growth Factor 
(HGF)
R & D system s 
(294-HG)
5 |J,g/ml 100 pM
Nicotinam ide (N ico) Sigm a (N 0636) 10 mM 10 mM
Sodium Butyrate (Sod But) Sigma (B 5887) 1 mM 1 mM
Table 2.3.1 Differentiation agents used in the course o f  this work 
2.3.1.1 Reconstitution of Diferentiation Agents
_ __ _ _  n
RA was reconstituted in 95% EtOH to a final concentration o f  10' M. R A  was 
aliquoted and wrapped in foil as it is light sensitive, it was routinely stored at -80°C . 
db cAM P was re-suspended in UH P (pH adjusted to exactly 7.0) to a final 
concentration o f  100 mg/ml. The resulting solution was aliquoted, wrapped in foil (it 
is also light sensitive) and stored at - 2 0  °C. Immediately prior to differentiation 
assays, cAM P stocks were diluted by a factor o f  203.5 in complete m edium to achieve 
the correct working concentration (10'3M ) . This was then filter sterilised. The stock 
solutions o f  the recombinant proteins activin A , BTC and HGF were made up in PBS-
0.1% B S A  to the desired concentration. These were aliquoted in working volum es and 
stored at - 2 0  °C until required. Imm ediately prior to differentiation assays, these stock 
solutions were diluted in complete m edium  to the working concentration and filter 
sterilised using a 0.22 |im filter. Both nicotinamide and sodium butyrate were
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supplied in stable powder form and were reconstituted to the correct working 
concentrations imm ediately prior to any differentiation experiments. The 
reconstitution was carried out in complete medium and they were dissolved at 37°C, 
after which, they were filter sterilised.
2.3.1.2 Diferentiation Asays
2.3.1.2.1 Stage 1 (Endodermal) Diferentiation
All differentiation assays were carried out on F9 monolayers or on F9 EBs (Section
2.2.4). M onolayer experiments were carried out in 6  w ell plates (pre-coated in 0.1% 
gelatin) w hile EB experiments were carried out in mini-petri dishes. M onolayers were 
seeded at 1 x 104  cells/w ell and to generate EBs, F9 cells were seeded at 1 x  105 
cells/m l in m ini petri dishes (2 m l/ dish). M onolayer cells were allow ed to attach
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overnight, and the follow ing day, were treated w ith R A  (10“ M) or R A  in 
combination with db cAM P (10 ' 3 M). EBs were treated with R A  (10 "7 M ) only. The 
cells were exposed to these compounds for 72 hours at 37°C in a 5% CO2 atmosphere. 
The plates and dishes were wrapped in foil as R A  and db cAM P are light sensitive.
2.3.1.2.2 Stage 2 (Endocrine) Diferentiation
For second stage (endocrine differentiation), cells from Stage 1 differentiation were 
fed directly in their w ells with the agents listed in Table 2.3.1, combinations o f  the 
individual agents w ith activin A  were also used. On day 3, the w ells were fed again 
with the endocrine differentiation agents. Re-feeding o f  the EBs has already been  
outlined (Section 2.2.4). On day 5 the w ells and EB dishes were subcultured to 
prevent overconfluence. M onolayer w ells were rinsed in 1 ml PBS and then exposed  
to 200 \i\/ trypsin-EDTA per well. The trypsin reaction was incubated for 5 min at 
37°C. To stop the trypsin action, 1 m l o f  complete m edium was added/well. The cell 
suspensions were then centrifuged at 125 x g for 10 minutes and l /3 rd o f  the each 
pellet was re-seeded in to a new well. On this day also, the EBs were subcultured as 
outlined (Section 2 .2.4) but each pellet (representing the EBs from 1 dish) was re­
suspended in enough differentiation medium for 2 m ini petri dishes. The treatments 
were again carried out on day 7-8 and the experiments were sampled on day 10 
(Section 2.3.1.3).
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2.3.1.3 Sampling Differentiation Assays
2.3.1.3.1 Fixing Cels for Imunofluorescence/Imunocytochemistry
Upon reaching the end o f  stage 1 or stage 2 differentiation, m onolayer samples were 
rinsed 3X  in PBS. 2 ml o f  ice cold methanol was added to each w ell and the plates 
were incubated at —20°C for 7 minutes and removed. The plates were allow ed to air- 
dry, wrapped in foil and stored at -20°C . EB samples were seeded on to gelatin coated 
w ells for 48 hours. This allow ed the outgrowth o f  the differentiated outer layer prior 
to fixing and storage.
Immunofluorescence and immunocytochemistry are described in Section 2.5.2.2.
2.3.1.3.2 Taking Samples for Western Analysis
Upon reaching the end o f  stage 1 differentiation, m onolayer w ells were trypsinised as 
indicated in Section 2 .3 .1 .2 .2 , the resultant cell pellets (in universals) were washed in 
PBS (X2). PBS washes were follow ed by centrifugation at 1000 rpm (to ensure a firm 
pellet). The excess PBS was allowed to drain o f f  and the pellets were stored at -80°C  
until required for protein extraction and western analysis (Section 2.5.2.1). EB pellets 
were generated by directly centrifuging the EBs from solution as during subculture 
(Section 2.2.4) and then washing the resulting pellets in PBS (2X ) using 1000 rpm 
spins. These pellets were drained and stored at -80°C  until required.
2.3.1.3.3 Taking Samples for RT-PCR Analysis
Samples for RT-PCR were taken in exactly the same manner as in obtaining cell 
pellets for western blotting except the pellets were then dissolved in TriReagent™ 
(Sigma, T9424). These samples were then stored in pre-autoclaved eppendorf tubes 
(Eppendorf, 0030 121 023) at -80°C  until required for R N A  isolation (Section
2.5.1.2.1).
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2.3.2 Miniaturised In Vitro Toxicity Assays
In vitro  toxicity assays were carried out to determine the lethal ranges o f  antibiotics 
prior to transfection experiments and to determine the effectiveness o f  transfected 
constructs (e.g. Section 3.3.1.2).
2.3.2.1 Asay Procedure
Cells in the exponential phase o f  growth were trypsinised as outlined in Section 2.2.3 
and were then seeded in to 96 w ell plates (Costar, 3599). The seeding density 
reflected the growth rate o f  the cell line being used i.e. cell lines with high growth 
rates were seeded at lower densities (Table 2.3.2). The seeding density was chosen to 
allow  a healthy growing cell line to achieve 80-90%  confluence in 7 days. When 
carrying out toxicity assays on F9 cells, the plates needed to be coated with 0.1%  
gelatin prior to use. This was carried out by adding 50 p.1 0.1% gelatin/well for 2 hours 
at 4°C followed by 3X  UHP rinses (100 |xl/well/rinse). A ll rinsing and seeding work 
with 96 w ell plates was carried out using a multichanell pipette.
Cel Line Seding Density For 96 Wel Plates
BHK-21 5 x 102/w ell
F9 5 x 102/w ell
M in6 5 x 103/w e ll- l x  104/w ell
Table 2.3.2 96 w ell plate seeding densities for in vitro  toxicity assays.
The cells were seeded to the w ells and m ixed gently to give an even spread o f  cells 
and to prevent clumping. The plates were incubated overnight at 37°C to allow  the 
cells to attach. The follow ing day the culture m edium was removed and 100 |il 
aliquots o f  antibiotic containing medium was added to each w ell. The antibiotic 
concentrations were arranged in an ascending fashion and untreated cells were 
included as controls. The plate was laid out so that each concentration o f  antibiotic 
corresponded to an entire row (i.e. the plate is arranged in an 8  x  1 2  grid) therefore 
each concentration o f  the antibiotic was exposed to 8  individual w ells (i.e. n= 8  for 
each concentration point used). After 6  days culture (or when the control w ells were
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80% confluent) the effects o f  the antibiotic were calculated using the acid phosphatase 
assay (Section 2.3.2.2).
2.3.2.2 Asesment of Cel Number via Acid Phosphatse Asay
Follow ing the in vitro  toxicity assay the m edia was removed from the plates and the 
plates were rinsed 3X  in PBS (100 (.il/well). Upon removal o f  the PBS the cells were 
incubated (100 (il/w ell ) in freshly prepared acid phosphatase substrate (10 mM  p -  
nitrophenol phosphate (Sigm a 104-0) in 0.1 M sodium acetate (Sigm a, S8625), 0.1%  
triton X -100 (BDH , 30632), pH 5.5). This incubation w as carried out for 2 hours at 
37°C and the plates were wrapped in foil due to the light sensitive nature o f  the p -  
nitrophenol phosphate. The reaction was stopped by addition o f  50 jj,l 1M NaOH to 
each w ell. The plates were read at 405 nM  using a Spectramax plus plate-reader 
(Molecular D evices) and the data was processed using specialised software (SoftM ax 
Pro).
2.3.3 Measurement of Celular Proliferation
2.3.3.1 Proliferation Asay Experimental Protocol
M in6  cells were seeded at a density o f  5 x  104 cells/w ell in 24 w ell plates (Costar, 
3524). The cells were allowed to attach overnight at 37°C in a 5% CO2 incubator. On 
each day follow ing initial seeding, the cells were trypsinised (Section 2.2.3.1) and 
counted (Section 2.2.5). Each w ell was counted on both counting chambers o f  a 
Hem ocytom eter and three w ells were counted each day. Thus n= 6  for the count per 
day. The proliferation assay was carried out for a total o f  7 days (168 hours).
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2.3.4 Transfection of Mammalian Cell Lines
2.3.4.1 Optimisation of Transfection
Prior to any transfection experiments, the transfection protocol was optim ised for the 
plasmid, cell line and the transfection agent available. This was done using a reporter 
plasmid, pC H llO  (Invitrogen), which encodes p galactosidase activity.
Cells were seeded to w ells at different concentrations and allowed to attach and 
initiate growth overnight. The follow ing day, the cells were transfected with pC H l 10, 
using different amounts o f  plasmid (1-2 p,g) and transfection agent. The cells were 
generally transfected in the presence o f  serum for 24-48 hours. In the case o f  F9 cells, 
the differentiation-state o f  the cells was also altered to investigate i f  transfection 
efficiency could be further increased. Follow ing the transfection, the cells were rinsed 
2X  in cold PBS and fixed for 5 min in ‘fixing solution’ (2% Formaldehyde, (Sigma, 
F8775)). This was follow ed by 2X  PBS washes. Staining was carried out in x-gal 
medium (1M  M gCl2 (Sigma, M 8266), 5 M  NaCl (MERCK, K 1880814), 0.5 M  Hepes 
(Sigma, H 9136), 30 mM  Potassium Ferrocyanide (Sigm a, P9387), 30 m M  Potassium  
Ferricyanide (Sigm a, P8131), 2% X-gal (Sigm a B4252)). Positively transfected cells 
were identified by blue staining, thus the transfection method with the highest blue : 
unstained ratio was chosen for future transfection experiments.
2.3.4.2 Transient Transfection of F9 EC lines with Nuclear Transcription Factors
F9 cells were found to have very low  transfection efficiency upon transfection o f  
undifferentiated cells, thus, prior to transient transfections, cells were differentiated 
using stage 1 differentiation (Section 2.3.1.2.1) in the presence o f  R A  and db cAMP. 
On the day o f  the assay the liposom e transfection agent Fugene6 (Boehringer 
Mannheim, 1 814 443) was m ixed with the D N A  to be transfected in a 3:1 ratio and 
allowing 2 p.g D N A / w ell. The components were m ixed in 100 (il serum free medium  
(SFM ) per w ell to be transfected. The Fugene6 was added to the SFM and care was 
taken not to allow  it to touch the sides o f  the eppendorf. The D N A  was then added. 
The components were m ixed by gentle tapping and allowed to sit for 25 minutes at 
room temperature. During this period the medium was changed on the w ells to be 
transfected and on the control w ells. After 25 minutes had elapsed 100(4.1 o f  the
transfection m ix/w ell was added to the relevant w ells in a drop-wise fashion with  
constant swirling. The transfections were carried out over 48 hours and then the w ells  
were sampled for imm unofluorescence (Section 2 .3 .1 .3 .1) or RT-PCR (Section
2.3.1.3.3).
2.3.4.3 Generation of Stably Transfected Cel Lines
To generate stably transfected BHK-21 cells expressing PPI, glucokinase and GLUT2 
(the plasmids used are described in Section 2.4.1) four flasks were set up per 
transfection, i.e. three for transfection and one as a control. The cells were seeded at 3 
x 105 cells/flask and allowed to attach overnight. The transfection was carried out 
using the Lipofectamine Plus™ system  (Gibco BRL, 10964-013). For each plasmid
2.5 [xg (in 1 pi) was added to 9 (j.1 Lipofectamine Plus solution, and this was then 
added to 190 (j,l SFM. Simultaneously 12 pi Lipofectamine w as added to 188 (J.1 SFM. 
These solutions were allowed to sit at room temperature for 15 min before being  
added to 5.6 ml com plete medium (MEM). This was added to the three 25 cm 2 flasks 
for transfection (2ml/flask). The flasks were incubated overnight at 37°C and at 5% 
CO2 . The follow ing day, the flasks were rinsed 2X  in PBS to remove residual 
Lipofectamine reagents and were re-fed with complete medium. Antibiotic selection  
com m enced 48 hours after transfection and the relevant cells and their controls were 
selected with initial concentrations o f  10 jig/ml for zeocin  (Invitrogen, 46-0509) and 
hygrom ycin (Roche, 843 555) and 200 ng/ml G418 (Sigm a, G9516). The 
concentration o f  the selection agents were incrementally increased over time until the 
contents o f  the control flasks were all dead. The final selection concentrations reached 
in the BHK-21 system  were 150 |.ig/ml (Hygromycin), 100 pg/m l (zeocin) and 1 
m g/m l (G418).
2.3.4.3.1 Generation of Clonal Populations From Stably Transfected Mixed 
Populations
To generate clonal populations from stably transfected BHK-PPI cells, the cells were 
diluted and plated out in 96 w ell plates, such that, the probability was that one cell 
would be found in every third w ell (i.e. a plating suspension o f  3.3 cells/m l). These 
plates were incubated overnight at 37°C and at 5% CO2 . 12 hours after plating, the
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plates were examined and w ells containing single cells were highlighted and 
monitored. Up to 20 clones were usually isolated and gradually expanded to 12 w ell 
plates, 6 w ell plates and eventually flasks.
2.3.5 Insulin Secretion Asays for Monolayer Cels
2.3.5.1 Constitutive Insulin Secretion Asay
To determine the constitutive secretion rate for proinsulin secreting BHK-PPI-C16 
cells, 2 x  105 cells/w ell were seeded to 6 w ell plates and allowed to attach in complete 
medium (MEM) overnight. The next day, the cells were rinsed three times in PBS 
(pre-warmed) and then subsequently incubated in glucose-free m edium for two 
separate 15-minute periods. The cells were then exposed to serum-free MEM  
containing 0.1% B S A  for 0, 1, 2, 4, 8 and 24 hours o f  incubation. At each time point 
the medium was collected and stored at -20°C  for later analysis (Section 2.5.2.3) and 
the cells were lysed in lysis buffer (20 mmol Tris pH 8.0, 2 m m ol ethyleneglycol- 
bis(aminoethylether)-tetraacetic acid, 1 % Triton X -100, 10% glycerol, 1.5 mmol 
M gCL 137 m m ol NaCl, 1 m m ol, N a3V 0 4 , IX  protease inhibitor cocktail (Boehringer 
M annheim 169 7498), 5% BSA). These lysates were also stored at - 2 0  °C for insulin 
analysis (Section 2.5.2.3).
2.3.5.2 Glucose Stimulated Insulin Secretion (GSIS) Analysis Using BHK- 
Derived Clones
For GSIS analysis insulin secreting BH K  cells were seeded in to 6 w ell plates at a cell 
density o f  2 x 10s cells/w ell. The cells were allowed to attach overnight and in the 
morning were pre-treated in the same manner as the cells used for constitutive 
secretion assays (Section 2.3.5.1). For GSIS, the cells were exposed to serum-free 
MEM supplemented with 0.1% B S A  and increasing amounts o f  glucose (Sigma, 
G 6152) (i.e. to generate m edia containing 0, 5, 10, 15 and 20 mmol/1 glucose) for 2 
hours. The conditioned medium was removed after the assay and either directly 
analysed (Section 2.5 .2 .3) or stored at -2 0  °C for later analysis.
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2.3.5.3 GSIS Analysis of Cultured Min6 Cells
Due to the sensitive nature o f  M in6 cells and their slow  growth, M in6 cells were 
handled differently to m axim ise their GSIS response. M in6 cells o f  passage 16-23 
were used for GSIS during the course o f  this work.
M in6s were seeded at a cell density o f  2 x  105 cells/w ell in a 24 w ell plate (taking care 
not to generate a single-cell suspension (Section 2.2.3.1)). These cells were allowed to 
grow for 72 hours prior to the GSIS assay. On the day o f  the assay IX  KRB was 
prepared from a aliquot o f  frozen 10X stock (36.525g NaCl, 2 .2g KC1, 0.941 g 
CaCl2.2H20 ,  1.22g M gC l2.6H20 ,  29.8g HEPES dissolved in 500 m l H20 ) .  B SA  was 
added to a final concentration o f  0.1%. The K R B-BSA  was pH adjusted to 7.36 
exactly with 1 M NaOH. This was heated to 37°C and the pH was maintained in a 
37°C incubator with a 5% C 0 2 atmosphere (30 min). G lucose concentrations o f  0, 3.3, 
10, 16.7 and 26.7 mmol/1 were constituted in the conditioned IX  KRB and were then 
placed at 37 °C and 5% C 0 2 for 30 min. After this, the conditioned medium was 
removed carefully from the Min6 w ells and the w ells were rinsed (X 2) in IX  KRB. 
The M in6 cells were then equilibrated at 3.3 mM  glucose for 30 minutes at 37°C. 
After equilibration, the 3.3 mM  glucose was removed, and the glucose containing 
stimulation m edia were administered (lm l/w ell). GSIS was carried out over 60 
minutes and was stopped by placing the entire plate on ice. 500 fa.1 o f  conditioned 
medium was removed from each w ell and placed in an ice-cold  eppendorf. These 
were spun at 2500 rpm for 5 minutes and 200 (0.1 o f  the supernatant was taken and 
stored at -20°C  until analysis (Section 2.5.2.3). The attached cells were lysed in 0.1 M 
NaOH and stored at -20°C  for later protein analysis (Section 2.5.2.1.2).
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2.4.1 Plasmids Used During the Course of this Thesis
2.4 Plasmid DNA Manipulation
cDNA Plasmid Source
(3 Galactosidase PCH110 Invitrogen
Cell Trap Construct PGK-TKCAT-Zeo/pBS Cytom yx (Cambrige)
PDX1 P cD N A 3-P D X -1 (FLAG) Y. Kajimoto (Japan)
Beta2 PCR3.1-Beta2 J. Tsai (Baylor Inst.)
Ngn3 PcDN A3-Ngn3 I. Kojim a (Japan)
N kx2.2 PBAT12.shNkx2.2 M. German (UCSF)
PPI* PT-PPI Cytom yx (Cambrige)
Glucokinase** PcDN A3.1/H yg/G CK Cytom yx (Cambrige)
GLUT2** PcD N A 3. l/Zeo/G LUT2 Cytom yx (Cambrige)
* The human PPI cD N A  in pBM Gneo-hlnsulin was kindly donated by Prof. H. 
Nakauehi (University o f  Tsukuba, Japan).
** Glucokinase and GLUT2 supplied as phIGLK2 and P-7-G LUT2 by Prof. M. A. 
Permutt (W ashington School o f  M edicine, St Louis, MO).
Upon receipt o f  plasmids bacteria were transformed with the plasm id to create ‘Mini 
Preps’ o f  the plasmid for analysis, upon confirmation o f  plasm id integrity further 
glycerol bacterial stocks were prepared and ‘M axi Preps’ o f  plasm id D N A  were 
prepared.
2.4.2 Transformation of Bacteria
100 fil o f  competent JM 109 bacterial cell suspension (Promega, L2001) was m ixed  
w ith 1-50 ng D N A  (in a volum e not greater than 10 p.1) in a pre-chilled eppendorf and 
m ixed by flicking. The tubes were placed on ice for 10 minutes. Follow ing this, the 
tubes were heat shocked at exactly 42°C for 50 seconds after which they were 
returned to the ice for 2 minutes. 900 (il o f  cold LB medium (lO g Tryptone (Oxoid, 
L42), 5g Yeast Extract (Oxoid, L21), lOg NaCl (Merck, K 1880814), made up to 1 L 
with UHP, pH adjusted to 8.0 with NaOH and autoclaved) w as added to the JM109 
cell suspension. The JM 109 cells were then incubated at 37°C for 60 min with shaking
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(~  225 rpm). Follow ing this, the cell suspension was diluted 1/10 and 1/100 and all 
three were plated out on LB agar plates (4 g Tryptone, 2g Yeast Extract, 2g NaCl, 6 g 
Agar (Sigma, A 5054) m ixed in 400 ml UHP and pH adjusted to 7.5. The agar was 
then autoclaved. To pour the plates, the agar was m elted gently in an autoclave) 
containing 100 pg/m l Am picillin (Sigm a, A 9393) (Am picillin was added to the 
molten agar once it had cooled to < 55°C). These plates were incubated overnight at 
37°C. Single colonies were isolated the next day and streaked on fresh LB-Agar 
plates.
2.4.3 DNA Miniprep of Plasmids
Single colonies were isolated from LB/Amp plates and incubated in universals 
containing 5 mis LB/Amp. These were shaken at 180-225 rpm for 16-24 hours. 
Follow ing this, 1.5 m l was taken from each tube, placed in an eppendorf and 
centrifuged at 8500 rpm on a bench-top microfuge. The supernatant was decanted and 
another 1.5 ml o f  culture was added and spun down as before. The samples were 
mini-prepped using the Stratagene Clearcut™ system  (Stratagene, 400732). The cell 
preps were re-suspended in 105 jo.1 solution 1. To this, 125 pi solution 2 was added 
and the tube was m ixed by inversion. Finally, 125 pi solution 3 was added and m ixed  
by inversion, the eppendorf was then placed on ice for 5 minutes. The tubes were then 
spun at 8500 rpm for 5 minutes and the supernatants were carefully removed. Also  
supplied with the kit was a specific D N A  binding resin that w as re-suspended by  
vortexing. 15 pi o f  this resin was added to the supernatant from the previous step and 
m ixed-in by  inversion. The resin-supernatant m ixes were loaded on to the provided 
‘spin cups’ and centrifuged at 13,000 for 30 s. These cups allow ed the resin and its 
bound D N A  to be preferentially retained. 400 pi o f  the supplied wash buffer 
(generated b y  diluting a concentrate solution 1:2 with 100% EtOH) was then passed 
through the spin cup by centrifuging at 13,000 for 30 s (this step was carried out 
twice). The D N A  was eluted by adding 50 pi UHP to the spin cup and placing it in a 
clean, autoclaved eppendorf which was then spun at 13,000 for 30 s. The eluted D N A  
could be stored at -2 0  until required.
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2.4.3.1 Quantification of DNA Using a UV Spectrophotometer
The plasmid D N A  was quantified using a U V  spectrophotometer (M olecular D evices) 
at 260 rnn, B y  simultaneous measurement o f  the OD at 280 nm the relative purity o f  
the sample could be ascertained. The amount o f  D N A  was calculated from the 
follow ing formula:
OD 260 x  50 x Dilution factor/1000 =  D N A  amount (p.g/fil)
The relative purity could be calculated using:
Purity =  OD 260/O D 280 
Purity values o f  1.8 -  2 were considered suitable for transfection and PCR purposes.
2.4.4 Restriction Enzyme Digestion of Plasmid DNA
A ll plasmids isolated were electrophoresed on 1% agarose gels (Section 2.5.1.5.3) to 
check for degradation, upon confirmation o f  undegraded plasmid D N A , the plasmids 
were digested using restriction enzym es (REs) to confirm the plasm id contained the 
correct fragments in the correct orientation. The standard RE digestion m ix is outlined 
below:
Component Volume per Reaction (u.1)
H20  (UHP) 11
RE Buffer 2
B S A  (1 m g/m l) 2
D N A  (0.5 ng/(il) 1
R E #  1 2
RE #  2 2
Total Volume 20 ill.
Specific REs are more efficient in particular RE buffers, in cases where two REs were 
optimised for different buffers, a comprom ise was made to m axim ise cutting 
efficiency for both. This information can be obtained in the Promega Catalogue.
The digests were carried out at 37°C in a water bath for 1 hour.
D igests were examined by the addition o f  2 fil 6X  electrophoresis loading buffer 
(Section 2 .5 .1 .5 .3) to 10 |il o f  the digestion m ix and electrophoresed on 1% agarose 
gels with an appropriate size marker. The banding pattern was then examined for the 
expected fragments.
2.4.5 Large Scale Plasmid Preparation
A  single colony o f  transformed bacteria (Section 2.4.2) was inoculated in to 1 ml o f  
LB broth containing 100 |ig/m l Am picillin. This was allowed to grow for at least 8 
hours at 37°C with shaking (-2 2 5  rpm). After 8 hours the 1 m l inoculum was 
transferred under sterile conditions to 400 ml (LB-Amp) and grown overnight at 37°C 
with shaking. This culture w as then split between two centrifuge buckets and spun at
6,000 x g in a Beckman centrifuge (JA-14 rotor) for 15 minutes at 4°C. For 
purification o f  the plasmid D N A  from these transformed bacterial pellets, The 
Quiagen M axi (100) kit was used (Quiagen, 12165). The pellets were re-suspended in 
10 m l buffer PI (ensuring that RNase A  solution (provided) had been added to a final 
concentration o f  100 (J-g/ml) until no cell clumps remained (this was to ensure 
efficient lysis). Once the pellets had been re-suspended, 10 ml o f  buffer P2 was added 
to each re-suspended pellet, and gently m ixed by inversion, these solutions were 
allowed to incubate at room temperature for 5 minutes. 10 ml o f  buffer P3 was then 
added and im m ediately m ixed by inversion (gently). The resultant solutions were 
centrifuged at 20,000 x g for 30 min at 4  °C (JA-14 rotor) and the plasmid containing 
supernatant w as imm ediately removed to pre-washed, autoclaved, polypropylene 
tubes. The supernatant was m ixed gently and immediately re-centrifuged at 20,000 x 
g at 4°C for 15 minutes (JA-17 rotor). The D N A  extraction colum ns (Quiagen-tip 
500) to be used were equilibrated during this step. This was done by  adding 10 ml o f  
buffer QBT to the tip and allow ing it to drain through via gravity. Once the tip was 
pre-equliabrated, the re-centrifuged supernatant was loaded on to the tip and drained
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b y gravity. Once the supernatant had passed com pletely through the Quiagen tip it 
was washed tw ice in the provided wash buffer (QC). The D N A  w as finally eluted 
using 15 ml buffer QF per tip. Isolation o f  the D N A  was carried out b y  adding 10.5 ml 
room temp isopropanol to the eluted DNA/Q F-contaim ng solution with m ixing. The 
precipitated D N A  was isolated by centrifuging the tubes at 15,000 x  g for 30 minutes 
at 4 °C. The D N A  pellet was washed (X 2) using 5 m l 100% EtOH follow ed by spins 
o f  15,000 x  g for 10 minutes. The washed D N A  pellet was air-dried for 5-10 m in and 
finally dissolved in 100-200 jlxI  TE buffer (10m M  Tris, 1 m M  EDTA). The D N A  was 
quantified as described (Section 2.4.3.1) and run out on a 1% agarose gel to confirm  
plasmid integrity and size (Section 2.5.1.5.3).
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2.5 Analytical Techniques and Assays
2.5.1 RNA Analysis
2.5.1.1 Preparation for RNA Analysis
R N A is easily degraded by RNase enzym es which are ubiquitous, thus the following  
precautions were taken prior to RN A work.
All solutions for R N A  related work, i.e. that would com e in to contact w ith the R N A  
were prepared from sterile UHP that had been treated w ith 0.1% diethyl 
pyrocarbonate (DEPC) (Sigma, D 5758) before autoclaving. Solutions for R N A  work 
were made in bottles that had been baked at 180°C for 8 hours or more. A ll 
eppendorfs PCR tubes used etc. were RNase free and pre-autoclaved prior to use as 
were G ilson pipette tips. Disposable nitrile gloves were worn at all tim es during RNA  
work (to protect the operator and to prevent RNase degradation). The gloves were 
changed frequently during R N A  manipulation. For a full review o f  the precautions to 
be taken w hile working with R N A  then it is advised to refer to O ’ D riscoll et al. 
(1993).
2.5.1.2 RNA Isolation
2.5.1.2.1 RNA Isolation using TriReagent
RNA was extracted from cultured cells, cells follow ing differentiation treatment and 
transfected cells from a variety o f  sources including flasks, plates and petri dishes. In 
all cases the cells were initially trypsinised (Section 2.2.3) to pellet form, lysed in 
TriReagent (Section 2 .3 .1 .3 .3) and stored at - 8 0  °C until required.
The follow ing protocol outlines the method whereby pure R N A  was isolated from 
TriReagent. The frozen TriReagent samples were allow ed to thaw at room  
temperature and upon thawing, were allowed to sit for at least 5 m inutes to ensure 
complete dissociation o f  nucleoprotein com plexes. 0.2 ml o f  chloroform was added 
per ml o f  TriReagent in the sample. This was shaken vigorously for 15 s and the
samples were allowed to stand for 15 minutes at room temperature. The sample was
97
then centrifuged at 13,000 rpm for 15 minutes at 4 °C. Follow ing centrifugation, the 
sample separated in to three layers, the upper aqueous layer containing the RNA, the 
interphase (D N A ) and the red layer containing the protein. The upper layer w as thus 
carefully removed to a fresh eppendorf and 0.5 m l o f  isopropanol (Fluka, 59304) was 
added to the aqueous R N A  solution per ml o f  TriReagent used initially. The tubes 
were m ixed w ell and allowed to stand at room temperature (15-20 minutes). This 
effected the precipitation o f  the RNA, which was then recovered by  centrifugation at
13,000 rpm for 10 min. The R N A  was washed (2X ) in 75% EtOH and air dried for 5- 
10 minutes. The recovered R N A pellet was then dissolved in 12-20 pi DEPC treated 
H 2 O with repeated pipetting. To aid re-suspension o f  the RN A, the sample was also 
heated to 55°C for 10 minutes followed by cooling on ice. R N A  was aliquoted and 
stored at -80°C  until required.
2.5.1.2.2 RNA Isolation for DNA Aray Analysis
2.5.1.2.2.1 RNA Isolation Using RNeasy Spin Columns
For reproducible results using D N A  arrays the initial R N A  had to be o f  extremely 
high quality, thus the RN easy (Quiagen 74104) system  was used. Cell pellets for 
R N A  extraction (pellets had been flash frozen in liquid nitrogen upon harvesting and 
stored at -80°C .) were re-suspended in 1.2 ml o f  buffer RLT (which was 
supplemented with 10 pl/m l o f  (3 mercaptoethanol) which was then vortexed to loosen  
the pellet. The lysed pellet was aspirated a number o f  tim es and vortexed until the 
sample was com pletely hom ogenised. 1 volum e (1.2 m l) o f  70% EtOH was added to 
the hom ogenised sample and m ixed w ell by pipetting. This mixture was then loaded 
in 700 pi aliquots on to an R N easy m ini column which was placed in a collection tube 
and centrifuged at 8,000 x g for 15 seconds (i.e. this was continued until the entire 
mixture had been passed through the column). Once all the hom ogenised cells had 
been passed through the column, the washes were carried out. Initially 700 pi RW1 
was loaded on to the column and centrifuged at 8,000 x g for 15 s. This was closely  
follow ed by 2 x washes in buffer RPE (also follow ed by centrifuging at 8,000 rpm for 
15 s). To com pletely dry the spin column, it was placed in a fresh collection tube and 
centrifuged at full speed for 1 minute. The R N A  was eluted by passing two lots o f  25 
pi R N ase free water (supplied) through the column by centrifuging it at 8 ,000 rpm for
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1 minute. The eluted R N A was then quantified (Section 2.5 .1 .3) and carried on for 
D N ase I treatment.
2.5.1.2.2.2 DNase I Treatment of RNA for DNA Aray Analysis
A ny D N A  isolated with the R N A  during the extraction procedure would affect the 
results in D N A  array analysis thus the samples were treated with D N ase I to remove 
any contaminating D N A . The D N ase I used is characterised as being RN ase free 
(Promega, M 6101). The typical DN ase I reaction components are listed below:
R N A  (100 pg) X  pi
10X D N ase I Buffer (supplied) 20 pi
D N ase I 10 jj.1
H20  (170-X ) pi
Final V olum e 200 pi
The samples undergoing D N ase I digestion were incubated for 30 minutes at 37 °C. 
The reaction was terminated by the addition o f  20 pi Termination m ix. The D N ase I 
was inactivated by heating the reaction m ix for 10 minutes at 65 °C.
The R N A was re-purified from the DN ase I digestion m ix using R N easy spin columns 
again, in brief, 100 pi o f  sample was m ixed with 350 pi RLT buffer (including 10 
pl/m l P mercaptoethanol). 250 pi 100% EtOH was then added and m ixed by 
pipetting. The sample was applied to an R N easy spin column and centrifuged at 8,000 
x g for 15 s. The collection tube and the flow-through were discarded at this point. 
The spin column was transferred to a new  collection tube and washed tw ice in buffer 
RPE. The second wash was eluted by centrifuging at 8,000 x g for 2 minutes. To 
ensure that all the RPE was eluted, the column was placed in a fresh collection tube 
and centrifuged at full speed for 1 minute. The purified R N A  was eluted by adding 25 
pi RNase-free H20  to the spin column and centrifuging it in to a fresh collection tube 
for 1 minute at 8,000 rpm. This step was repeated once more to ensure all the R N A  
was isolated. The R N A  was quantified (Section 2.5 .1 .3) and electrophoresed on an
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agarose gel to determine that it was o f  sufficient quality for array analysis (Section
2.5.1.4).
2.5.1.2.2.3 Purification of Poly (A)+ RNA from Total RNA
Poly A  purification was carried out using the Atlas™ Pure Total R N A  Labelling 
System  (Clontech, PT3231-1). The methods used are outlined below.
The streptavidin magnetic beads (supplied) were m ixed by inverting and tapping the 
tube. 15 ml beads per reaction were transferred to a new  tube. These beads were 
separated from their supernatant using a m agnetic particle separator (Clontech) and 
were washed 4 tim es w ith binding buffer 1 (after each w ash the beads were separated 
using the magnetic separator). The beads were eventually re-suspended in 15 jo.1 IX  
binding buffer. 45 (ig o f  total R N A  was placed in a sterile eppendorf tube ( if  the 
volum e was found to be less than 45 (0,1, deionized water was added to a final volum e 
o f  45 (il). 1 (il o f  biotinylated oligo(dT) was added and m ixed thoroughly by  
pipetting. These samples were then placed at 70 °C in a preheated thermal cycler. 
Follow ing this, the tube was cooled at room temperature for 10 minutes. Once the 
sample was cool, 45 jj,1 2X  binding buffer was added and m ixed by  pipetting. The 
washed beads were re-suspended and 15 jil was added to the R N A  sample. The beads 
were m ixed continuously through the R N A  sample for 25-30 minutes on a vortex 
shaker set to 1,500 rpm. The beads were isolated using the magnetic separator and 
washed twice in 50 (il IX  wash buffer and then re-suspended in IX  reaction buffer. 
The beads were m agnetically isolated once more and re-suspended in 3 (al H20 .  The 
poly (A )+ R N A  was then taken directly to the probe synthesis reaction for D N A  arrays 
(Section 2.5.1.6.1).
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2.5.1.3 RNA Quantification
RNA (like D N A ) was quantified using a U V  spectrophotometer. The O D 260 was used 
to quantify the R N A in the sample using the follow ing equation:
OD 260 x  40 x D ilution Factor/1000 =  R N A  content ((ig/fil)
B y sim ultaneously measuring the OD2so the purity o f  the sample could be estimated.
Purity = OD 26o/OD2 8o
This was typically in the range o f  1.8-2.0. A  ratio o f  <1.6 indicated that the R N A  m ay  
not be fully in solution. The R N A was diluted to 1 jog/jul stocks for reverse 
transcription (RT-reaction).
2.5.1.4 Gel Electrophoresis of RNA to Determine Quality
A ll solutions to be used for the gel electrophoresis (covered extensively in Section
2.5.1.5.3) o f  R N A  were prepared in DEPC treated water (Section 2.5.1.1) including 
the electrophoresis buffer and the gels. The samples (containing approximately 5 (j,g 
R N A /w ell) were run on 0.8% agarose gels. To sink the R N A  in to the w ells, pre- 
autoclaved glycerol was m ixed with the R N A to a final concentration o f  10% (v/v).
2.5.1.5 Reverse-Transcription Polymerase Chain Reaction (RT-PCR) Analysis
2.5.1.5.1 Reverse Transcription of RNA (cDNA Synthesis)
To form cD N A  the follow ing components were m ixed in a 0.5 ml eppendorf tube 
(Eppendorf, 0030 121 023) and heated to 70 °C for 10 minutes follow ed by cooling on
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1 fil O ligo dT 12-18 primers (0.5 (.ig/fil)
1 (ol R N A  (1 /j,g/|_tl)
3 ¡11DEPC H20
This step gets rid or R N A  secondary structure and allows the oligo dT to bind the 
poly (A )+ tail o f  the RNA.
A s this mixture was heating, the follow ing reaction m ix was generated (all volumes 
listed in master m ix assume 1 fig total RNA).
4 fil 5X buffer (Sigm a, P2317)
2 |il 100 mM DTT (Sigm a, D 6059)
1 |il RNasin (40 U /|il) (Sigma, R2520)
1 (ol dNTPs (10 mM each) (Sigma, DN TP-100)
6 jol DEPC H20
1 \xl M M LV-RT (200U/(ol) (Sigm a, M l302)
Once the R N A  mixture had cooled (~2 minutes) 15 (J.1 o f  the master m ix was added 
and m ixed by flicking. The resultant mixture was given a rapid centrifuge to collect 
the material in the bottom o f  the tube and then incubated at 37°C for 1 hour. The 
resultant cD N A  was stable at 4°C but for prolonged storage was maintained at -20°C .
2.5.1.5.2 Polymerase Chain Reaction (PCR)
The cD N A  was then analysed for the expression o f  genes o f  interest by PCR.
The standardised PCR m ix is listed below  and did not change significantly with any 
o f  the PCRs carried out in this thesis.
2.5 |il cDNA was added to the following reaction components.
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12.25 (olH20
2.5 \i\ 10X PCR buffer (Sigma, P2317)
1.5 (ol 25 mM  M gCl2 (Sigma, M 8787)
4 (0.11.25 m M  dNTP
0.5 (0.1 each o f  the forward and reverse primers (250 ng/(ol) for the target gene (Oswel 
D N A  Service, Southhampton)
0.5 |ol each o f  the forward and reverse primers to the housekeeping gene o f  interest
1.e. p Actin (25 ng/(ol) or GAPDH (25 ng/(ol), (also synthesised by O sw el D N A  
Service).
0.25 (ol Taq Polymerase (5U/|ol) (Sigma, D4545).
The samples were m ixed and centrifuged before being placed on the thermocycler 
(Biometra).
A  typical PCR protocol is outlined below  however annealing temperatures can vary 
from primer set to primer set therefore a full list o f  the primers used in this thesis and 
the annealing temperatures are listed in Table 2.5.1
95 °C for 3 minutes (Denaturation step)
25-30 cycles o f :
95 °C for 30 s (Denaturation)
52-60 °C for 30 s (Annealing)
72 °C for 30 s (Extension)
and
72 °C for 7 minutes (Extension)
PCR products were stored at 4 °C until they were analysed by gel electrophoresis.
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2.5.1.5.3 Gel Electrophoresis of PCR Products
Typically 2% agarose (Sigm a, A 9539) gels were used for PCR gel electrophoresis, 
these gels were prepared and run in IX  TBE (10 .8g Tris base, 5.5 g  Boric Acid, 4 ml 
0.5M  ED TA and made up to 1L with UHP) and were m elted in a laboratory 
microwave. Upon cooling, the gel was supplemented with 5 |il ethidium bromide (10  
m g/m l) (to allow  visualisation o f  the DN A. The gel was then poured in to the 
electrophoresis unit (Biorad) and allowed to set. B y placing a comb in to the top o f  the 
gel prior to hardening, sample w ells were formed.
To run the samples, 2 fil o f  6X  loading buffer (50% Glycerol, 1 m g/m l bromophenol 
blue, 1 mM  EDTA) was added to 10 jal PCR product and loaded to the gel with an 
appropriate size marker (Sigm a, D 0672). The gels were electrophoresed at 120-150  
m V  for 1-2 hours (depending on size o f  the target gene, i.e. to get adequate 
separation). Once the internal control and target bands were seen to have migrated to 
the required extent, then the gel was taken to the gel analyzer (an EpiChemi II 
Darkroom, UVP Laboratory Products), photographed and densitometrically analysed 
using Labworks software (UVP).
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Gene Sequences 
(all sequences listed 5 ’ to 3 ’)
Annealing Temp 
(°C)
Fragment size 
(bp)
PPI agcgtggcttcttctacacacc
ggtgcagcactgatccacaatg
54 158
PDX1 ggtggagctggcagtgatgtt
accgcccccactcggggtcccgc
60 125
HGLUT2
(Human)
tggcagctgctcaactaatcac
aaacaggtttgctgataccagc
52 759
MGLUT2
(Mouse)
cacactctctgaagacgccagga
gaggcatcgactgagcagaaggtc
52 729
GCK gatgctggatgacagagccaggatg
agatgcactcagagatgtagtcga
54 392
Pax4 tggcttcctgtccttctgtgagg
tccaagacacctgtgcggtagtag
52 242
Pax6 aagagtggcgactccagaagt
accatacctgtattcttgcttcagg
60 545
Ihh aaggcccacgtgcattgctct
tgtccgcaatgaagagcaggtg
60 298
Shh gctgatgactcagaggtgcaa
agtcgaaacctgcttccacag
60 227
PP aggatggccgtcgcatactg
gagctgcactccaggaagtc
60 249
Somatostatin ccgtcagtttctgcagaagt
cagggtcaagttgagcatcg
60 356
Glucagon actcacagggcacattcacc
ccagttgatgaagtccctgg
60 353
Ngn3 tggcgcctcatcccttggatg
cagtcacccacttctgcttcg
54 160
Isll acgtctgatttccctgtgtgttgg
tcgatgtggtacaccttagagcgg
60 276
Nkx2.2 cggagaaaggtatggaggtgac
ctgggcgttgtactgcatgtgctg
60 188
Beta2 cttggccaagaactacatctgg
ggagtagggatgcaccgggaa
60 229
ß Actin (Long) gaaatcgtgcgtgacattaaggagaagct
tcaggaggagcaatgatcttga
Variable* 383
ß Actin (Short) tggacatccgcaaagacctgtac
tcaggaggagcaatgatcttga
Variable* 142
GAPDH catgaccacagtccatgccatc
caccctgttgctgtagccgtattc
Variable* 451
Table 2.5.1 Primer sequences used during the course o f  this work.
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* These internal standard primers were used at a range o f  temperatures from 52-60°C  
depending on the target gene being examined.
2.5.1.6 DNA Aray Analysis of RNA Expresion
2.5.1.6.1 cDNA Probe Synthesis
For cD N A  probe synthesis for D N A  arrays highly purified po ly  (A )+ R N A  was used 
(Section 2.5.1.2.2.3).
A s the arrays involved the comparison o f  two different RN As, the probes were 
generated simultaneously to reduce variation between reactions. Thus, the following  
probe synthesis reaction m ix is a 2 .5X  master mix. These components were all 
supplied in the Atlas™ Pure Total R N A  Labelling System  (Quiagen, PT3231-1).
The follow ing labelling reaction master m ix was prepared in a 0.5 m l tube at room  
temperature:
10 (ol 5X  Reaction Buffer 
5 (ol dNTP M ix (minus dATP)
12.5 (ol [a 33P]dATP (>2,500 Ci/m m ol, 10 foCi/|ol) (Amarsham, BF1001)
1.25 DTT (100 mM )
A  PCR thermal cycler was heated to 65°C. W hile this was heating, 4 (0.1 CDS primer 
m ix was added to the re-suspended poly (A)+ RNA-containing beads (Section
2.5.1.2.2.3). This mixture was heated on the 65°C block for 2 minutes, when the time 
was up, the temperature o f  the block was reduced to 50 °C and the tubes were 
incubated for another 2 minutes. During this phase 5 (ol M M LV-RT enzym e was 
added to the labelling master m ix and m ixed by pipetting. W hen the beads and primer 
m ix had been at 50 °C for 2 minutes, 13.5 (ol o f  the labelling reaction master m ix was 
added to each reaction tube and m ixed w ell by pipetting. This reaction w as allowed to 
incubate for 25 minutes at 50 °C. To end the reaction, 2 jol termination m ix was 
added. The probe was then purified using column chromatography (Section 2.5.1.6.2).
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2.5.1.6.2 Purification of Radioactive cDNA Probes Using Column 
Chromatography
The materials for column chromatography were all included with the Atlas™ M ouse
1.2 Array (Clontech, 7853-1).
The probe synthesis reactions (Section 2 .5.1.6.1) were diluted to 200 (0.1 by addition o f  
buffer NT2 and were m ixed w ell by pipetting. A  N ucleoSpin colum n was placed in a
2 ml collection tube and the sample was placed on the column. This was then 
centrifuged at 14,000 rpm for 1 min. The collection tube and radioactive contents 
were discarded appropriately. The column was placed in a fresh tube and washed with 
buffer NT3 (diluted in EtOH) three times. Each time the wash solution was eluted by  
a spin o f  14,000 rpm and the collection tube was changed on each occasion. The 
purified probe was eluted using buffer N E , which was allow ed to soak in to the 
column for 1 minute, and then centrifuged at 14,000 for 1 minute to elute the purified 
probe. The probes were checked for radioactivity by taking 2 p.1 o f  probe and m ixing 
it in to 5 ml scintillation fluid w ith vortexing. The counts were m ultiplied by a factor 
o f  50 to account for the dilution. Probes generated from pure poly  (A )+ R N A  typically 
had counts o f  2-10 x 106 CPM.
2.5.1.6.3 Hybridization of cDNA Probes to Arays
15 ml o f  hybridization solution (ExpressHyb) was pre-warmed to 68°C (in the 
hybridization oven), during this period 1.5 m g o f  sheared salm on testes D N A  was 
heated to 95°C on a PCR thermocycler for 5 minutes follow ed by cooling on ice. The 
heat denatured salm on testes D N A  was then added to the hybridization fluid and 
maintained at 68°C until required. The hybridization bottles were filled to the brim 
with UHP and the array membranes placed inside carefully. B y  pouring o ff  the UHP 
the array remained attached to the sides o f  the bottle with no air bubbles. At this point
7 ml heated hybridization fluid was added to each bottle and the arrays were pre­
hybridized for 30 minutes w ith continuous rotation at 4-7 rpm. During pre­
hybridization the probe was prepared by  adding 5 fal C0t-1 D N A  to the pool o f  each 
labelled probe (Section 2.5.1.6.2). The C0t-1 D N A  ‘spikes’ the array to generate guide 
spots for subsequent alignment and analysis. The probes were denatured at 100°C for
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2 minutes followed by cooling for 2 minutes on ice. Upon cooling, the probes were 
then added to their respective hybridization bottles (they were added to the 
hybridization fluid and swirled, raw probe was not allowed to touch the array 
membrane) and hybridization was carried out overnight at 6 8  °C with rotation at 4-7 
rpm.
The follow ing day the arrays were washed four times in pre-warmed wash solution 1 
(2X  SSC, 1 % SD S) and once in pre-warmed wash solution 2 (0.1X  SSC, 0.5% SDS). 
Washing was carried out at 6 8 °C with continuous agitation. The array membranes 
were then rinsed w ell in 2X  SSC and wrapped in cellophane (still damp, to prevent 
drying). The wrapped array membranes were fixed to a developing cassette and 
exposed to phosphoimager screens for 4-10 days at room temperature.
2.5.1.6.4 Developing the Arays and Subsequent Analysis
After the required period, the phosphoimager screens were taken and placed on the 
drum o f  phosphoimager (Cyclone, Packard) and visualised using OptiQuant software 
(Cyclone, Packard). The array image could then be manipulated to minimise 
background and highlight the spots. The array data was processed using Atlaslmage™  
(Clontech) software.
2.5.1.6.5 Striping Arays for Re-Use
After the arrays had been analysed they were stripped for re-use (nylon arrays can be 
re-used 3-4 times). The arrays were stripped by boiling each membrane in 500 ml 
0.5% SDS for 5-10 minutes. The solution was allowed to cool ( -1 0  minutes) and then 
rinsed in wash solution 1. At this point the array membrane w as checked for residual 
radioactivity. If the array was fully  stripped then it was either re-used imm ediately or 
wrapped in cellophane and placed in storage at -2 0  °C until needed.
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2.5.2 Protein Analysis
2.5.2.1 Western Blotting analysis
2.5.2.1.1 Sample Preparation
Cell pellets were taken from flasks o f  cells in culture and follow ing differentiation 
experiments or transfection experiments. These pellets were usually washed X2 in 
PBS, dried and stored at -80°C until needed. Cell pellets were lysed in N P-40 lysis 
buffer (62.5 mM  Tris-HCl pH 6 .8 , 12.5% glycerol, 2 % Nonidet P40 (Sigm a, N 6507),
2.5 mM  PM SF (Sigma, P7626), 1.25 mM  EDTA, 12.5 |ag/ml leupeptin (Sigma, 
L2884), 116 |og/ml aprotinin (Sigma, A 1153)). Lysis was carried out on ice for 30 
minutes follow ed by sonication in a Labsonic U  (Braun) unit. The cells were pulsed 3-
5 times on ice using a repeating duty cycle o f  0.3s. Once 60-80%  o f  the cells were 
determined to be lysed (by checking a sample o f  lysate under a m icroscope), the 
sonication was stopped. The sonicated samples were then centrifuged at 2,500 rpm for
5 minutes on a benchtop microfuge to remove cellular debris. The supernatant was 
carefully removed and aliquoted to eppendorf tubes. Protein samples were stored at -  
20°C until required for quantification or analysis (Section 2.5.2.1.2).
2.5.2.1.2 Protein Quantification by DC Protein Assay
Protein quantification could be carried out using the DC protein assay (Biorad, 500- 
0116) which is based on the Lowry protein assay. To quantify the protein extracted, 
serial dilutions o f  the protein were prepared in duplicate (all sample and standard 
dilutions were made in lysis buffer) and a standard curve was generated using serial 
dilutions o f  a lm g/m l B S A  (Sigm a, A 9543) stock. 5 (il o f  standards and samples were 
loaded on into a clean 96 w ell plate. 25 (J.1 o f  solution A  (provided) was added to each 
w ell follow ed by 200 fil solution B. The plate was m ixed gently and the colour was 
allowed to develop for 15 minutes. The plates were quantified using a Spectra max 
plus plate reader (M olecular D evices) at 750 nm and the data was processed using 
Soft max Pro software.
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2.5.2.1.2.1 Protein Quantification by Bradford Protein Assay
The Bradford assay based Bio-Rad protein assay (Bio-Rad; 500-0006) was also used 
as a method for quantifying protein during the course o f  this thesis. A  standard curve 
was prepared from the stock 1 m g/m l B S A  using lysis buffer as the diluent (Section
2.5.2.1.2). 10 p,l o f  each standard was then added to clean, dry eppendorf tubes. 10 (il 
o f  each sample (appropriately diluted 1 / 1 0 - 1 / 2 0  w ith lysis buffer) were also added to 
clean eppendorf tubes. The BioRad stock solution was pre-filtered using 3 mm filter 
paper (Schleicher & Schuell, 311647) and diluted 1/5 with UHP. 490 (j,l o f  diluted 
Biorad solution was added to each standard and sample eppendorf tube and the tubes 
were m ixed by vortexing. 1 0 0  (j,l aliquots o f  these samples and standards were then 
added in triplicate to a clean, dry, 96 w ell plate. These plates were analysed on a 
Spectra max plus plate reader (M olecular D evices) at 570 nm and the data was 
processed using Soft max Pro software.
2.5.2.1.3 Acrylamide Gel Electrophoresis
Proteins were separated by SDS polyacrylamide gel electrophoresis (SD S PAGE). 
The resolving and stacking gels were prepared as outlined in Table 2.5.2. The gels 
were poured in to clean 1 0  cm x 8  cm  gel cassettes consisting o f  an alumina plate and 
a glass plate separated by 0.75cm  plastic spacers. The resolving gel was poured 
initially, allow ed to solidify, and overlayed with the stacking gel. Before the stacking 
gel w as set, a comb was inserted to generate sample w ells. Gels were generally used 
immediately, but could be stored at 4°C overnight i f  wrapped w ell in foil. For most 
applications 50 )_ig o f  protein was loaded to each well. Samples were m ixed with 5X  
loading buffer (6.25 m l 1.25 M  Tris-HCl pH 6 .8 , 2.5 g SD S, 14.5 m l glycerol, .025%  
bromophenol blue, this was made up to 50 m l with H 2O). The samples were boiled  
for three minutes prior to loading and were run in parallel w ith protein size markers 
(Isis, P77085). The electrophoresis conditions were 250 V  and 45 m A. The gels were 
run for 1-1.5 hours (time depends on the size o f  the protein to be studied, i.e. larger 
proteins were run for longer).
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Component Resolving 
Gel (7.5%)
Resolving Gel 
(10%)
Stacking Gel (5%)
30 % Acrylamide Stock 
(Sigma, E344-500M L-C)
3.8 ml 5 ml 0 . 8  ml
UHP 8  ml 6 . 8  ml 3.6 ml
1.875 M  Tris-HCl (pH
8 .8 )
3 ml 3 ml
1.25 M  Tris-HCl 
(pH 6 .8 )
0.5 ml
1 0  % SDS 150 (il 150 |al 50 (al
10 % Ammonium  
Persulphate (Sigma, 
A 1433)
60(al 60 j_il 17 [i\
TEMED  
(Sigma, T8133)
9 \xl 9 nl 6  (il
Table 2.5.2 Preparation o f  Acrylamide Gels
2.5.2.1.4 Western Blotting
Follow ing electrophoresis, gels were equilibrated in transfer buffer (25 m M  Tris, 192 
mM  Glycine (Sigm a, G 7126) pH 8 .3-8.5 without adjustment) for 15 minutes with  
agitation. Protein gels were transferred to Hybond ECL nitrocellulose membrane 
(Amarsham, R PN  2020D ) using semi-dry electroblotting (using a semi-dry transfer 
cell (Biorad)). For this, 8  sheets o f  Whatman 3 mm filter paper (Whatman, 1001824) 
were soaked in transfer buffer and placed on the cathode plate o f  a semi-dry blotting 
apparatus. E xcess air was removed from between the filters by  rolling a glass pipette 
over the filter paper. Nitrocellulose, cut to the same size o f  the gel, w as soaked in 
transfer buffer and placed over the filter paper, making sure there were no air bubbles. 
The acrylamide gel was placed over the nitrocellulose and 8  more sheets o f  pre­
soaked filter paper were placed on top o f  the gel. Excess air was again removed by  
rolling the pipette over the filter paper. The proteins were transferred from the gel to 
the nitrocellulose at a current o f  34m A at 15V for 20-25 min.
I l l
A ll incubation steps from now on, including the blocking step, were carried out on a 
revolving apparatus (Stovall, Bellydancer) to ensure even exposure o f  the 
nitrocellulose blot to all reagents.
The nitrocellulose membranes were blocked for 1-2 hours at room  temperature with 
fresh, filtered, 5% non-fat dried m ilk (when probing for glucokinase 2.5% Marvel was 
used) (Cadburys; Marvel skimmed milk) in TBS (8.76 g NaCl, 6.09 g Tris-HCL in 1L 
UH P)/ 0.1% Tw een (Sigm a P1379) pH 7.5.
After blocking, the membranes were rinsed with TBS-tween and incubated with 
primary antibody (Table 2.5.3) overnight at 4°C. The primary antibody was removed  
and the membranes rinsed 3 times with TB S/ 0.1% Tween. The membranes were then 
washed for 15 min, and then tw ice for 5 minutes in TB S/ Tween. Bound antibody was 
detected using enhanced chem ilum inescence (ECL).
Follow ing chemiluminescent detection, blots were again washed and blocked as 
described and re-probed for an internal standard e.g. p actin. This was carried out as 
before.
2.5.2.1.5 Enhanced Chemiluminescence Detection
Protein bands were developed using the Enhanced Chem ilum inescence Kit (ECL) 
(Amersham, R PN 2109) according to the manufacturer’s instructions.
Secondary antibody (diluted appropriately, Table 2.5.3) was added to the blots with 
shaking for 1 hour at room temperature. The secondary antibody was removed and 
the membranes were washed as before. A  sheet o f  cellophane was flattened over a 
smooth surface, e.g. a glass plate, making sure all air bubbles were removed. The 
membrane was then placed on the cellophane, and excess fluid removed. 1.5ml o f  
ECL detection reagent 1 and 1.5ml o f  reagent 2 were m ixed and covered over the 
membrane. Charges on the cellophane ensured the fluid stayed on the membrane. The 
reagent was removed after one minute and the membrane wrapped in cellophane. The 
membrane was exposed to autoradiographic film  (Kodak; X-O M A T S, 500 9907) in 
an autoradiographic cassette for various times (depending on the level o f  signal). The 
autoradiographic film  was then developed.
1 1 2
The exposed film was developed for 5min in developer (Kodak, LX 24) diluted 1:6.5 
in water. The film was briefly immersed in water and transferred to a Fixer solution 
(Kodak, FX-40) diluted 1:5 in water, for 5min. The film was transferred to water for 5 
min and then air-dried.
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2.5.2.1.6 Antibodies Used for Western Blotting
Antibody Host Supplier Dilution *
p i Integrin Rabbit Chemicon
(A B1952)
1/500
Activin R U B M ouse NeoMarkers
(M S-677-P0)
1 / 2 0 0
c-met Goat R & D  System s 
(AF527)
1/500
Acetylated Histone 
H3
Rabbit Upstate
Biotechnology
(06-599)
1/800
GLUT2 Rabbit Chemicon
(A B 1342)
1/2,500
Glueokinase Goat Santa Cruz 
(G C K N -19, SC- 
1980)
1 / 1 0 0
P actin M ouse Sigma
(A 5441)
1 / 1 0 , 0 0 0
a  tubulin M ouse Sigma
(T5168)
1 /2 , 0 0 0
M ouse IgG Sheep Sigma
(A 6782)
1 / 1 , 0 0 0
Rabbit IgG Goat Sigm a
(A 4914)
1/5,000
Goat IgG Rabbit Sigma
(A 5420)
1/1,000-1/5,000
Table 2.5.3 Antibodies used in for western blotting 
*A11 antibodies were diluted in TBS.
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2.5.2.2 Immunofluorescence/Immunocytochemical Analysis.
The fixation o f  samples for imm unoeytochem ieal and immunofluorescent analysis is 
already outlined in Section 2.3.1.3.1. This method was found to be compatible with all
analyses carried out
2.5.2.2.1 Immunofluorescence Analysis
2.5.2.2.1.1 Basic Immunofluorescence
Basic imm unofluorescence was found to be adequate for immunofluorescence for 
keratins and other cytoplasm ic and membrane proteins. For this, frozen 6  w ell sample 
plates were removed from the -20°C  freezer and allowed to equilibrate to room  
temperature ( -1 0  minutes). Grease circles (DAKO pen, DAK O  Cat S2002) were then 
drawn within the w ells (to contain the solutions used in the subsequent analysis). The 
cells were re-hydrated using IX  TBS for 5 minutes. This was tapped o ff  and the 
relevant serum (listed in Table 2.5.4) (diluted 1/5) was added as a ‘blocker ‘ for 20 
minutes at room temperature. The serum was rem oved at this point and the primary 
antibody was applied (antibodies and dilutions are listed in Table 2.5.4). This was 
incubated overnight at 4°C in a m oist environment. The follow ing day, the primary 
antibody was rem oved and the w ells were washed three tim es in TBS-0.1%  tween at 5 
minutes per wash. The fluorescent secondary antibodies were prepared in the dark 
room under dim conditions and were coated in foil upon dilution with TBS (They are 
light sensitive). The secondary antibodies (Table 2.5.4) were incubated for 60 minutes 
and the plates were wrapped in foil to maintain dim conditions. A ll work from this 
point onwards was carried out in the dark to prevent ‘quenching’ fluorescent signal. 
After 60 minutes incubation the antibodies were removed and the plates were washed  
three tim es in TBS-0.1%  tween. The w ells were then mounted using fluorescent 
mounting medium (Dako, S3023) and covered with coverslips (Chance Propper, 22 x 
22 mm). Fluorescent staining w as visualised using a fluorescent m icroscope (Nikon) 
and the appropriate filters, i.e. for FITC labelled m ouse IgG (Dako, F0261) the B2 
filter was used and for TRITC labelled rabbit IgG (Dako, R 0156) the G 2A filter was 
used.
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2.5.2.2.1.2 Immunofluorescence for Nuclear Transcription Factors
To visualise the nuclear transcription factors PD X1, Ngn3, Beta2 and N kx2.2 more 
clearly the imm unofluorescence procedure was different and is outlined below.
As before the plates were rem oved from storage and grease circles were drawn. In this 
case however the cells were pre-incubated in 50 mM  N H 4CI (Riedel de Haen, 31107) 
for 30 minutes. Follow ing this the cells were incubated in IX  TBS for 5 minutes 
follow ed by blocking in blocking buffer (5% swine serum (Dako, X 0901) diluted in 
PBS-1% BSA). B locking was carried out for 1 hour. The primary antibodies were 
diluted to the required level in the dilution buffer (PBS-1% BSA+0.1%  Triton X-100). 
These antibodies were allowed to incubate overnight at 4°C in a m oist environment. 
The follow ing day, the w ells were washed 3X  in TBS-0.1%  tween and the labelled  
secondary antibodies were applied (again these antibodies were prepared in the dark 
and they were also diluted in the dilution buffer listed above). The secondary 
antibodies were incubated in the dark at room temperature for 1 hour and mounted 
etc. as described in Section 2.5.2.2.1.1.
2.5.2.2.2 Immunocytochemical Analysis
The avidin-biotin com plex (ABC ) immunoperoxidase technique combined with the 
diaminobenzidine (D A B ) visualisation procedure was used in all 
immunocytochemistry experiments. The ABC method involves application o f  a 
biotin-labelled secondary antibody to cells probed with a primary antibody, follow ed  
by the addition o f  avidin-biotin-peroxidase com plex w hich results in a high staining 
intensity due to the formation o f  an avidin-biotin lattice w hich contains peroxidase 
m olecules. The peroxidase enzym e then reacts w ith a D A B  solution to give an 
insoluble, brown-coloured precipitate. The formation o f  this brown precipitate- 
coloured precipitate is indicative o f  primary antibody reactivity.
The procedure used is as follows:
Cell preparations on 6 -w ell tissue culture plates (which had been previously fixed in 
methanol and frozen at -20°C) were allowed to thaw and equilibrate at room  
temperature. A  grease pen (DAK O , S2002) was used to encircle cells in the tissue
culture plates to contain the various solutions involved during the procedure. The
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cells were incubated for 5 minutes w ith a 3% H 2O2 solution to quench any 
endogenous peroxidase activity that m ay be present in the cells and could lead to false 
positive results. The cells were then rinsed with UHP and placed in TBS for 5 
minutes. The plates were incubated for 20  minutes at room temperature (RT) with an 
appropriate serum diluted 1:5 in TBS to block non-specific binding. This was 
removed and 30-50|i.l o f  optim ally diluted primary antibody was adm inistered. The 
tissue-culture plates were placed on a tray containing m oistened tissue paper and 
incubated at 37°C for 2 hours. The primary antibodies used in these studies are listed 
in Table 2.5.4. The w ells were then rinsed in TB S/ 0.1% Tween, x3 for 5 m in each, 
and then incubated for 30 m in with a biotinylated secondary antibody diluted in TBS 
(Table 2.5.4). The w ells were rinsed as before and incubated with strepABCom plex/ 
Horse Radish Peroxidase (HRP) (DAKO, K 377) for 30 min at RT, after which they  
were rinsed x3 in TBS/ 0.1% Tween. The cells were then incubated with a D A B  
solution (DAKO, S3000) for 7-10 min. Excess D A B  solution was then rinsed o ff  
with UHP water. The w ells were then mounted using a commercial mounting solution  
(DAKO, S3023).
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Antibody Host Supplier Dilution Serum for 
Blocking
C K 8 M ouse C hem icon
(M A B 3 2 2 8 )
1/300 R a bb it 
(D ako , X 0 9 2 )
C K 18 M ouse C hem icon
(M A B 3 2 3 4 )
1/100 R a bb it
C K 7 M ouse C hem icon
(M A B 3 2 2 6 )
1/200 R a bb it
C K 1 9 M ouse D ako
(M 07 72 )
1/50 R a bb it
A F P R abb it N eoM arke rs
(R B -3 15 -R 7 )
R eady fo r  
Use
Swine 
(D ako , X 09 01 )
P ro insu lin M ouse B iogenesis
(5330-3369)
1/300 R abb it
Som atostatin R abb it D A K O
(A 05 66 )
1/400 Sw ine
PP R abb it D A K O
(A 06 19 )
1/600 Sw ine
P D X 1 R abb it G if t  f ro m  C .V .E . W r ig h t 
V a n d e rb ilt, T N
1/500 Sw ine
Beta2 R a bb it C hem icon
(A B 5 6 8 6 )
1/25-1/50 Sw ine
N gn3 R a bb it C hem icon
(A B 5 6 8 4 )
1/25 Sw ine
N k x 2 .2 M ouse D eve lopm enta l H yb rid o m a  B ank 
(74 .5 A 5 )
N ea t Serum Sw ine
A n t i M ouse 
(F IT C )
R abb it D ako
(F0261)
1/30 N /A
A n t i R a bb it 
(T R IT C )
G oat D ako
(R 0156)
1/40 N /A
A n t i M ouse 
(B io  t in )
R abb it D ako
(E0354)
1/300 N /A
A n t i R a bb it 
(B io t in )
G oat D ako
(E0432)
1/300 N /A
A n t i G oat 
(B io  t in )
R a bb it D ako
(E0466)
1/300 N /A
Table 2.5.4 Antibodies used in Immunofluorescent/Immunocytoehemieal studies 
including the labelled secondary antibodies.
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2.5.2.3 ELISA Analysis for Insulin and Proinsulin
Insulin secretion studies have already been described (Section 2.3.5). These analyses 
were carried out using ELISA kits i.e. a proinsulin kit (Mercodia, 10-1124-10) and a 
specific human insulin kit for processed insulin (Mercodia, 10-1113-10). The kits 
were fully inclusive and all reagents, standards etc. were supplied. The generalised 
protocol for their use is outlined below. Samples from insulin secretion studies were 
generally diluted (1/10 -  1/20 depending on the application) w ith PBS and m ixed w ell 
by vortexing. 25 (0.1 o f  the standards and samples were added directly to the test plate 
(in duplicate). 50 ul conjugate solution (stock conjugate diluted 1+ 10 in conjugate 
buffer) was then applied to the samples and standards. The plate was wrapped in foil 
(to prevent debris falling in to the w ells) and incubated with shaking at room  
temperature for 2  hours on a belly  dancer set to maximum speed (human insulin plates 
were incubated for 1 hour only). Follow ing this, the conjugate/sample m ixes were 
tapped o ff  in to a sink and the w ells were washed X 6  using the washing solution 
(stock diluted 1 + 20 in UHP prior to use). W ashing was carried out using a wash 
bottle with a w ide bore nozzle and care was taken not to overflow  w ells during 
washing (to prevent cross contamination between samples). After washing, the plate 
was tapped firm ly on tissue to rem ove the excess wash solution. At this point 200 (0.1 
peroxidase substrate was added to each w ell. This reaction was allowed to develop in 
the dark (the plate was re-wrapped in foil) for 15 minutes after which, it was stopped 
by adding 50 (il stop solution per w ell. The plates were m ixed gently and any bubbles 
were burst manually. The plates were read at 450 nm on a plate reader (Labsystems 
M ultiskan Ex) and the data was processed using Genesis™ software.
2.5.2.4 Alkaline Phosphatase Determination
Alkaline phosphatase determination was carried out on fresh cells cultured on 6  well 
plates or on frozen fixed samples (Section 2.3.1.3.1). A lkaline phosphatase staining 
was carried out by adding the assay components (16.5(ol BCIP (Roche, 1383 221) (5 
Brom o-4chloro-3-indolyl-phosphate, 4 toluidine salt (X-phosphate, 4 toluidine salt) 
and 33 (il N B T  (Roche, 1383, 213) (nitro blue tetrazolium chloride)) to 5ml alkaline 
phosphatase buffer (100 mM  Tris, 100 mM  NaCl, 50 mM  M gCL in 100 m l UHP). In 
this system, BCIP was used as a substrate for alkaline phosphatase. The 5 bromo-4
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chloro-3 indoxyl formed generates an insoluble purple dye. Nitro blue tetrazolium 
chloride was used as the electron acceptor in the reaction rather than O2 to enhance 
the colour formed.
The staining solution was applied directly to the test w ells and the colour was allowed 
to develop. Colour development depended on the application and ranged from 30 
minutes to 8  hours. Once the colour had developed the w ells were washed X3 in UHP 
and the plates were photographed.
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3.0 RESULTS.
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3.1. Initial differentiation of F9 cells
F9 cells are characterised by the inability to differentiate spontaneously and thus are 
termed a nullipotent cell line (A lonso e t al. 1991). Differentiation o f  F9 cells using 
agents such as Retinoic A cid (RA) or a combination o f  RA and dibutyryl cyclic  
adenosine monophosphate (db cAM P) is w ell established (Section 1.4.1.2.1). This 
differentiation is typically accompanied by a number o f  phenotypic changes as the 
cells assume different lineages. M onitoring the changes that occur can indicate the 
cell types being generated within the population and these changes may in certain 
cases be exploited to purify certain desirable cells from the population as a whole. In 
this experiment F9 cells were differentiated as monolayers and EBs in the presence o f  
RA and db cAM P to initiate endodermal differentiation (Section 2.3.1.2.1).
3.1.1 Morphological Changes in Monolayer F9 Cells Grown in the Presence of 
Retinoic Acid and db cAMP
From Figure 3.1.1 the effects o f  RA (10 ' 7 M ) treatment carried out over 72 hours can 
be seen. RA treated F9 cells (F9-RA), (Figure 3.1.1 (C&D)) are seen to be larger than 
the untreated cells (Figure 3.1.1 (A& B)). The R A  treated cells are separated from one 
another and pointed cell processes extend from the differentiated cells. Granular 
structures are present within the RA treated cells also (Figure 3.1.1 (D)).
Treatment o f  F9 cells with a combination o f  RA (10 ‘ 7 M) and db cAM P (10 ‘ 3 M) 
(RA/db cAM P) over 72 hours leads to the cells becom ing more rounded in appearance 
(Figure 3.1.1 (E&F)) and som e cellular processes emerge which are indicative o f  
neural processes (Arrow Figure 3.1.1 (F)). Both RA/db cAM P and the RA treatment 
o f  the cells resulted in reduced cell numbers, suggesting that the differentiation is 
accompanied by reduction in the growth rate. The effect was m ost apparent in RA/db 
cAM P treated cells (F9-RAC).
These results show that, despite the short duration o f  the differentiation protocol (72 
hours), the partially differentiated F9 cells are already displaying the morphological 
changes normally associated with R A  and db cAM P (Darrow e t al., 1990; Moore et 
al., 1986).
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Figure 3 .1 .1  The m orphological changes that occur upon differentiation o f  F9 cells 
(A& B) using R A  (C& D) or RA/db cAM P (E&F) over 72 hours. M agnification = 1 0  
X  (A , C & E) or 40 X  (B, D  & F). Bar =  50 ^m in all cases.
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The differentiation o f  F9 cells is associated with changes in expression levels o f  a 
number o f  proteins, including tissue-type plasm inogen activator and extracellular 
matrix proteins such as laminin and collagen type IV. For subsequent experiments it is 
important to be able to monitor the differentiation o f  the F9 cells via methods other 
than m orphology, thus differentiation markers were chosen to visualise the 
development o f  F9 cells follow ing 72 hours differentiation. The markers chosen were 
selected not only to monitor continuing differentiation, but to also provide 
information as to the lineages emerging within the differentiating population.
3.1.2.1 Alkaline Phosphatase Expression in Differentiating F9 cells
Alkaline phosphatase expression is a characteristic marker o f  stem cells and has been 
used as a marker to identify undifferentiated stem cells in similar applications where 
the differentiated progeny are o f  scientific interest (Lumelsky e t al., 2001). Reduction 
in the expression o f  alkaline phosphatase therefore is indicative o f  increasing 
differentiated state. Thus alkaline phosphatase levels were investigated in 
differentiating F9 cells as outlined in Section 2.5.2.4
Undifferentiated F9 cells stained intensely for alkaline phosphatase (Figure 3.1.2 (A)). 
Follow ing 72 h RA treatment the intensity o f  staining is greatly reduced (Figure 3.1.2
(B)), and is almost com pletely absent in the RA/db cAM P treated cells (Figure 3.1.2
(C)). Residual staining can be seen in both differentiated types and m ay reflect sub­
populations o f  cells that were resistant to differentiation. These differentiation 
resistant cells (i.e. the stained cells within the differentiated population in Figure 3.1.2 
(B)) are o f  similar morphology to the undifferentiated cells in Figure 3.1.2 (A) and 
may represent differentiation resistant cells, i.e. subpopulations o f  cells that are 
refractory to the action o f  RA or db cAM P.
3.1.2 Investigation of the Expression of Differentiation Markers in Treated
Monolayer F9 Cells
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(C)
Figure 3.1.2 Alkaline Phosphatase expression in differentiating F9 cells. 
Undifferentiated cells (A) show intense blue/black staining, while differentiation 
using RA (B) or RA/db cAM P (C) leads to a progressive loss o f  this staining. 
M agnification =  I0X  in all cases. Bar =  50 |im.
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3.1.2.2 The Expression of Cytokeratins in Differentiating F9 cells
Cytokeratins are characteristically expressed in epithelial cells. The expression o f  
cytokeratins has been used in a number o f  studies to monitor the differentiation state 
o f  developing cells. Exocrine acinar and endocrine cells in the pancreas has been 
found to contain the paired cytokeratins 8  and 18, while the less differentiated tissues 
o f  the ducts are found to contain cytokeratins 7 and 19 (Bouwens, 1998). Cytokeratins 
are also indicators o f  parietal endoderm. Immunofluorescence studies were conducted 
to investigate the pattern o f  cytokeratin expression in F9 cells follow ing R A  or RA/db 
cAM P mediated differentiation (ref. Sections 2.3.1.2.1 & 2.5.2.2.1.1).
Untreated F9 cells do not express any o f  the cytokeratins examined. Cytokeratins 8  
and 18 are clearly expressed in approximately 20 % o f  RA treated cells (Figure 3.1.3 
(B& D)). Expression o f  cytokeratins 7 and 19 was difficult to detect at 72 hours but 
these cytokeratins could be detected follow ing 7 days o f  RA treatment and were 
expressed in 10% and 5-10% o f  treated cells respectively. In general, cytokeratins 
were found to be present in the cells demonstrating stretched m orphology as opposed  
to the large rounded cells that are also observed follow ing RA treatment.
F9 cell populations treated with RA/db cAM P are also found to be positive for 
cytokeratins 8  and 18 (Figure 3.1.3 (F&H)). Positive cells account for up to 50 % o f  
the entire cell population. RA/db cAM P treated F9 monolayers also contain small 
clumps o f  pointed cells that express high levels o f  cytokeratin 7 (Figure 3.1.3 (J)). 
Cytokeratin 19 expression was extremely low  as measured by this method. Again, as 
with R A  treatment, the expression o f  all cytokeratins studied was found to be more 
intense follow ing 7 days o f  RA/db cAM P treatment.
These results indicate that that the partially differentiated monolayer cells can express 
the catalogue o f  cytokeratins associated with the pancreatic islets (Section 1.1.4).
For all the im m unofluorescence carried out, negative controls were included where 
the primary antibody w as not applied. A ll o f  these controls were negative for 
fluorescence thus demonstrating that the fluorescence displayed is not due to non­
specific binding o f  the labelled secondary antibody.
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Figure 3.1.3 Cytokeratin expression profiles of F9 cells differentiated in the presence 
of RA or RA/db cAMP over 72 hours. The figures presented indicate the phase 
contrast view of the labelled cells (A, C, E, G & I) and the corresponding fluorescent 
image depicting cytokeratin expression (B, D, F, H & J). RA treated cells (A-D) 
expressed CK8 (B) and CK18 (D), while RA/db cAMP treated cells (E-J) were found 
to be positive for CK8 (F), CK18 (H) and CK7 (J). Magnification = 40X.
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3.1.3 Morphological Changes during the Culture of F9 Embryoid Bodies in the 
Presence of RA (10'7 M)
Embryoid bodies (EBs) were generated by seding lxl05 cels/ml in mini 
bacteriological grade petri dishes (to a final volume of 2 ml), and incubating overnight 
(Section 2.2.4). EBs cultured for 72 hours in normal DMEM were generaly spherical 
with a smoth outer layer of undiferentiated cels. Embryoid bodies cultured in the 
presence of RA (10'7M) also displayed a general spherical shape, although distorted 
spheres were found which had iregular outer layers of protruding (diferentiated) 
cels.
The embryoid bodies shown in Figure 3.1.4 were plated onto gelatin coated plates for 
48 hours. This resulted in the outgrowth of the outer layer of the EB onto the gelatin, 
forming a ‘halo’ around the anchored EB. Undiferentiated embryoid bodies retained 
their spherical shape and the cels that were observed growing out from the bodies 
resembled the undiferentiated F9 cels as sen in Figure 3.1.1 (A). These cels also 
demonstrate similar growth paterns to those sen in undiferentiated F9 cels, i.e. the 
cels grow in tight clusters within the halo.
The cels growing out from the diferentiated EBs were larger than the ‘halo’ cels 
from undiferentiated EBs and were similar in moiphology to the diferentiated cels 
presented in Figure 3.1.1 (C). These cels were also sen to be more distinct from one 
another i.e., the cels were spread out over a larger area than in the undiferentiated 
case.
The undiferentiated embryoid bodies were found to have an average diameter of 
32.23 (j,M whereas the diferentiated bodies had an average diameter of 24.27 (J.M, 
which presumably reflects the reduction in growth rate found to be asociated with 
increased diferentiation state.
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(B )
Figure 3.1.4 M orphological changes in embryoid bodies associated with 
differentiation in the presence o f  RA. Untreated EBs (A) are more spherical and are 
surrounded by a halo o f  tightly compacted cells (indicated by arrows). RA treated EBs 
(B) however, are distorted spheres and the component cells o f  the halo are elongated 
and stretched (indicated by arrows). M agnification = 10X B ar=  150 (am.
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3.1.4 Investigation of the Expresion of Diferentiation Markers in F9 Embryoid 
Bodies
EB diferentiation is unique as within it are 3-D cel-cel contacts present that are 
absent in cel monolayers, thus EBs have ben compared to early (5-6 day) embryonic 
mases. The expresion of diferentiation markers in EBs folowing RA diferentiation 
was investigated to determine the posible lineages that were evolving.
3.1.4.1 Alkaline Phosphatase Expresion in Diferentiating F9 cels
From Figure 3.1.5 (A&B) it was observed that the central mas of the EBs stained 
intensely for alkaline phosphatase. The halo of cels surounding the undiferentiated 
EB also stained for the enzyme. The cels within the halo growing out from the EB 
treated with RA showed litle or no staining and displayed the elongated morphology 
typicaly observed folowing treatment of F9 cels with RA (indicated by arows in 
Figure 3.1.5 (B).
(B )
Figure 3.1.5 Alkaline phosphatase activity during embryoid body diferentiation. (A) 
Untreated EBs grown for 72 h in DMEM and cultured for 48 h on gelatin to promote 
halo formation. Folowing this the cels were fixed and stained. (B) EBs cultured in 
the presence of RA for 72 hours prior to plating on gelatin, fixing and staining. 
Magnification = 10X. Bar - 50 |im.
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3.1.4.2 Cytokeratin Expression in Differentiating Embryoid Bodies
The paired cytokeratins 8 and 18 were expresed in the cels growing out from both 
diferentiated and undiferentiated EBs (Figure 3.1.6 (B&D) & Figure 3.1.7 (B&D). 
The staining in the undiferentiated EBs was of leser intensity than that in the RA 
treated EBs and far les widespread. Staining for cytokeratins in RA treated EBs was 
predominantly observed in the ‘halo’ surounding the EB and the isolated cels that 
had broken of from the halo. The low intensity staining in the untreated EBs is 
noticed within the smal number of cels that were sen to exhibit diferentiated 
morphology including those cels that had broken of from the halo (Figure 3.1.6 
(A&B).
The paired cytokeratins 7 and 19 were also expresed in the outgrowths from the 
undiferentiated (Figures 3.1.8 & 3.1.9 (B) and diferentiated EBs (Figures 3.1.8 & 
3.1.9 (D). Contrary to the observations with cytokeratins 8 & 18, it was found that 
the intensity of staining was similar (cytokeratin 7) or slightly greater (cytokeratin 19) 
in untreated EBs. Staining was predominantly noted in the periphery of the EBs and 
within the surounding halo.
Figure 3.1.6 Cytokeratin 8 expresion in undiferentiated EBs (A&B) and RA treated 
EBs (C&D) including phase contrast views of the fixed EBs (A&C). The cytokeratin 
staining was noted in the halo region surounding the EB and was more intense in the 
RA treated EBs. Magnification = 40X
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Figure 3.1.7 Cytokeratin 18 expresion in undiferentiated EBs (A&B) and RA 
treated EBs (C&D) including phase contrast images of the fixed EBs (A&C). Staining 
was most intense around the periphery of the EBs and into the halo surounding the 
central region. Magnification = 40X
Figure 3.1.8 Cytokeratin 7 expresion in undiferentiated EBs (A&B) and in RA 
treated EBs (C&D) including phase contrast images of the fixed EBs (A&C). Staining 
was in the periphery of the EBs and was of similar intensity in both untreated EBs and 
RA treated EBs. Magnification = 40X
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(D)
Figure 3.1.9 Cytokeratin 19 expresion in undiferentiated EBs (A&B) and in RA 
treated EBs (C&D) including phase contrast images of the fixed EBs (A&C). Staining 
was in the periphery of the EBs. Magnification = 40X.
3.1.4.3 Alpha Fetoprotein Expresion in Diferentiating EBs
Alpha fetoprotein (AFP) expresion is a characteristic of visceral endoderm. The 
actual endodermal origins (visceral or parietal) of (3 cels is unknown; thus AFP 
expresion levels were investigated in diferentiating EBs. From Figure 3.1.10 it is 
clear that AFP expresion was present in the periphery of the EBs treated with RA. 
Untreated EBs did not have detectable levels of the protein using this method.
Figure 3.1.10 Alphafeto protein expresion in diferentiating (A) EBs and (B) RA 
treated EBs. Staining is predominantly in the periphery of the EB. Magnification =
40X.
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3.1.5 pi Integrili Expression in Differentiating F9 cells and Embryoid Bodies
(A)
pi Integrin gene expresion is critical to F9 diferentiation and its role apears to be in 
the morphological changes that ocur during diferentiation of F9 cels (Stephens et 
al., 193).
As shown in Figure 3.1.1 it is dear that pi Integrin protein expresion increased 
significantly upon diferentiation of F9 cels and EBs. There was a 9-fold increase in 
expresion upon diferentiation of EBs and a 2-3 fold increase when F9 monolayer 
cels were treated with RA and RA/db cAMP respectively.
pi rs rs
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Figure 3.1.1 Western Blot 
monolayers and EBs. The blot 
independent experiments. P-actin was 
densitometry (B).
Integrin expresion in diferentiating F9 
(A) is representative of at least thre 
as an endogenous control for
*# This faint banding in the pi Integrin western blot is due to overflow from the EB-RA well.
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3.2 Second Stage Differentiation of Endodermal cells Generated from F9 Cells
From Section 3.1 it was sen that both visceral and parietal endoderm could be 
generated from F9 cels by diferentiating the monolayers/EBs in the presence of RA 
or RA/db cAMP. p cels are generaly acepted to be of endodermal origin, thus the 
imature endodermal cels generated during the initial stages of F9 diferentiation 
were considered an ideal starting point from which to generate endocrine cels. 
Previous studies have identified various diferentiation factors and growth factors 
which are critical in pancreatic neogenesis in the developing embryo (Section 1.1.3.4), 
these agents and others have ben exploited to generate endocrine tisue in in-vitro 
situations (Section 1.3.4). The protocols employed for secondary diferentiation and 
sampling are as outlined in Section 2.3.1.2.2
3.2.1 Identification of Receptors for Critical Second Stage Diferentiation Factors
It is known that the betacelulin (BTC) receptor (Epidermal Growth Factor Receptor; 
EGFR) increases upon endodermal diferentiation of F9 cels (Alonso et al., 191). 
However the efects of diferentiation on levels of Activin A and HGF receptors were 
unknown. Antibodies were sourced for these receptors and western bloting 
experiments were caried out (Section 2.5.2.1).
3.2.1.1 Activin RII B expresion in Diferentiating F9 Cels
Activin A receptors are clasified as type I, II or III, the type II receptors are further 
composed of A and B categories. The role of Activin RI B in development has ben 
shown in experiments with Xenopus embryos. In diferentiating EBs and monolayer 
F9 cels there is a slight increase in Activin RI B levels upon diferentiation with RA 
or RA/db cAMP (Figure 3.2.1). [3 actin was employed as an endogenous control in al 
blots for denstiometric analysis. This result confirms the presence of receptor 
expresion for subsequent secondary treatments.
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3.2.1.2 HGF Receptor (c-Met) Levels in Differentiating F9 Cells
From Figure 3.2.2 it can be seen that levels o f  c-met increase upon differentiation o f  
F9 cells and EBs. Levels are low in undifferentiated F9 cells but there are appreciable 
levels o f  the receptor in undifferentiated EBs. (3 actin levels w ere used as an 
endogenous control for densitometric analysis. As with the investigation o f  Activin 
RII B levels, the increase in protein levels is not as important as the qualitative data, 
i.e. that there are receptors present for HGF treatments. As indicated there is a large 
increase in c-met expression in untreated EBs compared to untreated F9 cells and this 
has been observed previously in other ES cell systems (Schuldiner et al., 2000).
137
Activin RIIB  
(56 kDa)
P Actin 
(44 kDa)
8
0.99
0.96
0.97
0.96
0.95
1
f f i  RA F9 F9RA F9RAC
Figure 3.2.1 Levels o f  A ctivin RII B in differentiating F9 monolayers and EBs. F9 
cels were differentiated w ith RA  (F9-RA) or R A / db cAM P (F9-RAC) for 72 hours. 
EBs were generated overnight and then treated w ith RA  (EB-RA) for 72 hours.
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Figure 3.2.2 Levels o f  c-M et in differentiating F9 monolayers and EBs. F9 cells were 
differentiated w ith RA  (F9-RA) or RA/ db cAM P (F9-RAC) for 72 hours. EBs were 
generated overnight and then treated w ith RA  (EB-RA) for 72 hours.
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3.2.2 Diferentiation of RA Treated F9 Monolayers (F9-RA) with Endocrine 
Diferentiation Agents
Treatments Concentration
Activin A  (Act) {Sigma} 2 n M
Betacellulin (BTC) {Sigma} 1 nM
Hepatocyte Growth Factor (HGF) 
{R&D Systems}
100 pM
N icotinam ide (Nico) {Sigma} 10 mM
Sodium Butyrate (Sod But) {Sigma} 1 mM
Table 3.2.1 Endocrine differentiation agents employed in the secondary 
differentiation o f  F9 derived endodermal cells. Combinations o f  all the above agents 
w ith activin A  w ere also carried out using the same working concentrations used for 
single application. Reconstitution o f  these agents to working stocks is described in 
Section 2.3.1.1.
3.2.2.1 PDX1 Expresion in F9-RA Monolayers
From Figure 3.2.3 it can be seen that low-level PDX1 transcription was present in the 
untreated F9 cell population. PDX1 levels w ere found to increase almost two-fold 
after exposure o f  the cells to RA for 10 days. Subsequent treatments did not cause an 
increase in PDX1 mRNA levels, w ith the exception o f  the combination o f  HGF and 
activin A  w hich resulted in a 2.5 fold increase in PDX1 expression when compared to 
untreated F9s. Despite these increases, PDX1 levels were still far lower in treated F9- 
RA cells than in M in6 P cells.
3.2.2.2 PPI Expresion in F9-RA Monolayers
Untreated F9 cells w ere found to have low level PPI gene expression which can be 
clearly seen in Figure 3.2.4. Treatment o f  the cells with RA increased levels o f  PPI 
mRNA in the cells. Subsequent treatm ent w ith endodermal differentiation agents 
resulted in increased PPI mRNA  levels especially in the case o f  the combination
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treatment o f  HGF and activin A  which caused a 3-4 fold increase in PPI mRNA levels 
(compared to untreated F9 cells). This treatm ent coincides w ith an increase in PDX1 
(Section 3.2.2.1).
3.2.2.3 Pax6 Expresion in F9-RA Monolayers
F9 cells were found to express high levels o f  Pax6 mRNA. Large increases in Pax6 
levels were noted following treatment w ith nicotinamide or a combination o f 
nicotinamide and activin A. Pax 6 levels w ere decreased by a factor o f  tw o following 
activin A  and betacellulin combination treatm ent and likewise following HGF and 
activin A  exposure (Figure 3.2.5). It is interesting that this treatment also results in the 
highest expression o f  PPI and PDX1 and may represent a possible inhibitory role o f 
Pax6 overexpression in p cell development.
3.2.2.4 Indian hedgehog (Ihh) Expresion in F9-RA Monolayers
As shown in Figure 3.2.6, Indian hedgehog (Ihh) mRNA levels increased 10 fold 
upon differentiation w ith RA, while all subsequent treatments involving pancreatic 
differentiation agents caused Ihh levels to decrease to approximately basal levels. 
Treatments involving nicotinamide, sodium butyrate and the combination o f  sodium 
butyrate and activin A  increased levels o f  Ihh compared to the other treatments and 
untreated F9 cells. The wide variation in Ihh levels possibly indicates the development 
o f  different cell lineages w ith differing requirements for hedgehog signalling.
3.2.2.5 Pancreatic Polypeptide (P) Induction in F9-RA Monolayers
F9 cells were found to be negative for pancreatic polypeptide (PP) mRNA as were F9- 
RA  cells. However, subsequent treatm ent o f  F9-RA monolayers w ith sodium butyrate 
or the com bination o f  sodium butyrate and activin A  resulted in the appearance o f PP 
mRNA (Figure 3.2.7). A s sodium butyrate or activin A have not had any substantial 
effects on any other genes exam ined so far, it seems that these treatments are acting 
directly on the PP gene. M in6 cells were also found to contain significant levels o f  PP 
transcripts which does not appear to have been reported before.
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3.2.2.6 Somatostatin Gene Induction in F9-RA Monolayers
Large increases in somatostatin mRNA levels were noted in F9-RA monolayers 
treated with either sodium butyrate or a combination o f  sodium butyrate and activin A 
and to a lesser extent following treatment w ith activin A, betacellulin or HGF (Figure 
3.2.8). There w as a slight increase in somatostatin expression in the presence o f  both 
sodium butyrate and activin A  that may represent a slight additive effect (i.e. as 
activin A  had moderate effects on somatostatin mRNA levels when used alone). As 
with PP mRNA levels, the data here indicates that the substantial increases in 
somatostatin appear to be due to a direct effect o f  sodium butyrate on the somatostatin 
gene.
3.2.2.7 Other Genes Examined in F9-RA Monolayers
The expression levels o f  a num ber o f  other pancreatic genes were examined in F9-RA 
monolayers however these genes were not found to be expressed in F9 cells and were 
not induced as a result o f  any o f  the treatments. The other genes investigated were:
•  GLUT2
•  Glucokinase
•  Pax4
•  Sonic Hedgehog (Shh)
•  Glucagon
Min6 cells were used as a positive control in each case.
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Figure 3.2.3 PDX1 expression in F9-RA cells treated w ith endocrine differentiation 
agents. Untreated F9 cells are included for comparison. All treatments were carried 
out over 10 days. M in6 cells and w ater w ere em ployed as positive and negative 
controls, respectively. The results presented are representative o f  repeat gels from two 
individual treatm ent experiments.
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Figure 3.2.4 PPI expression in F9-RA cells treated w ith endocrine differentiation 
agents. U ntreated F9 cells are included for comparison. A ll treatments w ere carried 
out over 10 days. M in6 cells and w ater were used as positive and negative controls, 
respectively. The results presented are representative o f  repeat gels from two 
individual treatment experiments.
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Figure 3.2.5 PAX6 expression in F9-RA  cells treated w ith endocrine differentiation 
agents. Untreated F9 cells are included for comparison. A ll treatments were carried 
out over 10 days. The results presented are representative o f  repeat gels from two 
individual treatment experiments.
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Figure 3.2.6 Indian hedgehog (Ihh) expression in F9-RA cells treated w ith endocrine 
differentiation agents. Untreated F9 cells are included for comparison. All treatments 
w ere carried out over 10 days. M in6 cells and w ater w ere used as positive and 
negative controls, respectively. The results presented are representative o f  repeat gels 
from two individual treatm ent experiments.
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Figure 3.2.7 Pancreatic Polypeptide (PP) induction in F9-RA cells treated with 
endocrine differentiation agents. Untreated F9 cells are included for comparison. All 
treatments w ere carried out over 10 days. M in6 cells and w ater w ere used as positive 
and negative controls, respectively. The results presented are representative o f  repeat 
gels from two individual treatm ent experiments.
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Figure 3.2.8 Somatostatin gene induction in F9-RA cells treated with endocrine 
differentiation agents. Untreated F9 cells are included for comparison. All treatments 
were carried out over 10 days. M in6 cells and water were used as positive and 
negative controls, respectively. The results presented are representative o f  repeat gels 
from two individual treatm ent experiments.
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3.2.3 Differentiation of RAC treated Monolayers
As outlined previously, (Section 3.1) RAC monolayers were generated over 72 hours 
by exposing F9 cells to a combination o f  RA  (10'7 M) and db cAM P (10'3 M). These 
cells w ere then treated w ith the endocrine differentiation agents listed in Table 3.2.1.
3.2.3.1 PDX1 Expresion in F9-RAC Monolayers
PDX1 gene expression was present at low level in F9 cells and increased upon 
treatm ent w ith RA and db cAMP. There were no substantial increases in PDX1 
m RNA levels after any o f  the other treatm ents although expression was found to be 
slightly reduced following activin A  treatm ent (Figure 3.2.9).
3.2.3.2 PPI Expresion in F9-RAC Monolayers
PPI gene expression was detected in F9 cells (as in Figure 3.2.4) and was present in 
all treatments examined. The levels o f  PPI did not change substantially w ith any 
treatm ent although there was a slight (< 2-fold) increase in expression upon treatment 
o f  the cells w ith sodium butyrate or the com bination o f  sodium butyrate and activin A 
(Figure 3.2.10). This increase in PPI levels did not correspond w ith similar increased 
levels in PDX1 expression but did coincide with slightly decreased levels o f  Pax6 
expression (Figure 3.2.11), which is similar to observations in F9-RA  monolayers 
(Section 3.2.2.3).
3.2.3.3 Pax6 Expresion in F9-RAC Monolayers
From  Figure 3.2.11 it can be seen that there are high levels o f  expression o f  Pax6 
m RNA in F9 cells. Levels o f  Pax 6 w ere found to decrease upon treatm ent o f  the cells 
w ith the com bination RA/db cAM P however the endocrine differentiation agents 
resulted in an increase in Pax6 transcripts (not as obvious following the treatments 
involving sodium butyrate). The highest levels o f  Pax6 were found following 
treatm ent o f  F9-RAC cells w ith nicotinam ide or the combination o f  nicotinamide and 
activin A  w hich is similar to findings w ith F9-RA monolayers (Figure 3.2.5) and EBs 
(Figure 3.2.17).
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3.2.3.4 Indian Hedgehog (Ihh) Expression in F9-RAC Monolayers
Indian hedgehog (Ihh) expression was present at low level in F9 and F9-RAC cells 
after 10 days treatment. This indicates that strong differentiation in the presence o f  db 
cAM P can be inhibitory to Ihh expression as Ihh was present at high levels following 
long term  RA treatment o f  F9 cells (Figure 3.2.6), and following short term treatment 
with RA and db cAM P (Figure 3.3.27). Ihh mRNA levels increased upon endocrine 
treatments, however there w ere no substantial differences in expression levels 
between the treatments, other than slightly decreased expression following 
betacellulin treatment (i.e. com pared to the other treatments) (Figure 3.2.12).
3.2.3.5 Pancreatic Polypeptide (P) Induction in F9-RAC Monolayers
Pancreatic polypeptide (PP) m RN A transcripts were observed in F9-RAC cells 
following treatment with sodium butyrate and sodium butyrate combined with activin 
A  (Figure 3.2.13). mRNA expression levels were similar between the two treatments 
however sodium butyrate alone did result in slightly higher expression o f PP. As with 
F9-RA monolayers (Figure 3.2.7), the data indicates that the effect is mediated by 
sodium butyrate alone and is a direct effect.
3.2.3.6 Somatostatin Gene Induction in F9-RAC Monolayers
Somatostatin gene transcripts were found to be present in F9-RAC cells that were 
exposed to sodium butyrate or a combination o f  sodium butyrate and activin A  for 10 
days (Figure 3.2.14). Expression levels (even following the treatments) were very low 
and difficult to detect. The slight additive effect o f  activin A  is again noted here 
despite that it had no effect on its own. However the data again suggests that the 
appearance o f  somatostatin m RN A  transcripts is more closely linked to the action o f 
sodium butyrate.
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3.2.3.7 Other Genes Examined in F9 Monolayers
The expresion levels of a number of other pancreatic genes were examined in F9- 
RAC monolayers. However these genes were not found to be expresed in either F9 
cels and were not induced as a result of any of the treatments. The other genes 
investigated were:
• GLUT2
• Glucokinase
• Pax4
• Sonic Hedgehog (Sh)
• Glucagon
Min6 cels were used as a positive control in each case
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Figure 3.2.9 PDX1 expression in F9-RAC cells treated w ith endocrine differentiation 
agents. U ntreated F9 cells are included for comparison. All treatments were carried 
out over 10 days. Min6 cells and w ater were used as positive and negative controls, 
respectively. The results presented are representative o f  repeat gels from two 
individual treatm ent experiments.
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Figure 3.2.10 PPI expression in F9-RAC cells treated w ith endocrine differentiation 
agents. Untreated F9 cells are included for comparison. A ll treatm ents w ere carried 
out over 10 days. M in6 cells and w ater w ere used as positive and negative controls, 
respectively. The results presented are representative o f  repeat gels from two 
individual treatm ent experiments.
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Figure 3.2.1 Pax6 expresion in F9-RAC cels treated with endocrine diferentiation 
agents. Untreated F9 cels are included for comparison. Al treatments were caried 
out over 10 days. Min6 cels and water were used as positive and negative controls, 
respectively. The results presented are representative of repeat gels from two 
individual treatment experiments.
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Figure 3.2.12 Indian hedgehog expression in F9-RAC cells treated with endocrine 
differentiation agents. Untreated F9 cells are included for comparison. A ll treatments 
were carried out over 10 days. M in6 cells and water were used as positive and 
negative controls, respectively. The results presented are representative o f  repeat gels 
from two individual treatm ent experiments.
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Figure 3.2.13 PP expression in F9-RAC cells treated w ith endocrine differentiation 
agents. U ntreated F9 cells are included for comparison. A ll treatments were carried 
out over 10 days. Min6 cells and w ater were used as positive and negative controls, 
respectively. The results presented are representative o f  repeat gels from two 
individual treatm ent experiments.
155
►nvo
>0
1 
>
Gd
H
n
W ffi
o  o►n ti
O  o.
oO
>o
C/5O
&
s '
3 C/3
öd oCu
I
Gd
d
p
o> >/—V  1—‘ or+
so ' S'
o > 0\
GAPDH
Som atostatin
0.6
0.5
0.4
8 °-3
0.2
0.1
F9 RAC Act Btc Act/BTC HGF HGF/Act Nco Mco/Act SB SB/Act
Treatment
Figure 3.2.14 Somatostatin expresion in F9-RAC cels treated with endocrine 
diferentiation agents. Untreated F9 cels (F9) are included for comparison. Al 
treatments were caried out over 10 days. Min6 cels and water were used as positive 
and negative controls, respectively. The results presented are representative of repeat 
gels from two individual treatment experiments.
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3.2.4 Diferentiation of RA Treated Embryoid Bodies (EBs) with Endocrine 
Diferentiation Agents
EBs w ere generated as already described (Section 2.2.4) and treated for 72 hours with 
RA. These EBs were then treated using the differentiation agents outlined in Table
3.2.1 for a period o f  10 days in accordance w ith the secondary differentiation protocol 
(Section 2.3.1.2.2).
3.2.4.1 PDX1 Expresion in EB-RA Bodies
From Figure 3.2.15 it can be seen that PDX1 mRNA was present in appreciable levels 
in the untreated EBs and levels o f  the transcription factor were not substantially 
changed as a result o f  any o f  the endocrine differentiation treatments. The highest 
level o f  PDX1 expression was found to be as a result o f  sodium butyrate treatm ent or 
following a combination o f nicotinam ide and activin A. The levels o f  PDX1 in the 
untreated EBs is much higher than in untreated F9 cells (Figure 3.2.3 or Figure 3.2.9), 
which is similar to findings by Gerrish et al., (2000) and Schuldiner et al., (2000), 
upon generating EBs from ES cells.
3.2.4.2 PPI Expresion in EB-RA Bodies
PPI mRNA was found to be present in untreated EBs and appeared to be unaffected 
by RA treatment. All o f  the endocrine differentiation agents caused an increase in PPI 
gene transcription levels o f  approximately 1.5-2 fold, but the treatments did not differ 
from one another to any notable extent (Figure 3.2.16).
3.2.4.3 Pax6 Expresion in EB-RA Bodies
EBs w ere found to contain Pax6 transcripts and expression o f  Pax6 was upregulated 
following RA treatment (~2 fold). Nicotinam ide/activin A  treatment resulted in 
further upregulation o f  Pax6 expression (almost 3 fold greater than untreated EBs) 
and this is similar to findings w ith F9-RA (Figure 3.2.5) and F9-RAC (Figure 3.2.11), 
monolayers. Pax6 expression w as decreased following treatment o f  EB-RA bodies
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w ith HGF, sodium butyrate and the combination o f  sodium butyrate and activin A 
(Figure 3.2.17).
3.2.4.4 Indian Hedgehog (Ihh) Expresion in EB-RA Bodies
Ihh expression in EBs was increased following RA  treatment. None o f the endocrine 
differentiation agents caused any further increase o f  Ihh expression however. Activin 
A, and the com bination o f  activin A  with betacellulin or HGF all caused Ihh levels to 
fall below those in untreated EBs (Figure 3.2.18). The observed increase in Ihh levels 
upon RA  treatm ent o f  F9-RA monolayers (Figure 3.2.6), the increase observed here 
and the lack o f  Ihh expression following 10 days RAC treatm ent indicates preferential 
expression o f  Ihh in prim itive endoderm and visceral endoderm types rather than 
parietal endoderm.
3.2.4.5 Pancreatic Polypeptide (P) Expresion in EB-RA Bodies
PP mRNA expression was found to be negligible in EBs. Low levels o f  PP transcripts 
w ere detected in EB-RA bodies, EB-RA bodies treated w ith activin A, HGF and also 
following a combination treatm ent o f  nicotinam ide and activin A. M ore substantial 
expression was induced following treatment with sodium butyrate (whether alone or 
in combination with activin A) (Figure 3.2.19). The discovery o f  PP transcripts in a 
w ider range o f  treatments confirms that the cells generated from EB-based 
differentiation are unique compared to either o f  the m onolayer populations generated.
3.2.4.6 Somatostatin Gene Expresion in EB-RA Bodies
From Figure 3.2.20 it can be seen that untreated EBs were found to contain low levels 
o f  somatostatin transcripts; these levels were not significantly altered in EB-RA cells. 
EB-RA cells treated with betacellulin contained low levels o f  somatostatin gene 
transcripts while combination treatments o f  activin A  w ith HGF or sodium butyrate 
resulted in further increases in mRNA levels. In previous experiments activin A  has 
had minor effects on somatostatin expression in monolayers (Figure 3.2.8 & Figure 
3.2.14), but the data presented in Figure 3.2.20 suggests that it has a more positive 
role in inducing levels o f  somatostatin mRNA.
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3.2.4.7 Other Genes Examined in Differentiated EBs
The expresion levels of a number of other pancreatic genes were examined in EB-RA 
bodies, however these genes were not found to be expresed in either F9 cels and 
were not induced as a result of any of the treatments. The other genes investigated 
were:
• GLUT2
• Glucokinase
• Pax4
• Sonic Hedgehog (Sh)
• Glucagon
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Figure 3.2.15 PDX1 expression in EB-RA cells treated with endocrine differentiation 
agents. U ntreated EBs are included for comparison. A ll treatments were carried out 
over 10 days. Min6 cells and w ater w ere used as positive and negative controls, 
respectively. The results presented are representative o f  repeat gels from two 
individual treatm ent experiments.
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Figure 3.2.16 PPI expression in EB-RA  cells treated w ith endocrine differentiation 
agents. U ntreated EBs are included for comparison. All treatm ents were carried out 
over 10 days. M in6 cells and w ater were used as positive and negative controls, 
respectively. The results presented are representative o f  repeat gels from two 
individual treatm ent experiments.
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Figure 3.2.17 Pax6 expression in EB-RA cells treated w ith endocrine differentiation 
agents. U ntreated EBs are included for comparison. A ll treatments were carried out 
over 10 days. M in6 cells and w ater w ere used as positive and negative controls, 
respectively. The results presented are representative o f  repeat gels from  two 
individual treatm ent experiments.
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Figure 3.2.18 Indian hedgehog (Ihh) expression in EB-RA cells treated with 
endocrine differentiation agents. U ntreated EBs are included for comparison. All 
treatm ents w ere carried out over 10 days. M in6 cells and w ater were used as positive 
and negative controls, respectively. The results presented are representative o f  repeat 
gels from tw o individual treatm ent experiments.
163
0.25
0.2
0.15
□
o  I
0.1
0.05
RA Act Bta Act/Btc HGF HGF/Act Meo Nco/Act SB S&Act
Treatment
Figure 3.2.19 Pancreatic polypeptide 
w ith endocrine differentiation agents.
(PP) expression in EB-RA cells treated 
Untreated EBs are included for
comparison. A ll treatments w ere carried out over 10 days. Min6 cells and water
w ere used as positive and negative controls, respectively. The results
presented are representative o f  repeat gels from  two individual treatment
experiments.
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Figure 3.2.20 Somatostatin expression in EB-RA cells treated with endocrine 
differentiation agents. Untreated EBs are included for comparison. All treatments 
were carried out over 10 days. Min6 cells and w ater were used as positive and 
negative controls, respectively. The results presented are representative o f  repeat gels 
from two individual treatm ent experiments.
F9-RA F9-RAC EB-RA
Gene Highest Level 
of Expression
Lowest Level 
of Expression
Highest Level 
of Expression
Lowest Level 
of Expression
Highest Level 
of Expression
Lowest Level 
of Expression
PDX1 HGF/Activin A N/A* SB/Activin A N/A* SB** BTC**
PPI HGF/Activin A N/A* SB** HGF/Activin
A
HGF/Activin
***
N/A*
Pax6 Nicotinamide 
(Nico) or 
Nico/ Activin A
Activin A/ 
Betacellulin or
HGF/Activin A
Nicotinamide or 
Nico/ Activin A
RAC Nico/ Activin 
A
HGF, SB or 
SB/Activin A
Ihh RA N/A* Sodium
Butyrate***
N/A* RA or
SB/Activin A
Activin AJ 
Betacellulin or 
HGF/Activin 
A
PP Sodium 
Butyrate (SB) or 
SB/Activin A
N/A* Sodium 
Butyrate or 
SB/Activin A
N/A* Sodium 
Butyrate or 
SB/ Activin A
N/A*
Somato-
Statin
Sodium 
Butyrate (SB) or 
SB/Activin A
N/A* Sodium 
Butyrate (SB) or 
SB/Activin A
N/A* SB/Activin A A Number of 
Treatments 
Showed no PP 
Expression
GLUT2 Negative Negative Negative Negative Negative Negative
Glucokin
-ase
Negative Negative Negative Negative Negative Negative
Pax4 Negative Negative Negative Negative Negative Negative
Shh Negative Negative Negative Negative Negative Negative
Glucagon Negative Negative Negative Negative Negative Negative
Notes:
N/A* : indicates no reduction below level of untreated cells
** Treatment shows largest induction but is not significantly (>1.5 fold) higher than untreated 
cells.
*** Treatment shows highest levels of rnRNA, but many other treatments similar.
Table 3.2.2 Summary o f  treatments resulting in highest/lowest levels o f  expression o f 
the genes studied in the three differentiation systems i.e. F9-RA, F9-RAC and EB-RA 
cells.
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3.2.5 Protein Expresion Folowing Secondary Diferentiation of F9 Monolayers 
and Embryoid Bodies
A s the expression levels o f a number o f  genes were increased/induced following 
secondary differentiation o f  F9 monolayers and EBs, it was decided to investigate the 
expression o f  these genes at the level o f  protein expression. Levels o f  PPI, PDX1, PP 
and somatostatin protein were investigated using immunofluorescence 
/immunocytochem istry (and E l A in the case o f  PPI). PDX1 and PPI protein were 
found to be negligible (even in cases where transcript levels were found to be 
significantly upregulated e.g. F9-RA monolayers in the presence o f  HGF and activin 
A, Figures 3.2.3 & 3.2.4). Somatostatin and PP levels were investigated in F9-RA 
cells treated w ith sodium butyrate and the com bination o f  sodium butyrate and activin 
A  (these treatments dem onstrated the greatest induction levels o f  these mRNAs 
(Figures 3.2.7 & 3.2.8) and the protein expression levels are displayed below (Section
3.2.5.1 & Section 3.2.5.2).
A cetylated Histone H3 protein levels w ere also investigated in sodium butyrate 
treated cells to investigate a possible mechanism for the induction o f  these genes at an 
epi-genetic level.
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3.2.5.1 Celular Localisation of Pancreatic Polypeptide (P) Protein in F9-RA 
cels Treated with Sodium Butyrate and Activin A
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Figure 3.2.21 Pancreatic polypeptide expression in F9-RA cells treated with Sodium Butyrate (A & B) 
and a combination o f Sodium Butyrate and Activin A (C & D). Min6 cells were included as positive 
controls (E & F) while untreated F9 cells were used as a negative control (G). PP staining is present in 
localised clumps of treated F9 cells whereas it is widespread throughout the Min6 cell population. 
Staining is diffuse and is predominantly cytoplasmic. Magnification = 20 X (A, C, E & G) and 40 X 
(B, D & F). Bar = 50pM in all cases.
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3.2.S.2 Somatostatin Localisation within F9 cels treated with Sodium Butyrate 
and Activin A
G
Figure 3.2.22 Somatostatin staining can be clearly be identified in localised clumps of cells in F9-RA 
cells treated with Sodium Butyrate (A & B) or a combination o f Sodium Butyrate and Activin A  (C & 
D). Min6 cells have been used as positive (E & F) and untreated F9 cells (G) as a negative controls 
respectively. Staining is diffuse in the treated F9 cells and is predominantly cytoplasmic. Magnification 
=  20 X (A,C, E & G) and 40 X (B, D & F). Bar = 50 ^iM in all cases.
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3.2.5.3 Acetylated Histone H3 Expresion levels in F9-RA Monolayers Treated 
with Sodium Butyrate and Activin A
Sodium butyrate treatm ent alone (and in com bination with activin A) led to 
expression o f  PP and Somatostatin both at the transcriptional and translational levels. 
n-Butyrate is a naturally occurring short chain fatty acid produced in the colon 
through fermentation o f  dietary fibre and has already been identified as a potent agent 
in P cell differentiation (Otonkoski et al, 1999). n-Butyrate is a member o f  a class o f 
compounds known as histone deacetylase (HDAC) inhibitors, a group o f  compounds 
known to be inducers o f  growth arrest and differentiation. By inhibiting HDAC, 
histone acetylation (and in certain cases, protein acetylation) is increased. Actively 
transcribed genes are associated with chromatin fractions enriched in highly 
acetylated core histones. Thus to determine if  sodium butyrate was having such an 
effect on F9-RA cells, levels o f  acetylated histone H3 were examined using western 
blotting.
Preliminary results from western blot analysis indicate that sodium butyrate caused an 
increase in the levels o f  acetylated histone H3. Densitometric analysis indicates that 
the level o f  acetylated histone H3 increase 2-3 fold w hen F9-RA cells were treated 
with Sodium Butyrate and a combination o f  Sodium Butyrate and Activin A 
respectively (Figure 3.2.23).
This western blotting was carried out by Dr. Finbar O ’ Sullivan.
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Untreated F9 SB/Activin A Sodium Butyrate
Treatment
Figure 3.2.23 Comparison o f  acetylated histone H3 expression levels between 
untreated F9 cells and F9 cells exposed to two-step differentiation involving RA (10'7 
M ) , Sodium Butyrate (1 mM ) and Activin A  (2nM).
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3.3 Diferentiation of F9 cels using Gene Transfer Technology and Endocrine 
Diferentiation Treatments
Transfection o f  the c-fos proto-oncogene in to F9 cells has been shown to duplicate 
some o f the effects o f  RA differentiation (M uller & W agner, 1984). Transcription 
factor expression has also been used in directed differentiation experiments with 
AR42J cells to generate insulin secreting cell lines, thus it is clear that directed 
differentiation can be modified and refined by direct overexpression o f  relevant genes. 
To investigate such effects in F9 cells, a construct was generated to enable isolation o f 
PDX1 overexpressing cells from transfected cell populations, following secondary 
endocrine differentiation. It was hoped that these cells would provide an interesting 
model o f  p cell differentiation.
To investigate the effects o f  overexpression o f  other genes/transcription factors 
believed to be essential for pancreas/islet cell development, expression plasmids 
containing PDX1, Beta2, Ngn3 and Nkx2.2 cDNAs w ere obtained. Transient 
transfection protocols were designed to investigate the effects o f  their expression on 
endogenous gene(s) and pancreatic marker(s) expression in partially differentiated 
monolayers.
3.3.1 The Cel Trap Construct
The cell trap construct is designed with two antibiotic resistance genes, one o f  which 
is driven by a constitutive prom oter and the other under the control o f  a tissue specific 
promoter. The initial transfectants, i.e. the cells that have integrated the construct can 
be isolated and purified using the antibiotic under the constitutive promoter. Cells that 
assume appropriate lineages that enable them to express the tissue specific gene o f 
interest (i.e. PDX1 in this case) can subsequently be selected due to their acquired 
resistance to the antibiotic encoded by the resistance gene under the control o f  that 
promoter.
The cell trap construct em ployed in these experiments (PGK-TKCAT-Zeo/pBS) was 
designed from cDNAs available in our laboratory and material donated from an
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outside source (see * below). The com ponent plasm ids and the design specifications 
w ere sent to Cytomyx (Cambridge), who constructed the final vector. The plasmids 
used and the sequence o f  steps in building the construct are outlined in Figure 3.3.1. 
The construct was generated by initially digesting the PGK-Neo plasm id with 
X hol/K pnl, the 2 kb fragment containing the G418 resistance gene under the control 
o f  the constitutive pGK  prom oter was then subcloned into the multiple cloning site 
(M CS) in the expression plasm id pBluescript. The cDNA encoding the PDX1 
prom oter region w as excised from the PstBstII[Sense]pTKCAT(An) plasmid 
(♦generously supplied by Roland Stein, Vanderbilt M edical Centre, Tennessee) using 
H indlll and BamHI, and subsequently cloned in to the pBS-pGK-Neo plasmid. The 
gene encoding resistance against zeocin was copied from the pcDNA3.1/Zeo plasmid 
using PCR. The prim ers in this reaction w ere also designed to generate a BamHI site 
at the 5 ’ end o f  the product and a N otl site at the 3 ’ end. This product was then 
subcloned into these sites in the pBS-pGK-TKCAT plasm id to complete the construct.
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B1. PGK-Neo removed using Kpnl and 
Xhol and cloned into these stes in the 
MCS in pBluescript
's“ — K p n l 4 6 4 0  
t i c o R I  4 6 4 0  
P s t l  4 6 4 0
S s p l 2 8 5 0  S s p l 19
PstBst[Ssn8e]pTKCAT(An)
5 6 3 3  b p
2. PDX1 Promoter subcloned 
using HindJII and BamHI
D
Afilli T 3  Prom oter
E
3. Zeocin Resistance gene and poly A tail 
subcloned via PCR, BamHI and Notl sites 
generated at 5’ and 3’ ends respectively for 
cloning into pBluescript
4-
Figure 3.3.1 Generation o f  the cell trap construct PGK-TKCAT-Zeo/pBS (E) using PGK-Neo 
(A), PstBst[Sense]pTKCAT(An) (B), pcDNA3.1/Zeo (C) and pBluescript II KS+ (D).
3.3.1.1 Restriction Analysis of the Completed Construct
To verify that the PGK-TKCAT-Zeo/pBS construct was correctly assembled, 
restriction analysis was carried out (Section 2.4.4). The digests are discussed below 
and refer to Figure 3.3.2
Notl/Kpnl: This cut was designed to remove all o f  the subcloned DNA from the 
pBluescript backbone (2.9 kb). The presence o f  three bands is due to a second Kpnl 
site w ithin the PDX1 prom oter region (Figure 3.3.1 (B)). Thus the two lower bands 
represent (I) a fragment N otl-K pnl containing the zeocin resistance gene and most o f  
the PDX1 promoter region, and (II) a KpnI-Kpnl fragment containing mostly the 
G418 resistance gene w ith a small portion o f  the PGK promoter.
BamHI/Notl: This digest was designed to remove the zeocin resistance gene (652 bp) 
from the construct. The bands o f  652 bp and 5.9 kb are present as expected.
BamHI/Hindll: The 1 kb fragment corresponds to the PDX1 prom oter region being 
excised from the construct. The remainder o f  5.5.kb is correct.
Based on the data from these restriction digests it is clear that the plasmid was 
generated to the exact specifications.
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Figure 3.3.2 Restriction digests o f  the cell trap construct received from Cytomyx. 
Restriction digests w ere carried out for 1 hour at 37 °C in a w ater bath. 10 (xl o f  
digested product was mixed w ith 2 p.1 o f  6X loading dye and subsequently loaded on 
to  an agarose long gel (0.8 %).
3.3.1.2 Validation of the Cell Trap Construct
The cell trap construct PGK-TKCAT-Zeo/pBS presented should impart immediate 
G418 resistance upon transfection in to any cell line. Zeocin resistance will depend on 
the cells ability to drive the PDX1 promoter. Thus experiments were designed to 
validate the construct using suitable cell lines, i.e. cells with and without PDX1 
expression.
The cell trap construct was transfected into M in6 (PDX1+/+) and BHK-21 (PD X 1 ' ) 
cells (Figure 3.3.3). Following this transfection, cells w ere exposed to zeocin at levels 
o f  100 |ig/m l for BH K -21 and 500 (J.g/ml for M in6 (levels were chosen from 
preliminary toxicity assays (Section 2.3.2) to determine sensitivities o f  the cells to 
zeocin). A  significant num ber o f  transfected Min6 cells (Min6CT) cells survived 
while non-transfected Min6 were wiped out. A ll BHK-CT and BH K -21 cells were 
killed. To clarify that the PDX1 expressing cells transfected with PGK-TKCAT- 
Zeo/pBS had actually become resistant to zeocin while those without PDX1 had not, 
toxicity assays were carried out using non-transfected cells as controls. Thus, re­
transfected M in6CT and BHK-CT cells were selected using G418 (400 (ig/ml Min6- 
CT, 1000 pg/m l BHK-CT) to obtain homogenous populations o f  cells expressing the 
PGK-TKCAT-Zeo/pBS for the toxicity assays.
A ll transfected CT cells were found to show total resistance to G418 (Figure 3.3.4 
(A&C)), as expected, due to the constitutive nature o f  the G418 resistance gene. Only 
M in6CT cells however dem onstrated increased resistance to zeocin (Figure 3.3.4 (B)). 
This result indicated that the cells are expressing at least some level o f  the zeocin 
resistance gene (Sh blé) and this would be expected as Min6 cells express PDX1. The 
effect is less than w as anticipated however, i.e. w hen comparing parental Min6 cells 
to M in6CT cells. The level o f  resistance also appears to be lower in the stable 
M in6CT cell lines than in the freshly transfected mixed population tested directly with 
zeocin. It is presum ed that during the serial passaging o f  the M in6CT cells, while 
generating the stocks for toxicity assays (approximately 8-9 passages), that PDX1 
levels were reduced (an effect noted in other experiments, see Figure 3.4.11(A)). 
Impaired ability to drive the PDX1 promoter would therefore result in less zeocin
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resistance. The level o f  zeocin resistance o f  M in6CT cells observed was consistently 
higher than that o f  Min6 in a number o f  repeat experiments. BHKCT cells were 
resistant to G418 (Figure 3.3.4 (C)) but showed no resistance to zeocin (Figure 3.3.4 
(D)). Thus, the cell trap can only confer zeocin resistance to PDX14 4 cell lines.
GAPDII
PDX1
Figure 3.3.3 PDX1 expression levels in Min6 and BHK-21. PDX1 expression is 
present in the murine (3 cell line Min6 while the fibroblast line BHK-21 is negative for 
PDX1 transcripts. 1 r|g  PDX1 cDNA in the pcDNA3-PD Xl plasmid and H2O were 
used as positive and negative controls respectively.
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Figure 3.3.4 Toxcicity Assays on Min6 and 
trap construct PGK-TKCAT-Zeo/pBS. The 
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3.3.1.3 Generation of Cell Trap Cell Lines
Initially the PGK-TKCAT-Zeo/pBS construct was transfected in to undifferentiated 
F9 monolayer cells and after 24 hours these cells were selected w ith increasing levels 
o f  G418 (to a maximum o f 1000 |Jg/|il). Stocks o f  these F9-CT cells were prepared. 
F9-CT cells were set up as described in Section 2.3.1.2.1 i.e. as F9-RA monolayers 
and EB-RA bodies. These cells were then either immediately selected with zeocin (25 
(ig/ml) or treated w ith a num ber o f  agents known to increase PDX1 levels for 5-10 
days (Table 3.3.1) prior to zeocin selection (to a final selection concentration o f  100 
(ig/ml). Cells that were differentiated as EBs were grown on gelatin during the 
selection process.
F9-CT-RA EB-CT-RA
HGF/Act Sodium Butyrate
Sodium Butyrate N icotinam ide/ A ct
RA RA
Table 3.3.1 Treatments carried out on F9-CT and EB-CT cells prior to zeocin 
selections.
3.3.1.3.1 Zeocin Resistant Cel Lines Isolated
A  number o f  the treatments resulted in cell lines that were initially resistant to 100 
|ig/m l zeocin; however these cell lines eventually died through gradual cessation o f 
growth as opposed to cytotoxicity. Four monolayer cell lines (two o f which originated 
from the differentiated outer layer o f  EBs) and 2 suspension EB cell types were found 
to proliferate normally in 100 (J.g/ml zeocin. The cell lines generated are tabulated 
below in Table 3.3.2
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Cel Line Origin
Zeocin Resistant Cels Grown as Monolayers
F9-CT PGK-TKCAT-Zeo/pBS expressing F9 cells (untreated before zeocin selection)
F9-CT-RA F9-CT cells treated for 72 hours in RA (10'7 M) before zeocin selection.
EB-CT-N/A5 EBs grown in DMEM followed by 5 days exposure to a combination of 10 mM 
nicotinamide and 2 nM activin A. Selection was carried out on gelatin coated wells.
EB-CT-N/A10 EBs grown in DMEM followed by 10 days exposure to a combination of 10 mM 
nicotinamide and 2 nM activin A. Selection was carried out on gelatin coated wells.
Zeocin Resistant Cels Grown as Suspension EBs
EB-CT-RA-N/A(10) EBs grown in RA ( 10'7 M) followed by 10 days exposure to a combination o f 10 
mM nicotinamide and 2 nM activin A. Selection was carried out on gelatin coated 
wells, however these cells were found to grow better as suspension EBs.
EB-CT-N/A(5) EBs grown in RA ( 10'; M) followed by 5 days exposure to a combination of 10 mM 
nicotinamide and 2 nM activin A. Selection was carried out on gelatin coated wells, 
however these cells were found to grow better as suspension EBs.
Table 3.3.2 Cell lines expressing PGK-FKCAT-Zeo/pBS construct that were selected 
following treatm ent and capable o f  proliferating in the presence o f  100 |ig/ml zeocin.
3.3.1.3.2 Characterisation of the Isolated CT Cel lines
The cell lines isolated (and the two suspension EB-CTs) were subjected to RT-PCR, 
immunofluorescence and proinsulin EIA. It was found that although the CT cell lines 
had increased PDX1 (and in some cases PPI mRNA), that there was no detectable 
protein expression. In certain cases the level o f  zeocin used in the selection medium 
w as increased to determine if  highly resistant sub populations o f  cells could be 
isolated, these cells would then presumably have increased levels o f  PDX1. In these 
cases zeocin was em ployed at 200 |J.g/ml and 400 (ig/ml. However this did not result 
in further increases in PDX1 mRNA. Two o f the m onolayer cell lines which were 
found to express the greatest levels o f  PDX1 were selected for further analysis; F9- 
CT-RA and EB-CT-N/A-10. The PDX1 level in F9-CT-RA was slightly higher than 
that following RA treatm ent o f  F9 cells (Figure 3.3.5(A)), (when comparing both to 
F9 parent cells), how ever the PDX-1 level in EB-CT-N/A-10 was similar to that o f  
N /A  treated EBs (Figure 3.2.15). In the CT cell lines, however, the differentiation 
agent was no longer present in the medium and the PDX-1 levels were maintained by
181
the selective pressure o f  the zeocin. These cell lines were also found to have elevated 
levels o f  PPI gene transcripts (Figure 3.3.6), similar to those observed in treated F9 
cells and EBs (Figures 3.2.4. & 3.2.16).
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Figure 3.3.5 Characterisation o f  PDX1 mRNA levels in F9-CT cell lines and 
differentiated variants. W here the zeocin concentration used in the selection process 
was in excess o f  the typical selection concentration o f  (100 (J.g/ml) the concentration 
used is indicated in parentheses after the cell line name. F9 cells were included for 
comparison. Min6 cells and w ater were employed as positive and negative controls, 
respectively.
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Figure 3.3.5(A) Comparison o f  PDX1 levels in F9, RA treated F9 cells and in RA- 
treated F9 cells subsequently passed through cell trapping.
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Figure 3.3.6 Characterisation o f  PPI levels in F9-CT cell lines and differentiated 
variants. W here the zeocin concentration used in the selection process was in excess 
o f  the typical selection concentration o f  (100 p-g/ml) the concentration used is 
indicated in parentheses after the cell line name. F9 cells were included for 
comparison. M in6 cells and w ater w ere employed as positive and negative controls, 
respectively.
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3.3.1.4 Secondary Differentiation of Selected Cell Trap Cell Lines
As shown in Section 3.3.1.3.2 the cell trapping protocol resulted in overexpression o f  
PDX1 at the transcriptional level, which in turn caused an increase in PPI expression. 
However as the cells did not synthesise or secrete insulin (when analysed by 
immunofluorescence or EIA), it was decided to treat the w ith agents already 
established during the course o f  this study as differentiating F9 monolayers towards 
an endocrine fate (e.g. in Section 3.2 treatments involving sodium butyrate and activin 
A  were shown to result in somatostatin and PP expression). As already indicated the 
cell lines selected for further analysis w ere F9-CT-RA and E B -C T -N /A 10 , the 
treatments used are listed below:
•  R A (1 0 '7 M)
•  HGF (100 pM )/Activin A (2 nM)
•  Sodium Butyrate (1 mM )
•  Sod But (1 mM) /Activin A  (2 nM )
All treatments were preceded by 72 hours initial differentiation w ith 10'7 M  RA, the 
subsequent secondary differentiation was carried out over 10 days.
3.3.1.4.1 PDX1 Expresion in Treated CT Cels
A s shown in Figure 3.3.7, PDX1 expression was increased upon RA  treatment o f  both 
F9-CT-RA and EB-CT-N/A 10. The other treatments carried out did not alter the 
level o f  PDX1 expression com pared to untreated F9-CT-RA cells or E B -C T -N /A 10. 
Thus to clarify, the untreated cells on Figure 3.3.7 are untreated F9-CT-RA cells and 
untreated EB-CT-N/A_10, respectively. Parental F9 cells are not represented on these 
gels (Figures 3.3.7-3.3.10 inclusive).
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3.3.1.4.2 PPI Expression in Treated CT Cells
From  Figure 3.3.8 it is clear that the expression o f  the PPI gene was increased 
following RA treatm ent in F9-CT-RA. There was a slight increase in PPI expression 
in EB-CT-N/A_10 following RA treatment; however it w as not as large.
3.3.1.4.3 P Expresion in Treated CT Cels
A s with the other monolayer cell lines examined, PP expression was absent in the CT 
cells and was only induced following sodium butyrate treatment (either with or 
w ithout the presence o f  activin A) (Figure 3.3.9). PP transcript levels were similar in 
CT cell lines treated w ith sodium butyrate alone, and in combination with Activin A.
3.3.1.4.4 Somatostatin Expresion in Treated CT Cels
From Figure 3.3.10 it is clear that somatostatin expression was present in untreated 
F9-CT-RA cells and also in untreated E B -C T -N /A 10  cells. Somatostatin transcripts 
w ere not found to be present following RA treatment o f  F9 cells (Figure 3.2.8) or 
following N ico/Act treatment o f  EBs (Figure 3.2.20), and it is known that 
somatostatin is not expressed in F9 cells (Figures 3.2.8 & 3.2.14). Thus it appears that 
the PD X l-rich  CT cells co-express somatostatin at detectable levels. RA treatment o f  
F9-CT-RA cells resulted in the loss o f  somatostatin expression, all other treatments 
did not increase expression levels above those already present in the untreated cells. 
The proposed mechanism o f  somatostatin activation in CT cells is discussed in 
Section 4.4.3.2.
3.3.1.5 Proinsulin Synthesis in Treated CT Cel Lines
EIA analysis and immunofluorescence microscopy failed to detect any proinsulin in 
either o f  the treated cell lines, even though the cells w ere induced to increase PPI 
transcript levels though the combination o f  the cell trapping protocol and the 
subsequent treatments.
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Figure 3.3.7 PDX1 expression in CT cell lines treated w ith a selection o f  secondary 
endocrine differentiation agents. M in6 cells were used as a positive control. The result 
presented is representative o f  a  num ber o f  repeat gels.
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Figure 3.3.9 PP expression in CT cell lines treated with a selection of secondary 
endocrine differentiation agents. Min6 cells and H2O were used as positive and 
negative controls respectively. The result presented is representative of a number of 
repeat gels.
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Figure 3.3.10 Somatostatin expression in CT cell lines treated with a selection of 
secondary endocrine differentiation agents. Min6 cells and H2O were used as positive 
and negative controls respectively. The result presented is representative of a number 
of repeat gels.
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Previous overexpression studies with F9 cells have generally employed stable 
transfections (Griep & Westphal, 1988; Edwards et al., 1988). This is at least partly 
due to the difficulty in overexpressing viral promoters in undifferentiated F9 cells 
(Kelly & Condamine, 1982). Optimisation studies using the lipid based reagents 
Lipofectamine Plus, Fugene and (3 Gal expressing plasmid pCHllO, were performed 
as described (Section 2.3.4.1). As shown in Figure 3.3.11, Fugene is by far the 
superior transfection reagent for the purpose of this study and it was observed to be 
less cytotoxic to the F9 cells than Lipofectamine Plus. The ratio of Fugene to DNA 
was found to be critical in these transfections. Even in the most successful case 
however (3:1 Fugene/DNA ratio using 2|ig DNA), the transfection efficiency was less 
than 1%.
3.3.2.1 Optim isation o f Transfection Efficiency in  Undifferentiated F9 Cells
3.3.2 The Effects o f Transient Expression o f Beta Cell Transcription Factors in
F9 Cells
(A) (B)
v-
...¡'¡A
. • ", ’ • v> 1
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‘ * «  (C) * m . (D)
Figure 3.3.11 Initial optimization studies on F9 transfection using pCHllO. (A) 
Transfection of 1 pg pCHllO using Lipofectamine Plus. (B) Transfection of 1 fig 
pCHllO using Fugene in 3:1 ratio (|il Fugene: (ig DNA). (C) Transfection of 2 jig 
pCHllO using Fugene in 3:1 ratio. (D) Transfection of 2 (ig pCHllO using Fugene in 
6:1 ratio. Magnification = 10X. Bar = 50 pM in all cases.
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3.3.2.2 Optimisation o f pCHHO DNA Transfection into Differentiated F9 cells
Due to the poor transfection efficiency in undifferentiated F9 cells, it was decided to 
differentiate the cells prior to transfection. It was discovered that differentiating the 
cells using RA alone caused a dramatic increase in the number of cells found to be 
expressing the pCHllO plasmid. It was clear that it was predominantly differentiated 
cells that were expressing the gene (as determined from morphology). Combining RA 
with db cAMP further increased the transfection efficiency. It was found here also 
that it was predominantly differentiated cells that were expressing pCHllO. The 
relative percentage expression was increased not only due to the greater number of 
cells expressing pCHl 10, but also as a result of the reduced growth rate, thus reducing 
the overall cell count.
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Figure 3.3.12. Transfection efficiency studies using differentiated F9 cells. F9 cells 
differentiated over 72 hours using RA (A&B) or RA + db cAMP (C&D). 2 pg of 
pCHllO cDNA was transfected in each case employing a Fugene/DNA ratio of 3:1. 
Magnification = 10X. Bar = 50 pM in all cases.
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3.3.2.3 Transient Overexpression o f Pancreatic Transcription Factors in F9 ceils
The cDNAs for a number o f critical pancreatic differentiation factors were obtained 
(sources and plasmids listed in Table 3.3.3) and transfected in to partially 
differentiated F9 cells (F9-RAC). A  list o f the cDNAs transfected and combinations 
o f transcription factors is listed in Table 3.3.4. The co-transfections were chosen 
where it was suspected that synergistic/co-operative effects may be observed (Figure 
3.3.13 summarises the importance and interrelationships o f the transcription factors 
chosen). Overexpression at the mRNA level was achieved in each case. It was 
observed that untransfected F9 cells had low level expression o f each o f the genes 
examined. The levels o f these genes, prior to transfection, were largely unaffected by 
the combination o f the RA and db cAMP.
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Figure 3.3.13 Transcription factor expression in developing endocrine cells and their 
interrelationships.
Plasmid Name 
(cDNA)
Supplier
PcDNA3-PDX-1 (FLAG) Yoshita Kajimoto
(PDX 1) (Japan)
PCR3.1-Beta2 J. Tsai
(Beta2) (Baylor Institute, Texas)
PcDNA3-Ngn3 Itaru Kojima
(Ngn3) (Japan)
PBAT12.shNkx2.2 M. German
(Nkx2.2) (UCSF, San Francisco)
Table 3.3.3 Vectors containing pancreatic developmental genes for use in transient 
transfections of F9-RAC cells and their sources.
Transfection Figure
PDX1 3.3.14
Beta 2 3.3.15
Ngn3 3.3.16
Nkx2.2 3.3.17
PDX1/Beta2 3.3.14/3.3.15
PDX1/Ngn3 3.3.14/3.3.16
Table 3.3.4 Transfections and co-transfections carried out on F9-RAC cells.
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F9 F9-RAC P9-RAC-PDX1 F9-RAC-Pdx/Beta F9-RAC-Pdx/Ngn
C ell Line
Figure 3.3.14. RT-PCR analysis demonstrating overexpression of PDX1 in F9 cells 
following the transfection of the pcDNA3-PDXl plasmid. Overexpression was also 
achieved following co-expression of the PDX1 cDNA with Beta2 (PCR3.1-Beta2) or 
Ngn3 (pcDNA3-Ngn3). PDX1 was overexpressed at a similar level in all cases. H2O 
and the murine P cell line Min6 were used as negative and positive controls, 
respectively. GAPDH was used as an endogenous control for RNA quality and 
quantity. The result presented is representative o f repeat gels from independent 
experiments.
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Figure 3.3.15. RT-PCR analysis of Beta2 expression following transfection of 
PCR3.1-Beta2 in to F9 cells. Overexpression was also achieved following co­
transfection with the PDX1 cDNA (pcDNA3-PDXl). Beta2 was overexpressed at a 
similar level in both transfected cell lines. H2O and the murine [3 cell line Min6 were 
used as negative and positive controls, respectively. GAPDH was used as an 
endogenous control for RNA quality and quantity. The result presented is 
representative of repeat gels from independent experiments.
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Figure 3.3.16 Overexpression of Ngn3 in F9 cells following transfection of pcDNA3- 
Ngn3. Overexpression was also achieved following co-expression of the Ngn3 cDNA 
with the PDX1 cDNA plasmid (pcDNA3-PDXl). Ngn3 was expressed at a similar 
level in both transfected cell lines. H2O and the murine P cell line Min6 were used as 
negative and positive controls, respectively. GAPDH was used as an endogenous 
control for RNA quality and quantity. The result presented is representative of repeat 
gels from independent experiments.
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Figure 3.3.17 Overexpression of Nkx2.2 in F9 cells following transfection of the 
Nkx2.2 expression vector pBAT12.shNkx2.2. H2O and the murine P cell line Min6 
were used as negative and positive controls, respectively. GAPDH was used as an 
endogenous control for RNA quality and quantity. The result presented is 
representative o f repeat gels from independent experiments.
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3.3.2.4 Immunofluorescent Localisation o f Transfected Transcription Factors 
W ith in the Cells
PDX1 was expressed in the nuclei of both transfected F9-RAC cells (Figure 3.3.18 (A)) 
and Min6 (Figure 3.3.18 (C)). Overall there was increased staining in the transfected F9- 
RAC-PDX1 population while there was only faint background staining in untransfected 
F9-RAC cells probed as controls. The levels of over-expression ranged from the intense 
nuclear staining shown to fainter nuclear-associated staining. There also appears to be 
low-level cytoplasmic staining.
Beta2 expression was clearly present in the nuclei of transfected F9-RAC cells and Min6 
cells (Figure 3.3.19 (A&C)). Staining was seen to be associated with cells displaying 
differentiated morphology, this is in keeping with Section 3.3.2.2 where it was found that 
differentiated cells preferentially expressed transfected cDNAs. Staining in the Min6 cells 
appears to be nuclear membrane associated (Figure 3.3.9 (C)).
Ngn3 staining, although faint, was clearly expressed in the nuclei of the cells probed 
(Figure 3.3.20 (A&C)), likewise Nkx2.2 was selectively expressed in the nuclei of 
transfected cells (Figure 3.3.21 (A)).
Negative controls included non-transfected F9-RAC cells and transfected cells where the 
primary antibody was not applied. The non-transfected F9-RAC cells displayed diffuse 
background staining that was extremely faint i.e. there was none of the intense nuclear 
staining noticed in the transfected cells presented. In experiments where the primary 
antibody was omitted there was little staining, demonstrating that the fluorescence 
presented here is not due to non-specific binding of the labelled secondary antibody. 
Min6 cells were used in all cases as positive controls with the exception of Nkx2.2. It was 
found that Min6 cells did not cross react well with this antibody. The cDNA transfected 
(pBAT12.shNkx2.2) encodes hamster Nkx2.2, thus perhaps the antibody is less suitable 
for a murine antigen especially considering the antibody was raised in a mouse.
All photographs were taken at 40X magnification, the slight differences in cell sizes in 
the following images are due to differences in subsequent scanning of the photographs.
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Figure 3.3.18 PDX1 expression in F9-RAC-PDX1 (A). Min6 cells were used as a 
positive control (C). Also included are the relevant phase contrast images (B&D). 
Magnification = 40X in all cases.
Figure 3.3.19 Beta2 expression in F9-RAC-Beta2 (A). Min6 cells were used as a 
positive control (C). Also included are the relevant phase contrast images (B&D). 
Magnification = 40X in all cases.
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Figure 3.3.20 Ngn3 expression in F9-RAC-Ngn3 (A). Min6 cells were used as a 
positive control (C). Also included are the relevant phase contrast images (B&D). 
Magnification = 40X
Figure 3.3.21 Nkx2.2 expression in F9-RAC-Nkx2.2. This antibody did not cross 
react well with Min6 cells. The relevant phase contrast image is also presented (B). 
Magnification = 40X
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3.3.2.5 Endogenous Gene Expression in  Cells Transiently Transfected w ith 
Pancreatic Transcription Factors
3.3.2.5.1 Endogenous PDX1 Levels in Transfected F9-RAC Cells
Endogenous PDX1 expression levels were increased approximately 2 fold following 
RA/db cAMP treatment. Transient expression of Beta2 and Nkx2.2 in F9-RAC cells 
reduced endogenous PDX1 expression back to the level seen in untreated F9 cells, 
there is no explanation for this as these factors should act ‘downstream’ of PDX1 
(Figure 3.3.13). Ngn3 expression had no effect on the levels of PDX1 i.e. PDX1 
mRNA levels were comparable to those in F9-RAC cells (Figure 3.3.22).
3.3.2.5.2 Endogenous PPI Gene Levels in Transfected F9-RAC Cells
PPI gene expression increased 1.5-2 fold following initial RAC treatments, however 
subsequent overexpression of pancreatic transcription factors generally reduced PPI 
mRNA back to levels found in untreated cells (Figure 3.3.23).
3.3.2.5.3 Endogenous Beta2 Levels in Transfected F9-RAC Cells
Beta2 levels were quite similar in F9 cells and the RA/db cAMP treated cells (F9- 
RAC). However, in all cases where pancreatic transcription factors were expressed, 
Beta2 levels decreased by almost 2-fold (Figure 3.3.24). There is no obvious 
explanation for this observation
3.3.2.5.4 Endogenous Is ll Levels in Transfected F9-RAC Cells
Isll levels in F9 cells increased upon treatment with RA/db cAMP, further slight 
increases in endogenous expression were noticed following expression of PDX1 or 
Beta2, which are both ‘upstream’ of Isll (Figure 3.3.13). All other transfections had 
little effect on Isll levels, with the exception of Nkx2.2 which caused a reduction in 
Isll to untreated F9 levels (Figure 3.3.25)
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3.3.2.5.5 Endogenous Pax Gene Levels in Transfected F9-RAC Cells
Pax 4 was not expressed in any of the transfected populations or in any of the control 
populations (F9 & F9-RAC). Pax 6 expression however was abundant and its levels 
did not vary with treatment or transfection. There was a slight negative effect 
observed with Nkx2.2 expression (Figure 3.3.26).
3,3.2.5.6 Endogenous Indian hedgehog (Ihh) Gene Levels in Transfected F9-RAC 
Cells
As shown in Figure 3.3.27, Ihh transcripts were present at low-level in the parent F9 
population, however the RAC treated population showed a large increase in Ihh 
levels. Transient overexpresion of the selected transcription factors did not lead to any 
effects on Ihh expression.
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Figure 3.3.22 Endogenous PDX1 expression in F9-RAC cells transiently expressing 
pancreatic transcription factors. F9 and F9-RAC cells are shown for comparison. 
Min6 and water were used as positive and negative controls, respectively. The result 
shown is a representative of repeat gels from two independent experiments.
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Figure 3.3.23 Endogenous PPI gene expression in F9-RAC cells transiently 
expressing pancreatic transcription factors. F9 and F9-RAC cells are shown for 
comparison. Min6 and water were used as positive and negative controls, 
respectively. The result shown is a representative of repeat gels from two independent 
experiments.
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Figure 3.3.24 Endogenous Beta2 expression in F9-RAC cells transiently expressing 
pancreatic transcription factors. F9 and F9-RAC cells are shown for comparison. 
Min6 and water were used as positive and negative controls, respectively. The result 
shown is a representative of repeat gels from two independent experiments.
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Figure 3.3.25 Endogenous Isll expression in F9-RAC cells transiently expressing 
pancreatic transcription factors. F9 and F9-RAC cells are shown for comparison. 
Min6 and water were used as positive and negative controls, respectively. The result 
shown is a representative of repeat gels from two independent experiments.
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Figure 3.3.26 Endogenous Pax6 expression in F9-RAC cells transiently expressing 
pancreatic transcription factors. F9 and F9-RAC cells are shown for comparison. 
Min6 and water were used as positive and negative controls, respectively. The result 
shown is a representative o f repeat gels from two independent experiments.
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Figure 3.3.27 Endogenous Indian hedgehog (Ihh) expression in F9-RAC cells 
transiently expressing pancreatic transcription factors. F9 and F9-RAC cells are 
shown for comparison. Min6 and water were used as positive and negative controls, 
respectively. The result shown is a representative of repeat gels from two independent 
experiments.
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3.4 Loss o f p cell Phenotype Occurs Upon Continuous Culture o f M in6 cells
Min6 cells have been used throughout this thesis as a positive control for experiments 
ranging from insulin secretion studies (Section 3.5) to RT-PCR analysis o f P cell 
specific markers (Section 3.2). It was observed (and has been documented by others 
see Section 1.5.1.4), that as the cells were continuously cultured beyond passage 30 
that they were seen to lose the ability to secrete insulin in response to environmental 
glucose levels (i.e. glucose stimulated insulin secretion, GSIS). This effect was 
accompanied with morphological changes and an increase in the growth rate of the 
cells. It was considered that the loss o f such specialised p cell function and the 
associated morphological and proliferation changes may be due to a de-differentiation 
mechanism and thus this was investigated using EIA (Section 2.5.2.3), RT-PCR 
(Section 2.5.1.5) and DNA Array technology (Section 2.5.1.6).
Such a ‘de-differentiating’ system would be a useful tool for the identification of 
crucial pathways and markers involved in maintaining P cell function intact while in 
culture and also may provide useful information relevant to the production of insulin 
secreting p cell-like cell lines via the differentiation of stem cells. There are at least 
two possible mechanisms for the de-differentiation of the Min6 cells. One mechanism 
involves a gradual change in the gene expression profile of the cells over time in 
culture leading to a de-differentiated phenotype. It is also possible that the overgrowth 
of the differentiated cells by a less differentiated sub population with greater 
proliferative capability could occur over time and result in a less differentiated overall 
population, these issues are addressed later (Section 4.5.4).
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3.4.1 M orphological Changes Associated w ith Continuous Culture o f  M in6 Cells
The initial modification in Min6 cells that indicated a change in the nature of the cells 
was an alteration in the typical Min6 cell morphology and growth patterns. Low 
passage Min6 (passages 13-23) cells were found to grow in localised clumps, i.e. they 
did not form an even monolayer over the tissue culture surface o f the flask/well. The 
cells had pointed extensions but were mostly round in appearance (Figure 3.4.1 (A)). 
As the passage number was increased beyond passage 30, the cells no longer 
associated in clumps and were found to form even monolayers. The individual cells 
appeared to be slightly smaller than lower passage cells. The cells were also seen to 
have lost the round appearance o f the lower passage cells and were pointed in 
appearance (Figure 3.4.1 (B)).
Figure 3.4.1 Min6 cells at passage 17 (PI7) associate in to rounded clumps o f cells 
which can be seen to grow ‘upwards’ as well as outwards (A). At Passage 40 however 
the cells are observed to have formed a monolayer over the flask and no longer form 
discrete colonies (B). In this experiment, Min6 P17 and Min6 P40 were seeded at 2 x 
106 cells/flask and were grown for 1 week with 1 re-feed. Magnification = 20X and 
bar = 100 pM.
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3.4.2 Proliferation Rates o f  M in6 Cells at Low  and High Passages
As Min6 cells were passaged beyond P35 there was a noticeable increase in 
proliferation rates, in Figure 3.4.1 it is clear that there are far more cells in the P40 
flask even though the cells were seeded at the same density. Thus proliferation 
experiments (Section 2.3.3), were carried out to demonstrate the increase in 
proliferation more clearly. As shown in Figure 3.4.2 the rate o f proliferation at the 
higher passages (P40-P49) is approximately double that observed in the low passage 
cells tested (P17-P22). The high passage cells continued to proliferate after 7 days 
(168 hours); however the lower passage cells were found to cease proliferation after 
approximately 6 days (144 hours) as the ‘clumps’ had reached maximal size.
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Figure 3.4.2 Proliferation data comparing low (P17-P22) to high (P40-P49) passage 
Min6 cells. Cells were seeded at 5 x 104 cells/well in 24 well plates and 3 wells were 
counted each day. Each well was counted using two sections of a Neubauer™ 
counting chamber, thus each well was counted twice. The experiment was repeated 
for at least two independent cell populations at low and high passage numbers. The 
data presented equals mean cell number ± SD.
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The critical observation concerning high passage Minó cells was that the ability to 
regulate the secretion of insulin in response to external glucose signals (GSIS) was 
lost. Figure 3.4.3 clearly demonstrates this loss o f function. Basal proinsulin secretion 
in high passage Minó cells is higher than lower passage Minó cells, however this 
basal secretion rate level does not change significantly despite increasing 
environmental glucose levels. Low passage Minó cells increased proinsulin secretion 
approximately 6-8 fold over the glucose range tested (0 -  26.7 mM).
3.4.3 Glucose Stimulated Insulin Secretion (GSIS) in M in6 cells Continuously
Passaged in Culture
60
OrrfVI 3.3 mM 10 mM 16.7 mM 26.7 nW
Glucose Cone (m M)
Figure 3.4.3 Proinsulin secretion profiles with increasing glucose concentrations in 
low passage Min6 cells (P I6 & P I8) and high passage Min6 cells (P41 &  P44). 
Readings are given in pmol/ml/mg protein to allow for the increased growth rate of 
high passage Min6 cells. Data is presented as means ± SD from at least three 
experiments.
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As already indicated in Section 3.1.2.1, alkaline phosphatase activity is a 
characteristic of undifferentiated stem cells and can be seen to decrease following 
differentiation of the ES cells (Lumelsky et al., 2001; Sukoyan et al., 2002). The 
decrease in alkaline phosphatase expression with differentiation of EC cells has 
already been demonstrated with F9 cells (Figure 3.1.2 & Figure 3.1.5), thus the levels 
of alkaline phosphatase activity were examined in Min6 cells. As before, BCIP was 
used as the substrate for alkaline phosphatase (Section 2.5.2.4).
Figure 3.4.4 clearly shows that alkaline phosphatase staining is far more widespread 
in the higher passage Min6 cells (P51) than in the lower passage Min6 (PI9). At 
higher magnifications (Figure 3.4.4 B&D) it is clear that the intensity o f the staining 
is also increased in the high passage cells.
3.4.4 Alkaline Phosphatase Expression in Min6 cells Passaged Continuously in
Culture
Figure 3.4.4 Min6 cells stained for alkaline phosphatase expression, Min6 PI9 cells 
(A & B) were found to have much less staining than Min6 cells at passage 51 (C & 
D). Images were taken at 20X (A & C) and 40X (B & D). Bar = 50fim in each case.
215
3.4.5 Analysis o f  Serially Passaged M in6 cells by DNA Array
From the results already presented, it is clear that there is a significant change in the 
properties of Min6 cells as they are serially passaged in culture, most notably that the 
cells lose their ability to secrete insulin in response to increasing environmental 
glucose levels (Section 3.4.3). The loss of regulated secretory function and the 
observed changes such as increased proliferation (Section 3.4.2) and increased 
alkaline phosphatase expression (Figure 3.4.4), indicates that the high passage Min6 
cells are less differentiated than low passage Min6 cells with a resultant loss of 
specialised cell function.
RNA was extracted from Min6 cells at passages 18 and 19 (GSIS responsive), 47 and 
48 (incapable of GSIS) using RNeasy spin columns (Qiagen) (Section 2.5.1.2.2.1). 
This RNA was Dnase treated (Promega) and re-purified on RNeasy columns (Section 
2.5.1.2.2.2). The RNA quality was confirmed by OD 260/280 readings and by gel 
analysis (Sections 2.5.1.3 & 2.5.1.4) (Figure 3.4.5). Poly (A)+ RNA was purified from 
the total RNA using ‘The total RNA labelling system’ (Clontech). This poly (A)+ 
RNA was used to generate P33 labelled cDNA probes for hybridization to the Mouse
1.2 array (Clontech 7853-1). Aliquots of this RNA were also used in subsequent RT- 
PCR experiments to examine other genes and confirm results obtained in the array. 
The expression profiles o f four different RNA extracts were examined on four 
different membranes to examine the reproducibility of the technique (Figure 3.4.6).
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Figure 3.4.5 RNA extracted from (A) low and (B) high passage Min6 cells was run 
out on a 0.8% agarose gel to determine the quality o f the RNA. 2-5 ng was run out 
(depending on amounts available). All gel boxes and combs etc. were soaked in 0.5M 
NaOH for 1 hour prior to running the gel to prevent RNase degradation of the 
samples. Similarly, the gel and TBE electrophoresis buffer were prepared using DEPC 
treated H2O. Total RNA and RNA that had been DNase treated were examined for 
degradation.
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Figure 3.4.6 Array membranes from Array experiment 2 (Array 2) comparing Min6 
passage 19 with Min6 passage 48 (A) arrows indicate examples of altered and 
unchanged genes. (B) A comparative view of the array membranes superimposed and 
colour coded as indicated.
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3.4.5.1 Summary o f Results Obtained from  A rray Analysis o f Low and High 
Passage M in6 Cells
The 1.2 array contains 1,173 cDNAs immobilised on to a nylon membrane This 
corresponds to approximately 3.5% of the mouse genome (Wada, 2001). A total of 
129 genes were positively detected over the two separate array experiments. All of 
these 129 genes were detected in the second array experiment (i.e. Array 2; comparing 
Min6 P19 and P48) as a longer exposure time was used (10 days compared to 4 for 
Array 1). The shorter duration Array 1 experiment generated 80 positive genes. All of 
the genes detected using the short incubation were again detected in the second 
experiment (i.e. 80 out o f the total of 129 genes detected in that experiment). Of the 
80 ‘common genes’ detected between the repeat array experiments, 5 results were 
significantly contradictory and were mostly associated with apoptosis related genes 
(Table 3.4.1), (i.e. in one array experiment these genes appeared to either up-regulated 
or downregulated upon passaging Min6 cells while on the repeat experiment the result 
was reversed). A further 7 genes appeared to be regulated differently between the two 
array experiments, but in these cases the differences were <1.5 and therefore 
considered insignificant. Therefore of the 80 gene changes detected between the two 
array experiments 68 produced similar results using different RNA and membranes, 
corresponding to a reproducibility level of 85%.
Based on the results obtained it was decided to set a difference of 1.5 fold as the lower 
limit of significance thus, 57 genes were found to be upregulated/induced in the high 
passage Min6 cells (Section 3.4.5.3) and 35 genes were downregulated/silenced as a 
result o f the continuous culture (Section 3.4.5.4).
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Gen Bank 
Accession No.
Gene Name Classification Array 1 Array 2
U02098 Purine-rich 
element binding
protein A( PURA)
Stress Response 
Protein
Down Up
AF020185 Cytoplasmid 
dynenin light 
chain 1
Apoptosis
Associated
Down +2.5
U83628 Defender against 
cell death 
1(DAD1)
Apoptosis
Associated
-1.52 1.65
U171162 BCL2-associated
athanogene
(BAG1)
Apoptosis
Associated
Down +1.59
X67083 Growth Arrest 
and DNA damage 
inducible protein 
153 (GADDI53)
Apoptosis
Associated
Up Down
Table 3.4.1 Genes where significant differences were noted between Array 
experiment 1 and Array experiment 2. The low passage Min6 membrane was the 
reference in each case. Thus the case where a gene is described as ‘Up’ refers to 
incidents where genes were expressed in the high passage Min6 cells but not at the 
lower passages. Similarly ‘Down’ refers to cases where genes which were present in 
lower passages were silenced in the higher passage cells.
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3.4.5.2 Patterns o f Gene Expression Changes Observed after the Serial Passage 
o f M in6 cells
The Upregulated/Downregulated genes were examined separately under the following 
classifications (Section 3 .4 .5 .3  & Section 3 .4 .5 .4 ):
• Transcription associated
•  Cell Cycle
• Oncogenes and Tumor Suppressors
•  Stress associated
•  Apoptosis
•  Growth Factors and Receptors (including ligand receptors)
•  Signalling and Communication
• Housekeeping Proteins
•  Neuropeptides and Hormones
• Protein Turnover
•  Miscellaneous (including unclassified proteins, proteins involved in 
motility, carrier proteins surface antigens, etc.)
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3.4.5.3 Genes Found to be Induced or Upregulated in M in6 cells Serially
Passaged in Culture and Unresponsive to Environm ental Glucose Levels
Genbank
Accession No. Gene Name A rray 1 A rray 2
Transcription Associated
M60523 DNA-Binding Protein ID3 NP Up
S81932 Distal-less homeobox Protein 3 NP Up
U89876 Transcriptional Co-Activator of AML-1 & LEF-1 Up Up
U69270 LIM Domain-Binding Protein 1 Up Up
L21671 EGFR Kinase Substrate EPS8 Np Up
X53476 Non-histone Chromosomal Protein HMG-14 +3.4 Up
U78103 Embryonic Ectoderm Development Protein (EED) Np Up
U29762 D-Binding Protein (DPB) Np Up
X72310 Transcription factor E2F dimérisation Partner 1 Np Up
L12140 Groucho gene-related protein (GRG) 1.9 2.2
Cell Cycle
Z26580 G2/M Specific Cyclin A2 (CCNA2) Np Up
X75888 Gl/S Specific Cyclin El (CCNE1) Np Up
LO1640 Cell Division Protein Kinase 4 (CDK4) Up Up
AA289122 Cyclin-dependent kinases regulatory subunit 2 (CKS2) Np Up
U05341 P55CDC Up Up
D78382 Tob Antiproliferative Factor Np Up
AF068780 Geminin Up Up
D86725 MCM2 DNA replication licensing factor Np Up
X56135 Prothymosin alpha (PTMA) 3.4 2.9
X66032 G2/M-specific cyclin B2 (CCNB2) Up 2
D26090 MCM5 DNA replication licensing factor 2.3 1.8
U43918 Proliferation associated protein 1 (PLFAP)* 1.4 1.6
Oncogenes and Tum or Suppressors
X60671 Ezrin Np Up
Z50013 H-ras proto-oncogene Np Up
M94335 akt proto-oncogene Np Up
U57311 14-3-3 protein eta 1.6 1.6
X83974 Transcription termination factor 1 (TTF1)* 1.1 1.9
Stress Associated
L40406 Heat Shock 105 kDa Protein Np Up
U40930 Oxidative Stress-induced protein Np Up
M36829 Heat shock 84 kDa protein 1 (HSP84-1) 1.8 2.3
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Apoptosis
U77714 Survival Motor Neuron (SMN) Np Up
U39643 Fas-associated factor 1(FAF1) Np Up
AF033353 Sentrin Np Up
U44088 T-cell death gene 51 (TDAG51) Up 2.8
Growth Factors and Receptors (including ligand receptors)
S53216 Tyrosine-Protein Kinase ryk Np Up
AF028242 Calcitonin gene-related peptide receptor component Np Up
X81582 Insulin-like growth factor binding protein 4 precursor Np Up
M89797 Wingless related MMTV integration site 4 protein Np Up
AB006191 Comichon-like protein Np Up
AF020738 Fibroblast growth factor 12 (FGF12) Np Up
X97818 Semaphorin G 1.7 2.2
M85078 Granulocyte-macrophage colony-stimulating factor 
Receptor low affinity subunit precursor (GM-CSF-R) Np 1.5
Signalling and Communication
J00612 Pro-opiomelanocortin-alpha Np Up
M36777 Guanine nucleotide binding Protein Np Up
U34960 Transducin beta-2 Subunit Np Up
Y00703 Guanine Nucleotide binding Protein alpha stimulating 
activity polypeptide (GNAS) 1.7 2.5
Housekeeping Proteins
L31609 40S Ribosomal protein S29 (RPS29) 2 1.8
X51703 Ubiquitin 2.3 1.6
M32599 GADPH 1.7 1.5
D78647 Phospholipase A* 1.9 1.1
Miscellaneous
U97327 Calcyclin binding protein Up Up
X59379 Alzheimer’s disease amyloid A4 protein homologue Np Up
S50213 Structure Specific recognition protein 1 Up Up
M64292 Anti-proliferative B-cell translocation gene 2 (BTG2) Np Up
U95736 Frataxin (Friedreich ataxia protein; FRDA) Np Up
AF021031 DiGeorge Syndrome chromosome region 6
protein (DGCR6) Up 2
X02165 Neurofilament triplet L protein (NEFL)* 1.2 2
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A rra y l Array2
3.4.5.4 Genes Found to be Silenced or Down regulated in M in6 cells Serially
Passaged in Culture and Unresponsive to Environm ental Glucose Levels
Transcription
M20157 Early Growth Response Protein 1 (EGR1) Down Np
U71208 Eyes absent homologue 2 (EYA2) Np Down
M96823 Nucleobindin Down Down
L47650 Stat6 Down Down
L12721 Delta like homologue 1 (DLK1) -13 -9
X63963 Paired box protein 6 (PAX6) Down -1.8
M94087 Activating transcription factor 4* -1.1 -1.9
Oncogenes and Tum or Suppressors
U28423 58 kDa inhibitor of RNA-activated protein kinase -4.8 -3.6
Apoptosis
J04696 Glutathione S-transferase mu 2 (GSTM2) Down Down
L08235 Clusterin (CLU) Down Down
Neuropeptides and Hormones
AF026537 Beta-neoendorphin-dynorphin NP Down
X15830 7B2 neuroendocrine protein; secretogranin V -3.5 -6
Z46845 Preproglucagon -7 -4.1
U22516 Angiogenin Down -3.2
X68837 Secretogranin II* -1.1 -4.1
Growth Factors and Receptors (including ligand receptors)
M13177 Transforming growth factor beta 1 (TGF-beta 1) Np Down
X80992 Bone morphogenetic protein 6 (BMP6) Down Down
X59520 Cholecystokinin Down -65.8
J04806 Osteopontin (OP) Down -7
X96618 Recombination activating protein 1 gene
activation protein -1.8 -1.9
X16353 Prothmyosin beta 4 NP -1.8
L24755 Bone morphogenetic Protein 1 (BMP1) NP -1.6
Signalling and Communication Proteins
X53028 Chromogranin B (CHGB) Down -36
X95403 Ras-related protein RAB2* -2 -1.4
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U45977 45 kDa calcium binding protein (CAB45) -4.2 -4.1
Ml 0624 Ornithine decarboxylase (ODC) Down -1.8
Housekeeping genes
Protein Turnover
J05261 Carboxypeptidase C (Cathepsin A) Down -2.9
X53337 Cathepsin D Down -2.1
M55669 Neuroendocrine convertase 2
Prohormone convertase 2 (PC2) -3.3 -1.8
D00611 Basigin Precursor* -2.2 -1.4
Miscellaneous
M l4222 Cathepsin B1 Down Np
U13705 Plasma glutathione peroxidase (GSHPX-P) Down Down
D89076 Tranthyretin (TTR); Prealbumin -5 -10
X17320 Brain Specific Polypeptide Down -2.9
X05640 Neurofilament triplet M protein* Down -1.2
Notes:
• Array 1 refers to the experiment comparing Min6 PI 8 to Min6 P47, Array
2 refers to the comparison of Min6 P19 and Min6 P48. These experiments
were performed on different mRNAs and using different array membranes.
• NP indicates that a particular gene was not detected in that Array 
Experiment
• * In these cases there was a significant change in expression in one array 
experiment (> 1.5) but not in the other but the average of the two results is
> 1.5.
•  When a gene is detected on one membrane and not the other numerical
comparison is impossible, therefore if a gene is described as ‘UP’ then it is
only present in high passage Min6 cells and if  it is ‘Down’ then is can only 
be detected on the low passage membrane.
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Figure 3.4.7 Comparison of (A) positively and (B) negatively affected categories of 
genes in serially passaged Min6 cells.
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3.4.5.5 RT-PCR Confirmation Analysis o f Genes Detected on A rray
Primers were available for three of the genes detected using the Atlas™ array 
membranes, thus RT-PCR analysis was carried out to determine if the results obtained 
on the array could be reproduced. RT-PCR analysis was carried out for glucagon, 
Pax6 and Nkx2.2. (3 actin was used as the internal standard for cDNA quality and 
quantification as its levels were found to be unchanged at higher passages unlike 
GAPDH which showed increased mRNA expression (Section 3.4.5.3). Table 3.4.2 
below compares the results obtained using the array and RT-PCR analysis. Glucagon 
mRNA levels were decreased in both cases however the decrease was far more 
noticeable in the array experiments. Pax6 mRNA was reproducibly downregulated in 
both arrays, however in the RT-PCRs carried out there was no change in the levels of 
this gene. Nkx2.2 levels were not altered as a result of passaging in either the array or 
the RT-PCR.
Gene Name Fold Change 
Observed Using 
Atlas Array
Fold Change 
Observed Using RT- 
PCR
RT-PCR Results
Glucagon -4 to -7 -2 3.4.8
Pax6 -1.8 -1.1 (Unchanged) 3.4.9
Nkx2.2 - 1.4 (Unchanged) +1.2 (Unchanged) 3.4.10
Table 3.4.2 Comparison of data from Atlas array and RT-PCR results obtained for the
same genes.
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Figure 3.4.8 RT-PCR analysis o f glucagon expression in low (PI9) and high (P48) 
passage Min6 cells. Water was included as a negative control. The result presented is 
representative of repeat gels from two individual experiments.
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Figure 3.4.9 RT-PCR analysis of Pax6 expression in low (PI 8) and high (P47) 
passage Min6 cells. Water was included as a negative control. The result presented is 
representative of repeat gels from two individual experiments.
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Figure 3.4.10 RT-PCR analysis o f Nkx2.2 expression in low (P19) and high (P48) 
passage Min6 cells. Water was included as a negative control.
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3.4.6 RT-PCR Analysis o f Pancreatic M arkers in Low and H igh Passage Min6 
Cells
The Atlas™ array (Section 3.4.5) revealed many of the changes in gene expression 
associated with the increased passage number of Min6 cells. However few pancreatic 
markers were detected even though a number of these were represented on the array 
membrane e.g. PDX1 and GLUT2. Thus it was decided to carry out RT-PCR analysis 
to investigate if  the continuous culture led to changes in the expression of these genes.
3.4.6.1 PDX1 Expression in Low and High Passage M in6 Cells
PDX1 is a major transcription factor involved in PPI gene transcription and it levels 
are implicated in regulating GLUT2 and glucokinase transcript levels also. PDX1 
mRNA levels were found to be over two fold lower in the high passage Min6 cells 
than in the lower passage cells (Figure 3.4.11 (A)).
3.4.6.2 PPI Expression in Low and H igh Passage M in6 Cells
Earlier results (Figure 3.4.3) have shown that the high passage Min6 cells can secrete 
proinsulin and in fact secrete proinsulin at a greater rate than the lower passage cells 
tested. As Figure 3.4.11 (B) demonstrates, PPI gene transcript levels are not 
significantly altered in the high passage cells despite the reduction in PDX1.
3.4.6.3 GLUT2 Expression in  Low and High Passage M in6 Cells
GLUT2 mRNA levels were five fold greater in the high passage Min6 cells that were 
GSIS unresponsive than in the low passage GSIS-capable cells (Figure 3.4.12 (A)). 
This may be related to the cells increased growth-rate and thus their higher 
requirement for glucose.
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3.4.6.4 Glucokinase Expression in Low and High Passage M in6 Cells
Glucokinase mRNA levels were largely unaffected by the continuous passaging of the 
Min6 cells to a point where the ability to respond to external glucose had been lost 
(Figure 3.4.12 (B)).
3.4.Ó.5 Pancreatic Polypeptide Expression in Low and High Passage M in6 Cells
Min6 cells were found to contain high levels of PP transcripts in as shown in Section
3.2 and from Figure 3.4.13 (A) it is clear that the serial passaging did not affect the 
expression of this gene.
3.4.Ó.6 Somatostatin Expression in Low and H igh Passage M inó Cells
Minó cells are already characterised as possessing the ability to express somatostatin 
(Ohgawara et al., 1995) and this was also demonstrated in Section 3.2 of this thesis. 
Somatostatin expression was found to be eradicated after the serial passage of Minó 
cells to passage 47-48 (Figure 3.4.13 (B)).
3.4.Ó.7 Beta2 Expression in Low and High Passage M inó Cells
Beta2 is a crucial transcription factor which is required with PDX1 to ensure efficient 
transcription of the PPI gene (Section 1.2.1.3.1). As shown in Figure 3.4.14 (A) Beta2 
levels were unaffected by the serial passage of Minó cells through 47 passages and 
above.
3.4.Ó.8 Is ll Expression in Low and High Passage M inó Cells
Isll is another transcription factor that binds to the 5' region of the PPI gene to 
facilitate transcription. Isll transcript levels were found to be unchanged over 48 
passages (Figure 3.4.14 (B)).
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Figure 3.4.11 RT-PCR analysis of (A) PDX1 and (B) PPI in serially passaged Min6 
cells. Water was included in all PCR reactions as a negative control. The results 
presented are representative of repeat gels from two independent experiments.
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Figure 3.4.12 RT-PCR analysis o f (A) GLUT2 and (B) Glucokinase (GCK) levels in 
serially passaged Min6 cells. Water was included in all PCR reactions as a negative 
control. The results presented are representative o f repeat gels from two independent 
experiments.
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Figure 3.4.13 RT-PCR analysis of (A) PP and (B) somatostatin levels in serially 
passaged Min6 cells. Water was included in all PCR reactions as a negative control. 
The results presented are representative of repeat gels from two independent 
experiments.
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Figure 3.4.14 RT-PCR analysis of (A) Beta2 and (B) Isll levels in serially passaged 
Min6 cells. Water was included in all PCR reactions as a negative control. The results 
presented are representative o f repeat gels from two independent experiments, with 
the exception of Isll which is a preliminary result.
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3.5 Characterisation o f the Froinsulin Expressing Clone BHK-PP1-16
BHK21 cells were transfected with human preproinsulin (PPI) eDNA in the pT-PPI 
construct, which contains the human PPI cDNA. 20 cell lines resistant to 1 mg/ml 
geneticin were isolated. Once stocks of the clones had been created, initial 
characterisation was carried out, that led to the selection of the clone expressing and 
secreting the greatest levels of proinsulin. This clone (BHK-PPI-C16) was further 
characterised for (3 cell properties.
3.5.1 Human Preproinsulin mRNA Transcription in  BHK-PPI-C16
Expression of PPI in the selected clone, BHK-PPI-C16, was confirmed by reverse 
transcriptase PCR (RT-PCR). From Figure 3.5.1 it is clear that there is expression of 
PPI at the mRNA level, while the parental line BHK-21 does not transcribe the PPI 
gene. The plasmid pT-PPI and the P cell line Min6 were used as positive controls in 
this reaction.
a
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►ahd
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P Actin (383 bp)
PPI (158 bp)
Figure 3.5.1 RT-PCR analysis of human PPI expression in BHK-21 and in the 
transfected clone BHK-PPI-C16. P-actin was employed as an endogenous control in 
the reaction. MW refers to molecular weight marker.
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3.5.2 Im m im ocytochem istry for Proinsulin in BHK-PPI-C16
Figure 3.5.2 shows the expression of proinsulin within BHK-PPI-C16 fibroblasts. The 
cells were stained with a polyclonal antibody for proinsulin (Biogenesis). There is 
strong staining for proinsulin in the transfected clone whereas there is little or no 
staining in the parental cell line. Expression of the protein is diffuse within the 
cytoplasm and there is no evidence of discrete storage granules that are present in the 
mature P-cells, Min6 (Figure 3.5.2 (C)). The staining in this cell line is of a more 
granular nature, although the magnification is greater in this case and may allow 
granules to be seen.
(C)
Figure 3.5.2 Immunocytochemistry for Proinsulin expression in (A) BHK21, (B) 
BHK-PPI-C16 and (C) Min6 cells. The brown DAB staining indicates the presence of 
PPI in both BHK-PPI-C16 and the positive control cell line, Min6. Magnification = 
20 X for BHK21 and BHK-PPI-C16 and is at 40 X for Min6 due to the small size of 
the cells. Bar = 50 (im.
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3.5.3 Proinsulin Secretion from BHK-PPI-C16
Previous attempts to generate artificial P-cell lines from immortalised non (3-cell lines 
have been hampered by the high basal secretion of proinsulin from the cells (Selden et 
ah, 1987; Kawakami et ah, 1992). Preliminary experiments to determine the 
constitutive proinsulin release from BHK-PPI-C16 were carried out at 5.6 mM 
glucose. This is approximately the resting physiological glucose concentration in the 
blood and it is the glucose concentration to which the cells are typically exposed to 
while in culture.
Proinsulin was measured using a proinsulin El A (Mercodia). It was found that the 
cells released proinsulin at a steady rate o f 0.12 pmol/hour/lxlO5 cells. By lysing the 
cells at each time point, it was possible to measure the amount of proinsulin within the 
cells. The proinsulin levels within the cells remained relatively constant over the 
course of the experiment (24 hours), and was measured at 0.36 pmol ± 0.04. Thus the 
cells secrete approximately 34% of their proinsulin into the medium every hour 
(Figure 3.5.3).
Using a specific EIA kit (Mercodia) with a monoclonal antibody for mature human 
insulin, it was found that the cells do not secrete any processed insulin nor do they 
store any mature insulin within the cell.
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Figure 3.5.3 Constitutive Secretion of Proinsulin from BHK-PPI-16. The above 
graphs represent (A) the linear increase in proinsulin in the medium as a result of 
constitutive secretion and (B) the unchanging cellular proinsulin levels over the same 
24 hours. The data is presented as means ± SD of at least three individual 
experiments.
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3.5.3.1 Regulatable Proinsulin Secretion From BHK-PPI-C16 in Response to 
Glucose
Fibroblast cell lines have previously been described as possessing constitutive 
secretion pathways. Cells of this type can not be stimulated to secrete increased 
amounts of protein in response to extracellular signals; in fact the only modulator of 
secretion is protein availability (Halban and Irminger, 1994). Cells constitutively 
expressing and secreting insulin have been used in animal trials for diabetes 
(Taniguchi et al. 1997). The goal for an artificial P-cell, however, is that it would be 
responsive to glucose concentrations similar to those in the blood. It would be 
similarly desirable that the cells would respond to other secretagogues that stimulate 
the release of insulin from mature P-cells, e.g. the sulphonylurea drugs.
3.5.3.2 Investigation o f the Response o f BHK-PP1-16 to Glucose Concentrations 
Covering the Physiological Range
The physiological range for blood glucose is in the region 4-5 mM to 20 mM. For a 
cell to be a truly artificial P cell it should only begin active secretion of insulin once 
the glucose levels in its external environment exceed 4-5 mM. From Figure 3.5.4 it is 
clear that there is no significant response of the BHK-PPI-C16 cells to glucose over 
the physiological range. Secretion was constant regardless of external glucose 
concentrations and the cells secreted proinsulin only. No processed insulin was 
detected in the conditioned medium. Conversely, when cultured murine p cells (Min6) 
were stimulated for 30 minutes in conditions of increasing glucose there was a 
concomitant increase in proinsulin secretion which correlated with the increasing 
glucose concentration (Figure 3.5.5).
3.5.3.3 Investigation o f the Response o f BHK-PPI-16 to Glucose Concentrations 
Below the Physiological Range
Studies by Hughes et al. (1992) and Hohmeier et al. (1997) have generated cell lines 
expressing proinsulin that show GSIS at glucose levels < 1 mM. Thus it was decided 
to determine if  similar subphysiological GSIS could be achieved for BHK-PPI-C16. 
As indicated in Figure 3.5.6, proinsulin secretion rates were not influenced by glucose 
levels below the physiological range.
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Figure 3.5.4: The effect of physiological glucose levels on BHK-PPI-C16. The figure 
presented represents the average concentration of proinsulin secreted by 5 x 104 cells 
over two hours. The data presented is o f mean values ± SD of at least three 
independent experiments.
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Figure 3.5.5: The graph above represents the level of stimulation displayed by Min6 
cells after 30 minutes exposure to increasing levels of glucose. The Min6 cells were 
seeded at 2 x 105 cells/well in 24 well plates for 72 hours prior to the stimulation 
(Section 2.3.5.3). The data presented is of mean values ± SD, representative of at least 
three independent experiments.
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Figure 3.5.6 The effect of subphysiological glucose levels on the secretion of 
proinsulin from BHK-PPI-C16. This figure represents the concentration of proinsulin 
secreted by 5 x 104 cells over two hours. The data presented is of mean values ± SD of 
at least three independent experiments.
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3.5.4 Expression Levels o f the Glucose Sensing Proteins GLUT2 and Glucokinase 
(GCK) in BHK-PPI-C16
As the proinsulin expressing cell line BHK-PPI-C16 showed such general insensitivity to 
glucose, it was decided to determine if the components of the glucose sensing system 
were present, i.e. glucose transporter type 2 (GLUT2) and glucokinase (GCK). Levels of 
these proteins were determined by i mmunocytochem istry.
As shown in Figure 3.5.7 (A), it is clear that BHK-PPI-C16 does express the high km 
glucose transporter, GLUT2, but that expression levels are relatively low when compared 
to the P cell line, Min6.
The BHK-PPI-C16 cell line was also screened for the presence of the other component 
of the glucose sensing system i.e. GCK. From Figure 3.5.7 (E) it is again clear that low 
level GCK expression is present in the cytoplasm of the BHK-PPI-C16 cells. Min6 cells 
were used as a positive control for GCK in this experiment.
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Figure 3.5.7 Immunocytochemical analysis demonstrating GLUT2 expression in BHK- 
PPI-C16 (A) and in the positive control cell line Min6 (C). GCK expression was also 
found to be present in BHK-PPI-C16 (E) and again Min 6 was used as a positive control 
(G). Negative controls whereby the primary antibody was omitted were carried out in 
each case and are presented above (B, D, F & H). Magnification was 10 X for BHK-PPI- 
C16 but was increased to 20X (C&D) and 40 X for Min6 (G&H) due to the small size 
and localised growth of the cells. Bar = 50 (am.
3.5.5 Transfection o f Glucose Sensing Genes in to BHK-PPI-C16
The presence of low-level GLUT2 and GCK expression was confirmed in BHK-PPI-C16 
in Section 3.5.4. It was decided to investigate the effect of over-expression of the glucose 
sensing proteins in the insulin-expressing clone BHK-PPI-C16.
The glucose sensing genes, GLUT2 and glucokinase, were transfected in to BHK-PPI- 
C16 in two mammalian expression vectors. Glucokinase was transfected initially in the 
expression vector pcDNA3.1/Hygromycin (Invitrogen, Cat V870-20). GLUT2 was 
subsequently transfected in the pcDNA3.1/Zeocin construct (Invitrogen, Cat V870-20). 
The generation of these expression vectors was carried out by Cambridge Biosciences 
according to specifications, outline diagrams describing the vectors can be seen in Figure 
3.5.8 and 3.5.9. Upon transfection in to the cells, co-selection was carried out at levels of 
150 (ig/ml hygromycin and 100(Lig/ml zeocin.
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Ampicillin 2. The purified coding sequence was 
ligated in to PcDNA3.1/Hygro 
digested with Hindlll/BamHI.
G C KcD N A
S V40pA
Glu cokinase
Ampicillin
1. PCR Primers were generated for the GCK 
coding sequence. The resulting PCR product 
was digested with Hindlll/BamHI and gel 
Purified.
Hygromycin
R.E Sites within the GCK coding region are positioned relative to 
the 5’ end of the cDNA whereas RE sites on the plasmid are 
relative to an arbitrary zero position on the plasmid.
K>
4-
SV40 pA
Figure 3.5.8 Generation of Glucokinase cDNA expression plasmid for 
transfection in to BHK-PPI-C16 cells
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R.E Sites within the GLUT2 coding region are positioned relative 
to the 5’ end of the cDNA whereas RE sites on the plasmid are 
relative to an arbitrary zero position on the plasmid.
Cl 467
bndll! 824
iTOP 1613
1. Primers were designed specific for the GLUT2 
coding sequence (a kozak sequence was included 
before the ATG initiation codon). The 1575 product 
was then digested with BamHI/Xbal and gel 
purified.
HI
GLUT2
SV40 ori f1 ori
2. The gel purified coding sequence was 
then ligated in to pcDNA3.1/Zeo 
digested with BamHI/Xbal
Figure 3.5.9 Generation of GLUT2 cDNA expression plasmid for transfection in to 
BHK-PPI-C16
3.5.5.1 RT-PCR Analysis o f GCK Expression in Transfected BH K  cell lines
From Figure 3.5.10 it can be clearly seen that overexpression of GCK was achieved in the 
PPI expressing cell line BHK-PPI-C16 following GCK transfection alone (BHK-PPI- 
C16 GCK) or along with GLUT2 (BHK-PPI-C16 GCK GLUT). The low level GCK 
expression in BHK-21 identified by immunocytochemistry (Section 3.5.4) is confirmed 
here. This low-level expression is unaffected by the presence of the PPI gene transcripts. 
The plasmid pcDNA3.1-GCK was used as a positive control in the PCR reaction, while 
(3-actin was employed as an endogenous control.
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Figure 3.5.10 RT-PCR analysis of GCK expression in BHK-21 cell lines clearly 
demonstrating the overexpression of the transfected GCK cDNA in the two transfected 
populations i.e. BHK-PPI-C 16_GCK and BHK-PPI-C 16_GCK_GLUT.
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Using immunocytochemical analysis to investigate GCK expression in the cell lines 
transfected with GCK cDNA, it can be seen that there is no apparent change in GCK 
protein expression (Figure 3.5.11 (C)) when compared to the non-transfected population 
(Figure 3.5.11 (A)). Intensely stained cells however can be seen within the GCK 
transfected population and are highlighted with arrows, Figure 3.5.11 (C).
3.5.5.2 Immunocytochemical analysis o f GCK  expression in transfected BH K  cell
lines
(A)
(C)
(B)
(D)
Figure 3.5.11 Immunocytochemical analysis of GCK expression in (A) BHK-PPI-C16 
and in (B) the transfected population BHK-PPI-C16 GCK. There is no noticeable 
increase in GCK expression overall but intensely stained cells are present in the 
transfected population (indicated by arrows). Negative controls where the primary 
antibody was omitted were also included to demonstrate that the staining was not due to 
non-specific binding of the secondary antibody (B&D). Magnification = 20 X. Bar = 50 
(im .
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3.5.5.3 W estern Blot analysis o f GCK expression in BHK-PPI-C16
As immunocytochemistry is typically regarded as a qualitative rather than a quantitative 
technique, western blotting was carried out to determine if there was a noticeable up- 
regulation of GCK protein as a result o f the transfection of the GCK cDNA. From Figure 
3.5.12 it is clear that there is little or no up regulation of GCK protein. Densitometric 
analysis confirmed this by normalising the GCK bands against the levels of the 
housekeeping protein p-actin. The poorly differentiated cell human lung carcinoma cell 
line, DLKP, was employed as a positive control in this experiment, this has already been 
characterised as expressing GCK (O’ Driscoll et al., 2002).
GCK (50 kIJa)
P Actin (44 kDa)
QO
0.8
0.6
0.4
0.2
Figure 3.5.12 Glucokinase expression in BHK-21 cell lines. P-actin was used as an 
endogenous control for densitometry. DLKP was used as a positive control for GCK 
expression.
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From Figure 3.5.13 it is clear that the transfection of GLUT2 into the BHK-PPI-C16 cell 
line was successful and that GLUT2 over-expression was achieved. Faint traces of 
GLUT2 bands are clear in the BHK-21 and BHK-PPI-C16 cell lines which correlates 
with the immunocytochemical analysis in Section 3.5.4, (Figure 3.5.7 (A)). Expression of 
the PPI gene had no effect on the level of GLUT2 transcripts present.
3.5.5.4 RT-PCR Analysis o f GLUT2 expression in GLUT2 Transfected BHK-PPI-
C16 Cell Lines
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Figure 3.5.13 RT-PCR analysis o f GLUT2 in BHK-21 cell lines clearly demonstrating 
the overexpression of the GLUT2 cDNA in the transfected population BHK-PPI- 
C16_GCK_GLUT.
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3.5.S.5 Immunocytochemical analysis o f GLUT2 overexpression in  BHK-PPI-C16 
cells
The immunocytochemical analysis presented in Figure 3.5.14 appears to indicate that 
increased expression of GLUT2 was achieved as a result of the transfection of GLUT2 
cDNA in to BHK-PPI-C16 cells. It is clear that the population is not homogenous, i.e. 
there are cells within the population that are overexpressing GLUT2 to a greater degree 
than others.
(A) (B)
Figure 3.5.14 Immunocytochemical analysis ofGLUT2 expression in (A) BHK-PPI-C16 
and (C) in the transfected population BH K.-PPI-C 16 GCK GLUT. Arrows indicate 
intensely stained cells within the BHK-PPI-C16 GCK GLUT population. Also included 
are negative controls (B&D) where the primary antibody was omitted. This demonstrates 
that staining is not due to non-specific binding of the labelled secondary antibody. 
Magnification = 10X. Bar = 50 |xm.
250
3.5.5.6 W estern analysis o f GLUT2 Overexpression in BH K  Cells
To provide quantitative information regarding the expression of GLUT2 protein in BHK- 
PPI-C16 GCK GLUT cells, western blotting was carried out. From Figure 3.5.15 it is 
clear that the effect of the transfection was minor at the protein level. Densitometric 
analysis confirms that there is a slight up regulation of GLUT2 but it is not significant. 
Expression of GCK in BHK-PPI-C16 GCK had no significant effect on the endogenous 
GLUT2 levels. The poorly differentiated human lung carcinoma DLKP was employed as 
a positive control. This cell line has previously been assessed as being positive for 
GLUT2 (O’ Driscoll et al. 2002).
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Figure 3.5.15 GLUT2 expression in BHK Cell Lines. P-actin was used as an endogenous 
control for densitometric analysis. DLKP was included as a positive control for GLUT2 
expression.
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A s  il lu s t r a te d  in  F ig u r e  3 .5 .1 6 ,  i t  a p p e a rs  as i f  th e r e  is  a n  in c re a s e  in  p r o in s u l in  s e c re tio n  
in  th e  p o p u la t io n  e x p re s s in g  g lu c o k in a s e  ( B H K - P P I - C 1 6 G C K ) ,  u p  to  a  le v e l  o f  2 -5  m M  
g lu c o s e . A t  th e s e  g lu c o s e  c o n c e n tra t io n s  th e r e  w a s  a  m a x im a l  ( 2 - f o ld )  s t im u la t io n  in  
in s u l in  s e c re t io n  o v e r  b a s a l le v e ls . F u l l  G S IS  o v e r  th e  e n t ir e  p h y s io lo g ic a l  ra n g e  w a s  n o t  
a c h ie v e d , h o w e v e r ,  as th e  in c re a s e  d id  n o t  c o n t in u e  in  a  d o s e  d e p e n d e n t  fa s h io n  w i t h  
in c re a s in g  g lu c o s e ; in  fa c t  th e r e  w a s  a  f a l l - o f f  in  s e c re t io n  a t  h ig h e r  g lu c o s e  le v e ls .  
P r o in s u l in  s e c re t io n  w a s  n e g l ig a b le  in  th e  d o u b ly  t ra n s fe c te d  l in e  B H K - P P I -  
C 1 6 _ G C K _ G L U T .
3.5.5.7 Glucose Stimulation of the Cell Lines Transfected with the Glucose Sensing
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Figure 3 .5 .1 6  S e c re t io n  o f  P r o in s u l in  f r o m  B H K - P P I - C 1 6  G C K  a n d  B H K - P P I -  
C 1 6  G C K  G L U T  u p o n  s t im u la t io n  w i t h  in c re a s in g  g lu c o s e  le v e ls . T h e  f ig u re s  p re s e n te d  
re p re s e n ts  th e  c o n c e n tra t io n  o f  p r o in s u l in  s e c re te d  b y  5 x  1 0 4 c e lls  o v e r  tw o  h o u rs . T h e  
d a ta  a b o v e  re p re s e n ts  m e a n s  ±  S D  o f  a t  le a s t  th re e  in d e p e n d e n t  e x p e r im e n ts .
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3.5.5.8 Impaired Protein Synthesis in Transfected BHK-PPI-C16 Cells
P r o in s u l in  s e c re tio n  f r o m  B H K - P P I - C 16  G C K  G L U T  c e lls  w a s  c o m p le te ly  a b s e n t  
f o l lo w in g  th e  tr a n s fe c t io n  o f  th e  tw o  c o m p o n e n ts  o f  th e  g lu c o s e  s e n s o r ( G L U T 2  a n d  
G C K ) ,  d e s p ite  th e  fa c t  th a t  th e re  w e r e  s ig n i f ic a n t  le v e ls  o f  P P I  m R N A  in  th e s e  c e lls  
(F ig u r e  3 .5 .1 7 ) .  T h e  p r o b le m  a p p e a re d  to  b e  a t  th e  le v e l  o f  p r o te in  s y n th e s is ; th is , a n d  th e  
o b s e rv a t io n  th a t  th e  c e lls  e x h ib ite d  a  re d u c e d  g r o w th  ra te  in d ic a te d  a  n e g a t iv e  e f fe c t  d u e  
to  in c re a s e d  tra n s fe c t io n . T h e  le v e ls  o f  t w o  ‘ h o u s e k e e p in g  p r o te in s ’ (P  a c t in  a n d  a  
tu b u l in )  e x p re s s e d  in  e q u a l c e l l  n u m b e rs  w e r e  e x a m in e d  a n d , as i t  c a n  b e  s e e n  in  F ig u r e  
3 .5 .1 8 ,  th e r e  is  a  la rg e  re d u c t io n  in  e x p re s s io n  le v e ls  o f  th e s e  p ro te in s  a s s o c ia te d  w i t h  th e  
in c re a s in g  n u m b e r  o f  tra n s fe c te d  g e n e s . B io r a d  a n a ly s is  ( B r a d fo r d  b a s e d  p r o te in  assay; 
S e c t io n  2 .5 .2 .1 . 2 .1 )  o f  p e lle ts  o f  e q u a l c e l l  n u m b e r  c o n f ir m e d  th a t  c e l lu la r  p r o te in  le v e ls  
w e r e  2 - f o ld  lo w e r  in  th e  B H K - P P I - C  1 6 G C K G L U T  c e lls  w h e n  c o m p a re d  to  th e  B H K -  
P P I - C 1 6  c e l l  l in e  (F ig u r e  3 .5 .1 9 ) .
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Figure 3.5.17 P P I  g e n e  e x p r e s s io n  in  B H K - P P I - C  1 6  a n d  d e r iv a t iv e  c e l l  p o p u la t io n s . T h e  
P P I  c D N A  v e c to r  p T - P P I  a n d  H 2O  w e r e  u s e d  as p o s it iv e  a n d  n e g a t iv e  c o n tro ls , 
re s p e c t iv e ly  a n d  P a c t in  w a s  e m p lo y e d  as a n  e n d o g e n o u s  c o n tro l.
253
Figure 3.5.18 H o u s e k e e p in g  p r o te in  le v e ls  in  B H K - P P I - C 1 6  a n d  d e r iv a t iv e  c e l l  
p o p u la t io n s . P e lle ts  o f  4  x  1 0 5 c e lls  w e r e  ly s e d  o n  ic e  in  5 0  ^il N P - 4 0  ly s is  b u f f e r .  5 0  |^1 o f  
2 X  lo a d in g  b u f f e r  w a s  a d d e d  to  ly s a te  a f te r  3 0  m in u te s . F o l lo w in g  3  m in u te s  b o i l in g ,  1 0  
| i l  o f  th e  ly s a te  w a s  lo a d e d  o n  to  th e  a c r y la m id e  g e l. T h u s  e a c h  la n e  c o n ta in e d  th e  
e q u iv a le n t  o f  4  x  1 0 4 c e lls .
0.5 
= 0.4D>
T  0.3 u c o° 0.2 c
5o 0.1 
a.
0
BHK-PPI-C16 BHK-PPI-C16-GCK BHK-PPI-C16-GCK-GLUT2
Cell line
Figure 3.5.19 B r a d fo r d  p r o te in  a n a ly s is  o f  B H K - P P I - C 1 6  c e lls  a n d  d e r iv a t iv e  c e l l  
p o p u la t io n s . T h e  a b o v e  d a ta  is  b a s e d  o n  p r o te in  le v e ls  in  4  x  1 0 4 c e lls . T h e  d a ta  is  b a s e d  
o n  p r o te in  e x tr a c te d  f r o m  a t  le a s t th re e  d i f f e r e n t  p e lle ts  a n d  a s s a y e d  in  t r ip l ic a te .
3.5.6 Stimulated Secretion Mediated by Increasing Intracellular cAMP
cA M P  inducing agents have previously been shown to increase secretion o f  insulin from 
P cells e.g. forskolin (activates adenyl cyclase) and theophylline (inhibits cA M P  
phosphodiesterase) (U llrich et al. 1996; Sim pson et al. 1997). From  Figure 3.5.20 it is 
clear that these agents result in an increase in the levels o f  secreted proinsulin. To 
validate the results, tw o other agents know n to increase intracellular cA M P  w ere chosen 
for repeat stimulation assays. G lucagon is an adenyl cyclase activator and 3-isobutyl-l- 
methylxanthine (IB M X ) is a cA M P  phosphodiesterase inhibitor, i.e. these compounds are 
sim ilar in action to those initially mentioned. Table 3.5.1 summarises the stimulatory 
effects on proinsulin secretion due to the different agents. The data presented indicates an 
approxim ately 1.5-2 fold m axim al secretion upon stimulation o f  B H K -P P I-C 16  w ith 
agents that increase intracellular cA M P .
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Basai Forskolìn (0.5 ug/ml) Theophylline (10 Glucagon (10 nmol/l) IBMX(500 nmol/l)
mmol/l)
Secretagogue
Figure 3.5.20 Secretion o f  Proinsulin from B H K -P P I-C 16  in the presence o f  agents that 
increase intracellular cA M P . This figure represents the concentration o f  proinsulin 
secreted from 5 x  104 cells over tw o hours. A l l  treatments w ere carried out in triplicate 
and repeated 4 tim es (n=12) in the case o f  forskolin and theophylline, and repeated tw ice 
(n=6) in the case o f  glucagon and IB M X . (Basal = basal medium without addition o f  
cA M P  stimulating agents). A l l  data presented represent means ± SD.
Medium Type Fold Stimulation over Basal Secretion
Forskolin 1.8
Theophylline 1.4
G lucagon 1.6
IB M X 1.6
Table 3.5.1 Sum m ary o f  stim ulation o f  proinsulin secretion upon exposure to cA M P  
inducing agents.
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4.0 DISCUSSION.
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4.1 General Introduction.
ID D M  is a chronic illness and conventional treatments do not preserve the level o f  
norm oglycem ia maintained by a functioning pancreas, thus efforts are being made to 
generate functional replacem ent tissue from cultured cell lines. These cell lines are 
being derived through differentiation o f  multipotent tissue or through direct gene 
transfer into established ce ll lines.
It has been previously shown that E S  cells can be differentiated into insulin secreting 
cells via  spontaneous or directed methods (Schuldiner et a l, 2000; Soria et a l , 2000a; 
A ssady et al., 2001; Lum elsky et al, 2001). E C  cells are known to exhibit a number 
o f  similarities to E S  cells and in m any cases are easier to culture in vitro. F9 cells 
have been characterised as a  pluripotent ce ll line w ith the capacity to express multi­
lineage markers upon careful differentiation (Koopm an &  Cotton, 1987). Directed 
differentiation o f  F9 cells towards an endocrine fate had not been attempted prior to 
this study despite the ease at w hich  these cells adopt endodermal lineages (H ogan et 
al, 1981; M oore et al., 1986; B ecker et al, 1997; M iki et al, 1999), w hich is where 
the pancreas derives from in the developing gut (M adsen et al, 1996; K im  &  Melton, 
1998; Edlund, 2001). Thus the F9 ce ll line w as considered an excellent model in 
w hich to study islet neogenesis v ia  directed differentiation.
The cultured p cell line M in6 has been observed to lose its specialised functions e.g., 
G SIS , w hile in  culture for long periods, and it was postulated that this m ay be due to 
de-differentiation (K ayo et al., 1996) although overgrowth o f  an already present 
poorly differentiated subpopulation remains a possibility. Thus M in6 cells were 
considered a  potentially useful m odel in  w hich  to study p ce ll differentiation in 
reverse.
Finally, B H K -21 cells have been used in a human somatic cell therapy trial for A L S  
(A ebischer et al., 1996), thus these cells m ay represent a useful recipient for transfer 
o f  a  functional human insulin gene to diabetic patients.
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4.2 Initial Differentiation of F9 Cells
The pancreatic islets develop from prim itive endoderm within the developing gut 
(Section 1 .1 .1) , thus in designing a directed differentiation protocol for E C  cells, 
endodermal differentiation w as considered to be the logical first step. F9 E C  cells are 
characterised as differentiating to endodermal subtypes upon a straightforward one- 
step differentiation. F9 cells treated w ith R A  differentiate to a prim itive endoderm 
(PrE) stage that m ay be differentiated towards visceral endoderm (V E ), or parietal 
endoderm (PE). Culture o f  F9 aggregates in suspension (EBs), in the presence o f  R A  
leads to predominantly V E  in the outer layer (Hogan et al, 1981; M oore et al, 1986; 
B ecker et al, 1997; M iki et al., 1999). The addition o f  db cA M P  modulates the R A  
differentiation o f  F9 m onolayers and enhances the generation o f  PE (Strickland et al., 
1980 Lethonen et al., 1989; A lon so  et al., 1991). A s  already mentioned, the pancreas 
is o f  endodermal origin, but it is unclear i f  it is derived from PE or VE. Recent w ork 
w ith E S  cells how ever demonstrates the associated expression o f  V E  markers, e.g. 
A F P  and G A T A 4 , during differentiation o f  these cells towards p cells (Schuldiner et 
al, 2000; Lum elsky et al, 2001). Thus F9 differentiation serves as a useful model to 
study the em ergence o f  the different types o f  endoderm and to possibly assign 
lineages to the differentiated progeny.
4.2.1 Short Term Treatment With RA and RA/db cAMP Induce Differentiation 
in F9 Cells
Initial differentiation protocols w ere carried out over 72 hours (Section 2 .3 .1.2 .1), 
w hich  is shorter than m ost R A  or RA/db cA M P  based differentiation protocols.
<T
Previous reports indicate that strong differentiation in the presence o f  10' R A  
eventually leads to purely PE thus reducing the number o f  possible lineages 
(K oopm an &  Cotton, 1987). T o avoid  this, the follow ing system , involving a 72-hour 
differentiation procedure, w as designed to capitalise on all the possible endodermal 
permutations (Figure 4.2.1). F ollow in g these initial ‘ partial-differentiations’ , the 
expression levels o f  differentiation markers were exam ined to investigate i f  they had 
sim ilar features to the strongly induced differentiated cells described earlier (Section
1.4.2).
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RA(10-7 M) for 72 Houra
Parietal Endoden» (PE)
Primative Endoderm (PrE)
Visceral Endoderm (VE) ?
RA (10~7 M) + db cAMP 
(lfr3) for 72 Hours
Parietal Endoderm (PE)
Aggregate Culture on Bacteriological Grade Plastic @ IxlO5 cells/ml
RA (IO 7 M) for 72 Hours Visceral Endoderm (VE)
Figure 4.2.1 First stage differentiation o f  F9 cells to m axim ise endodermal types 
generated for stage tw o directed differentiation.
4.2.1.1 RA and RA/db cAMP Induce Morphological Changes in F9 Monolayers
W hen the undifferentiated F9 ce ll population (as evidenced by m orphological features 
i.e., the typical polygonal cells in tightly packed three dimensional colonies) were 
exposed to 10'7 M  R A  (R A  treatment), or a  com bination o f  10'7 R A  and 10'3 M  db 
cA M P  (R A C  treatment), for 72 hours, induction o f  a differentiated phenotype was 
indicated by m orphological changes. RA. treated F9 cells w ere observed to exhibit at 
least tw o sub populations w ith different m orphologies, including large flattened cells 
that contained cytoplasm ic vacuoles and more structured cells with stretched 
processes emanating outwards from  the cell. Both cell types within R A  treated F9 
m onolayers were quite granular. The R A C  treated cells w ere more homogenous in 
nature and the cells were m orphologically sim ilar to the smaller, structured cells 
observed within the R A  treated population. Based on the similarities between the 
structured cells in R A  and the R A C  treated F9 cells, it was considered possible that 
this represents a  sub-population o f  PE  w ithin the R A  treated cells. These results are 
sim ilar to those obtained by M oore el al. (1986), when differentiating F9 cells. Those 
researchers however, considered the R A C  treated cells as a unique cell-type (i.e. not a 
hom ogenous population o f  the P E -like cells seen in the R A  treated population).
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The m orphological changes during the differentiation are accom panied by a reduction 
in growth rate as indicated by the low er degree o f  confluency in differentiated 
cultures. Alternatively, it could be considered that the differentiated phenotype 
observed m ay be as a result o f  the reduction in growth rate w hich allows 
differentiation to occur (Lethonen et a l 1989).
4.2.2 Morphological Changes in the Outer Layer of RA Treated EBs
Culture o f  F9 cells at a density o f  lx lO 5 cells/ml on bacteriological-grade plasticware 
leads to the formation o f  evenly sized aggregates known as em bryoid bodies (EBs). 
Culture o f  E B s in the presence o f  R A  results in the outer layer differentiating to form 
predominantly V E  (Hogan et al., 1981). Differentiated E B s in culture are surrounded 
by an uneven layer o f  differentiated cells, whereas untreated E B s are smooth. To 
facilitate examination o f  the outer layers, E B s w ere cultured on gelatin (resulting in 
them attaching to the surface) thus allow ing the outer later o f  cells to grow  outwards 
and form a ‘h alo ’ around the central core o f  the E B. C ells  grow ing out from the R A  
treated E B  are long and stretched w ith pointed processes, whereas the cells growing 
out from untreated E B s resem ble normal F9 cells. The undifferentiated E B s were 
generally o f  a larger size than those form ed in the presence o f  R A  (on average 36%  
larger), and this presum ably reflects the faster growth rate o f  undifferentiated cells. 
There is no m orphological evidence for any spontaneous differentiation in the outer 
layers in untreated EBs. L ow -level spontaneous differentiation has previously been 
observed in the outer layers o f  F9 E B s (B ecker et al., 1997). The lack o f  obvious 
differentiation m ay be due to the shorter differentiation period em ployed here (72h 
com pared to 7  days).
4.2.3 Induction of Differentiation Marker Expression by RA and RA/db cAMP 
Treatments
M orphological analysis, as described in Section 4.2.2, clearly indicated that 
differentiation w as occurring. The nature o f  the differentiation is unclear however 
unless the presence o f  differentiation markers is established.
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4.2.3.1 Differentiation of EC Cells is Correlated with a Decrease in Alkaline 
Phosphatase Expression and a Concomitant Increase in Cytokeratin Expression
A lkalin e phosphatase is a typical marker o f  stem cells and has been previously 
reported as a method o f  monitoring stem ce ll differentiation (Lum elsky et al., 2001; 
Draper et al., 2002). A lkaline phosphatase staining was observed to decrease upon 
treatment o f  F9 cells w ith R A , how ever within the R A  population there are still 
regions o f  closely grouped cells that exhibit intense staining. These cells correspond 
to sub-populations within the F9 population that are characterised as being refractory 
to the action o f  R A  (Alonso et al., 1991), and thus do not differentiate. The cells at the 
periphery o f  the ce ll clusters show  m uch less staining and are sim ilar in m orphology 
to the R A C  treated cells. The R A C  cells are observed to be almost entirely free o f  
alkaline phosphatase staining. These observations co llectively  indicate that the cells 
w ithin the R A  population w hich are m orphologically sim ilar to the R A C  treated cells 
are not the same, how ever, as they still have residual alkaline phosphatase activity. 
This w ould agree with these cells being a transitory population (as proposed by M oore 
et al., (1986)) towards the fully  parietal cells seen follow ing the R A C  treatment. The 
outer ‘h alo ’ o f  differentiated E B s also demonstrated m uch reduced alkaline 
phosphatase staining w hile the central, inner portion o f  the E B  stains intensely (Figure 
3.1.5). This is sim ilar to observations w ith  E B s taken directly from  the transplantable 
teratocarcinoma O T T  6050 (Paulin et al., 1982).
The importance o f  cytokeratin expression in differentiating system s is discussed with 
regard to m onitoring pancreatic islet developm ent in Section 1.1.4. Differentiation o f  
F9 cells in the presence o f  R A  or R A C  is know n to induce cytokeratin expression and 
cytokeratins are present in both V E  and PE. C K s 8 and 18 have already been 
identified in differentiated F9 populations (Ramaekers et al., K urki et al., 1989; 
Lethonen et al., 1989). The full cytokeratin profile for F9 cells is unknown however. 
Im m unofluorescence studies failed  to detect any cytokeratin expression in 
undifferentiated F9 m onolayers but there w as evidence for low -level cytokeratin 
expression in undifferentiated E Bs. Specifically  C K 8, C K 18 , C K 7  &  C K 19  (Section
3.1.4.2), w ere detected in the periphery/halo region o f  the EBs. Spontaneous 
differentiation o f  untreated E B s w as not indicated by either the m orphology o f  the 
outer layer or by alkaline phosphatase staining, however, as the level o f  spontaneous
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differentiation appears to be low, it is likely  that it required the increased sensitivity o f  
im m unofluorescence to be detected.
Treatment o f  F9 m onolayers w ith R A  for 72 hours led to the induction o f  cytokeratins 
8 and 18 in around 20 %  o f  the cells w h ich  agrees w ith the w ork  o f  K urki et al. 
(1989). Cytokeratins 7  and 19 w ere also exam ined but w ere not readily detected at 
this point (they were detectable how ever after 7 days treatment w ith RA ). These 
results demonstrate the capability o f  R A  treated F9 cells to express the critical 
endodermal cytokeratins associated w ith the pancreas (Bouw ens et al., 1994; 
Bouw ens, 1998a). Cytokeratin staining is more associated with the P E -like cells rather 
than the PrE like cells in the R A  treated population, and this is confirm ed by the level 
and intensity o f  cytokeratin staining in R A C  treated F9 cells. C K 7  w as also readily 
detectable after 72 hours R A C  treatment. A s  w ith R A  treated cells, C K 19  w as present 
follow in g 7 days R A C  treatment. The role o f  cA M P  in R A  mediated differentiation is 
unknown and there are conflicting reports regarding its function, i.e. whether or not it 
can illicit an effect on its ow n (D arrow  et al, 1990; Alonso et al, 1991).
R A  treated E B s also demonstrated low -level cytokeratin staining and, as mentioned, 
had already displayed low -level spontaneous differentiation. There w as slightly 
intensified C K 8 and 18 staining in R A  treated E B s but not in the case o f  C K 7  and 
C K 19 . The restriction o f  cytokeratin expression to the periphery o f  E B s has been 
observed in a sim ilar situation b y  Paulin et al. (1982).
4.2.3.1.1 Implications of Cytokeratin Expression in Differentiated F9 Cells
Cytokeratins are markers for epithelial cells w hich show  defined tissue distribution 
allow ing for putative epithelial tissue characterisation based on the cytokeratin profile 
(Section 1.1.4). Sim ple epithelia o f  the liver and gallbladder are enriched in C K s 8 , 1 8  
and to a lesser extent 7  and 19 as are tracheal epithelium and com plex glands (M oll et 
a l, 1982). H ow ever as already discussed (Section 1.1.4), cytokeratin-based 
characterisation is purely speculative (especially considering the ‘prom iscuity’ o f  
certain cytokeratins e.g. C K 1 9  (H atzfeld &  Franke, 1985)). Thus, all that can be 
inferred from  the cytokeratin profiles o f  the three partially differentiated F9 types is 
that they exhibit a sim ilar cytokeratin expression profile to that o f  the pancreas.
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Cultured cells are very different to the in vivo situation how ever, and cytokeratin 
profiles o f  cells often bear lim ited resem blance to their tissue o f  origin. C K s 8 &  18 
have also been shown to be very com m on in cultured cells (M oll et a l, 1982).
4.2.3.2 Alpha fetoprotein is Expressed in Differentiated EBs
Alpha-fetoprotein (A FP) expression is a m arker o f  V E  (Hogan et a l, 1981), and was 
detected only at lo w  levels on the periphery/halo o f  R A  treated E B s (in accordance 
w ith the w ork o f  H ogan et al, (1981)). The low -level nature o f  the staining was 
surprising as R A  treated E B s are characterised as being rich in Y E , how ever the short 
duration o f  the treatment (72 hours) m ay not have resulted in enough protein to be 
detected easily. In a study b y  B ecker et a l  (1997), A F P  expression was only 
detectable after 5-6 days treatment w ith R A . A F P  expression was not found in R A C  
or R A  monolayers.
4.2.3.3 (31 Integrin Expression Increases Upon Differentiation of F9 Cells
p i  integrin facilitates the m orphological changes occurring in differentiating F9 cells 
(Stephens et a l, 1993), thus it was not surprising to find large changes in the p i  
integrin subunit fo llow ing all three types o f  differentiation (Figure 3.1.11).  Integrins 
facilitate information transfer from the E C M . This m ay serve to explain the low -level 
p i  integrin expression in E B s i.e., they are in suspension and have no contact with the 
ECM. The observed increase in p i  integrin level upon RA treatment is in keeping 
with observations b y  Stephens et al, (1993). The role o f  cA M P  in enhancing p i 
integrin expression follow in g R A C  treatment appears to be modulatory as cA M P  
alone was shown to have no effect on p i  integrin levels in F9 cells (Ross et al, 1994). 
The correct expression o f  P 1 integrin is crucial to the terminal differentiation o f  a 
number o f  cell types and is im plicated in the differentiation o f  the neural crest 
(Bronner-Fraser, 1986). D ifferentiation o f  the C N S  is closely  related to that o f  the 
developing pancreas (Section 1.1.2.6). Correct integrin expression is also crucial for 
maintaining P cell function in culture (Section 1.2.4.2.1).
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4.2.4 Overview of F9 Cells Differentiated Towards An Endodermal Lineage
Examination of the various endodermal types via morphology and differentiation 
markers clearly indicates that the cells are differentiating despite the short duration of 
the initial differentiation protocol. The differentiation markers that are being 
expressed are relatively common, in that the lineages evolving cannot be definitively 
characterised. It is clear, however, that there are similarities in protein expression 
between the tissue derived from these experiments and pancreatic tissue. These are 
listed in Table 4.2.1. The main point is however, that these cells clearly resemble 
primitive endodermal cells and thus are differentiating in the correct ‘direction’ 
towards pancreatic p cells.
Marker F9 F9-RA F9-RAC EB-RA* Pancreas 
(p Cells)
Alkaline
Phosphatase
+++ + +/- +/- +/- (p Cells) 
(Figure 3.4.4)**
K8 - + (20%) + (50%) + (<20%) Endocrine Islets
K18 - + (20%) + (50%) + (<20%) Endocrine Islets
K7 - U + (20%) + (<20%) Exocrine Ducts
K19 - U U + (<20%) Exocrine Ducts
p i Integrin -/+ + ++ ++ p Cells
Alpha
Fetoprotein
+ (<20%)
Table 4.2.1 Comparison of markers fount to be expressed in partial y differentiated
F9 cells with pancreatic markers. (+) indicates the presence of a marker while (-) 
denotes its absence. (U) denotes markers that were undetectable after 72 hours 
differentiation but were detectable after longer periods (6-7 days). Approximate 
percentages of cells expressing the proteins studied are included in parentheses where 
applicable.
Notes
* This column corresponds to the outer halo of differentiated cells surrounding the EB 
when it is cultured on 0.1% gelatin.
** Fully differentiated functional Min6 cells have low levels of alkaline phosphatase 
activity, such that colour development took up to 8 hours.
265
4.3 Secondary Differentiation of Endoderm with Differentiation Agents
The differentiation protocols discussed in Section 4.2 resulted in the generation of PE, 
VE and some PrE endodermal types, and, due to the short duration of the initial 
treatments, it was expected that the cells would retain plasticity/multipotency. Thus it 
was hoped that within one of these populations, cells would be present that are similar 
in nature to the fetal endoderm from which all pancreatic cell types originate. These 
three heterogeneous populations were considered an ideal starting point from which to 
investigate the effects of endocrine differentiation agents outlined in Section 1.3.4. 
The relatively long duration of the secondary treatments were based in part on a 
similar set of experiments involving the treatment of ES cells with various agents 
(Schuldiner et al„ 2000). It has also been found that longer periods in culture (22-35 
days) result in greater chance of multiple-lineage differentiation in RA treated F9 cells 
(Koopman & Cotton, 1987).
The secondary differentiation agents (Section 1.3.4) were carefully chosen based on 
their reported involvement in islet cell neogenesis in vivo and also due to previously 
characterised actions on cultured cells. In the case of activin A and HGF, the effects 
of the initial differentiation step on the levels of their receptor proteins was unknown, 
thus these proteins were investigated via western blotting (Section 2.5.2.1). The 
actions of the agents on the endodermal cells from stage 1 were examined using RT- 
PCR (Section 2.5.1.5) and, where applicable, immunofluorescence and 
immunocytochemistiy (Section 2.5.2.2). The experiment is outlined in Figure 4.3.1.
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R A  Treated F9 R A C  Treated F9 R A  Treated EBs
Identify Receptor 
Availability for 
Activin A  and HGF
10 Day Differentiation 
in Presence of 
Endocrine
Differentiation Agents
Immunofluorescence/
Immunocytochemistry 
Where Applicable
Figure 4.3.1 E n d o d e r m a l - l i k e  c e l ls  f r o m  s ta g e  1 d i f f e r e n t ia t io n  w e r e  e x a m in e d  f o r  th e  
p r e s e n c e  o f  a p p r o p r ia t e  r e c e p to r s  a n d  s u b s e q u e n t ly  d i f f e r e n t ia t e d  u s in g  e n d o c r in e  
p r o m o t in g  a g e n ts  ( S e c t io n  1 .3 .4 ) .  T h e  a n a ly s is  is  p r e d o m in a n t ly  R T - P C R - b a s e d  w i t h  
i m m u n o lo g ic a l  p r o t e in  d e t e c t io n  m e t h o d s  e m p lo y e d  w h e r e  a p p l ic a b le .
4.3.1 Analysis of Receptor Expression Following Stage 1 Differentiation
F 9  c e l ls  a r e  k n o w n  t o  e x p re s s  a c t i v in  A  r e c e p to r s  in c lu d in g  a c t iv in  R I I  B  ( K o n d o  et 
al,  1 9 8 9 ;  W a n  et al,  1 9 9 5 ) .  A c t i v i n  ty p e  I I  r e c e p to r s  h a v e  b e e n  s h o w n  t o  b e  th e  
c r i t i c a l  c o m p o n e n t  i n  m e d ia t in g  t h e  re s p o n s e  o f  e n d o t h e l ia l  c e l ls  t o  a c t i v in  A  a n d  
b i n d in g  o f  a c t i v in  A  is  l i m i t e d  b y  th e  a v a i l a b i l i t y  o f  th is  r e c e p t o r  ( M c C a r t h y  &  
B i c k n e l l ,  1 9 9 4 ) .  I t  w a s  u n k n o w n  h o w e v e r  i f  th e  s ta g e  1 d i f f e r e n t ia t io n  w o u l d  a f f e c t  
a c t i v i n  R I I  B  p r o t e in  le v e ls  ( i t  is  t r a n s c r ip t io n a l ly  u p r e g u la t e d  i n  d i f f e r e n t ia t e d  F 9  
c u lt u r e s ,  S e c t io n  1 .4 . 1 . 2 . 3 ) .  T h e  m o d e r a t e  in c r e a s e  i n  p r o t e in  le v e ls  f o l l o w i n g  a l l  
t h r e e  m o d e s  o f  d i f f e r e n t ia t io n  is  f a r  le s s  t h a n  th e  in c r e a s e s  n o t e d  i n  th e  t r a n s c r ip t  
le v e ls  ( W a n  et al,  1 9 9 5 ) ,  o r  i n  s p o n ta n e o u s ly  d i f f e r e n t ia t in g  E B s  g e n e r a t e d  f r o m  E S  
c e l ls  ( S c h u ld in e r  et al,  2 0 0 0 ) .  A c t i v i n  R I I  B  m R N A  le v e ls  w e r e  n o t  e x a m in e d  as  th is  
w a s  a  q u a l i t a t iv e  e x e r c is e  t o  c o n f i r m  th e  p r e s e n c e  o f  r e c e p t o r  p r o t e in  e x p r e s s io n  p r io r
267
t o  t r e a t m e n t  w i t h  a c t iv in  A ,  th u s  i t  is  n o t  k n o w n  i f  a c t iv in  R I I  B  m R N A  le v e ls  w e r e  
u p r e g u la t e d  f o l l o w i n g  th e  7 2  h o u r  d i f f e r e n t ia t io n  c a r r ie d  o u t  h e re .
T h e  H G F  r e c e p t o r  ( t h e  c - m e t  p r o to o n c o g e n e ) ,  s im i la r l y ,  s h o w s  a  s l ig h t  in c r e a s e  u p o n  
R A / R A C  m e d ia t e d  d i f f e r e n t ia t io n ,  h o w e v e r  t h e r e  is  a  > 2 - f o l d  in c r e a s e  b e t w e e n  th e  
le v e ls  o f  c - m e t  i n  F 9  m o n o la y e r s  a n d  i n  E B s .  T h is  w a s  a ls o  o b s e r v e d  u p o n  E B  
f o r m a t io n  f r o m  m u l t ip o t e n t  H 9  E S  c e l ls  ( S c h u ld in e r  et al., 2 0 0 0 ) .  A s  w i t h  t h e  a c t iv in  
R I I  B  r e s u l t ,  th e  in c r e a s e s  a n d  d e c re a s e s  w e r e  c o n s id e r e d  s e c o n d a r y  t o  th e  f a c t  t h a t  a  
r e c e p t o r  h a d  b e e n  i d e n t i f i e d  f o r  th e  s e c o n d  s ta g e  d i f f e r e n t ia t io n  u s in g  H G F .
B e t a c e l lu l in  is  k n o w n  t o  in t e r a c t  a t  le a s t  p a r t l y  t h r o u g h  t h e  E G F R  a n d  th is  h a s  a lr e a d y  
b e e n  s h o w n  t o  in c r e a s e  u p o n  F 9  d i f f e r e n t ia t i o n  ( G r e ip  &  D e  L u c a ,  1 9 8 6 ) .  B e t a c e l lu l in  
h a s  a ls o  b e e n  s h o w n  t o  in t e r a c t  w i t h  a n o t h e r  p r o t e in  i n  A R 4 2 J  c e l ls .  T h is  1 9 0  k D a  
p r o t e in  w a s  id e n t i f i e d  b y  im m u n o p r e c ip i t a t in g  I 125 la b e l l e d  b e t a c e l lu l in  t h a t  h a d  
b o u n d  i t s  r e c e p to r s  o n  t h e  A R 4 2 J  c e l ls  ( I s h i y a m a  el al., 1 9 9 8 ) .  I t  w a s  n o t  p o s s ib le  t o  
s c re e n  d i f f e r e n t ia t e d  F 9  c e l ls  f o r  th is  p r o t e in  h o w e v e r  a s  i ts  id e n t i t y  is  u n k n o w n .
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4.3.2 RT-PCR Analysis Reveals Changes in Expression of Islet Markers 
Following Secondary Differentiation of RA-Monolayers
The changes in gene expression observed as a result o f  secondary differentiation o f 
F9-RA monolayers are summarised in Table 4,3.1
T reatment 
----------►
Gene ^
F9
(Untreated)
RA Act BTC Act/
BTC
HGF HGF/
Act
Nico Nico/
Act
SB SB/
Act
Min6
PDX1 +/- + + + + + ++ + + + + +++
PPI +/- + + ++ + ++ +++ ++ ++ ++ ++ +-H-
Pax6 ++ ++ ++ + +/- + +/- -H-+ +++ ++ ++ ++
Ihh +/- ++++ + + + ++ ++ -H-+ ++ +++ +++ +/-
PP - - - - - - - - - + + 1 1 1 1
lomatostatin - - +/- +/- - +/- - - - ++ -H- ++++
Table 4.3.1 Summary o f  the changes in gene expression following secondary 
treatm ent o f  F9-RA monolayers. For each mRNA, the level o f expression in the 
parental F9 population is used as the reference level. M in6 cells are included for 
comparison. The relative expression levels were determined from densitometric 
analysis.
As shown in Table 4.3.1, undifferentiated F9 cells were shown to express a number o f 
tissue specific genes at low levels. This so called ‘leaky’ expression o f  lineage- 
specific transcription factors is not uncom mon and has also been noticed in 
hematopoietic stem cells (HSCs) where subsequent com mitment is associated w ith the 
loss o f  expression o f  genes that are unrelated to the intended lineage (Wagers et al., 
2002). Treatment o f  F9 monolayers with RA alone resulted in increased levels o f 
PDX1, PPI and Ihh (Section 3.2.2). It is known that increased Ihh gene expression is 
implicated in  enhancement o f  PPI gene expression (Thomas et al., 2000). Ihh levels 
are much lower in HGF/Act treated F9 RA  cells, however, whereas PPI expression is 
almost 2-fold higher than in RA treated F9 cells. These differences do not indicate a 
direct Ihh-mediated m echanism  for PPI stim ulation in  the F9 system. Increases in 
PDX1 and PPI gene expression following HGF/Act treatm ent o f  AR42J cells were 
also observed by M ashim a et al. (1996b). These researchers proposed that the action
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o f HGF was similar to that o f BTC in combination w ith activin A  (Mashima et ah, 
1996a). In this study, Act/BTC did not result in the same level o f PPI or PDX1 up- 
regulation as HGF/Act. A  possible explanation for this may involve a novel BTC 
receptor discovered on AR42J cells (see Section 4.3.1). This receptor seemed far more 
important to the differentiation-related actions o f BTC than does EGFR (Ishiyama et 
ah, 1998). I f  this protein were absent from F9 cells then it is possible that the effects 
o f BTC would be less marked.
Immunofluorescence analysis did not detect any PDX1 or PPI expression in either 
untreated F9 or any o f the F9-RA cultures treated w ith differentiation inducing agents. 
It is possible that expression levels o f these proteins were too low for protein 
detection (mRNA levels were much lower than in Min6, which had clearly detectable 
PPI and PDX1 protein). When attempting to determine the order o f appearance o f the 
islet hormones in the developing pancreas, the data differs upon comparing RT-PCR 
analysis and immunohistochemical data (Gittes &  Rutter, 1992; Herrera et ah, 1991; 
Teitelman et al., 1993; Upchurch et ah, 1994). The order o f appearance o f the 
immunoreactive islet hormones correlates w ith the proportion o f each cell type, i.e. 
insulin and glucagon expressing cells are present in high numbers in islets and these 
proteins were detected first, while PP cells account for 1-2% o f the islet cell mass and 
PP was the last protein detected. Thus, immunological methods may not be sensitive 
enough to detect the levels o f PPI and PDX1 present in treated F9 cells, even 
following the elevated mRNA levels induced by such treatments as HGF/Activin A. It 
is also possible that the F9 cells are not translating these mRNAs.
The Pax6 gene is highly expressed at the mRNA level in F9 cells. Its levels were 
increased in the nicotinamide treatments, but this was not correlated with any other 
major changes in gene expression. Pax6 expression was very low in the HGF/Act 
treatments, however, and this treatment was associated with increased levels o f PPI 
and PDX1. Pax6 expression is present in all four endocrine types in the islet, but it is 
far more important for a  cell formation than that o f p cells (St-Onge et al., 1997; 
Sander et ah, 1997). Pax4 expression is considered crucial for p cell expression in 
vivo and it acts, at least partly, by competitive binding with Pax6 thus inhibiting Pax6 
and a  cell development (Smith et ah, 1999; Ritz-Laser et ah, 2002). Pax4 was not
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detected in F9 cells, either prior to or following any treatment, thus it was apparently 
not present to modulate the effects o f Pax6. HGF/Act treatment resulted in  reduced 
Pax6 expression and may have substituted for Pax4 effects. Some Pax6 expression is 
required for pancreatic hormone gene expression and also for efficient transcription o f 
PDX1 (Sander et al., 1997; Samaras et al, 2002).
The other treatments all showed increased PPI gene expression and were not 
markedly different from one another in repeat experiments. Changes such as increased 
PPI expression upon RA treatment (compared to parental F9), and HGF/Act 
treatment, were consistent over a number o f experiments. M inor changes in 
expression between treatments i.e., <1.5 (as judged from densitometry) were not 
considered significant and were therefore regarded as being unchanged from one to 
another.
Shh was not found to be expressed in F9 or in PE differentiated F9 cells which is in 
agreement w ith work by Becker et al. (1997), and it was not induced by any o f the 
treatments. RT-PCR o f a positive control indicated that the primers were suitable and 
the procedure was conducted successfully.
4.3.2.1 Sodium Butyrate Leads to Expression of PP and Somatostatin mRNAs in 
F9 RA Monolayers
The expression o f the mRNAs for all four islet hormones was investigated following 
the secondary treatment o f F9 RA monolayers. It was found that both somatostatin 
and PP were expressed at high level following sodium butyrate treatment or sodium 
butyrate treatment with activin A. The results indicate that the effect is being 
mediated directly by sodium butyrate, as activin A  has no effect on PP alone and only 
a minor effect on somatostatin expression. Unlike the situation with PPI, the induction 
o f PP and somatostatin expression was observed at the protein level also (Section
3.2.5.1 &3.2.5.2).
The expression o f these pancreatic islet hormones was encouraging as it indicated that 
the differentiation protocol did induce endocrine differentiation even i f  insulin was 
not expressed. Lumelsky et al., (2001) also generated somatostatin expressing cells
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during their differentiation of ES cells towards insulin secreting cells. This would 
indicate that the protocols employed here might generate insulin secreting cells with 
more modification or possibly using different cells.
Minó cells were used as positive controls in all RT-PCRs for islet hormones. It was 
already known that Min6 express IAPP, glucagon and somatostatin (Kanatsuka et al., 
1992; Ohgawara et al., 1995) but there do not appear to be any previous reports in 
which Minó cells were shown to express PP.
4.3.2.2 Sodium Butyrate Causes an Increase in Acetylated Histone H3 Levels in 
F9-RA Monolayers
Sodium butyrate is a member of the HD AC (histone deacetylase) inhibitor family, and 
it has been shown to promote P cell differentiation (Section 1.3.4.5). It has effects on 
a number of genes within F9 cells (Section 1.4.1.2.2), including endo A (CK AJ CK 8) 
expression. The action of sodium butyrate on endo A is related to histone acétylation 
(Myiashita et al., 1994). Examination of sodium butyrate treated F9 cells showed that 
levels of acetylated histone H3 protein were increased, and the presence of activin A 
had an additive effect. Upon closer examination of Figures 3.2.8, 3.2.14 & 3.2.20 it 
can be seen that in the case of the monolayers the presence of activin A did appear to 
have a slight additive effect on somatostatin mRNA levels, whereas activin A was 
required with sodium butyrate for somatostatin expression in EBs. Histone H3 
méthylation is already known to be crucial for the active expression of genes (Santos- 
Rosa et al., 2002), which confirms the importance of histone modifications and 
chromatin structure in gene transcription. Histone modifications are reported to act in 
concert, i.e. the combination of acetylation/deacetylation and méthylation, etc., may 
serve to either bind or prevent binding of transcriptional complexes (Sartorelli & Puri, 
2001). Acétylation is also linked to the expression of genes in the developing 
pancreas, and defective acetyltransferase-dependent transcription has been linked to 
mature onset diabetes of the young (MODY) (Sartorelli & Puri, 2001).
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4.3.2.3 Summary of Secondary Treatment of F9-RA Monolayers
Secondary treatment of F9 monolayers resulted in altered expression of a number of 
genes and in certain cases possible cascades, or fragments of cascades may have been 
identified (examples of which are illustrated in Figure 4.3.2). However, while 
individual treatments may result in some common effects e.g. decreasing Pax6, the 
subsequent ‘knock on’ events may be altered due to the differing effects of the 
individual treatments on other genes not examined during this experiment. This leads 
to difficulty in assigning mechanisms to F9 endocrine differentiation, except in cases 
like that of sodium butyrate, which appears to act independently of all of the genes 
examined in its enhancement of somatostatin and PP mRNA expression.
RA HGF/Act Sodium Butyrate ®ut// ^
Intermediates ?
Somatostatin
F ig u r e  4 .3 .2  Summary of main changes in hormone gene expression following 
endocrine differentiation of F9-RA cells. Genes in blue were shown to be increased at 
th e  mRNA level following the indicated treatment, while those in red were 
downregulated. Green arrows indicate ‘knock on’ effects of treatments e.g. down 
regulation of Pax6 as a result o f HGF/Act treatment may allow P cell differentiation 
and therefore increase PPI gene expression.
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4.3.3 Secondary Endocrine Treatments of RAC Monolayers
The levels of the different genes examined following secondary differentiation of F9 
cells are summarised in Table 4.3.2.
TreatmentIfcb
F9
(Untreated)
RAC Act BTC Act/
BTC
HGF HGF/
Act
Nico Nico/
Act
SB SB/
Act
Min6
Gene X
PDX1 +/- + + + + + + + + + + +++
PPI + + + + + + + + + ++ ++ +++
Pax6 + +/- + ++ ++ + + +++ +++ + + +++
Ihh +/- +/- + + + + + ++ ++ ++ + +/-
PP - - - - - - - - - + +
Somatostatin - - - - - - - - - + + ++++
Table 4.3.2 Summary of the changes in gene expression following secondary 
treatment of F9-RAC monolayers. For each mRNA, the level of expression in the 
parental F9 population is used as the reference level. Min6 cells are included for 
comparison. The relative expression levels were determined from densitometric 
analysis.
The expression of PDX1 is increased following initial RAC treatment however the 
levels of PPI were not similarly affected. Sodium butyrate treatment alone, and with 
activin A leads to increases in PPI mRNA levels. These treatments all coincide with 
slightly lowered levels of Pax6 mRNA, which may be implicated in P cell 
differentiation (as already discussed in Section 4.3.2). Ihh expression is not induced 
following 10 days treatment in RAC medium. This is interesting as Ihh was strongly 
induced following 3 days RAC treatment (Figure 3.3.27). Becker et al. (1997) found 
significant levels of Ihh protein in RAC-derived PE after 5 days treatment. It was 
reported that Ihh expression immediately preceded the VE marker AFP and was 
expressed at the same time as the PE marker a6 p i integrin during F9 differentiation. 
Transfection studies indicated that Ihh could induce the expression of markers of VE, 
and to a lesser extent PE, in the absence of RA (Section 1.4.1.4.1). It is possible that
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Ihh action promotes the formation of a transitory endodermal cell which can then go 
on to PE or preferentially VE. Ihh expression is also preferentially maintained in 
visceral endoderm in vivo. It is therefore possible that 10 days continuous culture in 
the presence of RAC could have generated a homogenous culture of highly 
differentiated PE with little or no PrE or VE, resulting in the loss of Ihh expression.
4.3.3.1 Expression of PP and Somatostatin Following Sodium Butyrate 
Treatment
As with the RA generated monolayers, sodium butyrate induced PP and somatostatin 
gene expression and again activin A did not modulate this activity to any considerable 
extent. PP expression was approximately equivalent in sodium butyrate treated RAC 
monolayers and RA monolayers. Somatostatin expression however was not as strong 
in this case which suggests that db cAMP may have some effect that inhibits 
somatostatin mRNA levels. If it can be assumed that VE is the lineage from which 
the islet cells originate, then islet hormone gene expression may be harder to induce in 
the more homogenous PE population resulting from RAC treatment.
4.3.3.2 Summary of Secondary Differentiation of F9-RAC Monolyers
The changes that occurred during the differentiation of F9-RAC do not reveal any 
obvious mechanistic actions for pancreatic development from F9 cells and it is 
possible that the treatments are favouring other cell types. The poor induction of 
somatostatin may suggest that the endoderm derived from F9-RAC cells might be too 
committed to PE and thus might not be as open to directed differentiation towards an 
endocrine lineage.
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4.3.4 Secondary Differentiation of RA Treated EBs
For ease o f reference, the levels of the genes expressed in secondaiy differentiated 
EBs are summarised in Table 4.3.3.
Treatment EB
(Untreated)
EB
(RA)
Act BTC Act/
BTC
HGF HGF/
Act
Nico Nico/
Act
SB SB/
Act
Min 6
W
Gene ^
PDX1 + + + + + + + + + -H- + +++
PPI + + ++ ++ ++ ++ ++ ++ ++ ++ ++ ++++
Pax6 + ++ ++ ++ ++ +/- ++ + +++ +/- +/- +++
Ihh + +++ +/- ++ +/- ++ +/- ++ ++ ++ +++ +
PP - +/- +/- - - + - - + ++ -H - ++++
Somatostatin + + - + - - + - - - ++ ++++
Table 4.3.3 Summary of the changes in gene expression following secondary 
treatment of RA treated EBs. For each mRNA, the level of expression in untreated 
EBs is used as the reference level. Min6 cells are included for comparison. The 
relative expression levels were determined from densitometric analysis.
There are considerable levels of PDX1 and PPI expression in untreated EBs. Previous 
studies with ES cells have already noted that EB formation alone led to the expression 
of PPI and PDX1 (Gerrish et ah, 2000; Schuldiner et al., 2000; Shiroi et ah, 2002). 
Sodium butyrate had a slight effect on PDX1 expression (compared to RA treated 
EBs), and all secondary treatments resulted in increased PPI mRNA transcripts. There 
were no differences between the individual treatments however. Unfortunately the 
increased PPI gene expression in all the secondary treated EBs does not coincide with 
any other sweeping changes in gene expression. Pax6 expression was increased 
following nicotinamide and activin A treatment, which is similar to results obtained 
using both the RA and RAC monolayers. Pax6 expression was also increased 
following RA treatment of EBs but it was unchanged following RA treatment of F9 
monolayers. These differences highlight the fact that the three different initial 
differentiation steps resulted in three different cell types with heterogeneous responses 
to external stimuli and signals. Similarly the Ihh expression profiles are different.
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These differences in the expression levels o f the different genes make it difficult to 
identify common differentiation mechanisms and pathways.
4.3.4.1 PP and Somatostatin Expression in Secondary Differentiated EBs
PP and somatostatin expression are widespread in treated EBs. It is hard to relate the 
expression profiles of PP and somatostatin to any of the other genes examined, but it 
is possible that the naturally elevated levels of PDX1 in EBs may encourage 
somatostatin expression (Section 4.4.3.2). It is also possible that the curved nature of 
the cells or the cell-to-cell contacts in EBs could alter gene expression profiles 
compared to those of monolayers. Miki (1999), postulated that the curved nature of 
the cells on the outer layer of an EB may have added to the differentiation capacity of 
those cells and that the underlying cells were not as important.
For both PP and somatostatin, the highest levels of expression resulted from the 
combination treatment of sodium butyrate and activin A. In the case of somatostatin, 
sodium butyrate alone was ineffective. So far it has appeared that the expression of 
somatostatin has depended on sodium butyrate only, but it has been shown that the 
presence of activin A resulted in increased levels of acetylated histone H3 (Figure 
3.2.23). There also appeared to be a slight additive effect of activin A on sodium 
butyrate action as shown in Figures 3.2.8 & 3.2.14. Thus, activin A may play a more 
active role in PP and somatostatin gene expression, but it may be specific to certain 
situations e.g., in EB-derived endoderm in our system. In RA-derived endoderm, 
somatostatin was moderately induced by activin, betacellulin and HGF. EBs also 
show widespread expression of both somatostatin and PP. Again this may infer that 
the development of islet hormone cells is linked to VE, i.e. in RAC treated F9 cells 
(predominantly PE) PP and somatostatin expression were restricted to sodium 
butyrate-containing treatments only.
4.3.4.2 Summary of Secondary Treatment of RA Treated EBs
The initial high levels of PPI and PDX1 in untreated EBs and the expression of PP 
and somatostatin following treatments suggest that EB derived endoderm is the best 
cell type (i.e. VE) from which to differentiate pancreatic cells. This is in keeping with
the association of VE markers in stem cells differentiating towards insulin secreting 
cells e.g. as shown by Lumelsky et a l (2001).
4.3.5 Somatostatin and Pancreatic Polypeptide Transcription
The somatostatin gene is positively regulated by cAMP (Montminy et a l , 1996) and 
PDX1 (Schwartz et al., 2000). More significantly, however, it has been shown that the 
somatostatin gene can be regulated by proteins involved in histone methylation. 
Coactivator-associated arganine methyltransferase 1 (CARM1) is a methyl transferase 
that methylates three Arg residues on histone H3. Methylation through the action of 
CARM1 can inhibit CREB (cAMP responsive binding element binding protein) 
signalling in vivo. This results in decreased somatostatin expression (Xu et al., 2001). 
This is a precedent for the involvement of epigenetic-associated control in 
somatostatin gene transcription. There is little known about the biological activities of 
pancreatic polypeptide except that it stimulates secretion of enzymes from the 
exocrine pancreas and relaxes the gall bladder. Its secretion is normally stimulated by 
fasting and hypoglycemia (Kreymann & Bloom, 1991). PP expression is upregulated 
in human pancreatic islet tumors, but studies on the PP gene have not linked this to 
differences in the structure of the gene (Leiter et al, 1985).
The evidence in this thesis points to an epigenetic mechanism for the induction of PP 
and somatostatin gene expression in sodium butyrate-treated F9-derived endoderm- 
like cells. Confirmation of this mechanism would involve further analysis of the 
chromatin itself e.g. by DNase I digestion, i.e., histone acetylation results in 
chromatin modifications that can render it more susceptible to DNase I digestion (see 
Section 5.2.7).
4.3.6 Overall Summary of Secondary Endocrine Differentiation
F9 cells were found to express a number of islet marker genes in their undifferentiated 
state. There are numerous reports in the literature indicating that many genes linked to 
differentiation may be expressed at low level, or in subpopulations of, ES and EC 
cells (e.g Murtomaki et al., 1999). The secondary treatments resulted in altered gene 
expression, especially in the case of developmental transcription factors Pax6 and Ihh.
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However, the effects on the terminal differentiation markers (PPI and PDX1) were 
less obvious. This may infer the cells are adopting lineages other than pancreatic, e.g. 
treatment of ES cell-derived EBs with activin or HGF resulted mostly in mesodermal 
marker expression with only some endodermal differentiation (Schuldiner el ah, 
2000). Directed differentiation of cultured ES cells is not an exact science at this time, 
e.g. studies where ES cells are differentiated via the action of powerful neuronal 
differentiation factors often result in only approximately 50% neurons. This is likely 
to be due to the lack of proper tissue architecture and cell signalling in cultured cells 
(Vogel, 1999).
This study has again addressed the issue of F9 pluripotency, and has revealed that F9 
EC cells can be differentiated towards pancreatic-like cell types with ease in a simple 
two-step differentiation protocol. Comparison of F9-RA, F9-RAC and EB-RA cells 
taken through secondary differentiation does not reveal any obvious patterns and this 
presumably reflects the different nature of the cells generated as a result of stage 1 
differentiation. Examples of the kind of putative mechanisms that can be generated 
from the data obtained here are illustrated in Figure 4.3.2. Table 4.3.4 compares the 
mRNAs that were found to be expressed during the course of this experiment with 
those found in pancreatic islets. It is clear that F9 cells and their differentiated 
progeny do share a number of genes in common with islet cells.
The main similarity between the three endodermal populations generated was the role 
of sodium butyrate in effecting PP and somatostatin expression. As sodium butyrate 
did not have major effects on any of the other genes examined and as it had a similar 
effect in F9-RA, F9-RAC and EB-RA cells, it is suggested that sodium butyrate is 
acting directly on the promoter regions of somatostatin and PP. This is in accordance 
with previous observations on the action of sodium butyrate and with the noted 
increase in acetylated histone H3 levels demonstrated here.
Expansion of the mRNA screening beyond those genes involved in pancreatic 
development may provide a more ‘global’ view regarding the mechanisms of 
differentiation of the agents employed in this study. Thus, such genes as albumin 
(liver), neurofilament (CNS) or enolase (muscle) could be examined (see Section
5.2.1).
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Gene F9 Cell Type Islet Cell Type
PPI A ll P
Glucagon Negative a
Somatostatin Sodium butyrate treated cells & EBs 
(treated and untreated)
8
PP Sodium butyrate treated cells and some 
treated EBs
PP
PDX1 All P& 5
Glucokinase Negative P
GLUT2 Negative P
Pax4 Negative P, 8 & PP
Pax6 A ll (varying levels, nicotinamide and 
nicotinamide with activin A generally 
increased mRNA levels)
a, P, 8 &PP
Ihh A ll (except F9-RAC) P
Shh Negative Negative
T a b l e  4 .3 .4  A comparison of the genes expressed in F9 cells (treated and untreated) 
and in pancreatic islets. In certain cases (e.g. PP), only the treatments resulting in high 
levels of expression are listed.
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4.4 F9 Differentiation Through the use of ‘Cell Trapping’
Cell trapping was initially used as a method for purification of differentiating cells by 
Klug et a l (1996). In this system, differentiated cardiomyocytes were specifically 
purified from ES cells due to their ability to transcribe aminoglycoside 
phosphotransferase (G418 resistance gene), under the control of the a-cardiac myosin 
heavy chain promoter. The resultant cardiomyocyte population was > 99 % pure. The 
use of cell trapping to isolate insulin secreting cells has also been successful (Soria et 
al, 2000), and is described in more detail in Section 1.3.2.1.
In this study, the ability to drive the PDX1 promoter region was employed as the 
purification criterion. Low-level PDX1 expression has already been observed in the 
undifferentiated F9 population (e.g. Figure 3.2.3), and it is known that PDX1 
expression can be increased through RA treatment or through the formation of EBs. 
The critical importance of PDX1 to P cell development and function has already been 
discussed (Section 1.1.3.5.1 & 1.2.1.3.1). Based on this, it was decided that the 
isolation of purified cells expressing PDX1 would be an excellent method of 
investigating the role of PDX1 in developmental biology and its effects on gene 
transcription. The cell trap (CT) derived cells could potentially resemble early islet 
progenitors or the more terminally differentiated cell types expressing PDX1 i.e., p 
cells and certain 8 cells.
4.4.1 Analysis of PGK-TKCAT-Zeo/pBS Demonstrate Its Fitness for use in Cell 
Trapping
The cell trap construct PGK-TKCAT-Zeo/pBS was generated from component 
plasmids available in our laboratory and most critically, the PDX1 tissue specific 
promoter region (PstBstII[Sense]pTKCAT(An)), which was supplied by Prof. Roland 
Stein (Vanderbilt Medical Centre, Tennessee). This region of the PDX1 promoter was 
initially described by Wu et a l (1997). Following construct design in our laboratory, 
the plasmid was generated by Cytomyx (Cambridge, UK) who also carried out 
restriction and orientation analysis of the final construct (outlined in Figure 3.3.1).
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Upon receiving the plasmid, repeat restriction analysis confirmed that the construct 
had been generated in accordance with our specifications.
Prior to any lengthy differentiation experiments the construct had to be validated for 
function, i.e. did the construct specifically confer zeocin resistance to PDX1 
expressing cell lines. Min6 and BHK-21 cells were chosen as positive and negative 
controls respectively as they have been characterised as being PDX1+/+ and PDXl7' 
(Kajimoto et al, 1997; Wu et al, 1997), which was again confirmed prior to these 
experiments (Figure 3.3.3). Following initial transfection of the construct into BHK- 
21 and Min6, initial selection was carried out in zeocin containing medium. 
Cytotoxicity assays had already shown that Min6 cells were more resistant to the 
effects of zeocin than BHK-21, so the Min6-CT cells were exposed to higher levels of 
zeocin. (The increased resistance to zeocin may be as a result of the slower growth 
rate of Min6 cells, since zeocin works best on actively dividing cells (Invitrogen, 
Technical Support Data Sheet)). This selection resulted in the death of all BHK-21, 
BHK-CT and Min6 cells; the Min6-CT wells were, however, seen to contain 
surviving colonies of cells. This is what was expected as the Min6-CTs should have 
been driving the PDX1 promoter and therefore the zeocin resistance gene. The 
transfection efficiency was quite low so there were only a few small surviving 
colonies. To obtain a more representative picture of the functioning construct, stable 
Min6-CT and BHK-CT cells were generated via transfection of PGK-TKCAT- 
Zeo/pBS and selection using the constitutive G418 promoter (Figure 3.3.1). This 
experiment proved difficult as the efficiency of transfection for Min6 was extremely 
low using the liposome based Fugene (Roche). This transfection method was used 
because F9 transfections had been optimised using this system and this was a control 
experiment. Following isolation of stable mixed populations, toxicity assays were 
carried out to test the functioning construct. Min6-CT and BHK-CT were resistant to 
G418 (as expected), but only Min6-CT showed increased zeocin resistance (compared 
to Min6). The level of increased resistance in Min6-CT was lower than expected but 
this may be explained by the initial low transfection efficiency. Following selection, 
small numbers of isolated transfected cells survived. These cells grew very slowly and 
in clumps. To expand this population, the cells needed to be trypsinised regularly to 
separate the clumps and to seed new wells (of 6 well plates). Over a number of weeks 
the cell number had reached a point where the cells could be seeded to flasks for
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generation of stocks and cytotoxicity assays. However it has been shown that PDX1 
expression in Min6 is passage dependent and reduces over time in culture (Figure 
3.4.11(A)). Cell contact is also critical for the correct maintenance of Min6 cells (Dr. 
Per Bendix Jeppesen, personal communication), and this was lost at the initial stages 
of the selection process. The increased resistance in the stable Min6-CT population 
was reproducibly present over a number of experiments and the effect was specific to 
the p cell population, thus the construct was considered fit for use in cell trapping 
differentiating cells.
4.4.2 Differentiated F9-CT Cells Show Resistance to Zeocin
Stable PGK-TKCAT-Zeo/pBS expressing F9-CT cells were generated and selected as 
described (Section 3.3.1.3). These cells were morphologically similar to the parental 
population and exhibited the same rapid proliferation. Thus it was assumed that the 
CT construct did not induce differentiation. F9-CT and EB-CT cells were 
differentiated as indicated in Table 3.3.1 (following initial endodermal differentiation, 
Figure 4.2.1). The treatments were chosen on the basis of two criteria i.e., that they 
had increased PDX1 (see Section 3.2), but also because these treatments had not been 
harsh on the differentiating cells (an important consideration for subsequent antibiotic 
selection). Following the differentiation, antibiotic selection was initiated at 25 jig/ml 
zeocin and increased up to 100 M-g/ml.
Initially there were a number of differentiated zeocin resistant cell lines in culture, but 
several of these gradually ceased proliferation. This post-differentiation senescence 
can be a feature of F9 cells and is usually followed by the outgrowth of differentiation 
resistant cells which are often still present (Alonso et al., 1991). This did not occur 
here due to the nature of cell trap purification i.e., the differentiation-resistant cells did 
not survive selection with zeocin. A few CT-cell lines did continue to proliferate and 
grow however, i.e., they did not terminally differentiate (see Table 3.3.2). It is 
interesting to note that a small proportion of undifferentiated F9-CT cells survived the 
zeocin selection and presumably represents a subpopulation of cells expressing 
enough PDX1 to effectively drive the zeocin resistance gene. F9 cells have previously 
been shown to contain subpopulations within the undifferentiated parental population
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(Murtomaki et al., 1999). The selection of low density clonal populations would also 
have facilitated spontaneous differentiation (Zakany et al., 1984), and due to the 
selective pressure in the environment (100 jag/ml zeocin), this would have favoured 
the differentiation of PDX1 expressing cells.
4.4.2.1 Zeocin Resistant Cell Lines Show Increased Levels of PDX1 mRNA 
Transcripts
RT-PCR analysis demonstrated that the CT cell lines selected in zeocin showed 
increased levels of PDX1 when compared to the parental F9 population (Figures 3.3.5 
& 3.3.5(A)). This was important as it demonstrates again that the PGK-TKCAT- 
Zeo/pBS was functioning correctly, and that the zeocin resistant cells were not as a 
result of spontaneous mutations. The levels of PDX1 in CT cells vary in that in certain 
cases the level of PDX1 is higher than that achieved following treatment alone (F9- 
CT-RA) and in others are similar to the levels of PDX1 following secondary 
differentiation. However in the CT system, the cells grow continuously without the 
presence of the differentiation agents and the levels of PDX1 are always maintained. 
This is critical for F9 cells as it has been shown that continuous culture of F9 cells for 
long periods can lead to enhanced differentiation (Koopman & Cotton, 1987). 
Attempts to generate cells expressing very high levels of PDX1, by increasing the 
level of zeocin in the selection medium from 100 |ug/ml to 200 and 400 jj.g/ml, did not 
result in similarly large increases in PDX1 expression. Presumably the level at which 
the PDX1 promoter was functioning in selected cells was sufficient to endow 
resistance to a wide range of zeocin concentration.
4.4.2.1.1 The Mechanism of Zeocin Resistance in Transfected Mammalian Cell
Lines
Zeocin is the commercial name for phleomycin D l, which is a member of the 
bleomycin family of antibiotics. These antibiotics can bind and break the DNA strand 
at low concentrations. Resistance to zeocin is conferred by expression of the bacterial 
Sh ble gene, and this resistance is a result of reversible binding of Sh ble protein (14 
kDa) to zeocin, thus preventing DNA cleavage (Gatignol et al., 1988). This protein
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binds zeocin with high affinity in a one-to-one ratio, thus conferring effective 
resistance to stably transfected mammalian cells. This implies that a cell expressing 
Sh ble to a level where the cell is resistant to 100 jug/ml, will be resistant to higher 
levels of zeocin also.
4A.2.2 Cell Trap Lines Selected for High Levels of PDX1 Also Show Enhanced 
PPI mRNA Levels
To further characterise the isolated CT cell lines generated, RT-PCR was carried out 
for PPI, and it was found that a number of the CT cell lines showed increased PPI 
gene transcripts. The effects of PDX1 on PPI transcription have been outlined in 
Section 1.2.1.3.1, so an increase in PPI mRNA was expected (Figure 3.3.6). This 
result infers that PDX1 is being activated properly and is crossing the nuclear 
membrane to exert its effect (Macfarlane et al., 1999). This could not be confirmed, 
however, due to difficulties in detecting PDX1 via western blot. PDX1 is unable to 
stimulate transcription of PPI alone and requires the presence of Beta2, which has also 
been confirmed to be expressed in F9 cells (Figure 3.3.24).
4.4.2.3 Cell Lines Expressing High Levels of PDX1 and PPI mRNA do not have 
Detectable Levels of Either Protein
Despite showing overexpression of PDX1 and PPI in certain lines, the CT lines 
derived from F9 cells did not appear to translate equivalent levels of these proteins. 
Immunofluorescence and insulin EIAs did not detect any increases in the protein 
level. This could imply a translational block or translational repression of some kind. 
A similar repression has been seen in this laboratory where the poorly differentiated 
lung cell line DLKP was shown to have transitionally repressed keratin expression. In 
that system, increasing the expression of eIF4E (one of the initial factors to interact 
with RNA in translation initiation) through treatment with BrdU, was able to 
overcome this (Derek Walsh, PhD Thesis, 1999). The CT population may possibly 
contain a translational repressor; however, this would have to be identified. PDX1 has 
a 5’ UTR (untranslated region) of 281 bp, whereas 90% of vertebrate mRNA UTRs 
are between 10 and 200 bp long (Willis, 1999). Growth related 5’ UTRs tend to be
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long with complex structures that impede the progress of the scanning ribosome and 
renders these RNAs suceptible to translational regulation (van der Velden & Thomas,
1999). The PDX1 5’ UTR is moderately GC rich (61% GC) and this can also be 
associated with translational regulation (Willis et al., 1999).
The glucose concentration is another important factor in this system, as already 
shown in the development of insulin secreting cells via cell trapping (Soria et al,
2000). In that study it was found that the insulin content of the ‘trapped’ cells was 
significantly reduced and that there was no GSIS present if the final stage 
differentiation had been carried out at high glucose (30 mM). These cells would still 
have been able to express the PPI gene, however, as otherwise they would not have 
made it through the cell trapping procedure. High glucose levels have a wide range of 
effects on p cells in culture and in vivo including glycogen deposition, increased 
insulin secretion at low glucose, hypertrophy and loss of p cell differentiation (Roche 
et al, 1997; Roche et al, 1998; Jonas et al, 1999). This ‘glucose-effect’ may have 
impaired PPI expression at a protein level.
Observations that PPI levels were increased and that somatostatin can be induced in 
CT cell lines (Section 4.4.3.2), indicate the presence of functional PDX1. It is possible 
that the reason PDX1 protein has not been detected is that, despite overexpression at 
mRNA level compared to the parental F9 cells, that its levels are still too low to detect 
by immunofluorescence. It may, however, be present at levels high enough to exert its 
effect over time.
4.4.3 Differentiation of Selected Cell Trap Lines Does Not Result in Translation 
of PDX1 & PPI
F9-CT-RA and EB-CT-N/A10 were selected for further analysis as the cells 
expressed high levels of PDX1 and PPI mRNA, respectively. It was decided to 
differentiate the cells using a selection of the agents already employed in Section 3.2. 
The agents selected have already been shown to increase PDX1 expression and in the 
case of sodium butyrate to effect 8-like and PP cell-like differentiation, thus it was 
hoped that the increased levels of PDX1 in the starting population would lead to more
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committed p cell differentiation. In both CT cell lines, RA alone increased levels of 
PDX1 and PPI gene expression but did not lead to the expression of these proteins. 
Again, it is possible that the glucose level (25 mM) used to culture F9s and employed 
during differentiation may adversely affect the biosynthesis of insulin.
These cells were not found to have detectable levels of the glucose sensing genes, 
glucokinase and GLUT2, either even though PDX1 expression is reported to 
positively regulate their expression (McKinnon & Docherty, 2001).
4.4.3.1 F9-CT-RA and EB-CT-N/A10 Express PP Upon Treatment with Sodium 
Butyrate
As with the monolayers and EBs described in Section 3.2, PP gene expression was 
noted following treatment with sodium butyrate (and the combination of sodium 
butyrate and activin A). There were no substantial differences in PP expression levels 
between the partially differentiated F9 endoderm and the F9-CT cells, indicating that 
increased PDX1 is not implicated in PP induction. This is additional evidence that 
sodium butyrate is having a direct effect on the gene itself rather than working 
through the transcription factor cascades.
4.4.3.2 F9-CT-RA and EB-CT-N/A10 Constitutively Express Somatostatin
Both of the cell trap cell lines selected were found to express the somatostatin gene 
constitutively. It has already been shown that parental F9 cells do not show any 
somatostatin expression and RA treatment alone did not induce any somatostatin 
mRNA (Section 3.2.2.6). Parental EBs were found to contain low-level somatostatin; 
however, EBs treated with nicotinamide and activin A did not (Section 3.2.4.6) and 
this was the treatment employed in generating the EB-CT-N/A10 cell line (Section
3.3.1.3.1).
Treatment of the cells with sodium butyrate resulted in a slight increase in 
somatostatin gene expression in both CT lines, but the combination of sodium 
butyrate and activin A did not have any such effect. RA treatment of F9-CT-RA
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abolished somatostatin expression but reasons for this are unknown other than this 
treatment may have promoted PE-like differentiation in cells that had already 
differentiated in the presence of RA.
One of the early reports describing PDX1 referred to it as STF1 (somatostatin 
transactivating factor 1), where it was shown to stimulate somatostatin expression in 
islets (Leonard et al., 1993). This was confirmed in embryonic neural cells by 
Schwartz el al, (2000). The promoter region of the somatostatin gene has at least four 
regions with a common TAAT core motif (this motif is also present in the A boxes of 
the PPI gene to which PDX1 binds), these regions are referred to as UE, T l, T2 and 
T3 (Leonard et al., 1993; Schwartz el al., 2000; McKinnon & Docherty, 2001). 
PDX1 preferentially binds to these regions during activation of the somatostatin gene 
(Figure 4.4.1).
TATAA
-900 -750 -600 -450 -300 -150 +1
Figure 4.4.1 The 5’ region of the somatostatin promoter identifying the regions to 
which PDX1 preferentially binds.
Thus the continuously elevated levels of PDX1 in the CT cells lines could have 
facilitated binding of PDX1 to the somatostatin promoter. PDX1 levels are induced in 
untreated EBs (Figure 3.2.15) and somatostatin expression is found to be present after 
10 days culture in normal medium. However there are obviously more factors 
involved in this situation as sodium butyrate treated EBs have high levels of PDX1
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but do not have active somatostatin expression. In the selective pressure based 
environment of the cell trap system, PDX1 expression is continuously favoured, thus 
it appears when PDX1 is continuously present for binding to the somatostatin 
promoter it can effect transcription of that promoter. As already discussed, F9 cells 
cultured for long periods (22-35 days) can differentiate towards multiple lineages 
when carefully differentiated (Koopman & Cotton, 1987). Thus it is suggested that the 
continuous presence of PDX1 in CT cells could, over time, lead to further changes 
within the CT cells, including constitutive expression of somatostatin mRNA. These 
results are in agreement with a recent study where overexpression of PDX1 in an 
islet-derived cell line caused 10-100 fold overexpression of the somatostatin gene 
(Itkin-Ansari et al., 2000).
The induction of somatostatin following cell trapping i.e., via PDX1, is considered to 
be separate to that observed following sodium butyrate treatment as sodium butyrate 
did not enhance PDX1 expression (Section 3.2).
4.4.3.3 An Overview of Cell Trapping of F9 Cells
Cell trapping of F9 resulted in continuously proliferating cell lines that were resistant 
to high levels of zeocin due to their ability to drive the PDX1 promoter. 
Concomitantly, these cells expressed PDX1 at levels equivalent to, and above, those 
obtained during secondary differentiation (Section 3.2). Although the PDX1 protein 
was not detected via immunological methods there was evidence for the presence of 
functional PDX1 protein, through the observed increases in PPI and somatostatin 
mRNA. Prior to these experiments, somatostatin mRNA expression was limited to a 
few treatments e.g. the direct action of sodium butyrate. Thus purification of F9 cells 
continuously expressing PDX1 appears to promote endocrine differentiation of F9 
cells towards 8 cells.
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4.4.4. High Efficiency Transfection of F9 Cells Depends on Transfection System 
and on Differentiation State of the Cells
Prior to studying the effects of transient overexpression of critical transcription factors 
on the differentiation-state and the gene expression profile of F9 cells, protocols had 
to be optimised to increase transfection efficiency. Initial transfection studies with the 
plasmid pCHllO (Section 2.3.4.1) demonstrated extremely low transfection 
efficiencies even when using Fugene (Roche). This is a reported feature in 
undifferentiated F9 cells and represents a transcriptional ‘block’ on viral promoters. 
Previous reports indicated that this could be overcome by differentiation of the cells 
(Darrow et al., 1990; Alonso et al., 1991), and this is clearly shown in Figure 3.3.12. 
In fact, the X-gal staining clearly highlights that it is the morphologically 
differentiated cells that are preferentially expressing the transfected plasmid.
4.4.5 Expression of Critical Transcription Factors Does Not Activate 
Endogenous Genes in F9-RAC Cells
F9 cells have been differentiated by direct transfection in the past e.g. through the 
expression of c-myc antisense and through c-fos overexpression (Griep & Westphal, 
1988; Muller & Wagner, 1988). The overexpression of pancreatic transcription factors 
has also resulted in number of ‘knock-on’ effects in various systems (Table 4.4.1). 
PDX1, Beta2, Ngn3 and Nkx2.2 were all transfected into F9-RAC separately and 
PDX1 was co-transfected with Beta2 andNgn3. As discussed, the effects of PDX1 are 
critically dependent on the presence of Beta2 (Serup et al., 1996; Madsen et al., 1996; 
Harmon et al., 1998), and Ngn3 is known to induce Beta2 expression (Huang el al.,
2000). Despite overexpression of all of the genes at mRNA level and nuclear 
localisation of the transfected proteins, none of the P cell determinants examined were 
induced, in fact in the case o f endogenous PDX1, levels were decreased following 
Beta2 or Nkx2.2 transfection. There appears to be no explanation for this as both of 
these factors are indicated to act downstream of PDX1 in pancreatic development 
(Naya et al., 1997; Sussel et al., 1998). Immunofluroescence analysis for PPI 
confirmed that it was not ‘switched-on’ as a result of the transient transfections.
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In order to increase transfection efficiency, the F9 cells were partially differentiated 
with RA and db cAMP prior to transfection, thus pushing the cells towards a 
relatively homogenous parietal fate. This may limit the differentiation potential of the 
cells and thus the effects that the transcription factors may have if the islets were 
found to be more associated with VE as indicated in some recent ES cell work 
(Schuldiner et a l, 2000; Lumelsky et al., 2001).
Cell Line Gene Transfected Gene 
Expressed/1 nduced
Reference
ocTCl.6 PDX1 IAPP Watada et al. (1996)
Trm6 PDX1 Somatostatin Itkin-Ansari et al.
(2000)
IEC-1 PDX1 IAPP, Glucokinase 
&Nkx6.1
Yoshida et al. (2002)
Capan 1 PDX1 Insulin Zhou et al. (2002)
AR42J Ngn3 PP Zhang et al. (2001)
AR42J Nkx2.2 PP Palgi et al. (2000)
Table 4.4.1 Transcription Factor Expression Studies Resulting in ‘Knock-on’ Gene 
Induction.
4.4.5.1 Previous Studies Where Transient Overexpression Studies did not Result 
in Knock-On Effects on Endogenous Genes
There have been a number of reported cases whereby transcription factor expression 
did not result in the desired knock-on effects, e.g., nuclear expression of PDX1 had no 
effect on insulin expression in aTC1.9 cells (Serup et al., 1995), while expression of 
PDX-1, isl-1 and Nkx6.1 (separately, or in combination) had no effects on gene 
expression in AR42J-B13 cells (Palgi et al., 2000). It is not always apparent why the 
overexpression of transcription factors (especially PDX1) can elicit such large 
changes in one cell line but not in another. In the case of PDX1, it is known that it can 
associate with PBXlb and MRG1 homeodomain proteins to enhance transcription of 
the pancreatic Elastase I gene in acinar cells (Swift et al, 1998). This may explain its
291
f a i lu r e  to  in d u c e  P P I  g e n e  t r a n s c r ip t io n  in  A R 4 2 J - B 1 3  c e lls ,  i .e .  i f  P D X 1  h a s  a lr e a d y  
b e e n  s e q u e s te re d  b y  o th e r  h o m e o d o m a in -b in d in g  p r o te in s  ( P a lg i  et al., 2 0 0 0 ) .  T h u s  i t  
is  p o s s ib le  th a t  c o m p le x  fo r m a t io n  b e tw e e n  tra n s fe c te d  h o m e o d o m a in  p ro te in s  a n d  
n a t iv e  p r o te in s  c o u ld  a c t  as  t r a n s c r ip t io n a l re p re s s o rs  in  c e r ta in  s y s te m s .
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4.5 Continuous Culture of Min6 Cells Results in Loss of Specialised Function
The continuous culture of a number of P cell lines leads to loss of specialised function 
i.e. insulin synthesis, storage and secretion in response to glucose. Cell lines such as 
HIT-T15, RIN-38 and PTC gradually lose their p cell phenotype through negative 
effects involving insulin gene transcription factors, such as PDX1, and unfavourable 
hexokinase/glucokinase ratios (Harmon et al, 1998; Clark el al, 1990; Knaack et al, 
1994). The Min6 cell line is considered an excellent model for functional P cells in 
culture (due to its preserved GSIS), but these cells also lose insulin processing ability 
and functional GSIS over time. Loss of function in Min6 has been seen to be 
accompanied by a decrease in the insulin processing enzyme PC2, and an increase in 
furin; these changes were considered indicative of a de-differentiating system (Kayo 
et al, 1996). It is also possible that the observed loss o f differentiation in Min6 cells 
may be due to the overgrowth of a more rapidly proliferating, less differentiated, 
population of cells. Such poorly differentiated subpopulations have been previously 
identified in Min6 (Minami et al, 2000) and the overgrowth of differentiated F9 
populations with less differentiated ‘differentiation-resistant’ cells has also been 
described (Alonso et al, 1991).
Min6 cells in culture are also continuously growing in the presence of 
supraphysiological levels of glucose (physiological glucose levels are around 5-6 mM, 
Min6 cells grow in 25 mM glucose). Continual exposure to high glucose has wide 
ranging effects on p cells, including high rates of insulin secretion at low glucose, 
glycogen deposition and increased proliferation (Roche et al., 1997; Roche et al.,
1998). These changes are correlated with a number of changes in the expression of 
genes involved with differentiation, glucose regulation, insulin processing, 
proliferation and the transcription of islet specific hormones (Roche et al., 1997; Kayo 
et al, 1996; Jonas et al., 1999; Itkin-Ansari et al., 2000).
This system has the potential to highlight crucial pathways/systems in p cell 
development. It is, however, also crucial to identity methods of preserving p cell 
function while in culture for possible future applications involving cultured 
replacement tissue. To investigate this, Min6 cells were studied with respect to their
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GSIS capability, and their proliferation rates. Upon arrival at the proposed ‘less 
differentiated state’ (judged by the loss of GSIS), DNA array analysis and RT-PCR 
were carried out to compare the gene expression profiles of fully functional Min6 
cells and ‘de-differentiated’ Min6 cells.
4.5.1 Continuous Culture Results in Morphological and Growth Pattern Changes 
in Min6 Cells
Low passage Min6 cells are seen to grow in three dimensional clumps; i.e. they do not 
form the monolayers typical of many cultured cell types (this growth pattern 
facilitates cell-to-cell contact and gap junction formation). GSIS has been shown to be 
severely disrupted when Min6 cells are unable to contact one another and form gap 
junctions (Linzel el al., 1988; Meda el al., 1991; Vozzi el al, 1995). At higher 
passages, however, there is a noticeable change in Min6 morphology, the cells are 
seen to be smaller, and exhibit a lot of pointed processes spreading outwards in all 
directions (Figure 3.4.1). Most significantly, however, the cells do not form clumps 
and instead adopt the more conventional monolayer growth pattern. Both of these 
changes are significant for (3 cell function in vitro i.e., the loss of cell contact (as 
discussed) and smaller p cells show reduced levels of insulin secretion and GSIS 
(Giordano et al., 1993). Even though the clustered nature of low passage Min6 cells 
often conceals the number of cells present in a flask, it is clear that there are more 
cells in the higher passage flask, thus suggesting changes in the proliferation rate.
In Section 3.4.2 it can be clearly seen that the high passage Min6 cells are 
proliferating at almost double the rate of the lower passage cells. Towards the end of 
the growth curve of low passage Min6 there is a plateau that is representative of the 3- 
D clumps having reached their maximal size; however, the higher passage cells can 
continue to grow until the entire tissue culture surface is coated. This is the opposite 
of what occurs upon differentiation of F9 cells, i.e. lengthening of the G1 phase and a 
reduction in the proliferative capacity of the cells (Linder et al. 1981; Kurki et al., 
1989), and following the BrdU mediated differentiation of DLKP (McBride et al., 
1999). Thus based on morphology and proliferation, Min6 cells are seen to undergo
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changes that are the opposite o f what occurs in two differentiating species previously 
studied in this laboratory.
High passage Min6 cells were also found to express considerable amounts of alkaline 
phosphatase compared to their low passage counterparts. Again this is the opposite of 
what occurs upon differentiation of F9 cells where the reduction in alkaline 
phosphatase activity has been correlated directly to increasing differentiation (Moore 
et al., 1986). These observations tend to confirm that high passage Min6 cells are less 
differentiated than their lower passage counterparts.
4.5.2 Min6 Cells Lose Functional GSIS After 40 Passages in Culture
Consistent with other reports, Min6 cells were found to have lost their functional 
GSIS after 40 passages in culture (Miyazaki et al., 1990; Ishihara et al, 1995; Kayo 
et al, 1996). It is also interesting to note the increased secretion of insulin at low 
glucose levels, this is particularly noticeable at 0 mM glucose. In cells with regulated 
storage and processing pathways such as heptocytes, mature insulin is stored until 
required while some proinsulin is constitutively secreted (Simpson et al, 1995). Thus 
with increasing passage number and progressive loss of PC2 expression (Kayo et al,
1996), increased amounts of unprocessed proinsulin would accumulate for 
constitutive release. As the EIA kit employed in determination of immunoreactive 
insulin (IRI) in these experiments detects both proinsulin and mature insulin (Section
2.5.2.3), the increase in secretion at low glucose may be attributable at least in part to 
increased proinsulin levels. It is also possible that the high passage Min6 cells were 
not able to store insulin as efficiently in the granules. In the de-differentiating Min6 
cells identified by Kayo et al. (1996), chromogranin A was also reduced (this protein 
is associated with the secretory granules of neuroendocrine cells). The most likely 
explanation for the increase in constitutive secretion is a combination of both 
ineffective processing and depleted storage granules (processing and storage are 
inextricably linked). Human islets have also been seen to preferentially secrete 
proinsulin and show a marked decrease in storage granules when cultured at high 
glucose levels for lengthy periods (Bjorklund & Grill, 1999). This ties in with 
observations discussed later regarding the down-regulation of crucial granule-related 
genes in high passage Min6 cells (Section 4.5.3.2.4).
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4.5.3 Comparative DNA Array Analysis of Low and High Passage Min6 Cells
To more closely examine the differences between the GSIS-capable low passage 
Min6 cells and the higher passage cells, and to endeavour to explain the phenotypic 
changes occurring, DNA array analysis was carried out. The array chosen was the 
Atlas1M Mouse 1.2 array (Clontech), which is a general array with 1,173 genes 
covering a number of categories and functions.
4.5.3.1 An Introduction to DNA Arrays
Microarray experiments can be used to compare the levels of gene expression on a 
large scale that is not possible with conventional RT-PCR or RNase protection assays. 
The rate at which genomes are being sequenced is increasing all the time and modern 
drug and therapeutic-target discovery is operated on a high-throughput basis.
Microarrays consist of cDNA or oligodeoxynucleotides (oligos) immobilised on to a 
support such as nylon, plastic or glass. These oligos represent specific regions of 
particular genes. Atlas™ arrays (Clontech) have cDNAs of 200-600 bp to minimise 
non-specific hybridisation in their array experiments. The arrays themselves can be of 
low complexity (100-1000 probes), to the very high complexity arrays with 100,000 
probes (Cuzin, 2001). To carry out this analysis, RNA (preferably pure poly (A)+ 
RNA) must be purified from the cells or tissues to be examined. This poly (A)+ RNA 
is then converted into a labelled cDNA probe via the incorporation of a labelled 
nucleotide during the reverse transcriptase (RT) reaction. In the array experiment 
carried out in Section 3.4, the probes were labelled via the incorporation of P33 
labelled dATP (Amarsham). P33 was preferentially chosen due to the specificity of its 
signal. The probes are then hybridised to the arrays and the expression levels 
examined by the appropriate detection method e.g. X-ray film, phosphoimager or 
fluorescence reader. Analysis of the arrays can be carried out using a software 
package such as Atlaslmage™ (Clontech), and these can be used to compare a 
number of experiments to highlight the differentially expressed genes.
There are numerous literature examples of research involving array analysis of a 
number of related samples e.g. a series of tumors. This is done to determine common
features and to compare gene expression profiles with clinical outcomes. This 
information can be used to identify a related series of changes e.g. novel pathways 
which can then be investigated via more specific means of analysis (RT-PCR, protein 
etc). This type of research has numerous applications for diagnosis of diseases.
This technology is also finding a number of applications in the field of p cell research 
e.g. to demonstrate the glucose regulation of secretory and metabolic genes (Webb et 
al., 2000) or the effect of growth arrest on cultured P cells (Zimmer et at, 1999). This 
has led to the manufacture of a specific diabetes microarray, the PancChip (Scearce et 
at, 2002).
4.5.3.2 High Passage Min6 Cells Show Large Differences in Their Gene 
Expression Profile
The results obtained in Section 3.4.5 indicate that analysis using the Atlas™ 1.2 array 
is a reproducible and robust system. Of the 80 shared gene changes (i.e. upregulated 
and downregulated) detected in two separate experiments using different membranes 
and RNA samples, 85% of these were direct repeats. The results that were found to be 
contradictory (e.g. a gene that was found to be upregulated in high passage Min6 in 
the first experiment was found to be downregulated in the second experiment) 
between the repeat experiments, were all stress/apoptosis related. This may reflect a 
variation in harvesting conditions, which could effect rapid changes in the levels of 
those genes. 1.5 or greater fold changes in expression levels were chosen as a cut-off 
point for tolerance. The genes obtained were classified under a number of headings 
(Section 3.4.5.2), however most genes may be listed under several headings e.g., 
PDX1 is a transcription factor, it is part of the gluco-regulatory machinery of the P 
cell and it is a developmental determinant. The gene designations used here follow 
those outlined in the Atlas™ array gene list, and this convention is used to maintain 
consistency throughout.
From Figure 3.4.7 it can be seen that the main differences between the low and high 
passage Min6 cells are that a large number of cell cycle genes are up-regulated while 
genes for hormones, specialised peptides and the genes involved in processing them
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are down regulated. In fact upon closer examination of all the up-regulated genes, 
23% of them are associated with proliferation or proliferating cells while 29% of the 
down regulated genes are involved in protein secretion and processing. These 
observations tie-in directly with the observations already made and tend to confirm 
that the loss of p cell phenotype is as a result of de-differentiation. The possible 
mechanisms of de-differentiation are discussed in Section 4.5.4.
Certain clusters of genes affected illustrate that high passage Min6 cells are less 
differentiated than low passage Min6 cells and are summarised below.
4.5.3.2.1 Min6 Cells Show Increased Expression of Primitive-Cell Markers at 
High Passage
The polycomb group gene EED is found to be upregulated in high passage Min6 cells. 
This gene is required in early mouse organogenesis (Morin-Kensicki et a l, 2001). The 
EED gene product operates through the formation of multimeric protein complexes 
e.g., EED interacts with YY1 to induce neurogenesis in Xenopus (Satijn et al., 2001). 
The groucho gene related protein (Grg) is also upregulated in high passage Min6 
cells. This gene is implicated in mouse development, especially that of the 
mesenchyme and the developing nervous system (Mallo et al., 1993; Leon & Lobe, 
1997). p55CDC is not an embryonic marker, as such, but this protein has been 
identified in all exponentially growing mammalian cell lines. Levels of p55CDC are 
seen to disappear upon induction of differentiation as cells fall out of the cell cycle 
(Weinstein et al., 1994), and significantly, it is only found in high passage Min6 cells. 
These findings all indicate that the high passage Min6 cells have more in common 
with primitive developing cells than fully differentiated cells.
4.5.3.2.2 Continuous Passage in Glucose Induces GAPDH Expression
The p cell is a uniquely fuel-sensitive cell type due to its GSIS function, thus it is not 
surprising that there would be changes in the genes involved in the glucose 
metabolism following sustained culture in high glucose. Increased expression of these 
genes is associated with amplified glucose metabolism, which has been linked to
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increased (3 cell proliferation and insulin release at low glucose concentrations (Roche 
et a l, 1997). Glucose consumption and metabolism were significantly increased in a 
non-glucose responsive sub-clone of Min6 (m l4) compared to the glucose responsive 
clone m9 (Minami et al, 2000). The observed increase in GAPDH in the high passage 
Min6 cells is not surprising, as it ties in perfectly with the other observed changes i.e., 
the increased insulin secretion at low glucose and the rapid proliferation. That is, rapid 
proliferation requires increased metabolism and proliferation is negatively associated 
with the expression of proteins in the insulin secretory pathway (Zimmer et a l, 1999).
4.5.3.2.2.1 Implications for Changes in Housekeeping Genes in Normalization of 
Expression
The increase in GAPDH had implications for later analysis as it is considered a 
‘housekeeping gene’ and is therefore used as an internal control in RT-PCR to assess 
RNA quality and quantity. As a result of the observed increase in GAPDH with high 
passage, P actin was used in RT-PCR as the internal control when comparing low and 
high passage Min6 cells (its levels were found to be unchanged at high passage). 
Normalization of the arrays was not based on housekeeping genes as even these genes 
are susceptible to change given the correct stimulus. This method of normalisation is 
only recommended when a very large number of differentially expressed genes are 
expected e.g., when comparing divergent tissues. Global normalisation is the method 
of choice when examining similar tissues. The ‘sum method’ was automatically 
applied in the software used for these studies (Atlaslmage™) and involved the 
calculation of all the signals in excess o f background on both arrays to calculate a 
normalization coefficient based on :
n
^(In ten sity  -  Background)i 
Normalization Coefficient = ----------------------------------
^  (Intensity -  Background) j
j=i
i = Genes on Array 1 
j = Genes on Array 2 
n = Number of genes on array.
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4 .5 .3 .2 .3  C o n t in u o u s  C u l t u r e  R e s u lts  in  t h e  D o w n  R e g u la t io n  o f  D i f f e r e n t i a t i o n  
R e la t e d  G e n e s
A number of the genes downregulated in the high passage Min6 cells are markers of 
differentiated islet cells (e.g. pre pro glucagon and PC2) and their down regulation is 
indicative of de-differentiation. These genes are discussed separately below.
Pax6 and Delta-like homologue 1 (DLK1) were both found to be downregulated in the 
high passage Min6 cells. DLK is a transmembrane protein and belongs to the EGF- 
like homeotic protein family which also includes the Notch receptor and Notch 
ligands, such as Delta (Laborda, 2000). As discussed already, Notch signalling is very 
important in specifying (3 cell fate in the developing pancreas (Apelqvist et a l, 1999; 
Section 1.1.3.5.2), and acts through Ngn3. Ngn3 causes increased Delta expression on 
the cell surfaces which can inhibit neighbouring c e lls  from adopting an endocrine fate 
(Section 1.1.3.5.2). Ngn3'/_ mutants fail to form any endocrine cells and also do not 
express many important transcription factors, including Pax6 (Gradwohl et al., 2000). 
DLK appears to have a more positive role than Delta in endocrine differentiation and 
is preferentially localised to insulin secreting cells in adults (Carlsson, et a l , 1997). It 
is also noteworthy that, upon comparison of two clones of Min6 with differing GSIS 
capabilities, DLK was more highly expressed in the cell line with the functional GSIS 
(Minami el a l, 2000). That result and the observations made here tend to implicate 
this gene product in regulated insulin secretion also. The importance of Pax6 in the 
developing islet has been covered in Section 1.1.3.5.5 and outlines the role of Pax6 in 
islet structure and in a  cell determination. However Pax6 has also been implicated in 
regulating PDX1 expression in p c e lls  through interaction with HNF 3p (Foxa 2) 
(Samaras et al, 2002). Thus, this may be at least part of the reason why PDX1 levels 
were reduced in the high passage Min6 cells (Figure 3.4.11(A)). (An oligo specific for 
PDX1 was represented on the array but it was not detected despite being shown to be 
present in large quantities by RT-PCR, this is discussed later (Section 4.5.3.2.6)). 
Pax6 can directly bind the regulatory regions of the glucagon, insulin and 
somatostatin genes and is known to transactivate both insulin and glucagon (Sander et 
al, 1997), which is interesting as levels glucagon and somatostatin are found to be 
reduced in high passage Min6 cells (Sections 3.4.5.4, 3.4.5.5 & 3.4.6.6). It should be
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mentioned, however, that Pax6 levels were not found to be downregulated using RT- 
PCR analysis (Figure 3.4.9). This and other observations serve to highlight the 
differences between RT-PCR and arrays (Section 4.5.3.2.6).
4.5.3.2.3.1 Ornithine Decarboxylase is Downregulated in High Passage Min6, 
Impaired Polyamine Synthesis?
Nicotinamide has been shown to have inductive effects on insulin expression in 
cultured islets. It aids in maintaining (3 cell function in vitro and causes differentiation 
of precursor cells to insulin secreting cells (Sjoholm et al, 1994; Otonkoski et al,
1999). This agreed with previous findings linking polyamines to (3 cell function 
(Sjoholm et a l, 1990; Welsh & Sjoholm, 1988). Ornithine decarboxylase (ODC) is a 
critical rate-limiting enzyme in polyamine synthesis (Shantz & Pegg, 1999). 
Inhibition of ODC can prevent polyamine-mediated p cell replication (Sjoholm et al, 
1994). High passage Min6 cells show reduced ODC levels (Section 3.4.5.4), 
therefore, if ODC is so important for maintaining P cell function, then it is not 
surprising to find that it is downregulated in p cells which have lost a number of their 
specialised functions. This could indicate a target for studies to prevent loss of 
function of P cells in culture i.e., to devise methods to maintain ODC levels in 
cultured Min6 cells.
4.5.3.2.4 High Passage Min6 Cells Exhibit Differential Gene Expression in the 
Protein Secretion and Processing Pathway
One of the first indicators that the Min6 population is approaching a de-differentiated 
state is that the cells demonstrate impaired regulated insulin secretion. This 
observation is confirmed by a number of changes in genes involved in the storage and 
processing of insulin. The regulated pathway of secretion is outlined in Section
1.2.4.1 however in summary: reduced unfolded preproinsulin is synthesised in the 
rough endoplasmic reticulum (RER) where it is converted to proinsulin and packaged 
in microvesicles. These are transported to the Golgi apparatus where the insulin is 
processed while the secretory granule matures. The secretory granules are then stored
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until glucose signals their translocation to the membrane to release their insulin, 
which is facilitated by microtubules and requires Ca2+ signalling (Howell, 1991).
A number of the secretion/processing-related genes found to be downregulated in high 
passage Min6 cells are discussed below in their approximate chronological order as 
they occur in the secretion and processing pathway.
Nucleobindin is a resident protein within the Golgi apparatus where it is involved in 
maintaining Ca2+ homeostasis (Lin et al., 1998). Ca2+ levels are critical in endocrine 
cells and Ca2+ ‘spikes’ or oscillations facilitate secretory responses upon stimulation.
These ‘spikes’ can be propagated to neighbouring cells to allow a co-ordinated
2+
response to stimuli (Kanno, 1998), however in periods of non-stimulation, the Ca 
levels need to be maintained in a steady state. Calcium signalling in response to 
stimuli is unique in P cells as nutrients increase Ca2+ levels. One of the methods 
through which this increase is mediated is through the proteins involved in Ca2+ 
homeostasis (Soria et a l, 2000). Therefore the down regulation of nucleobindin can 
be linked to the disruptions in regulated secretion in Min6 cells.
RAB2 is also downregulated and its role in cells involves the trafficking of vesicles 
from the RER to the Golgi apparatus (Tisdale & Bach, 1996; Cheung et al, 2002).
A number of proteins associated with the secretory granules are downregulated in 
high passage Min6 cells including secretogranin II, 7B2 neuroendocrine protein 
(secretogranin V), chromogranin B and PC2. Of these, PC2 is possibly the most 
important as it is one of the pair of enzymes that process proinsulin to mature insulin 
within the granule (Bennett et al, 1992). PC2 requires secretogranin V in the granule 
as a chaperone protein (Sarac et al., 2002). This is similar to the observation by Kayo 
et al., (1996), i.e., where PC2 was reported to be sensitive to passage number. Kayo et 
al. (1996) also reported that PCI decreased only slightly, which was also found in this 
study using the Atlas™ 1.2 array (it was down regulated by a factor o f -1.1, which 
was considered unchanged).
302
Other secretion-associated genes found to be downregulated using the Atlas™ array 
include P-neoendorphin-dynorphin which has been implicated in the regulation of 
insulin secretion (Josefsen et a l, 1998), cholecystokinin which in involved in 
enhancing post prandial insulin secretion (Hardikar et al, 2002), and CAB45 which 
localises to the secretory pathways of mammalian cells (Honoré & Vorum, 2000).
The increased proliferation in high passage Min6 cells can also be linked to the 
negative effects on the secretion and processing of insulin. In a situation where 
cultured P cells could be held in a quiescent phase through a ‘tet-off-system of 
controlling proliferation (the p cell line was conditionally transformed by the SV40 T 
antigen (Tag) under the control of the regulatory elements of the bacterial tetracycline 
(tet) operon), administration of tetracycline to arrest growth caused induction of the 
secretory granule genes, chromogranin A and synaptogyrin 3, along with insulin 
(Zimmer et a l, 1999). This is probably due to the fact that a non-proliferating situation 
is similar to the in vivo P cell condition.
4.5.3.2.S Hormone Expression is Decreased in Serially Passaged Min6 Cells
The preproglucagon gene expression was reduced in both array and RT-PCR analysis 
whereas somatostatin expression was found to be eradicated based on RT-PCR alone. 
PPI or PP mRNA expression levels were not substantially altered in the high passage 
Min6 cells. PDX1 is implicated in the regulation o f PPI and somatostatin, however it 
has been shown to continue to transactivate the PPI gene even following an 86 % 
reduction through antisense expression (Kajimoto et al, 1997). Therefore, even 
though the reduction in PDX1 is substantial in high passage Min6 cells (Figure 
3.4.11(A)), there is still PDX1 present and thus the PPI gene can be transcribed as 
normal. The somatostatin gene has been shown to be induced in non-hormone 
expressing islet cells via overexpression of PDX1 (Itkin-Ansari et al, 2000), and it is 
possible that the endogenous somatostatin expression noted in Min6 cells is due to the 
high PDX1 levels present, therefore reducing PDX1 could adversely affect 
somatostatin transcription in Min6. As noted earlier, Pax6 is implicated in the 
expression of insulin, somatostatin and glucagon (Sander et al, 1997), and this was 
also shown to be downregulated on the Atlas™ array. The downregulation of
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specialised hormones in Min6 cells is symptomatic of a de-differentiating system and, 
as such, fit in with the other observations leading to this conclusion.
4.5.3.2.6 Confirmation of Array Results by RT-PCR Highlights Differences 
Between the Two Techniques
To determine if the array results could be considered real and to validate the results 
obtained, confirmatory RT-PCR was carried out on the same RNA samples as had 
been used in the arrays (where primers were available). On comparing the RT-PCR 
results with the array it can be seen that, in the examples chosen (Section 3.4.5.5), 
semi-quantitative RT-PCR does not appear to be as sensitive as the array, and the 
likelihood of a similar result in the RT-PCR is enhanced by a large change in gene 
expression (as indicated by the array). This leads to other somewhat contradictory 
observations regarding RT-PCR and arrays however, in that certain genes that were 
represented on the array, were not detected at all, even when found to be abundantly 
present within the cells when amplified by RT-PCR e.g., PDX1. When using this 
array a P33 label was employed; this is not as ‘hot’ as a P32 label and therefore is not as 
sensitive. P33 however is far less prone to signal-bleed or non-specific binding, i.e. the 
signal from P32 can give a powerful signal which can spread out and cover other loci 
and mask the expression of other genes. The reasons for these differences between the 
array and RT-PCR are unknown. Kudoh el ah (2000) reported only 58% success in 
validation of array results by RT-PCR and attributed this to various factors such as 
sequence content and to unknown PCR related factors.
4.5.3.2.7 RT-PCR Analysis of Other |3 Cell Genes Reveals the Capacity for 
Increased Glucose Transport in High Passage Min6 Cells
RT-PCR analysis of other Min6 genes was carried out to examine the expression of 
genes that were not represented on the array or that were present but were not 
detected. As mentioned, PDX1 levels were found to be > 2 fold lower in the high 
passage cells than in the lower passage Min6 cells. This has previously been observed 
in cultured insulinoma cells before e.g. HIT-T15 cells continuously cultured in high 
glucose show reduced PDX1 levels (Olson et ah, 1995). As PDX1 is considered to be
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one of the p cells most defining features, it is clear that the loss of this gene marks the 
transition of high passage Min6 cells towards another less defined cell-type.
The lack of glucose sensing ability in certain cell lines is associated with the absence 
of GLUT2 or glucokinase expression, however glucokinase mRNA levels were 
similar in low and high passage Min6 cells while GLUT2 mRNA was appreciably 
increased in high passage cells. GLUT2 has been characterised as a glucose sensitive 
gene (Waeber et a i, 1994), and chronic elevation of glucose has been shown to 
increase GLUT2 transcript levels in INS 1 cells while glucokinase mRNA levels were 
unaffected (Roche et ah, 1997). As already discussed, the metabolism of the high 
passage cells appears to be increased when compared to the low passage Min6 cells 
(as evidenced by the increase in GAPDH), thus the increase in GLUT2 should 
facilitate the increased requirement for glucose which fuels the increased metabolic 
and proliferation rates. Other important P cell transcription factors, i.e. Beta2 and Isll, 
were unaffected by the continuous culture. The effects on insulin and the other 
hormone levels has already been discussed. A number of other genes critical for 
pancreatic function and differentiation state were not included on this array e.g. Indian 
hedgehog (Ihh), however this array was chosen as it was general enough to afford an 
overall view of all the changes taking place in the cell with increasing passage 
number.
4.5.4 Continuous Culture of Min6 Cells Leads to a Number of Phenotypic and 
Genotypic Changes Consistent With De-Differentiation
In summary, the serial passage of Min6 cells led to initial observable changes in 
morphology, growth and insulin secretion. These were accompanied by the increased 
activity of markers typical of undifferentiated cells. The increases in growth were 
correlated with increases in genes required for glucose transport and metabolism. The 
altered secretion was shown to be associated with the down regulation of a number of 
critical features o f the regulated secretion pathway. The reduction of terminal 
differentiation markers such as PDX1 and the hormones glucagon and somatostatin all 
additively confirm that these cells are de-differentiating while continuously cultured 
in the presence of supraphysiological levels of glucose. The data presented here does
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not indicate whether the de-differentiated population resulted from the overgrowth of 
the Min6 culture with rapidly proliferating, undifferentiated cells or if the de- 
differentiation was as a result of gradual changes in the gene expression profile of the 
cells leading to a less specialised cell type. Previous studies in the literature show 
many of the changes observed in high passage Min6 cells can occur upon culture of 
islets or (3 cells in high levels of glucose and that these changes can occur within 2 
days - 1 week (Roche et al., 1997; Roche et al., 1998; Jonas et al, 1999). This is not 
enough time for a population of cells to be completely overgrown by a subpopulation 
of undifferentiated cells, therefore there is a definite possibility that the de- 
differentiation observed in Min6 cells could be due to a number of gradual changes in 
the levels of critical genes in the population as a whole. These possible mechanisms 
are illustrated in Figure 4.4.1.
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Figure 4.4.1 Possible mechanisms of Min6 ‘ de-differentation ’. (A) Continuous 
passaging in conditions of elevated glucose result in gradual alterations in the gene 
expression profile such that the cells regress to a less specialised phenotype. (B) 
Subpopulations of poorly differentiated cells within the Min6 cell population 
gradually take over the population, with time in culture, until a homogenous 
population of these cells results.
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4.6 In Vitro Generation of Insulin Secreting Cells via Direct Gene Transfer
Cultured cell lines expressing human insulin have been considered for somatic cell 
therapy for diabetes. The techniques to express proteins of choice in cells are 
standardised and generally very efficient. The choice of cell line however is a critical 
factor. Ideally the cell line should be capable of storing and secreting protein in a 
regulated fashion and should also be capable of sensing glucose over the entire 
physiological range. The only cell line that carries out all of these functions however 
is the p cell; thus the goal of cell engineering for p cell replacement is to generate 
cells genetically modified so as to resemble a functional P cell, e.g. through the co­
expression of insulin and the glucose sensing machinery. Aside from all the 
considerations regarding the mechanics of GSIS, the most important point regarding a 
modified cell for therapeutic use is that it must be considered safe to implant in to 
humans (in a suitably encapsulated form). Some of the more P cell-like lines secrete 
other proteins which might cause problems if implanted to humans e.g. the release of 
ACTH from AtT20 cells. BHK-21 cells have been used in a human clinical trial and, 
while the effect of the released protein did not significantly alter the disease state, the 
trial was of interest because the cells were able to grow and survive while secreting 
their product, without endangering the patient (Aebischer et al., 1996). Thus on the 
basis of clinical usefulness, BHK-21 cells were considered to be an appropriate choice 
for an insulin delivery vehicle.
4.6.1 BHK-PPI-C16 Constitutively Release Proinsulin in an Unregulated Fashion
Following transfection of the human insulin gene into BHK-21 cells and 
characterisation of the 20 derived cell lines, BHK-PPI-C16 was isolated for further 
work. Expression of the gene was confirmed using RT-PCR, immunocytochemistry 
and EIA. Immunocytochemical analysis indicated that the proinsulin was present 
throughout the cytoplasm and there did not appear to be any storage granules present. 
Fibroblasts are not characterised as having these granules (Kelly, 1985), however 
upon transfection of insulin in to the HEP G2 cell line it was found that the new HEP 
G2ins cells were able to store insulin in membrane bound vesicles that were not 
present in the parental population (Simpson et al., 1995). Characterisation of the
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proinsulin synthesised by BHK-PPI-C16 revealed that it was entirely proinsulin and 
that it was being released constitutively, i.e. that no processing was taking place. 
Previous studies with fibroblasts have also identified this phenomenon (Selden et al, 
1987; Kawakami et al, 1992; Taniguchi et al, 1997; O’ Driscoll el al, 2002). 
Constitutive secretion is not typically associated with proprotein processing; however, 
rat hepatoma cells (FAO cells) were shown to process insulin (albeit inefficiently), 
while constitutively secreting it (Vollenweider et al, 1992). The steady release of the 
proinsulin per hour accounted for approximately 34% of the cellular insulin within 
BHK-PPI-C16, which is similar to findings by O’ Driscoll et a l (2002). This release 
rate is due to the continuous transport of proinsulin from the trans golgi network 
(TGN) to the plasma membrane, a process which takes approximately 10 minutes 
(Kelly, 1985; Halban & Irmanger, 1994). The cellular proinsulin content presumably 
represents the proinsulin that is ‘in-transit’ to the plasma membrane and the steady- 
state level of intracellular proinsulin over 24 hours signifies the cells ‘holding 
capacity’ rather than storage.
BHK-PPI-C16 cells were unable to regulate the secretion of proinsulin to 
environmental glucose levels despite expressing both components of the glucose 
sensor, i.e., GLUT2 and glucokinase. The observation that the cells did not modulate 
their proinsulin secretion in the subphysiological range of glucose concentrations 
(Figure 3.5.6), indicated that the lack of GSIS is not as a result of the unfavourable 
GLUT1/GLUT2 or hexokinase/glucokinase ratios seen in Min7 and AT20ins 
(Ishihara, 1993; Davies et a l, 1998). However, confirmation of this was sought 
through the overexpression of both GLUT2 and glucokinase in BHK-PPI-C16.
4.6.2 Overexpression of the Glucose Sensing Genes Does Not Confer Glucose 
Sensitivity Over the Physiological Range in BHK-PPI-C16
Glucokinase and a combination of glucokinase and GLUT2 were transfected into 
BHK-PPI-C16 and the overexpression of both at the mRNA level was confirmed by 
RT-PCR. Immunocytochemical analysis revealed the existence of intensely stained 
cells within the transfected populations, but these were relatively sparsely distributed 
within the population. Immunocytochemical analysis can only be considered semi- 
quantitative however, thus western blotting analysis was carried out to determine the
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levels of the transfected proteins. Western analysis did not indicate substantial 
increases in the levels of glucokinase and GLUT2 in the transfected BHK-PPI- 
C16 GCK and BHK-PPI-C16 GCK GLUT populations. Despite this, however, it 
was found that the BHK-PPI-C16 GCK population exhibited a moderate sub- 
physiological secretory response, whereas the BHK-PPI-C16GCKGLUT 
population was no longer found to secrete proinsulin. Transfection of glucokinase into 
RIN-38 cells resulted in a large increase in the capacity for GSIS which was also in 
the subphysiological range (i.e. < 5-6 mM glucose) (Hohmeier et ah, 1997). Actively 
regulated secretion through secretagogues, however, requires a pool of stored material 
which was not found in BHK-PPI-C16. Regulated secretion has been achieved 
previously with fibroblasts through the action of an inducible promoter (Kawakami et 
al., 1992), however this is not regulated at the level of secretion, rather, increasing 
transcription increases the biosynthesis of proinsulin. Cells have a consistent ‘holding- 
capacity’, thus the extra proinsulin must be secreted at a faster rate through the 
constitutive pathway. This is regulation of secretion at the ‘level of availability’ 
(Halban & Irmanger, 1994). This implies that there is more insulin available for 
secretion in BHK-PPI-C16 GCK in the range 2-5 mM glucose, which is not 
surprising as it is within the range at which the cells normally grow. Assuming that 
there is an increase in functional glucokinase within the BHK-PPI-C16 GCK 
population, this could allow for increased metabolism and therefore an increase in 
biosynthetic activity within the optimal glucose range for BHK-21 cell culture.
The loss of insulin secretion despite unaltered mRNA expression in the co-transfected 
population BHK-PPI-C16_GCK_GLUT may be due to an increase in metabolic load 
due to the expression of too many constitutively expressed genes. Concomitant with 
the loss of insulin expression is the finding that the levels of the two housekeeping 
proteins P actin and a  tubulin are also reduced. This reduction could be correlated 
with increased number of transfected genes. A Bradford assay (Section 2.5.2.1.2.1) of 
cell lysates also indicated a similar reduction in cellular protein levels following 
double and triple transfection. Recombinant bacteria have been shown to exhibit 
lower growth rates than their wild type counterparts due to the increased metabolic 
load/burden resulting from the expression of the exogenous protein (Glick, 1995). 
Similar observations have been made in mammalian cells by Kim et ah (1998).
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Yallop & Svendsen (2001) found that aggressive selection using G418 increased the 
copy number o f the neor (G418 resistance gene) gene and this was responsible for 
increases in the metabolic load in BHK-21 cells. In the BHK-PPI-C16GCK GLUT 
system there are 6 constitutively expressed genes i.e. PPI, glucokinase, GLUT2 and 
the resistance genes for G418, zeocin and hygromycin. Thus, if aggressive selection 
can increase the expression of the resistance genes then it is probable that the negative 
effects noted in BHK-PPI-C16 GCK GLUT are due to increased metabolic load and 
cellular exhaustion. Although the difference in cellular protein levels between BHK- 
PPI-C16 GCK and BHK-PPI-C16 GCK GLUT is minor, the protein levels in the 
BHK-PPI-C16 GCK GLUT are lower. It is possible that there are other effects of 
increasing the metabolic load that are not visible through direct analysis of cellular 
protein levels, which may play a more direct role in the loss of secretion ability.
4.6.3 Agents Causing an Increase in Intracellular cAMP Increase Proinsulin 
Secretion From BHK-PPI-C16
cAMP has been shown to increase insulin secretion in a number of cell lines (Nielsen 
et a l, 1985; Hammonds et a l, 1987; Ullrich et a l, 1996; Simpson el a l, 1997; Lu el 
al, 1997). This effect is at least partly mediated through membrane depolarisation 
(Ullrich et al, 1996). cAMP can act as a second messenger for stimulated insulin 
release by insulinotropic hormones such as GLP-1 (Drucker et al., 1987). Upon 
stimulation of BHK-PPI-C16 with forskolin and theophylline there was a 
heterogeneous, but consistent, increase in the proinsulin levels secreted. Forskolin acts 
through activation of adenyl cyclase while theophylline is a cAMP phosphodiesterase 
inhibitor. Using two similar compounds, glucagon (an adenyl cyclase activator) and 
IBMX (a cAMP phosphodiesterase inhibitor), also resulted in increased insulin 
secretion. As discussed already (Section 4.6,2), it seems unlikely that BHK-PPI-C16 
could be stimulated to secrete proinsulin due to its inherent constitutive protein 
secretion pathway and that increased secretion could only be effected by an increase 
in intracellular insulin, i.e. to create a positive pressure to encourage increased 
secretion. cAMP can also directly stimulate transcription of the human insulin gene 
through interactions with four cAMP responsive elements (CREs) (Inagaki et al., 
1992), however, cAMP was not found to have any enhancing effects on PPI 
transcription in BHK-PPI-C16. Roesler et a l (1988) described cAMP as the most
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important regulatory molecule with diverse functions ranging from co-ordinating 
metabolic processes to specific enzyme synthesis and that the effects of cAMP are 
varied in nature. It is therefore possible that cAMP is influencing proinsulin 
biosynthesis in BHK-PPI-C16, resulting in an increased rate of secretion.
4.6.4 Implications for Use of BHK Cells Secreting Human Insulin
BHK-PPI-C16 cells produce proinsulin, which can function in an insulin-like manner 
although the efficiency is only 8-20% of mature insulin (Selden et al., 1987; 
Taniguchi el al., 1997; Falqui et a l, 1999). Previous studies have shown that the 
continuous release of proinsulin from genetically engineered fibroblasts (Ltk+Ins) 
could aid in maintaining normoglycemia in mice for up to 50 days (Taniguchi et al,
1997). The Diabetes Control and Complications Trial (DCCT) (1987) stated that the 
residual release of insulin significantly improves metabolic control in IDDM, 
therefore BHK-PPI-C16 could provide such a role. This function could possibly help 
prevent the long-term damage associated with diabetes, e.g. renal failure and 
peripheral neuropathy, which are all associated with long term additive effects of 
transient hyperglycemic episodes, that occur during loss of diabetic control.
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5.0 CONCLUSIONS AND FUTURE W ORK.
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5.1 Conclusions
A major focus of this thesis was the development of protocols and conditions whereby 
the murine EC cell line, F9, could be differentiated along an endocrine differentiation 
pathway. The F9 cells were differentiated along characterised endodermal 
differentiation pathways using retinoic acid and db cAMP (di butyryl cyclic adenosine 
monophosphate). These endodermal cells were then treated with secondary 
differentiation agents associated with (3 cell differentiation. Lineage determination 
was carried out by RT-PCR analysis of critical differentiation markers and 
develop mentally regulated genes. To investigate the importance of the transcription 
factor PDX1 in endocrine differentiation, PDX1 expressing cells were isolated from 
differentiating F9 cells, using cell trapping techniques and were studied. Experiments 
were also carried out on continuously cultured [3 cell lines, to investigate if these cells 
were de-differentiating, with the aim of identifying important features for the 
maintenance of a p cell phenotype in culture. Finally, the use of the cultured cell line 
BHK-21 to express the human insulin gene was investigated.
The following conclusions were made as a result of this research:
• Endodermal differentiation of F9 cells can lead to the expression of the full 
complement of cytokeratins associated with the pancreas i.e., cytokeratins 7, 19, 8 
& 18 with a concomitant loss in expression of the stem cell marker alkaline 
phosphatase.
• By shortening the duration of the RA (10"7M retinoic acid) and RAC (10~7 M 
retinoic acid with 10’3JV1 di butyryl cyclic adenosine monophosphate) mediated 
differentiation, the potential of F9 cells to differentiate in to a wide variety of 
tissue types is retained.
• Examination of the morphological evidence and the expression levels of 
differentiation markers , such as cytokeratins and alpha fetoprotein, lead to the 
conclusion that RA and RAC mediated differentiation resulted in the formation of
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three types of endoderm i.e. parietal endoderm (PE), visceral endoderm (VE) and 
primitive endoderm (PrE).
• Treatment of the three endodermal cell types with a selection of differentiation 
agents (characterised for their ability to direct differentiation towards an endocrine 
lineage), leads to a number of changes in gene expression. The developmental 
genes Pax6 and Ihh showed the greatest amount of variation in expression levels 
between the different treatments.
• RT-PCR analysis detected the expression of a number of pancreatic genes in 
differentiating F9 cells including preproinsulin (PPI), somatostatin, pancreatic 
polypeptide (PP), pancreatic duodenal homeodomain protein (PDX1), Pax6 and 
indian hedgehog (Ihh). This again indicates that F9 cells are capable of 
differentiating in multiple directions.
• The absence of typical pancreatic transcription factor cascades/pathways may 
indicate that the treatments are facilitating other cell types to develop e.g. 
mesodermal cells as was found in the treatment of ES cells with activin A 
(Schuldiner et al., 2000). The wide range of responses of the three F9-derived 
endodermal types reveals that the cells differ in their responses to external stimuli.
• Sodium butyrate can lead to the expression of pancreatic polypeptide and 
somatostatin genes in F9 derived endoderm. Its effects can be enhanced by activin 
A in specific circumstances. The fact that sodium butyrate did not have any 
similar effects on any of the other genes examined suggests that is likely that 
sodium butyrate is having a direct effect on the expression of these genes.
• Sodium butyrate may be exerting its effects on the somatostatin and pancreatic 
polypeptide genes through direct interaction with the structure of the chromatin, as 
evidenced by sodium butyrate-mediated increases in acetylated hi stone H3.
• Overall analysis of the results obtained here tend to suggest that visceral 
endoderm (VE) is the lineage from which to differentiate pancreatic cells. The
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gene expression profiles associated with VE derived from embryoid bodies (EBs) 
show more similarities to the pancreatic cell types, i.e. EBs have elevated levels of 
PDX1 and PPI, and show wider expression of the endocrine markers somatostatin 
and pancreatic polypeptide than homogenous PE derived from RAC treated cell 
lines. The latter do not show the same level of pancreatic differentiation.
• Cell trapping has been shown to be a powerful method for isolating populations of 
specific cells from a differentiating stem cell population. The cells isolated 
through PDX1-based cell trapping all expressed higher PDX1 mRNA levels than 
the parental population. Although it was not possible to visualise an increase in 
PDX1 protein levels, evidence for an increase in functional PDX1 protein was 
provided by associated increases in PPI gene and somatostatin gene expression, 
both of which are known to be transactivated by PDX1.
• Somatostatin gene expression appears to be transactivated by increased PDX1 
levels in differentiated F9 cells. In cell trapped cells where the levels of PDX1 are 
continuously elevated, somatostatin expression is constitutive. Untreated EBs also 
show elevated PDX1 levels compared to F9 cells and constitutively express 
somatostatin.
• F9 cells show low transfection efficiencies while undifferentiated. Previous 
studies have shown that this can be overcome through endodermal differentiation 
(Darrow et ah, 1990). In this study it was shown that the transfection efficiency 
was substantially increased upon partial differentiation with RAC medium for 
only 72 hours. The morphologically differentiated PE-like cells clearly show 
preferential expression of the transfected cDNA.
• Overexpression of pancreatic differentiation factors in partially differentiated F9 
cells does not lead to initiation of pancreatic transcription factor cascades. It is 
possible that the PE nature of the transfected population may be the incorrect 
lineage from which to initiate pancreatic development.
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• Min6 cells lose the ability to regulate insulin secretion in response to glucose 
when passaged continuously in culture. This is associated with other changes such 
as increased insulin secretion at low (i.e. subphysiological) glucose levels, 
increased proliferation and morphological changes. RT-PCR and DNA array 
analysis identified that these phenotypic changes are as a result of changes in the 
expression of critical genes. DNA array analysis specifically indicated increases in 
gene transcripts such as p55CDC, which is a marker for proliferating cell lines. 
Critical insulin processing and secretion proteins such as PC2, secretogranin V, 
secretogranin II and chromograinin B were all decreased at higher passages. The 
concomitant reduction in the expression of genes such as Pax6, DLK, ODC, 
somatostatin and glucagon all contribute to the evidence that the continuous 
culture of Min6 cells results in de-differentiation which may be at least partly due 
to impaired polyamine synthesis resulting from reduced ODC expression levels. 
The results obtained here do not reveal the mechanism of de-differentiation, 
however, and it is unclear if Min6 cells undergo gradual changes in gene 
expression over time or if the de-differentiation is as a result of the overgrowth of 
the Min6 population by a subpopulation of undifferentiated cells.
• Expression of the human PPI gene in BHK-21 cells leads to a high level of gene 
expression, and to translation of the gene product, proinsulin. However, possibly 
due to the constitutive nature of fibroblast protein secretion pathways, these cells 
were not able to regulate the secretion with external glucose levels. This inability 
to regulate secretion was at least partly caused by the lack of efficient storage, 
which was also linked to the inability to process the proinsulin to mature insulin.
• BHK-PPI-C16 cells were found to express low levels of the glucose sensing 
genes, GLUT2 and glucokinase. Overexpression of glucokinase did result in a 
moderate subphysiological glucose-related increase in secretion. This effect is 
thought to be due to ‘regulation through availability’ which was as a result of 
improved metabolism. Similar work with fibroblasts has achieved this regulation 
through the action of inducible promoters.
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•  Co-expression of GLUT2 and glucokinase in BHK-PPI-C16 resulted in impaired 
insulin secretion. This was accompanied by the reduction in the levels of two 
housekeeping proteins (a  tubulin and (3 actin), and a decrease in cellular protein as 
measured by the Bradford assay. These changes were linked to a deleterious 
increase in the metabolic load of the cells due to the constitutive expression of six 
exogenous genes.
• CAMP-inducing agents were found to increase proinsulin secretion from BHK- 
PPI-C16. It is believed that the increase in cAMP levels results in an increase in 
proinsulin biosynthesis, leading to increased proinsulin secretion.
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5.2 Future Work
The work carried out here identified a number of points regarding endocrine 
differentiation thus there are a series of experiments which could be carried out to 
further the work outlined here.
5.2.1 Elucidation of Possible Lineages Emerging From Secondary Treated F9 
Cells
To fully monitor the effects that the secondary differentiation agents may be having 
on F9 cells, a wider range of differentiation markers should be examined, i.e. markers 
outside of those involved in the developing pancreas. Examples of the type of markers 
that could be examined are listed below:
1. Ectodermal Markers including: Neurofilament Heavy Chain (Brain), and 
dopamine (3 hydroxylase (adrenal ectoderm).
2. Mesodermal: Enolase (Muscle), cartilage matrix protein (bone) and cardiac actin 
(heart).
3. Endoderm: Albumin (liver) and a l AT (liver).
5.2.2 Treatment of Differentiated F9 Cells With Bromodeoxyuridine (BrdU)
It has been shown in this laboratory that BrdU can overcome the translational 
repression of cytokeratin expression in DLKP cells through its induction of eIF4E 
expression (allowing for more efficient translation initiation). It would be interesting 
to determine if BrdU could elicit the same response in differentiated F9 cells which 
have been shown to have increased levels of PPI and PDX1 mRNA, but not their 
respective proteins.
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5.2.3 Cell Trapping at Low Glucose
It is unknown if  the seemingly poor expression of PDX1 and insulin in the cell 
trapped cell lines was due to differentiation in the presence of high levels (25 mM) of 
glucose, therefore it would be advisable to carry out the procedure at low glucose and 
monitor the effects on PDX1 and insulin proteins.
5.2.4 Generation of Stable F9 Cell Lines Expressing PDX1
Increased PDX1 levels were linked to the transactivation of the somatostatin gene in 
F9-CT (i.e. cell trapped (CT) F9 cells) cell lines. Direct transfection of 
undifferentiated F9 cells is inefficient and would not be suitable for transient 
experiments (as these experiments typically require transfection efficiencies of >15- 
20% to have any noticeable effect on endogenous gene expression), however stable 
cell lines could be generated. Thus an experiment to generate PDX1 overexpressing 
cell lines would be interesting to determine if this alone could activate the 
somatostatin gene. Other markers should also be investigated to determine if  PDX1 
could have an effect when expressed in totally undifferentiated F9 cells and without 
the pre-commitment to parietal endoderm (PE), as in the RAC treated F9 population.
5.2.5 Generation F9 Cells Stably Transfected with Nuclear Transcription Factors
As with the PDX1 overexpression in undifferentiated F9 cells, it would be worthwhile 
to generate F9 cell lines stably transfected with Beta2, Ngn3, Nkx2.2 and 
combinations of these. It would be interesting to determine if the expression of these 
proteins alone could lead to the differentiation of F9 cells. This would also serve to 
indicate if the PE lineage of RAC treated F9 cells, was responsible for the lack of 
knock-on effects (as noted in Section 3.3.2).
5.2.6 Cell Trapping of Other Embryonic Stem (ES) Cell Lines
The results obtained during the course of this thesis indicate that cell trapping is a 
excellent tool for cell isolation in differentiating F9 cells. For comparative purposes it
would be interesting to carry out the cell trapping protocol on differentiating ES cells 
and to purify the PDX1 expressing cells, that have been previously observed to be 
generated, following spontaneous differentiation of EBs (embryoid bodies) 
(Schuldiner et al., 2000; Gerrish et al., 2000).
5.2.7 Identification of the Mechanism of Action of Sodium Butyrate in Pancreatic 
Polypeptide (PP) and Somatostatin Induction
Treatment of all three types of endoderm from stage 1 differentiation with sodium 
butyrate resulted in PP and somatostatin expression (activin A was required for 
induction of somatostatin in EBs). Increases in acetylated histone H3 levels indicated 
that the sodium butyrate was having an effect through acétylation of chromatin. To 
confirm the mechanism of sodium butyrate activation of PP and somatostatin in F9 
cells the following experiments should be carried out:
1. Treatment of F9 endoderm samples with another histone deacetylase (HDAC) 
inhibitor e.g. trichostatin A or oxamflatin (Marks el al., 2000), to determine if 
HD AC inhibition is the mechanism by which the genes are induced.
2. Transcriptionally active chromatin is more soluble due to partial unwinding and a 
more open conformation, which is linked to histone acétylation. These 
modifications can make the chromatin more susceptible to DNase I digestion. 
Thus, nuclei from F9 EC and sodium butyrate treated F9 cells could be treated 
with DNase I, restriction digested to give fragments containing the relevant 
promoter region, southern blotted and probed for DNase I digestion.
3. ChlPs (chromatin immunoprécipitation protocol) analysis is another method 
whereby one can discover if  a gene is undergoing modifications due to histone 
acétylation, by immunoprécipitation of all acetyl histone of interest (previously 
crosslinked to DNA), and then checking the recovered DNA for the gene of 
interest, via PCR.
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5.2.8 Identification of the Mechanism of Loss of Min6 Phenotype
As already outlined in Section 4.5, the actual mechanism of de-differentiation in Min6 
is unknown, i.e. whether the cells are de-differentiating as a population or if the 
differentiated functional cells are being overgrown by less differentiated cells with 
faster proliferation rates. To elucidate this, clonal populations of Min6 cells should be 
generated and characterised for function. This could aid identification of rapidly 
proliferating sub-populations within the Min6 population as a whole. By identifying 
fully functional clones and passaging them over time one could discover if these cells 
also lose their ability to secrete insulin in response to glucose and if  they show similar 
differential gene expression to that seen in the high passage cells examined in this 
thesis. If these clones were not to lose their GSIS ability then it would indicate that the 
‘overgrowth theory’ was valid. If these cells, however, were to lose their GSIS in a 
similar manner to ordinary Min6 cells, then a mechanism involving the gradual de- 
differentiation of cultured Min6 cells through changes in expression in critical genes 
would be confirmed.
5.2.9 Protein Analysis in High Passage Min6 Cells
The DNA array studies indicated some very interesting changes in high passage Min6 
cells. These should be investigated by protein analysis, including studies of glucagon 
and somatostatin expression levels. Some proliferation proteins should also be 
investigated e.g. Ki67, as should the levels of the secretogranin and chromogranin 
proteins i.e. the proteins involved in regulated secretion. The polyamine levels should 
also be compared between high and low passage Min6 cells. These experiments 
would confirm the array data used to explain why Min6 cells lose their ability to 
regulate insulin secretion in response to glucose.
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5.2.10 Maintenance of Min6 Cells in Long Term Culture
During DNA array analysis of high passage Min6 celts it was noticed that the levels 
of ODC were reduced. If polyamine levels are shown to be reduced in high passage 
Min6 cells then a repeat passaging experiment should be earned out, except that one 
set of flasks should be grown in nicotinamide (to induce high polyamine levels), to 
investigate if P cell function can be maintained longer. This should be followed by 
comparative DNA array analysis to determine the effects of nicotinamide treatment.
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